5th EuropEan MolEcular IMagIng MEEtIng - ESMI
5th EuropEan MolEcular IMagIng MEEtIng - ESMI
5th EuropEan MolEcular IMagIng MEEtIng - ESMI
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
of the European network of excellence DiMI - Diagnostic Molecular Imaging, and is organised in collaboration with the<br />
ESR - European Society of Radiology, the European network of excellence CliniGene – Clinical Gene Transfer and Therapy,<br />
and is also supported through COST actions D38 and BM0607 – the European cooperation in science and technology.<br />
DAY<br />
0EMIM2010 is the <strong>5th</strong>annual meeting of the European Society for Molecular Imaging - <strong>ESMI</strong>. The EMIM2010 is also the final meeting
WarSaW, poland May 26 – 29, 2010<br />
committees<br />
5 th EMIM EXECUTIVE COMMITTEE<br />
Andreas H. Jacobs, <strong>ESMI</strong> President<br />
Renata Mikołajczak, Local Organiser<br />
Clemens W.G.M. Löwik, <strong>ESMI</strong> Vice President<br />
Bertrand Tavitian, <strong>ESMI</strong> Past President<br />
Silvio Aime, <strong>ESMI</strong> Secretary<br />
Simone Mergui, <strong>ESMI</strong> Treasurer<br />
5 th EMIM SCIENTIFIC COMMITTEE<br />
Ludwig Aigner, Salzburg (A)<br />
Silvio Aime, Torino (I)<br />
Veerle Baekelandt, Leuven (B)<br />
Hervé Boutin, Manchester (Uk)<br />
Harald Carlsen, Oslo (N)<br />
John Clark, Edinburgh (Uk)<br />
Marion Dejong, Rotterdam (Nl)<br />
Silvana Del Vecchio, Naples (I)<br />
Frédéric Dollé, Orsay (F)<br />
Eugeniusz Dzuik, Warsaw (Pl)<br />
Cornel Fraefel, Zuerich (Ch)<br />
Jorgen Frokiaer, Aarhus (Dk)<br />
Nicolas Grenier, Bordeaux (F)<br />
Denis Guilloteau, Tours (F)<br />
Uwe Haberkorn, Heidelberg (D)<br />
Mathias Höhn, Cologne (D)<br />
Andreas H. Jacobs, Münster (D)<br />
Fabian Kiessling, Aachen (D)<br />
Izabela Kozlowicz-Gudzinska, Warsaw (P)<br />
Leszek Krolicki, Warsaw (Pl)<br />
Tony Lahoutte, Jette (B)<br />
Adriaan Lammertsma, Amsterdam (Nl)<br />
5 th EMIM Young Investigator Award SELECTION COMMITTEE<br />
Veerle Baekelandt<br />
Hervé Boutin<br />
Peter Brader<br />
John Clark (Chair)<br />
Frédéric Dollé<br />
Nicolas Grenier<br />
Fabian Kiessling<br />
Adriaan Lammertsma<br />
LOCAL ORGANIZING COMMITTEE<br />
Iliana Chwalinska, Warsaw (P)<br />
Eugeniusz Dzuik, Warsaw (P)<br />
Izabela Kozlowicz-Gudzinska, Warsaw (P)<br />
Leszek Krolicki, Warsaw (P)<br />
Renata Mikolajczak, Warsaw (P)<br />
Bengt Långstrom, (S)<br />
Clemens W.G.M. Löwik, Leiden (Nl)<br />
Helmut R. Maecke, Freiburg (Ch)<br />
Adriana Maggi, Milano (I)<br />
Serge Maitrejean, Paris (F)<br />
Renata Mikolajczak, Warsaw (P)<br />
Chrit Moonen, Bordeaux (F)<br />
Klaas Nicolay, Eindhoven (Nl)<br />
Vasilis Nziachristos,Munich (D)<br />
Sabina Pappata, Naples (I)<br />
David Parker, Durham (Uk)<br />
Bernd PIchler, Tübingen (D)<br />
Anna Planas, Barcelona (E)<br />
Juha Rinne, Turku (Fin)<br />
Jorge Ripoll, Heraklion (Gr)<br />
Markus Rudin, Zürich (Ch)<br />
Michael Schäfers, Münster (D)<br />
Markus Schwaiger, Munich (D)<br />
Bertrand Tavitian, Orsay (F)<br />
Eva Tóth, Orleans (F)<br />
Annemie Van Der Linden, Antwerp (B)<br />
David Wyper, Glasgow (Uk)<br />
Renata Mikolajczak<br />
Chrit Moonen<br />
Klaas Nicolay<br />
Markus Schwaiger<br />
Bertrand Tavitian (Chair)<br />
Eva Tóth<br />
David Wyper
content – per topic<br />
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Day 0 - Wednesday 26,2010 6<br />
Overview oral presentations 6<br />
Welcome 8<br />
Venue 10<br />
Thank you! 11<br />
Programme at a Glance 12<br />
Programme Datails 14<br />
Inaugural Lecture by Christopher H. Contag 20<br />
Day 1 - Thursday May 27, 2010 22<br />
<strong>ESMI</strong> Plenary Lecture 1 by Violaine Sée 24<br />
Parallel Session 1: CANCER I - together with the ESR 26<br />
Parallel Session 2: NEUROSCIENCE I 32<br />
Parallel Session 3: TECHNOLOGY 38<br />
Parallel Session 4: PROBES - supported by COST actions 44<br />
<strong>ESMI</strong> Plenary Lecture 2 by Francesca Odoardi 50<br />
Plenary Session on Excellent and Late Breaking Abstracts 52<br />
Day 2 - Friday May 28, 2010 58<br />
<strong>ESMI</strong> Plenary Lecture 3 by Theodorus W.J. Gadella Jr. 60<br />
Parallel Session 5: NEUROSCIENCE II 62<br />
Parallel Session 6: CARDIOVASCULAR I - together with the ESR 68<br />
Parallel Session 7: PROBES II - together with the EANM 74<br />
Parallel Session 8: Gene and cell based therapies - together with CliniGene 80<br />
<strong>ESMI</strong> Plenary Lecture 4 by Hans-Jürgen Wester 86<br />
Plenary Session on Current Contribution of Imaging Technologies to<br />
Drug Development 88<br />
Day 3 - Friday May 29, 2010 92<br />
<strong>ESMI</strong> Plenary Lecture by Jagat Narula 94<br />
Parallel Session 9: CARDIOVASCULAR II 96<br />
Parallel Session 10: CANCER II - supported by COST actions 102<br />
Poster Session, guided poster walks, topics, and titles 108<br />
Index 224<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong>
6<br />
WarSaW, poland May 26 – 29, 2010<br />
overview oral presentations – per title<br />
Inaugural Lecture by Christopher H. Contag<br />
imaging life<br />
Day 0 - Wednesday May 26, 2010<br />
Point-of-Care Microscopy: Molecular Imaging with Cellular Resolution 20<br />
Day 1 - Thursday May 27, 2010<br />
<strong>ESMI</strong> Plenary Lecture 1 by Violaine Sée<br />
Transcription factors dynamics: from discrete pulses to oscillatory pattern to control gene expression 24<br />
Parallel Session 1: CANCER I - together with the ESR<br />
Multimodal imaging approaches for cell-cell interaction 26<br />
Molecular imaging for monitoring treatment with protein kinase inhibitors 27<br />
Potentials of imaging biomarkers in patients 28<br />
Pre-clinical screening of anti - HER2 nanobodies for molecular imaging of breast cancer 29<br />
[18F]-FDG/[18F]-FLT-PET and bioluminescence imaging of therapy response in B-cell lymphoma mice treated with<br />
cytotoxic and antiproliferative agents 30<br />
TF-Pimonidazole: an hypoxia marker suitable for in vivo 19 F MRS imaging 31<br />
Parallel Session 2: NEUROSCIENCE I<br />
[11C](R)-PK11195- a tricky tracer. Do we really need it to image microglial activation? 32<br />
Preclinical imaging of the type 1 cannabinoid receptor in neurodegenerative diseases<br />
Longitudinal non-invasive detection of amyloid plaques by combined molecular, functional and morphological imaging<br />
33<br />
in transgenic mouse models of Alzheimer‘s disease 34<br />
Serotonergic neurotransmission in early Alzheimer’s disease<br />
Qualitative and quantitative assessment of florbetapir F-18 PET (<br />
35<br />
18F-AV45) amyloid deposition PET imaging - validation<br />
by pathology. Preliminary report 36<br />
In-vivo imaging of a mouse traumatic brain injury model using dual-isotope quantitative spect/ct 37<br />
Parallel Session 3: TECHNOLOGY<br />
Molecular analysis of adaptive immune function through microscopic and mesoscopic imaging 38<br />
Magnetic resonance imaging – from structure to molecular interactions 39<br />
Imaging modalities: PET and SPECT 40<br />
In vivo fluorescence kinetic imaging for improved contrast and studies of temporal and quantitative biodistribution 41<br />
Cerenkov radiation imaging of a xenograft murine model of mammary carcinoma 42<br />
A system for 4D (3D+Kinetics) molecular imaging in bioluminescence and fluorescence 43<br />
Parallel Session 4: PROBES - supported by COST actions<br />
The alignment of target-specific lipoCEST MRI contrast agents 44<br />
Lanthanide-based in vivo luminescence imaging 45<br />
New perspectives for imaging molecules and metabolism in vivo 46<br />
In vivo biodistribution of radiolabeled matrix metalloproteinase-2 activatable cell penetrating peptides 47<br />
Bioresponsive MRI contrast agents based on self-assembling β-cyclodextrin nanocapsules 48<br />
Photochemical activation of endosomal escape of MRI-Gd-agents in tumor cells 49<br />
<strong>ESMI</strong> Plenary Lecture 2 by Francesca Odoardi<br />
Immune surveillance and autoimmunity: how encephalitogenic T cells enther their target organ 50<br />
Plenary Session on Excellent and Late Breaking Abstracts<br />
Exendin-4 derivatives labeled with radiometals for the detection of insulinoma: a “from bench to bed approach” 52<br />
Assessment of HIF transcriptional activity in a mouse tumor model using GPI anchored avidin– a novel protein<br />
reporter for in vivo imaging 53<br />
A leukocyte ligand of vascular adhesion protein-1 as an imaging tool in PET 54<br />
Clinical translation of ex vivo sentinel lymph node mapping for colorectal cancer using invisible near-infrared<br />
fluorescence light 55<br />
Development of strategies for in vivo MRI and Optical Imaging of neural stem cells distribution for the treatment of<br />
traumatic spinal cord injury 56<br />
Validation of bone marrow-derived stromal cell graft position by colocalisation of histology, bioluminescence and<br />
magnetic resonance imaging 57<br />
Day 2 - Friday May 28, 2010<br />
<strong>ESMI</strong> Plenary Lecture 3 by Theodorus W.J. Gadella<br />
New probe-based strategies for quantitative microscopy of signaling dynamics in single cells 60
Parallel Session 5: NEUROSCIENCE II<br />
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Potential to use transgenic animals for imaging of neurological diseases 62<br />
Specific cell labeling with imaging reporters in vivo by viral vectors: the challenges 63<br />
Optimization of an MRI method to measure microvessel density: application to monitor angiogenesis after stroke 64<br />
MRI study of intra-arterial bone marrow-derived macrophage administration after acute focal ischemic stroke in rats 65<br />
Inactivated paramagnetic tissue plasminogen activator predicts thrombolysis outcome following stroke 66<br />
Matrix metalloproteinase-9 – a possible therapeutic target in intractable epilepsy 67<br />
Parallel Session 6: CARDIOVASCULAR I - together with the ESR<br />
Potentials of new contrast agents for vascular molecular imaging in patients 68<br />
Protease specific nanosensors in atherosclerosis 69<br />
Imaging of inflamed carotid artery atherosclerotic plaques with the use of 99mTc-HYNIC-IL-2 scintigraphy in the<br />
end-stage renal disease patients 70<br />
Uptake of 68 Ga-Chloride in Atherosclerotic Plaques of LDLR -/- ApoB 100/100 Mice 71<br />
Hybrid imaging using dual energy µCT and FMT for characterization of atherosclerotic plaques in ApoE -/- mice 72<br />
Long circulating emulsion based ct contrast agents 73<br />
Parallel Session 7: PROBES II - together with the EANM<br />
Application of microfluidics to the ultra-rapid preparation of fluorine-18 and carbon-11 labelled compounds 74<br />
Radioligand for in vivo measuring neurotransmitters release 75<br />
18f-tracers for amyloid plaques 76<br />
Chelators for radiocopper: biological/pharmacokinetic differences of [Tyr3 ,Thr 8 ]octreotide conjugates 77<br />
[ 11C]SOMADAM: potential sert ligand for pet studies and comparison with [ 11C]MADAM 78<br />
MR imaging of extracellular redox by a thiolsensitive gd(iii)-do3a derivative 79<br />
Parallel Session 8: Gene and cell based therapies - together with CliniGene<br />
Everything but not cell replacement with somatic neural stem cell transplantation 80<br />
Mesenchymal stem cell transplantation: an option to promote remyelination? 81<br />
Viral vector-mediated transcriptional targeting of dendritic cells for antigen-specific tolerance induction in EAE/MS. 82<br />
Delivery of a bioluminescent transgene to a tumor via bone marrow engraftment and local control of gene expression<br />
by non invasive local hyperthermia<br />
Dendritic cell labelling with paramagnetic nanoparticles and<br />
83<br />
111In-oxine for in vivo magnetic resonance imaging and<br />
scintigraphic imaging 84<br />
The type 2 cannabinoid receptor as a new PET reporter gene for the brain 85<br />
<strong>ESMI</strong> Plenary Lecture 4 by Hans-Jürgen Wester<br />
Molecular imaging of CXCR4 receptors 86<br />
Plenary Session on Current Contribution of Imaging Technologies to Drug Development<br />
Evaluation of the temporal window for drug delivery following ultrasound mediated membrane<br />
permeability enhancement 88<br />
Integrisense: a novel near-infrared fluorescent probe for α β integrin and its applications in drug discovery v 3 88<br />
Harnessing the power of bioluminescence to cross the in vitro–in vivo divide 90<br />
In vivo imaging in drug discovery: the example of application in the development of novel estrogenic compounds 91<br />
Day 3 - Saturday May 29, 2010<br />
<strong>ESMI</strong> Plenary Lecture by Jagat Narula<br />
Molecular imaging of unstable coronary plaques 94<br />
Parallel Session 9: CARDIOVASCULAR II<br />
Advances in contrast-enhanced MRI of the mouse heart 96<br />
Molecular imaging of α β integrin expression with v 3 18F-galacto-RGD after experimental myocardial infarction:<br />
comparison with left ventricular remodeling and function 97<br />
Existing and emerging animal models mimicking cardiovascular disease and their relevance for molecular imaging<br />
Imaging of Matrix Metalloproteinase Activity in Vulnerable Human Carotid Plaques with Multispectral Optoacoustic<br />
98<br />
Tomography 99<br />
c-Jun N-terminal kinase promotes inflammation at atherosclerosis-prone sites by enhancing expression and activity<br />
of NF-κB transcription factors 100<br />
Absolute Quantification in Small Animal Pinhole Gated Myocardial Perfusion SPECT 101<br />
Parallel Session 10: CANCER II - supported by COST actions<br />
Cancer imaging 102<br />
Controlled drug delivery under image guidance 103<br />
Comparative biodistribution of twelve gastrin/CCK2 receptor targeting peptides 104<br />
Targeting cancer stem cells using radiolabeled Sonic Hedgehog 105<br />
Evaluation of the photosensitizer Bremachlorin for photodynamic treatment of breast cancer bone metastasis. 106<br />
In vivo targeting of HEK-hsst Xenografts by 2/3/5 111in-labeled [(DOTA)Ser 1 ,Leu 8 ,trp22 ,Tyr25 ]-SS-28 in SCID mice 107<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
overview oral presentations
8<br />
WarSaW, poland May 26 – 29, 2010<br />
Welcome to the 5 th EMIM in Warsaw, Poland<br />
Dear Colleagues,<br />
on behalf of the <strong>ESMI</strong> as well as the other organising and contributing societies and networks it is our great pleasure<br />
to welcome you to Warsaw, Poland, for the 5 th European Molecular Imaging Meeting. EMIM 2010 brings together top<br />
European scientists from 3 societies, 2 European Networks of Excellence (NoEs) and 2 COST actions. With great honour<br />
we may state that your fellow attendees represent not only colleagues from all over Europe, but also Asia and the US.<br />
The societies and networks with primary responsibility for organising the meeting are:<br />
• European Society for Molecular Imaging – <strong>ESMI</strong><br />
• NoE Diagnostic Molecular Imaging – DiMI<br />
• European Cooperation in Science and Technology – COST Actions D38 and BM0607<br />
• European Society of Radiology – ESR<br />
• We also gratefully acknowledge the contribution from the following participating organisations:<br />
• European Association of Nuclear Medicine – EANM<br />
• NoE Clinical Gene Transfer and Therapy – Clinigene<br />
All these organisations were working together, with input from a scientifically complementary scientific steering committee,<br />
to develop a strong scientific programme which integrates developments in imaging technologies and molecular<br />
imaging agents with applications for drug development, basic science investigations, and clinical translation with special<br />
emphasis in the main disease burdens of our society such as cancer, cardiovascular disease and neurodegeneration.<br />
We developed the 5 th EMIM scientific programme primarily on the outstanding strength of submitted abstracts.<br />
About 150 abstracts were submitted, reviewed and scored. Then, each of the concurrent session co-chairs reviewed<br />
the scored abstracts which were considered relevant to their particular sessions. Session co-chairs selected abstracts<br />
for oral presentation based on average abstract score, session content and structure. Attention was also paid to diversity<br />
of disciplines and geographical distribution. From this effort 39 abstracts were integrated into the Parallel as<br />
well as Plenary Sessions that bring attendees from different disciplines together for a comprehensive examination of<br />
the role of molecular imaging in particular biomedical problems. 21 of these oral abstract presentations will be held<br />
by Young Investigator Award (YIA) applicants. The YIA selection committee is going to select the best 3 YIA presentations<br />
to be held again during the final Plenary Session on Saturday where then THE Young Investigator Awardee<br />
will be announced. Furthermore, special attention has been put on seven guided poster walks which have been<br />
scheduled on Thursday and Friday afternoon with no other competing sessions in order to enhance the knowledge<br />
exchange of experienced and young researchers. Each of the guided poster walks will be chaired by two chairs and will<br />
result in one poster award. The seven Poster Awards will also be offered during the Closing Ceremony on Saturday.<br />
We are especially proud and thankful that Prof. Dr. Christopher Contag will give the inaugural lecture,<br />
entitled, “Point-of-care microscopy: molecular imaging with cellular resolution”. In addition, we have planned 5 exciting<br />
plenary lectures, covering topics on probe design, systems biology, cancer, neuroinflammation, and atherosclerosis.<br />
Furthermore, we have dedicated one Plenary Session each to Excellent, Late Breaking, and YIA Abstracts as<br />
well as to Current Contribution of Imaging Technologies to Drug Development.<br />
We would like to take this opportunity to acknowledge the support of this year’s sponsors of the conference, especially<br />
recognizing the continued interest and support from DG Research of the European Commission. Moreover<br />
we would like to thank YOU for participating in this year’s EMIM and making it possible by your attendance. We<br />
hope you will enjoy the conference. If this is not your first time attending an EMIM conference then welcome back<br />
and we hope you will establish new contacts and continue to expand your network of scientific excellence. Please<br />
help first-time attendees to meet others and generally make people feel at home. Regardless whether this is your<br />
first time with us or not we will endeavour to have you come back again in the future.<br />
As in previous years our intention is that this high-level meeting will foster the coherence of a sustainable European<br />
Molecular Imaging Community with the common goal to translate fundamental research discoveries into medical<br />
application and health benefit for the European Society.<br />
Sincerely,<br />
The <strong>5th</strong> Andreas H. Jacobs, <strong>ESMI</strong> President<br />
Renata Mikołajczak, Local Organiser<br />
Clemens W.G.M. Löwik, <strong>ESMI</strong> Vice President<br />
Bertrand Tavitian, <strong>ESMI</strong> Past President<br />
Silvio Aime, <strong>ESMI</strong> Secretary<br />
European Molecular Imaging Meeting Executive Committee<br />
Simone Mergui, <strong>ESMI</strong> Treasurer<br />
imaging life
Dear Colleagues,<br />
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
it is a pleasure for me to welcome you to the 5 th European Molecular Imaging Meeting in Warszawa. With an impressive<br />
history of previous successful meetings, this time the European Society of Molecular Imaging decided<br />
in favour for Poland, the country belonging to East as well as to Central Europe.<br />
In some way this in-between-situation is also characteristic for the field of MI: the discipline MI is not defined by<br />
a profession, no one is automatically a MI professional. Molecular Imaging is multidisciplinary. This makes it on<br />
the one hand difficult: we have to define ourselves and the direction of our research; it forces us to look beyond<br />
our bench and own disciplines. On the other hand this is also the advantage of MI: it means at any time to be in<br />
process, be in cross-communication and stay open-minded.<br />
Me and my colleagues involved in the organisation of this meeting believe that it will strengthen Molecular Imaging<br />
research activities within Eastern and Central Europe, as well as between the various disciplines working<br />
in the broad field of MI.<br />
The efforts of the <strong>ESMI</strong> to provide a platform for exchange have started to lead into the formation of a European<br />
MI community. This is just the beginning of our common efforts and with our activities and willingness for<br />
cross-interaction we can further establish this development.<br />
We hope that the familiar arrangement of the meeting venue will create a friendly atmosphere and provide a<br />
maximum of opportunities for you to meet friends and exchange views. Enjoy the interesting scientific programme<br />
of invited talks, oral and poster presentations as well as the technical exhibition. I also want to say<br />
thanks to the companies who are supporting this meeting and the MI community; especially to those who come<br />
to Warszawa.<br />
Do not forget that Warszawa is a lively city, with a number of historical sites, museums and parks. We are also in<br />
the year of Chopin; you can find a lot of information about his music and places he used to live. Take some time<br />
to immerse yourself in the history of the city.<br />
On behalf of local organizing committee I wish your visit to Warszawa will be informative, interesting and enjoyable.<br />
Sincerely, Renata Mikołajczak, Local Organiser<br />
Dear Ladies and Gentlemen,<br />
It is my great pleasure to welcome you to the 5 th annual meeting of the European Society for Molecular Imaging.<br />
In my capacity as president of the European Society of Radiology I would like to thank the organisers of this important<br />
event that has been organised in close cooperation with the ESR for their kind invitation.<br />
It is an honour to be here today as the ESR has supported the creation of the European Society for Molecular Imaging<br />
from the very beginning and many ESR representatives have been and are still represented in this organisation.<br />
We are looking forward to enhancing the successful cooperation between the European Society for Molecular Imaging<br />
and the European Society of Radiology in the future.<br />
Realising the importance of molecular imaging, latest research discoveries in this field and possible translations<br />
into medical practice, I will reinforce the topic of molecular imaging within the European Society of Radiology during<br />
my presidency and make sure that the work of all ESR bodies is coordinated with a special focus on this issue.<br />
I would also like to take this opportunity to invite you all to attend ECR 2011 from March 3 to 7 in Vienna, Austria.<br />
The ESR would be most happy to welcome you at its annual meeting.<br />
I thank you for having taken the time to be with us in Warsaw this week and I wish you a most successful meeting.<br />
Sincerely, Professor Maximilian F. Reiser, ESR President<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
Welcome
10<br />
WarSaW, poland May 26 – 29, 2010<br />
Why Warsaw?<br />
Warsaw, the capital of Poland, a captivating city with<br />
a distinctive atmosphere and definitely worth visiting.<br />
Warsaw is a perfect embodiment of changes that<br />
have taken place in Poland in the past 20 years. It is a<br />
city of many faces - a contrasting blend of historical<br />
and socrealist buildings neighbouring post-modern<br />
skyscrapers, of cosy cafes and vibrant clubs, of historical<br />
Żoliborz and artistic Praga district, but most of all<br />
it is a thriving European capital. Whether you come<br />
to Warsaw on a business trip, for a conference, or as a<br />
tourist, Warsaw will definitely exceed your expectations.<br />
Novotel Warsawa Centrum<br />
Marszałkowska 94/98, 00-510 Warszawa<br />
Tel: +48 22 596 25 48 | Fax: +48 22 596 01 22<br />
The Novotel Warsawa Centrum hotel provides excellent<br />
conference facilities. Close to the iconic Palace of Culture<br />
and Science and 500 m from the railway station with a<br />
convenient connection to the airport. The plenary lectures<br />
will take place in ROZA and IRYS, the parallel sessions will<br />
take place in ROZA or IRYS. Visit the exhibition in LILIA,<br />
FREZJA as well as in the FOYER; and get in communication!<br />
The poster sessions will take place in PROMENADA. You are<br />
mostly welcome to view the posters also besides of the<br />
“official” poster sessions.<br />
Floor Plan / Exhibition<br />
1<br />
2<br />
3<br />
coffee break<br />
exhibition and coffee<br />
7 8 9<br />
exhibition and coffee<br />
14 16<br />
15<br />
13<br />
coffee<br />
12<br />
4<br />
5<br />
6<br />
internal meetings<br />
internal meetings<br />
imaging life<br />
11<br />
19<br />
10<br />
lectures<br />
exhibition space 3x2m<br />
20<br />
office<br />
17<br />
How to get there<br />
From OKECIE Airport, take bus route No.175 to Centrum. From<br />
Warszawa Centralna railway station take tram No.7, 8, 9, 22, 24<br />
or 25 to Centrum (one stop). Via the E30, E77 or E67 highways,<br />
head in the direction of Centrum. By metro, alight at Centrum.<br />
Airport : WARSZAWA OKECIE AIRPORT<br />
Railway Station : WARSZAWA CENTRALNA STATION<br />
The Gala dinner will take place on Friday May 28, 2010 at<br />
Zamojski Palace Warsaw 2, Foksal street. Zamojski Palace is<br />
within walking distance. Looking forward to meeting you there.<br />
Floor plan<br />
poster session<br />
lectures<br />
18<br />
1. GEHC<br />
2. ART<br />
3. BIOSCAN/PHILIPS<br />
4. ZINSSER ANALYTIC<br />
5. CaliperLS<br />
6. MR solutions<br />
7. Carestream<br />
8. BRUKER<br />
9. VISUALSONICS<br />
10. SIEMENS<br />
11. BIOSPACE LAB<br />
12. LOT-Oriel<br />
13. CT Imaging<br />
14. SEDECAL<br />
15. VisEn<br />
16. LI-COR<br />
17. SKYSCAN/MILabs<br />
18. Polatom<br />
19. information
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
This meeting would not have been possible without your support.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
THANK YOU!
WMIC 2010 Speakers<br />
Keynote Address by Shizuo Akira, MD, PhD<br />
Professor of Department of Host Defense, Research Institute for Microbial<br />
Diseases and Director of the WPI Immunology Frontier Research Center<br />
(WPI-IFReC), Osaka University<br />
Featured Plenary Speakers<br />
Kevin Brindle, PhD<br />
Professor, Dept of Biochemistry<br />
University of Cambridge<br />
Robert J. Gropler, MD<br />
Chief, Cardiovascular Imaging Center,<br />
Mallinckrodt Institute of Radiology<br />
Gregory Lanza, MD, PhD<br />
Professor of Medicine<br />
Div. of Cardiovascular Diseases<br />
Washington University School of Medicine<br />
Herman P. Spaink, PhD<br />
Professor of Molecular Cell Biology<br />
Leiden University<br />
Jun Takahashi, MD, PhD<br />
Associate Professor<br />
Center for iPS Cell Research and Application (iCeMS)<br />
Kyoto University, Japan<br />
September 8-11, 2010<br />
Kyoto, Japan<br />
Scientific Sessions<br />
Preliminary List. For full list, visit our website.<br />
In Vivo Studies<br />
* Clinical Studies<br />
* Translational Studies<br />
* Animal Models<br />
Imaging Instrumentation and Methodology<br />
* Hybrid & Multimodality Imaging<br />
* Magnetic Resonance Imaging<br />
* Optical and Opto-acoustic Imaging<br />
* PET/SPECT/CT Imaging<br />
* Ultrasonic Imaging & Drug Delivery<br />
Development/Novel Use of Imaging Probes<br />
* CT<br />
* MRI<br />
* Multi-modality<br />
* Optical and Photoacoustic<br />
* PET/SPECT<br />
* Ultrasound<br />
Imaging Disease/Organ Processes<br />
* Cancer<br />
* Cardiovascular System<br />
* Central Nervous System<br />
* Immune System<br />
Drug and/or Radiation Therapy<br />
* Image Guided Therapy<br />
* Monitoring Therapy<br />
* Novel Therapy Development<br />
REGISTER NOW<br />
September 8-11, 2010<br />
Kyoto, Japan<br />
www.WMICmeeting.org
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
Wednesday - 26 May 2010 Thursday - 27 May 2010 Friday - 28 May 2010 Saturday - 29 May 2010<br />
room ROZA IRYS ROZA IRYS ROZA IRYS ROZA IRYS<br />
08:00-09:00 Registration Registration<br />
09:00-10:00<br />
<strong>ESMI</strong> Plenary Lecture 1 by Violaine Sée<br />
(Liverpool, UK)<br />
<strong>ESMI</strong> Plenary Lecture 3 by Theodorus W.J.Gadella<br />
(Amsterdam, The Netherlands)<br />
10:00-10:30 Coffee break & Exhibition Coffee break & Exhibition<br />
10:30-12:00<br />
PS 1: Cancer I -<br />
together with ESR<br />
PS 2: Neuroscience I PS 5: Neuroscience II<br />
PS 6: Cardiovascular I -<br />
together with ESR<br />
<strong>ESMI</strong> Plenary Lecture 5 by Klaas Nicolay<br />
(Eindhoven, The Netherlands)<br />
PS 9: Cardiovascular II<br />
12:00-13:00 Lunch break & Exhibition Break<br />
13:00-14:30 PS 3: Technology<br />
14:30-16:00<br />
16:00-17:00<br />
17:00-18:00<br />
Registration<br />
18:00-19:30<br />
Open Ceremony and Inaugural Lecture by<br />
19:00<br />
Christopher H. Contag (Stanford, USA)<br />
19:30 Opening Reception and Exhibition<br />
PS 4: Probes I -<br />
together with COST<br />
PS 7: Probes II<br />
PS 8: Gene and Cell<br />
Based Therapies -<br />
together with CliniGene<br />
Guided Poster Session 1 with Coffee break Guided Poster Session 2 with Coffee break<br />
<strong>ESMI</strong> Plenary Lecture 2 by Francesca Odoardi<br />
(Goettingen, Germany)<br />
<strong>ESMI</strong> Plenary Session on Excellent, Late Breaking<br />
and YIA Abstracts<br />
Sightseeing Tour<br />
<strong>ESMI</strong> Plenary Lecture 4 by Hans-Jürgen Wester<br />
(Munich, Germany)<br />
<strong>ESMI</strong> Plenary Session on Current Contribution of<br />
Imaging Technologies to Drug Development<br />
<strong>ESMI</strong> Executive Committee meets Industry<br />
Gala Dinner at Zamojski Palace<br />
Warsaw 2, Foksal street<br />
Programme at a Glance<br />
PS 10: Cancer II -<br />
together with COST<br />
12:30-13:30<br />
<strong>ESMI</strong> Plenary Session and Closing Ceremony<br />
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010
WarSaW, poland May 26 – 29, 2010<br />
ROZA IRYS GERBERA<br />
09:00-12:00 Exhibitor’s set up<br />
14:00-18:00 Registration<br />
13:00-15:00<br />
15:00-17:00<br />
imaging life<br />
Posters set up<br />
Speaker’s documents set up<br />
18:00-19:30 Opening Ceremony and Inaugural Lecture<br />
Mariusz Klubczuk plays Chopin:<br />
Nocturne B flat Minor Op.9 No 1; Mazurka C Major Op.24 No 2<br />
Welcome – Andreas H. Jacobs (<strong>ESMI</strong> President)<br />
Welcome – Renata Mikolajczak (EMIM Local Organiser)<br />
Welcome – Andrzey Siemaszko (NCP in Poland for EU research)<br />
Welcome – Maximilian Reiser (ESR President)<br />
Announcement of <strong>ESMI</strong> Award 2010, John Clark (<strong>ESMI</strong> Award Winner 2009)<br />
Mariusz Klubczuk plays Chopin:<br />
Etude C sharp Minor Op. 25 No 7; Etude A Minor Op. 25 No 12<br />
Inaugural lecture by Christopher H. Contag (Stanford, USA)<br />
Point-of-Care Microscopy: Molecular Imaging with Cellular Resolution<br />
19:30-21:00 Opening Reception and Exhibition<br />
DiMI WP Meetings<br />
(Closed Meetings)<br />
<strong>ESMI</strong> Executive Committee<br />
(Closed Meeting)<br />
<strong>ESMI</strong> Council Meeting<br />
(Closed Meeting)<br />
ROZA IRYS GERBERA<br />
08:00-08:45 DiMI SMB (Closed Meeting)<br />
08:00-09:00 Registration<br />
09:00-10:00<br />
<strong>ESMI</strong> Plenary Lecture 1 by Violaine Sée (Liverpool, UK)<br />
Transcription factors dynamics: from discrete pulses to oscillatory pattern to control gene expression<br />
Co-Chairs: Clemens WGM Löwik (Leiden, The Netherlands), Leszek Krolicki (Warsaw, Poland)<br />
10:00-10:30 Coffee break & Exhibition<br />
10:30-12:00<br />
Parallel Session 1: Cancer I (together with ESR)<br />
Co-Chairs: Markus Schwaiger (Munich, Germany),<br />
Peter Brader (Vienna, Austria)<br />
10:30-10:45 Multimodal imaging approaches for cell-cell interaction<br />
Steffen Maßberg, (Munich, Germany)<br />
10:45-11:00 Molecular imaging for monitoring treatment with<br />
protein kinase inhibitors<br />
Wolfgang Weber (Freiburg, Germany)<br />
11:00-11:15 Potentials of imaging biomarkers inpatients<br />
Bernard Van Beers (Paris, France)<br />
11:15-11:30 YIA Applicant’s Presentation: Pre-clinical screening of anti - her2<br />
nanobodies for molecular imaging of breast cancer<br />
Ilse Vaneycken (Brussels, Belgium)<br />
11:30-11:45 YIA Applicant’s Presentation: [18f]-fdg/[18f]-flt-pet and<br />
bioluminescence imaging of therapy response in b-cell lymphoma<br />
mice treated with cytotoxic and antiproliferative agents,<br />
Marijke De Saint-Hubert (Leuven, Belgium)<br />
11:45-12:00 tf-pimonidazole: an hypoxia marker suitable for in vivo 19f mrs<br />
imaging<br />
Arend Heerschap (Nijmegen, The Netherlands)<br />
12:00-13:00 Lunch break<br />
Day 0 - Wednesday May 26, 2010<br />
Day 1 - Thursday May 27, 2010<br />
YIA Selection Committee<br />
(Closed Meeting)<br />
Parallel Session 2: Neuroscience I<br />
Co-Chairs: Annemie van der Linden (Antwerp, Belgium),<br />
David Wyper (Glasgow, UK), Hervé Boutin (Manchester, UK)<br />
[11C](R)-PK11195- a tricky tracer. Do we really need it to image<br />
microglial activation?<br />
Alex Gerhard (Manchester, UK)<br />
YIA Applicant’s Presentation: Preclinical imaging of the type 1<br />
cannabinoid receptor in neurodegenerative diseases<br />
Cindy Casteels (Leuven, Belgium)<br />
YIA Applicant’s Presentation: Longitudinal non-invasive detection of<br />
amyloid plaques by combined molecular, functional and morphological<br />
imaging in transgenic mouse models of alzheimers disease,<br />
Florian C. Maier (Tübingen, Germany)<br />
Serotonergic neurotransmission in early Alzheimer’s disease,<br />
Steen G. Hasselbalch (Copenhagen, Denmark)<br />
Qualitative and quantitative assessment of florbetapir f-18 pet (18fav45)<br />
amyloid deposition PET imaging - validation by pathology.<br />
preliminary report<br />
Grzegorz Romanowicz (Gdańsk, Poland)<br />
YIA Applicant’s Presentation: In-vivo imaging of a mouse traumatic<br />
brain injury model using dual-isotope quantitative SPECT/CT<br />
Domokos Máthé (Budapest, Hungary)<br />
TOPIM2011 committee<br />
(Closed meeting)
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Parallel Session 3: Technology<br />
13:00-14:30 Co-Chairs: Jorge Ripoll (Heraklion, Greece),<br />
Markus Rudin (Zürich, Switzerland)<br />
13:00-13:15 Molecular analysis of adaptive immune function through<br />
microscopic and mesoscopic imaging<br />
Jens Stein (Bern, Switzerland)<br />
13:15-13:30 Magnetic resonance imaging – from structure to molecular interactions<br />
Markus Rudin (Zürich, Switzerland)<br />
13:30-13:45 Imaging modalities: PET/SPECT<br />
Sibylle Ziegler (Munich, Germany)<br />
13:45-14:00 In vivo fluorescence kinetic imaging for improved contrast and<br />
studies of temporal and quantitative biodistribution<br />
James Mansfield (Cambridge, UK)<br />
14:00-14:15 Cerenkov radiation imaging of a xenograft murine model of<br />
mammary carcinoma<br />
Federico Boschi (Verona, Italy)<br />
14:15-14:30 A system for 4d (3d+kinetics) molecular imaging in<br />
bioluminescence and fluorescence<br />
Serge Maitrejean (Paris, France)<br />
14:30-16:00<br />
16:00-17:00<br />
17:00-18:00<br />
ROZA IRYS GERBERA<br />
Parallel Session 4: Probes I (together with COST action D38)<br />
Co-Chairs: Eva Jakab-Tóth (Orléans, France),<br />
Silvio Aime (Torino, Italy)<br />
The alignment of target-specific lipoCEST MRI contrast agents<br />
Sander Langereis (Eindhoven, The Netherlands)<br />
Lanthanide-based in vivo luminescence imaging<br />
Stephane Petoud (Orléans, France and Pittsburgh, US)<br />
New perspectives for imaging molecules and metabolism in vivo<br />
Rolf Gruetter (Lausanne, Switzerland)<br />
YIA Applicant’s Presentation: In vivo biodistribution of radiolabeled<br />
matrix metalloproteinase-2 activatable cell penetrating peptides<br />
Sander Van Duijnhoven (Eindhoven, The Netherlands)<br />
YIA Applicant’s Presentation: Bioresponsive mri contrast agents<br />
based on self-assembling beta-cyclodextrin nanocapsules<br />
Jonathan Martinelli (Alessandria, Italy)<br />
Photochemical activation of endosomal escape of MRI-gd-agents in<br />
tumor cells<br />
Eliana Gianolio (Torino, Italy)<br />
Guided Poster Session 1 with Coffee break (see page 110)<br />
Poster Walk 1: Imaging Cancer Biology (P001-P012) & (P105-P106)<br />
Co-Chairs: Fabian Kiessling (Aachen, Germany), Markus Rudin (Zürich, Switzerland)<br />
Poster Walk 2: Technology & Data Analysis Methods (P070-P078) & (P097-P104)<br />
Co-Chairs: Serge Maitrejean (Paris, France), Adriaan Lammertsma (Amsterdam, The Netherlands)<br />
Poster Walk 3: Molecular Neuroimaging (P034-P047) & (P107)<br />
Co-Chairs: Sabina Pappata (Naples, Italy), Andreas H. Jacobs (Münster, Germany)<br />
Poster Walk 4: Probe Design (P058-P069)<br />
Co-Chairs: Frédéric Dollé (Orsay, France), Helmut Maecke (Freiburg, Germany)<br />
<strong>ESMI</strong> Plenary Lecture 2 by Francesca Odoardi (Göttingen, Germany)<br />
Immune surveillance and autoimmunity: how encephalitogenic T cells enter their target organ<br />
Co-Chairs: Renata Mikolajczak (Warsaw, Poland), Chrit Moonen (Bordeaux, France)<br />
Plenary Session on Excellent, Late Breaking, and Young Investigator Award Abstracts<br />
Co-Chairs: Renata Mikolajczak (Warsaw, Poland), Chrit Moonen (Bordeaux, France)<br />
17:00-17:10 Exendin-4 derivatives labeled with radiometals for the detection of insulinoma: a “from bench to bed approach”<br />
Damian Wild (Freiburg, Germany)<br />
17:10-17:20 YIA Applicant’s Presentation:<br />
Assessment of hif transcriptional activity in a mouse tumor model using gpi anchored avidin-<br />
a novel protein reporter for in vivo imaging<br />
Steffi Lehmann (Zürich, Switzerland)<br />
17:20-17:30 YIA Applicant’s Presentation:<br />
A leukocyte ligand of vascular adhesion protein-1 as an imaging tool in PET<br />
Anu Autio (Turku, Finland)<br />
17:30-17:40 YIA Applicant’s Presentation:<br />
Clinical translation of ex vivo sentinel lymph node mapping for colorectal cancer using invisible near-infrared fluorescence light<br />
Merlijn Huttemann (Leiden, The Netherlands)<br />
17:40-17:50 YIA Applicant’s Presentation:<br />
Development of strategies for in vivo MRI and optical imaging of neural stem cells distribution for the treatment of traumatic<br />
spinal cord injury<br />
Ramona Lui (Milano, Italy)<br />
17:50-18:00 Validation of bone marrow-derived stromal cell graft position by colocalisation of histology,<br />
bioluminescence and magnetic resonance imaging<br />
Nathalie de Vocht (Antwerp, Belgium)<br />
18:15-18:45<br />
19:00-20:00<br />
DiMI General Assembly<br />
(Closed Meeting)<br />
DiMI WP Meeting<br />
(Closed Meeting)<br />
DiMI WP Meeting<br />
(Closed Meeting)<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong>
08:00-08:45<br />
WarSaW, poland May 26 – 29, 2010<br />
imaging life<br />
ROZA IRYS GERBERA<br />
DiMI WP Meeting<br />
(Closed Meeting)<br />
08:00-09:00 Registration<br />
09:00-10:00<br />
<strong>ESMI</strong> Plenary Lecture 3 by Theodorus W.J. Gadella Jr. (Amsterdam, Netherlands)<br />
New probe-based strategies for quantitative microscopy of signaling dynamics in single cells<br />
Co-Chairs: Vasilis Nziachristos (Munich, Germany), Bengt Långström (Uppsala, Sweden)<br />
10:00-10:30 Coffee break & Exhibition<br />
10:30-12:00<br />
Parallel Session 5: Neuroscience II<br />
Co-Chairs: Markus Rudin (Zürich, Switzerland),<br />
Veerle Baekelandt (Leuven, Belgium),<br />
Mathias Hoehn (Cologne, Germany)<br />
10:30-10:45 Potential to use transgenic animals for imaging of neurological<br />
diseases<br />
Ludwig Aigner (Salzburg, Austria)<br />
10:45-11:00 Specific cell labeling with imaging reporters in vivo by viral vectors:<br />
the challenges<br />
Veerle Baekelandt (Leuven, Belgium)<br />
11:00-11:15 YIA Applicant’s Presentation: Optimization of an MRI method to<br />
measure microvessel density: application to monitor<br />
angiogenesis after stroke<br />
Philipp Boehm-Sturm (Cologne, Germany)<br />
11:15-11:30 MRI study of intra-arterial bone marrow-derived macrophage<br />
administration after acute focal ischemic stroke in rats<br />
Adrien Riou (Lyon, France)<br />
11:30-11:45 YIA Applicant’s Presentation: Inactivated paramagnetic tissue<br />
plasminogen activator predicts thrombolysis<br />
outcome following stroke<br />
Maxime Gauberti (Caen, France)<br />
11:45-12:00 Matrix metalloproteinase-9 – a possible therapeutic target<br />
in intractable epilepsy<br />
Grzegorz Wilczynski (Warsaw, Poland)<br />
12:00-13:00 Lunch Break<br />
13:00-14:30<br />
Parallel Session 7: Probes II<br />
(together with EANM)<br />
Co-Chairs: Frédéric Dollé (Orsay, France) ,<br />
Denis Guilloteau (Tours, France)<br />
13:00-13:15 Application of microfluidics to the ultra-rapid preparation of<br />
fluorine-18 and carbon-11 labelled compounds<br />
Philip Miller (London, UK)<br />
13:15-13:30 Radioligand for in vivo measuring neurotransmitters release,<br />
Christer Halldin (Stockholm, Sweden)<br />
13:30-13:45 18F-tracers for Amyloid plaques<br />
Denis Guilloteau (Tours, France)<br />
13:45-14:00 YIA Applicant’s Presentation: Chelators for radiocopper: biological/<br />
pharmacokinetic differences of [tyr3,thr8]octreotide conjugates,<br />
Abiraj Keelara (Basel, Switzerland)<br />
14:00-14:15 [11c]SOMADAM: potential sert ligand for PET studies<br />
and comparison with [11c]MADAM<br />
Fabienne Gourand (Caen, France)<br />
14:15-14:30 MR imaging of extracellular redox by a thiolsensitive<br />
gd(iii)-do3a derivative<br />
Giuseppe Digilio (Torino, Italy)<br />
Day 2 - Friday May 28, 2010<br />
<strong>ESMI</strong> Exec. Com. & <strong>ESMI</strong> Council<br />
Meeting (Closed Meeting)<br />
together with Treasurer<br />
Parallel Session 6: Cardiovascular I (together with ESR)<br />
Co-Chairs: Tony Lahoutte (Mons, Belgium),<br />
Nicolas Grenier (Bordeaux, France)<br />
Potentials of new contrast agents for vascular molecular imaging in<br />
patients<br />
Philippe Douek (Lyon, France)<br />
Protease specific nanosensors in atherosclerosis<br />
Eyk Schellenberger (Berlin, Germany)<br />
YIA Applicant’s Presentation: Imaging of inflamed carotid artery<br />
atherosclerotic plaques with the use of 99mtc-hynic-il-2 scintigraphy<br />
in the end-stage renal disease patients<br />
Marta Opalinska (Krakow, Poland)<br />
Uptake of 68ga-chloride in atherosclerotic plaques of ldlr-/apob100/100mice<br />
Johanna Silvola (Turku, Finland)<br />
YIA Applicant’s Presentation: Hybrid imaging using dual energy µct<br />
and fmt for characterization of atherosclerotic<br />
plaques in apoe -/- mice<br />
Felix Gremse (Aachen, Germany)<br />
YIA Applicant’s Presentation: Long circulating emulsion<br />
based CT contrast agents<br />
Anke De Vries (Eindhoven, The Netherlands)<br />
<strong>ESMI</strong> Training Committee<br />
(Closed Meeting)<br />
Parallel Session 8: Gene and Cell Based Therapies<br />
(together with Clinigene)<br />
Co-Chairs: Ludwig Aigner (Salzburg, Austria),<br />
Cornel Fraefel (Zürich, Switzerland)<br />
Everything but not cell replacement with neural<br />
stem cell transplants<br />
Stefano Pluchino (Milano, Italy)<br />
Mesenchymal Stem Cell Transplantation: An Option to Promote<br />
Remyelination? Ludwig Aigner (Salzburg, Austria)<br />
Viral vector-mediated transcriptional targeting of dendritic cells for<br />
antigen-specific tolerance induction in EAE/MS<br />
Christiane Dresch (Zürich, Switzerland)<br />
Delivery of a bioluminescent transgene to a tumor via bone marrow<br />
engraftment and local control of gene<br />
expression by non invasive local hyperthermia<br />
Pierre-Yves Fortin (Bordeaux, France)<br />
YIA Applicant’s Presentation: Dendritic cell labelling with<br />
paramagnetic nanoparticles and 111in-oxine for in vivo magnetic<br />
resonance imagingand scintigraphic imaging<br />
Cristina Martelli (Milan, Italy)<br />
YIA Applicant’s Presentation: The type 2 cannabinoid receptor<br />
as a new PET reporter gene for the brain<br />
Caroline Vandeputte (Leuven, Belgium)
14:30-16:00<br />
16:00-17:00<br />
17:00-18:00<br />
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
ROZA IRYS GERBERA<br />
Guided Poster Session 2 with Coffee break (see page 110)<br />
Poster Walk 5: Imaging in Cancer & Drug Development (P013-P030)<br />
Co-Chairs: Peter Brader (Graz, Austria), Nicolas Grenier (Bordeaux, France)<br />
Poster Walk 6: Imaging in Other Diseases (P031-P033) & (P079-P091)<br />
Co-Chairs: Bertrand Tavitian (Orsay, France), John Clark (Edingburgh, UK)<br />
Poster Walk 7: Imaging-guided Gene and Cell based and Targeted Therapies (P048-P057) & (P092-P096)<br />
Co-Chairs: Ludwig Aigner (Salzburg, Austria), Adriana Maggi (Milano, Italy)<br />
<strong>ESMI</strong> Plenary Lecture 4 by Hans-Jürgen Wester (Munich, Germany)<br />
Molecular Imaging of CXCR4 Receptors<br />
Co-Chairs: Adriana Maggi (Milano, Italy), Adriaan Lammertsma (Amsterdam, The Netherlands)<br />
Plenary Session on Current Contribution of Imaging Technologies to Drug Development<br />
Co-Chairs: Adriana Maggi (Milano, Italy), Adriaan Lammertsma (Amsterdam, The Netherlands)<br />
17:00-17:15 Evaluation of the temporal window for drug delivery following ultrasound mediated membrane permeability enhancement<br />
Matthieu Lepetit-Coiffe (Bordeaux, France)<br />
17:15-17:30 Integrisense: a novel near-infrared fluorescent probe for a v b 3 integrin and its applications in drug discovery<br />
Cyrille Sur, Merck Research Laboratories (Westpoint, USA)<br />
17:30-17:45 Harnessing the power of bioluminescence to cross the in vitro–in vivo divide<br />
John Watson, PROMEGA (Madison, Wisconsin, USA)<br />
17:45-18:00 In vivo imaging in drug discovery: the example of application in the development of novel estrogenic compounds<br />
Andrea Biserni, TOP Srl (Milano, Italy)<br />
18:00-19:00<br />
19:30 Gala Dinner at Zamojski Palace<br />
08:00-08:45 <strong>ESMI</strong> General Assembly (Closed Meeting)<br />
09:00-10:00<br />
<strong>ESMI</strong> Executive Committee<br />
meets Industry<br />
(Closed Meeting)<br />
ROZA IRYS GERBERA<br />
<strong>ESMI</strong> Plenary Lecture 5 by Klaas Nicolay (Eindhoven, The Netherlands)<br />
Multi-modality molecular imaging of atherosclerosis, usingtargeted contrast agents<br />
Co-Chairs: Uwe Haberkorn (Heidelberg, Germany), Helmut Maecke (Freiburg, Germany)<br />
10:00-10:30 Coffee break & Exhibition YIA Selection Committee<br />
10:30-12:00<br />
Parallel Session 9: Cardiovascular II<br />
Co-Chairs: Klaas Nicolay (Eindhoven, The Netherlands),<br />
Michael Schäfers (Münster, Germany)<br />
10:30-10:45 Advances in contrast-enhanced MRI of the mouse heart<br />
Gustav Strijkers (Eindhoven, The Netherlands)<br />
10:45-11:00 Molecular imaging of α v β 3 integrin expression with 18F-galacto-<br />
RGD after experimental myocardial infarction: comparison with left<br />
ventricular remodeling and function<br />
Antti Saraste (Turku, Finland/Munich, Germany)<br />
11:00-11:15 Existing and emerging animal models mimicking cardiovascular<br />
disease and their relevance for molecular imaging<br />
Michael Schäfers (Münster, Germany)<br />
11:15-11:30 Imaging of matrix metalloproteinase activity in vulnerable human<br />
carotid plaques with multispectral optoacoustic tomography<br />
Daniel Razansky (Munich, Germany)<br />
11:30-11:45 C-jun n-terminal kinase promotes inflammation at atherosclerosisprone<br />
sites by enhancing expression and activity<br />
of nf-κb transcription factor<br />
Paul Evans (London, UK)<br />
11:45-12:00 YIA Applicant’s Presentation: Absolute quantification in small<br />
animal pinhole gated myocardial perfusion SPECT<br />
Lode Goethals (Brussels, Belgium)<br />
Parallel Session 10: Cancer II(with COST action BM0607)<br />
Co-Chairs: Marion de Jong (Rotterdam, The Netherlands),<br />
Fabian Kiessling (Aachen, Germany)<br />
Cancer Imaging<br />
Uwe Haberkorn (Heidelberg, Germany)<br />
Controlled Drug Delivery under Image guidance<br />
Holger Grüll (Eindhoven, The Netherlands)<br />
Targeted radionuclide imaging and therapy (COST Action BM0607),<br />
Marion de Jong (Rotterdam, The Netherlands)<br />
Targeting cancer stem cells using radiolabeled sonic hedgehog,<br />
Izabela Tworowska (Houston, USA)<br />
YIA Applicant’s Presentation: Evaluation of the photosensitizer<br />
bremachlorin for photodynamic treatment of<br />
breast cancer bone metastasis<br />
Pieter Van Driel (Leiden, The Netherlands)<br />
In vivo targeting of hek-hsst2/3/5 xenografts by 111in-labeled<br />
[(dota)ser1,leu8,trp22,tyr25]-ss-28 in scid mice<br />
Theodosia Maina (Athens, Greece)<br />
12:00-12:30 Break YIA Selection Committee<br />
12:30-13:30<br />
<strong>ESMI</strong> Plenary Session and Closing Ceremony and Young Investigator Award Presentations<br />
Young Investigator Awards & Poster Awards Ceremony<br />
Co-Chairs: John Clark (Edinburgh, UK), Bertrand Tavitian (Orsay, France)<br />
Day 3 - Saturday May 29, 2010<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong>
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Do not forget:<br />
Join the next <strong>ESMI</strong> Winter Conference – TOPIM2011:<br />
further information/pre-registration<br />
send mail to office@ e-smi.eu<br />
WWW.E-SMI.Eu<br />
HOT TOPIC 2011: Emerging image-guided methods in Medicine<br />
Jan. 16-21, 2011 in Les Houches, France &<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
MY NOTES fl
20<br />
WarSaW, poland May 26 – 29, 2010<br />
Dr. Contag is an Associate Professor of Pediatrics in the Division of Neonatal and Developmental Medicine,<br />
and a member of the BioX faculty at Stanford University. He is the Director of the Stanford Infrared Optical<br />
Science and Photomedicine Program, director of Stanford’s Center for Innovation in In Vivo Imaging (SCI3)<br />
and co-director of the Molecular Imaging Program at Stanford (MIPS). Dr. Contag received his B.S. in<br />
Biology from the University of Minnesota, St. Paul in 1982; and earned his Ph.D. in Microbiology from the<br />
University of Minnesota, Minneapolis in 1988. He was a postdoctoral fellow at Stanford University from<br />
1990-1994, and joined the faculty in Pediatrics at Stanford in 1995 with a joint appointment in Microbiology<br />
and Immunology and a courtesy appointment in Radiology.<br />
Dr. Contag is a pioneer in the emerging field of molecular imaging and is developing imaging approaches<br />
aimed at revealing molecular processes in living subjects and advancing therapeutic strategies through<br />
imaging. His laboratory develops macroscopic and microscopic optical imaging tools and uses imaging to<br />
assess tissue responses to stress, reveal immune cell migration patterns, understand stem cell biology and<br />
advance biological therapies. He is a founding member, and a past president, of the Society for Molecular<br />
Imaging, and for his fundamental contributions in imaging, is a recipient of the Achievement Award from<br />
the Society for Molecular Imaging. Dr. Contag is a scientific founder of Xenogen Corp. – now Caliper<br />
LifeSciences. He is also a founder of ConcentRx Corp.<br />
Selected References<br />
• Cao, Y-A, Stevenson, DKS, Weissman, I, Contag, CH. 2008. Heme Oxygenase-1 Deficiency leads to disrupted response<br />
to acute stress in stem cells and progenitors. Blood. 112: 4494-4502<br />
• Banaszynski, LA, Sellmyer, MA, Thorne, SH, Contag, CH, Wandless, TJ. 2008. Chemical control of protein stability and<br />
function in living mice. Nature Med. 14 (10):1123-7.<br />
• Wender, PA, Goun, EA, Jones, LR, Pillow, TH, Rothbard, JB, Shinde, R, Contag, CH. 2007. Real-time analysis of uptake<br />
and bioactivatable cleavage of luciferin-transporter conjugates in transgenic reporter mice. Proc Nat Acad Sci, USA.<br />
104(25):10340-5.<br />
• Thorne SH, Negrin, RS, Contag, CH. 2006. Synergistic antitumor effects of immune cell-viral biotherapy. Science. 311:1780-1784.<br />
• Cao, Y-A, Wagers, A, Beilhack, A, Dusich, J, Bachmann, MH, Negrin, RS, Weissman, IL, Contag, CH. 2004. Shifting foci of<br />
hematopoeisis during reconstitution from single stem cells. Proc. Natl. Acad. Sci. USA. 101(1):221-226.<br />
• Hardy, JK, Chu, P, Gibbs, K, Contag, CH. 2004. Extracellular replication of Listeria monocytogenes in the gall bladder.<br />
Science. 303(5659): 851-853<br />
• Contag, CH and Bachmann, MH. 2004. The writing is on the vessel wall. Nature. 429:618-620.<br />
• Shachaf, CM, Kopelman, A, Arvanitis, C, Beer, S, Mandl, S, Bachmann, MH, Borowsky, AD, Ruebner, B, Cardiff, RD, Yang,<br />
Q, Bishop, JM, Contag, CH and Felsher, DW. 2004. MYC inactivation uncovers stem cell properties and induces the state<br />
of tumor dormancy in hepatocellular cancer. Nature, 431:1112-1117.<br />
• Contag, PR, Olomu, IN, Stevenson, DK, Contag, CH. 1998. Bioluminescent indicators in living mammals. Nature Med.<br />
4(2):245-247.<br />
imaging life<br />
Christopher H. Contag
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Point-of-Care Microscopy: Molecular Imaging with Cellular Resolution<br />
Contag C.H. .<br />
Division of Neonatal and Developmental Medicine, and a member of the BioX faculty at Stanford University.<br />
ccontag@stanford.edu<br />
Micro-optical designs are enabling the development<br />
of miniaturized microscopes that can reach inside<br />
the body to interrogate disease states microscopically.<br />
This is leading to an emerging field of in vivo<br />
pathology that is changing the diagnostic paradigm<br />
from biopsy<br />
and conventional<br />
histopathology to<br />
one of point-ofcare<br />
histopathology<br />
coupled with telepathology.<br />
These<br />
advances are closing<br />
the gap between<br />
micro–mirror<br />
the patient and the<br />
pathologist and<br />
have the potential of accelerating diagnosis and<br />
guiding therapy. While recent advances in this<br />
field have been significant, many issues must be<br />
resolved before this clinical transformation may be<br />
fully realized. There are technological and translational<br />
advances that are driving this field and are<br />
leading towards in vivo microscopy becoming a standard<br />
clinical tool. By removing the spatiotemporal<br />
separation between the pathologist and patient, we<br />
can accelerate clinical diagnosis and advance clinical<br />
care for patients with a wide variety of diseases.<br />
References<br />
1. Liu, JTC, Mandella, MJ, Loewke, NO, Haeberle, H, Ra, H,<br />
Piyawattanametha, W, Solgaard, O, Kino, GS, Contag,<br />
CH (2010) Micromirror-scanned dual-axis confocal<br />
microscope utilizing a gradient-index relay lens for<br />
image guidance during brain surgery. JBO. In Press.<br />
2. Piyawattabanetha, W, Ra, H, Mandella, MJ, Loewke,<br />
Wang, TD, Kino, GS, Solgaard, O, Contag, CH (2009) 3-D<br />
near-infrared fluorescence imaging using a MEMSbased<br />
miniatuire dual axis confocal microscope. IEEE J.<br />
Sel. Topics Quantum Electronics. 15(5): 1344-1350.<br />
3. Mackanos, MA, Hargrove, J, Wolters, R, Du, CB,<br />
Friedland, S, Soetikno, RM, Contag, CH, Arroyo, MR,<br />
Crawford, JM, Wang, TD (2009) Use of an endoscopecompatible<br />
probe to detect colonic dysplasia with<br />
Fourier transform infrared spectroscopy. J Biomed<br />
Optics 14, 044006. PMID: 19725718<br />
4. Liu, JT, Mandella, MJ, Crawford, JM, Contag, CH, Wang,<br />
TD, Kino, GS. (2008) Efficient rejection of scattered light<br />
enables deep optical sectioning in turbid media with<br />
low-numerical-aperture optics in a dual-axis confocal<br />
architecture. J Biomed Opt. 13(3):034020.<br />
5. Hsiung, P-L, Hardy, JW, Friedland, S, Soetikno, R, Du, CB,<br />
Wu, APW, Sahbaie, P, Crawford, JM, Lowe, AW, Contag,<br />
CH, Wang, TD. (2008) Detection of colonic dysplasia in<br />
vivo using a targeted fluorescent septapeptide and<br />
confocal microendoscopy. Nat. Med. 14(4): 454-8.<br />
6. Wang, TD, Triadafilopoulos, G, Crawford, JM, Dixon, LR,<br />
Bhandari, T, Sahbaie, P, Friedland, S, Soetikno, R, Contag,<br />
CH. (2007) Detection of Endogenous Biomolecules<br />
in Barrett’s Esophagus by Fourier Transform Infrared<br />
Spectroscopy. Proc. Natl. Sci, USA. 104(40): 15864-9.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
day0<br />
Inaugural Lecture by Christopher H. Contag
DAY<br />
1
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
• <strong>ESMI</strong> Plenary Lecture 1: Violaine Sée (Liverpool, UK)<br />
Transcription factors dynamics: from discrete pulses to oscillatory pattern to control gene expression<br />
Chairs: Clemens W.G.M. Löwik (Leiden, The Netherlands) , Leszek Krolicki (Warsaw, Poland)<br />
• Parallel Session 1: Cancer I – together with ESR<br />
Chairs: Markus Schwaiger (Munich, Germany), Peter Brader (Vienna, Austria)<br />
• Parallel Session 2: Neuroscience I<br />
Chairs: Annemie van der Linden (Antwerp, Belgium), David Wyper (Glasgow, UK),<br />
Hervé Boutin (Manchester, UK)<br />
• Parallel Session 3: Technology<br />
Chairs: Jorge Ripoll (Heraklion, Greece) , Bernd Pichler (Tuebingen, Germany)<br />
• Parallel Session 4: Probes I – together with COST<br />
Chairs: Eva Jakab-Tóth (Orléans, France) , Silvio Aime (Torino, Italy)<br />
• <strong>ESMI</strong> Plenary Lecture 2: Francesca Odoardi (Göttingen, Germany)<br />
Immune surveillance and autoimmunity: how encephalitogenic T cells enter their target organ<br />
Chairs: Renata Mikolajczak (Warsaw, Poland), Chrit Moonen (Bordeaux, France)<br />
• Plenary Session on Excellent and Late Breaking Abstracts<br />
Chairs: Renata Mikolajczak (Warsaw, Poland), Chrit Moonen (Bordeaux, France)<br />
Day 1 - Thursday May 27, 2010<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
day1<br />
Day 1 - Thursday May 27, 2010
24<br />
WarSaW, poland May 26 – 29, 2010<br />
Violaine Sée is a BBSRC David Phillips Research Fellow at the University of Liverpool. She graduated in<br />
Chemistry and Molecular and Cellular Biology at the University Louis Pasteur in Strasbourg (France). After a<br />
Master in Pharmacology, in 2001 she obtained her PhD in Pharmacology and Neurobiology at the University<br />
Louis Pasteur. She was then assistant lecturer and subsequently moved to the University of Liverpool as a<br />
Post-doctoral Research Fellow. In 2005, she obtained a prestigious David Phillips Fellowship, to develop<br />
her work on intracellular signalling dynamics. She is focusing on the imaging of single living cells in order<br />
to understand regulation of gene transcription and cell fate. She has recently been interested in using new<br />
techniques for single molecule imaging in live cells based on the use of gold nanoparticles.<br />
Selected References<br />
• Nelson, D. E., Ihekwaba, A. E., Elliott, M., Johnson, J. R., Gibney, C. A., Foreman, B. E., Nelson, G., See, V., Horton, C. A.,<br />
Spiller, D. G., Edwards, S. W., McDowell, H. P., Unitt, J. F., Sullivan, E., Grimley, R., Benson, N., Broomhead, D., Kell, D. B.,<br />
and White, M. R. (2004) Oscillations in NF-kappaB signaling control the dynamics of gene expression. Science 306,<br />
704-708<br />
• See, V., Rajala, N. K., Spiller, D. G., and White, M. R. (2004) Calcium-dependent regulation of the cell cycle via a novel<br />
MAPK--NF-kappaB pathway in Swiss 3T3 cells. The Journal of cell biology 166, 661-672<br />
• Nelson, D. E., See, V., Nelson, G., and White, M. R. (2004) Oscillations in transcription factor dynamics: a new way to<br />
control gene expression. Biochemical Society transactions 32, 1090-1092<br />
• Ashall, L., Horton, C. A., Nelson, D. E., Paszek, P., Harper, C. V., Sillitoe, K., Ryan, S., Spiller, D. G., Unitt, J. F., Broomhead, D.<br />
S., Kell, D. B., Rand, D. A., See, V., and White, M. R. (2009) Pulsatile stimulation determines timing and specificity of NFkappaB-dependent<br />
transcription. Science 324, 242-246<br />
• See, V., Free, P., Cesbron, Y., Nativo, P., Shaheen, U., Rigden, D. J., Spiller, D. G., Fernig, D. G., White, M. R., Prior, I. A., Brust,<br />
M., Lounis, B., and Levy, R. (2009) Cathepsin L digestion of nanobioconjugates upon endocytosis. ACS nano 3, 2461-<br />
2468<br />
• Meley, D., Spiller, D.G., White, M.R., McDowell, H., Pizer, B.L., and See, V. (2010) p53-mediated delayed NF-kB activity<br />
enhances etoposide-induced cell death in medulloblastoma. Cell Death and Disease 1, In press<br />
imaging life<br />
Violaine Sée
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Transcription factors dynamics: from discrete pulses to oscillatory pattern to control gene<br />
expression<br />
Sée V.<br />
Centre for Cell Imaging, University of Liverpool<br />
violaine@liverpool.ac.uk<br />
At a given time-point, cells in a population are<br />
heterogeneous in their functions and fate and it is<br />
therefore vital to develop and apply methods that<br />
allow the measurement of dynamic molecular processes<br />
in single cells. We have shown, using single<br />
cell imaging, the critical role of nucleo-cytoplasmic<br />
localisation oscillations of the NF-κB transcription<br />
factor to control downstream pattern of gene transcription<br />
(Nelson et al, Science 2004; Ashall et al,<br />
Science 2009). NF-κB regulates cellular stress and<br />
immune responses to infection. In most cases, oscillations<br />
had previously been masked in population<br />
level studies by cellular heterogeneity. We developed<br />
a protocol based on cell treatment by repeated short<br />
pulses of TNFα at various intervals to mimic pulsatile<br />
inflammatory signals. This allowed obtaining<br />
synchronous cycles of NF-κB nuclear translocation.<br />
We have also observed cell to cell heterogeneity in<br />
other signalling systems such as in cellular response<br />
to low oxygen environment (hypoxia). In both inflammatory<br />
and hypoxic signalling systems one<br />
source of heterogeneity is due to the presence of extrinsic<br />
dynamic processes that are functionally coupled<br />
and that are occurring over different time scales.<br />
We identified the cell cycle as one source of variability<br />
as cells must coordinate and prioritise their<br />
response to the environment depending on their<br />
cell cycle status. We apply mathematical modelling<br />
using the quantitative data generated by imaging<br />
experiments to predict the role of the negative feedback,<br />
to unravel new network motifs and to characterise<br />
the cross-talk between the signalling systems.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
day1<br />
<strong>ESMI</strong> Plenary Lecture 1 by Violaine Sée
26 Cell-cell<br />
WarSaW, poland May 26 – 29, 2010<br />
Multimodal imaging approaches for cell-cell interaction<br />
Massberg S.<br />
Deutsches Herzzentrum München, Technische Universität München<br />
massberg@idi.harvard.edu<br />
interactions play a pivotal role in the control<br />
of critical cellular functions, such as cell adhesion,<br />
cell migration as well as cell differentiation and<br />
proliferation. The scientific focus of our lab is on<br />
the mechanisms that regulate cell-cell interactions<br />
during scenarios, such as arterial or venous thrombosis,<br />
stem cell homing and differentiation, during<br />
inflammation as well as in cancer development and<br />
progression. To evaluate the interaction between<br />
different cell subsets in their physiological (micro-)<br />
environment, we have established novel imaging approaches<br />
that allow dissecting all the steps involved<br />
both in reductionist in vitro assays and in vivo.<br />
imaging life<br />
This includes the used of gene-targeted mice, in<br />
which distinct cellular lineages are genetically<br />
marked in combination with innovative imaging<br />
techniques, including intravital multi-photon microscopy.<br />
The in vivo approaches are complemented<br />
by sophisticated in vitro assays allowing investigation<br />
of cell-cell interactions on a subcellular and<br />
molecular level. The multimodal imaging approaches<br />
will contribute to a better understanding of the<br />
molecular mechanisms and the kinetic aspects of<br />
the dynamic process of cell-cell interactions under<br />
physiological conditions and in the disease states.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Molecular imaging for monitoring treatment with protein kinase inhibitors<br />
Weber W.<br />
University Freiburg, Germany<br />
wolfgang.weber@uniklinik-freiburg.de<br />
Targeted drugs that modulate the function of specific<br />
molecules in diseased tissues hold great promise for<br />
the treatment of many diseases including malignant<br />
tumors. However, there are several challenges for<br />
the efficient evaluation of these drugs in clinical<br />
trials as well as for the use in clinical practice.<br />
These include<br />
(i) the selection of patients likely to benefit from<br />
treatment with a specific targeted drug,<br />
(ii) finding the right dose and dose schedule,<br />
(iii) monitoring target inhibition, and<br />
(iv) assessing tumor response to therapy.<br />
Standard anatomic imaging continues to play an<br />
important role for addressing these challenges,<br />
but molecular imaging provides several new<br />
opportunities to make the use of targeted drugs more<br />
efficient. Using molecular imaging the expression<br />
of drug targets can be assessed non-invasively, the<br />
concentration of drugs can be measured in the<br />
tumor tissue, target inhibition can be monitored and<br />
tumor response to therapy can be evaluated earlier<br />
than with anatomic imaging techniques.<br />
Therefore it is expected that molecular imaging<br />
will play an increasing role for guiding molecularly<br />
defined therapeutic interventions.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
day1<br />
Parallel Session 1: CANCER I - together with the ESR
28 Introduction:<br />
WarSaW, poland May 26 – 29, 2010<br />
Potentials of imaging biomarkers in patients<br />
Van Beers B.E.<br />
Department of Radiology and INSERM U 773, Beaujon University Hospital, University Paris Diderot, France.<br />
bernard.van-beers@bjn.aphp.fr<br />
There is an increasing need for imaging<br />
biomarkers to objectively assess the prognosis and<br />
response to treatment in cancer.<br />
Methods: Quantitative anatomical, molecular, and<br />
functional characteristics can be used as imaging<br />
biomarkers.<br />
Results: The RECIST criteria are anatomical imaging<br />
biomarkers that are accepted surrogate endpoints<br />
in cancer treatment. However, they are not early<br />
biomarkers and are limited in the assessment of<br />
some tumors and targeted treatments.<br />
The use of molecular imaging biomarkers is<br />
restricted by their narrow target specificity and<br />
by the complexity of the biology in tumors. In a<br />
given tumor type, several different subgroups often<br />
exist with overexpression of different proteins and<br />
signaling pathways.<br />
Therefore, it is often preferred to assess downstream<br />
changes of molecular pathways with functional<br />
imaging life<br />
imaging. The rationale of this approach is that<br />
most cancers have acquired the same functional<br />
capabilities including upregulated glycolysis, limitless<br />
proliferation, extensive angiogenesis, resistance to<br />
apoptosis and metastasis formation. These capabilities<br />
are assessed with functional biomarkers using PET,<br />
dynamic contrast-enhanced CT and MRI, diffusionweighted<br />
MRI, MR elastography and spectroscopy.<br />
Conclusions: Functional biomarkers have an<br />
important potential to help in selecting the patients<br />
and assessing the response to new treatments,<br />
especially in phase 1 and 2 clinical trials.<br />
However, important efforts of validation and<br />
standardization remain to be done before the wide<br />
use of functional biomarkers and their acceptance<br />
as surrogate endpoints that can replace clinical<br />
endpoints such as survival or time to progression.<br />
References:<br />
1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell.<br />
2000;100(1):57-70.<br />
2. Rudin M. Imaging readouts as biomarkers or surrogate<br />
parameters for the assessment of therapeutic<br />
interventions. Eur Radiol. 2007 (10):2441-57.<br />
3. Padhani AR, Liu G, Koh DM, Chenevert TL, et al.<br />
Diffusion-weighted magnetic resonance imaging as a<br />
cancer biomarker. Neoplasia. 2009;11(2):102-25.<br />
4. Van Beers BE, Vilgrain V. Biomarkers in abdominal<br />
imaging. Abdom Imaging. 2009;34(6):663-7.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Pre-clinical screening of anti - HER2 nanobodies for molecular imaging of breast cancer<br />
Vaneycken I. (1) , Devoogdt N. (1) , Peleman C. (1) , Xavier C. (1) , Lahoutte T. (1) , Caveliers V. (1) .<br />
Vrije Universiteit Brussel, Belgium<br />
ilse.vaneycken@gmail.com<br />
Introduction: Nanobodies are small antigen-binding<br />
fragments of camelid heavy-chain antibodies. Besides<br />
therapeutic agents, they are also effective as a<br />
diagnostic tool for targeted imaging when labeled<br />
with a suitable radionuclide[1]. We produced Nanobodies<br />
for molecular imaging of Human Epidermal<br />
Growth Factor Receptor 2 (HER2) expression in<br />
breast cancer patients[2] for a phase I clinical trial.<br />
After production, a number of candidate binders<br />
are obtained. we designed a standardized selection<br />
procedure based on production yield, in vitro and<br />
in vivo criteria to identify the lead anti-HER2 Nanobody<br />
with the highest potential as a tracer for clinical<br />
translation.<br />
Methods: A camel was immunized with HER2 recombinant<br />
protein and serum IgG2 and IgG3 subclasses<br />
with heavy-chain-only antibodies were<br />
separated. Eleven different anti-HER2 Nanobodies<br />
were produced in E. coli, purified and labeled with<br />
99mTc(I)-tricarbonyl. In vitro saturation binding<br />
studies were performed on recombinant HER2 and<br />
HER2 positive SKOV3 cells with the native and radiolabeled<br />
anti-HER2 Nanobodies. Competition<br />
studies allowed assessing whether the anti-HER2<br />
99mTc-Nanobodies competed with the therapeutic<br />
anti-HER2 antibodies Trastuzumab and Pertuzumab.<br />
In vivo, the biodistribution and tumor targeting<br />
potential of all 99mTc-Nanobodies was evaluated<br />
using pinhole SPECT/micro-CT in nude mice bearing<br />
HER2 positive SKOV3 xenografts. The Nanobody<br />
showing the most favourable in vivo characteristics<br />
was additionaly evaluated in nude mice<br />
bearing HER2 positive LS174T and HER2 negative<br />
MDAMB4357d xenografts.<br />
Results: Nanobodies were labeled with 99mTc and<br />
purified to a final radiochemical purity of ≥99%.<br />
Saturation binding studies showed that 99mTc labeling<br />
was not associated with a significant reduction of<br />
immunoreactivity. The Nanobodies appeared to be<br />
not or only weakly competitive with the commercial<br />
therapeutic antibodies. In vivo biodistribution demonstrated<br />
that tumor accumulation varied between<br />
0,78 and 4,44 percent injected activity per gram<br />
(%IA/g). Of the eleven 99mTc-Nanobodies tested in<br />
SKOV3 xenografts, three presented a tumor uptake<br />
above 4 %IA/g. One was selected and also showed<br />
high tumor uptake (3,76±0,82 %IA/g) in LS174T xenografts,<br />
but low uptake in MDAMB435d xenografts<br />
(0,71±0,07 %IA/g). In addition, all 99mTc-Nanobodies<br />
displayed high renal uptake but low non-specific<br />
accumulation in liver, muscle and blood, resulting<br />
in high tumor-to-background ratios.<br />
Conclusions: Using a standardized selection procedure<br />
for identificiation of high affinity Nanobodies<br />
for molecular imaging of cancer, we identified one<br />
Nanobody as the lead compound for a phase I clinical<br />
trial. This Nanobody meets with all criteria that<br />
characterize a good diagnostic tracer.<br />
Acknowledgement: The research at ICMI is funded<br />
by the Interuniversity Attraction Poles Program–<br />
Belgian State–Belgian Science Policy. Tony Lahoutte<br />
is a Senior Clinical Investigator of the Research<br />
Foundation–Flanders (Belgium) (FWO).<br />
References:<br />
1. Gainkam LO, Huang L, Caveliers V, et al. Comparison of<br />
the biodistribution and tumor targeting of two 99mTclabeled<br />
anti-EGFR nanobodies in mice, using pinhole<br />
SPECT/micro-CT. J Nucl Med. 2008;49(5):788-795.<br />
2. Hicks,D.G. et al (2008). HER2+ breast cancer: review of<br />
biologic relevance and optimal use of diagnostic tools.<br />
American Journal of Clinical Pathology, 129, 263-273.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
YIA applicant<br />
day1<br />
Parallel Session 1: CANCER I - together with the ESR
YIA applicant<br />
30 Introduction:<br />
WarSaW, poland May 26 – 29, 2010<br />
[18F]-FDG/[18F]-FLT-PET and bioluminescence imaging of therapy response in B-cell<br />
lymphoma mice treated with cytotoxic and antiproliferative agents<br />
De Saint-Hubert M. (1) , Brepoels L. (1) , Devos E. (1) , Degroot T. (1) , Ibrahimi A. (1) , Tousseyn T. (1) , Verbruggen A. (1) ,<br />
Mortelmans L. (1) , Mottaghy F. (2) .<br />
(1) KULeuven, Belgium<br />
(2) RWTH Aachen.<br />
marijke.desainthubert@med.kuleuven.be<br />
Early and reliable evaluation of therapy<br />
outcome is essential for optimal medical care<br />
in oncology. Shortly after treatment the influx of<br />
inflammatory cells can interfere with [18F]-FDG<br />
uptake while [18F]-FLT is less hampered by this<br />
phenomenon. The aim of this study was to image<br />
[18F]-FDG and [18F]-FLT response to either cytotoxic<br />
or antiproliferative therapy and to correlate the<br />
response to the amount of viable cells assessed with<br />
Bioluminescence Imaging (BLI).<br />
Methods: Daudi cells (Burkitt lymphoma) were<br />
transduced with a lentiviral vector (blasticidin selection<br />
marker and firefly luciferase reporter gene) and<br />
inoculated in SCID-mice (n=57). When the tumors<br />
reached a diameter of 15mm2 animals were treated<br />
with either cyclophosphamide (125mg/kg, n=25)<br />
or temsirolimus (50mg/kg, n=25). [18F]-FDG and<br />
[18F]-FLT small-animal PET was performed on<br />
day0 (d0, before treatment) day (d) 2, 4, 7, 9 and 14.<br />
On these days we also imaged the tumor cells with<br />
BLI. At each time point, 2 mice of each treatment<br />
condition were sacrificed and tumors were excised<br />
for histopathology (H&E, Ki-67, CD20, TUNEL).<br />
Quantitative imaging data were expressed as % signal<br />
of the baseline signal measured on d0 and expressed<br />
as mean ± standard error of the mean (SEM).<br />
Results: [18F]-FDG uptake decreased immediately<br />
(-38% on d2) after cyclophosphamide treatment<br />
without a significant reduction in [18F]-FLT uptake<br />
which could be due to DNA repair as DNA FACS<br />
showed an increased amount of cells in the S-fase<br />
early after cyclophosphamide. From d7 [18F]-FLT<br />
uptake decreased significanlty corresponding to histology<br />
data (ki-67). [18F]-FDG uptake stabilized between<br />
d7 and d9 (-57% and -59% respectively) likely<br />
due to a high influx of inflammatory cells observed<br />
in histology (±40% on d7-d9). Caliper measurements<br />
showed tumor shrinkage from d7. Surprisingly the<br />
BLI measured an increased signal early after therapy<br />
(d2-d4) while only late after therapy a reduction in<br />
the signal was observed (d9-d14).<br />
Temsirolimus treatment reduced both the [18F]-<br />
FDG and [18F]-FLT uptake immediately (d2) after<br />
therapy. [18F]-FDG stabilized between d9 and d14<br />
imaging life<br />
maybe due to inflammation which was only observed<br />
on d14 but this might as well be due to regrowth. The<br />
early [18F]-FLT decrease corresponded well to ki-67<br />
stainings and to DNA FACS where an increase of the<br />
G0/G1 fase is observed. Tumor size reduced already<br />
from d4 after temsirolimus treatment. BLI showed<br />
the same signal increase as cyclophosphamide early<br />
after therapy and only in a late stage after therapy<br />
we observed a reduced amount of viable cells. This<br />
early increase might be due to an upregualtion of the<br />
promotor after therapy but further evalution of this<br />
phenomenon is on the way.<br />
Conclusions: [18F]-FDG reduced early after therapy<br />
but stabilized due to a temporary rise in inflammatory<br />
cells. [18F]-FLT-PET was able to detect a<br />
reduced proliferation after therapy. However, after<br />
cytotoxic therapy [18F]-FLT did not change probably<br />
due to DNA repair. Therefore caution should be<br />
made when imaging [18F]-FLT response immediately<br />
after cytotoxic therapy. Bioluminescence imaging<br />
showed an early increase which may have important<br />
implication for BLI monitoring of therapy.<br />
Acknowledgement: This work was financially supported<br />
by the Center of Excellence ‘MoSAIC’ of the<br />
K.U.Leuven.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
TF-Pimonidazole: an hypoxia marker suitable for in vivo 19 F MRS imaging<br />
Heerschap, A. .<br />
Centre for Molecular Life Science, University Nijmegen, The Netherlands<br />
a.heerschap@rad.umcn.nl<br />
Introduction: Hypoxia in tumours is associated<br />
with enhanced progression, increased aggressiveness<br />
and metastatic potential and poor prognosis.<br />
Moreover, hypoxic tumour cells are resistant to<br />
radiotherapy and some forms of chemotherapy.<br />
Over the years several approaches to assess hypoxia<br />
in vivo have been explored, ranging from<br />
needles measuring local pO 2 invasively to a range<br />
of non-invasive (imaging) methods using oxygen<br />
sensitive agents. Unfortunately until today none<br />
of these methods or agents has entered widespread<br />
clinical practice. Here we demonstrate a<br />
novel hypoxia marker completely analogous to<br />
the commonly used histological hypoxia marker<br />
Pimonidazole (PIMO) and labelled with fluorine<br />
for in vivo 19 F MRS imaging.<br />
Methods:1-(2-nitro-1H-imidazol-1-yl)-3-[4-<br />
(trifluoromethyl)piperidin-1-yl]propan-2-ol<br />
(TF-PIMO) was synthesized in a similar way as<br />
described in [1]. C57BL/6 mice carrying a C38<br />
colon carcinoma on the upper leg (size approx.<br />
250 mm 3 ) were given either 80 or 200 mg / kg TF-<br />
PIMO intraperitoneal (IP) at least 3 hours before<br />
MR investigations. The mice were anesthetized<br />
using a single urethane IP injection. This avoids<br />
any spectral interference by fluorinated inhalation<br />
anaesthetics. Experiments were performed<br />
on a 7 T horizontal bore MR system. A homemade<br />
14 mm solenoid coil was used for transmit/receive<br />
of 19 F and 1 H. After initial localization and basic<br />
1 H MR imaging (T2*w GRE) an unlocalized pulse<br />
acquire sequence (FID) on 19 F was used to detect<br />
TF PIMO validating correct injection of the compound.<br />
Subsequently a series of 3D 19 F chemical<br />
shift imaging (CSI) FID experiments using an<br />
ultrashort adiabatic half passage pulse was used<br />
for TF-PIMO 19 F imaging. Further settings of the<br />
MRSI sequence: FOV 32 × 32 ×32 mm, matrix<br />
8 × 8 × 8, TR 597 ms, acquisition time 58 m 02<br />
s, 256 averages, weighted phase encoding scheme.<br />
After MR, tumours were removed immediately<br />
and stored in liquid nitrogen. Frozen tumour sections<br />
of 5 μm thickness were cut for staining and<br />
further analysis. The tumor sections were subsequently<br />
stained and scanned for Hoechst and rabbit<br />
anti-pimonidazole.<br />
Results: Figure 1 shows a heat map generated from<br />
the 3D 19 F MRSI representing the in vivo TF-PIMO<br />
accumulation in a hypoxic C38 colon carcinoma as<br />
was validated by subsequent immunohistochemical<br />
analysis of the tumour tissue.<br />
Figure 1: 1H MRI of a C38 murine colon carcinoma on a mouse leg<br />
with a heat map generated from a 3D 19F MRSI representing the in<br />
vivo TF-PIMO accumulation over-layed.<br />
Conclusions: TF-PIMO was synthesized and shown<br />
to be a potential non-invasive marker to image tissue<br />
hypoxia in tumours by 19F MRSI. Background<br />
free functional images are obtained that can be coregistered<br />
with conventional MRI. In addition this<br />
marker has the advantage that it can be stained with<br />
the same anti-body as used to detect the common<br />
clinical used marker Pimonidazole and thus allows<br />
for easy matching of hypoxia by histology and by<br />
MR on the same tumour sample.<br />
Acknowledgement: This work is supported in part<br />
by EMIL (LSHC-CT-2004-503569) and NWO (VIS-<br />
TA and INV911-06-021)<br />
References:<br />
1. Raleigh, J. A. et al; Magn Reson Med 22:451-466 (1991)<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
day1<br />
Parallel Session 1: CANCER I - together with the ESR
32 Detailed<br />
WarSaW, poland May 26 – 29, 2010<br />
[11C](R)-PK11195- a tricky tracer. Do we really need it to image microglial activation?<br />
Gerhard A. .<br />
Wolfson Molecular Imaging Centre Manchester, UK<br />
alex.gerhard@manchester.ac.uk<br />
experimental and human post mortem<br />
studies have shown that activation of microglia, the<br />
brain’s resident tissue macrophages, has a particularly<br />
close association with active brain pathology. One<br />
of the molecules expressed de novo during the<br />
‘activation’ of microglia is the translocator protein<br />
(18kDa), TSPO.PK11195 is a selective ligand for the<br />
TSPO.<br />
In vivo and in the absence of invading blood-borne<br />
cells the de novo expression of TSPO occurs primarily<br />
in activated microglia. Based on this relative cellular<br />
selectivity [11C]PK11195 PET has been used to<br />
image microglial activation in vivo for about 20 years<br />
now and it has been possible to demonstrate patterns<br />
of increased signal distribution in the brain that<br />
correspond well with the localisation of pathological<br />
changes in a number of neurological disorders (1).<br />
Recently [11C](R)- PK11195 PET has even<br />
successfully been used to show in vivo the effect of a<br />
pharmacological intervention in a neurodegenerative<br />
disorder on microglial activation (2).<br />
imaging life<br />
Nevertheless there are methodological challenges<br />
when using [11C]PK11195 particularly an<br />
unfavourable signal to noise ratio. Therefore<br />
numerous new ligands for the TSPO have been<br />
evaluated at different stages over the last years<br />
with some of them having also been assessed in<br />
diseases known to be accompanied by microglial<br />
activation (3).<br />
The talk will give a brief overview of relevant studies<br />
with PK11195, as well as newer TSPO tracers, and<br />
will try to highlight their potential advantages and<br />
problems.<br />
References:<br />
1. Venneti S, Lopresti BJ, Wiley CA. The peripheral<br />
benzodiazepine receptor (Translocator protein<br />
18kDa) in microglia: from pathology to imaging. Prog<br />
Neurobiol. 2006;80(6):308-322. Epub 2006 Dec 2006.<br />
2. Dodel R, Spottke A, Gerhard A, et al. Minocycline 1-year<br />
therapy in multiple-system-atrophy: Effect on clinical<br />
symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial).<br />
Mov Disord. 2010;25(1):11.<br />
3. Chauveau F, Boutin H, Van Camp N, Dolle F, Tavitian<br />
B. Nuclear imaging of neuroinflammation: a<br />
comprehensive review of [(11)C]PK11195 challengers.<br />
Eur J Nucl Med Mol Imaging. 2008;1:1.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Preclinical imaging of the type 1 cannabinoid receptor in neurodegenerative diseases<br />
Casteels C. (1) , Van Laere K. (1) .<br />
University Leuven, Division of Nuclear Medicine, Belgium<br />
cindy.casteels@med.kuleuven.be<br />
The endocannabinoid system (ECS) is an important<br />
modulatory system in the brain. It consists of a family<br />
of naturally occurring lipids, the endocannabinoids,<br />
of transport and degradation proteins, and of<br />
cannabinoid receptors. Type 1 cannabinoid (CB1)<br />
receptors are abundantly expressed in all brain areas,<br />
especially those involved in the control of motor<br />
function. CB1 receptor stimulation modulates<br />
GABA, glutamate and dopamine neurotransmitter<br />
release in a dynamic activity manner.1<br />
Dysregulation of cannabinoid-mediated control<br />
of basal ganglia function have been suggested to<br />
play a critical role in the pathogenesis and symptom<br />
development of Parkinson’s disease (PD) and<br />
Huntington’s disease (HD), providing rationale for<br />
potential ECS-targeted therapy in these diseases.2<br />
However, at present, limited clinical pilot trials have<br />
been inconclusive. As only in vitro, ex vivo and<br />
post mortem data on the ECS existed until recently,<br />
functional in vivo imaging may play an important<br />
role in the further evaluation of the neurobiological<br />
and clinical impact of the ECS in PD and HD.<br />
Here, we present the in vivo characterization of CB1<br />
receptor alterations in preclinical models of PD and<br />
HD using PET and [18F]MK-94703. Both genetic<br />
and toxin-based experimental models will be presented.<br />
Their relevance to mimic the human condition<br />
will be discussed as well.<br />
Acknowledgement: Financial support of the Research<br />
Council of the Katholieke Universiteit Leuven<br />
(OT/05/58), the Fund for Scientific Research,<br />
Flanders, Belgium (FWO/G.0548.06), and the Institute<br />
for the Promotion of Innovation by Science and<br />
Technology in Flanders (SBO50151) is gratefully<br />
acknowledged. This work is performed under European<br />
Commission FP6-project DiMI,LSHB-CT-<br />
2005-512146<br />
References:<br />
1. Katona et al., Nat. Med. 2008;<br />
2. Maccarrone et al., Prog. Neurobiol. 2007;<br />
3. Burns et al., Proc. Natl. Acad. Sci. U.S.A. 2007.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
YIA applicant<br />
day1<br />
Parallel Session 2: NEUROSCIENCE I
YIA applicant<br />
34<br />
WarSaW, poland May 26 – 29, 2010<br />
Longitudinal non-invasive detection of amyloid plaques by combined molecular, functional<br />
and morphological imaging in transgenic mouse models of Alzheimers Disease<br />
Maier F. C. (1) , Wehrl H. F. (1) , Schmid A. (1) , Odenthal J. (2) , Reischl G. (3) , Wiehr S. (1) , Mannheim J. (1) , Stiller D. (4) , Jucker M. (2) ,<br />
Pichler B. (1) .<br />
(1) Laboratory for Preclinical Imaging and Imaging Technology of the Werner Siemens-Foundation,<br />
(2) Hertie Institute for Clinical Brain Research,<br />
(3) University Hospital Tuebingen, Radiopharmacy,<br />
(4) Drug Discovery Support, Boehringer Ingelheim Pharma GmbH & Co. KG.<br />
florian.maier@med.uni-tuebingen.de<br />
Introduction: Current small animal imaging<br />
instrumentation provides powerful tools to study<br />
disease characteristics and progression. However,<br />
biomarkers for imaging amyloid plaque deposition<br />
and associated physiological changes are not yet<br />
fully understood – impeding diagnosis in daily<br />
clinics. Thus our aims were to assess the ongoing<br />
plaque deposition in an animal model of Alzheimers<br />
Disease longitudinally using [11C]PIB, to compare<br />
the binding properties in different transgenic<br />
mouse models and to monitor perfusion differences<br />
with [15O]H2O and Arterial Spin Labeling (ASL) –<br />
reflecting disease induced changes in physiology.<br />
Methods: APPPS1 tg mice and Tg2576 mice<br />
with respective littermate controls were injected<br />
intravenously with 7.6±2.8 MBq [11C]PIB (specific<br />
activity > 50GBq/µmol) and with 28.5±3 MBq<br />
[15O]H2O for measurement of cerebral perfusion.<br />
Dynamic small animal PET scans were performed<br />
for 1h p.i. and the mice were anesthetised with<br />
1.5% isofluran in 100% oxygen. In addition, 3D MR<br />
images and ASL were acquired for each mouse. The<br />
PET images were analysed using cortical regions<br />
as target and the cerebellum as internal reference.<br />
The obtained time activity curves were processed<br />
with the Logan Plot and the simplified reference<br />
tissue model (SRTM) by Lammertsma. ASL-MRI<br />
data were analyzed with an inhouse programmed<br />
Matlab routine using a simplified version of the<br />
Bloch equation. Furthermore, the animals were<br />
analysed histopathologically.<br />
Results: Both analysis methods revealed<br />
significant differences in the binding potential<br />
(BP) of [11C]PIB in cortical regions of transgenic<br />
APPPS1 mice (Logan 0.28±0.10; SRTM 0.32±0.18)<br />
in comparison to littermate controls (Logan<br />
0.13±0.07; SRTM 0.05±0.07, n=8, p
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Serotonergic neurotransmission in early Alzheimer’s disease<br />
Hasselbalch S. G. (1) , Marner L. (1) , Madsen K. (1) , Lehel S. (1) , Barré W. (1) , Knudsen G. M. (1) .<br />
(1) Copenhagen University, Denmark<br />
sgh@nru.dk<br />
Introduction: Post mortem studies suggest involvement<br />
of the serotonin system in Alzheimer’s disease<br />
(AD) and serotonin 2A (5-HT2A) receptors are<br />
globally reduced early in the course of the disease<br />
(1). However, few studies have investigated other<br />
aspects of the serotonergic system, including presynaptic<br />
markers (serotonin transporters, SERT) as<br />
a measure of serotonergic degeneration (2). Further,<br />
recent evidence points to a disease-modifying effect<br />
of 5-HT4 agonism through a decrease in beta-amyloid<br />
load (3). Therefore, we have investigated SERT<br />
and 5-HT4 in early and compared these measures to<br />
the reduction in 5-HT2A receptors.<br />
Methods: For the SERT/5-HT2A comparison, we<br />
included 12 patients (mean age 73.7 ±7.6 years, 8<br />
males) with AD (average MMSE of 24, range 19-26)<br />
and 11 healthy age-matched subjects (mean age 72.5<br />
±6.8 years, 6 males). Subjects were investigated with<br />
a 90 min dynamic [11C]DASB-PET recording to<br />
measure SERT (4) and a 40 min steady-state [18F]<br />
altanserin-PET recording to measure 5-HT2A receptors<br />
(5). In a separate study of 5-HT4 receptors,<br />
the novel radioligand [11C]SB207145 was used in<br />
twelve healthy individuals (mean age 67.2 y, 6 males)<br />
and eleven newly diagnosed AD patients (mean age<br />
70.6 y, 6 males, mean MMSE 24, range 19-27) using<br />
the simplified reference tissue model. Volumes of<br />
interest (VOIs) were delineated automatically on coregistered<br />
3T MRIs, and partial volume correction<br />
was applied to correct for differences in atrophy.<br />
Results: The 5-HT2A receptors were markedly reduced<br />
(25-66%) in AD patients in all regions but<br />
the striatum. Inc contrast, we found a reduction of<br />
SERT binding by 34% (p=0.0003) in the hippocampus,<br />
while most other regions were unaffected.<br />
Midbrain showed no change in binding (p=0.30).<br />
No statistically significant differences in 5-HT4 receptor<br />
binding between healthy individuals and AD patients<br />
were found in any of the included brain regions:<br />
Hippocampus (p = 0.55), posterior cingulate gyrus<br />
(p = 0.22), amygdala (p = 0.77), parietal cortex (p =<br />
0.44), temporal cortex (p = 0.74) and prefrontal cortex<br />
(p = 0.43).<br />
Conclusions: We showed a marked decrease of<br />
5-HT2A binding in patients with mild AD, consistent<br />
with previous findings in MCI (1). The SERT<br />
binding was unaffected by the disease in almost all<br />
cortical regions and in midbrain, suggesting that<br />
the serotonergic innervations and the neuron bodies<br />
in dorsal nucleus raphe are intact, at least early<br />
in the disease. We interpret the SERT reduction in<br />
hippocampus in patients as a decreased serotonergic<br />
innervation, which could be secondary to the neuronal<br />
degeneration taking place in hippocampus of<br />
AD patients. The marked reduction in 5-HT2A may<br />
be related to beta-amyloid accumulation. In contrast<br />
to the 5-HT2A receptor subtype, the 5-HT4 receptor<br />
levels seemed to be unaffected in AD. However,<br />
5-HT4 binding in relation to cognitive function,<br />
neuropsychiatric symptoms and beta-amyloid load<br />
should be further investigated.<br />
Acknowledgement: Supported by The Lundbeck<br />
Foundation, Rigshospitalet, and the Danish Medical<br />
Research Council. The John and Birthe Meyer Foundation<br />
is gratefully acknowledged for the donation<br />
of the Cyclotron and PET-scanner. These studies<br />
were funded in part by the EC - FP6-project DiMI,<br />
LSHB-CT-2005-512146.<br />
References:<br />
1. S. G. Hasselbalch et al., Neurobiol. Aging. 29, 1830<br />
(2008).<br />
2. K. Nielsen et al., Synapse. 59, 270 (2006).<br />
3. S.J. Robert, et al., Neurodegener Dis 5(3-4):163 (2008).<br />
4. M. Ichise et al., J Cereb. Blood Flow Metab. 23, 1096<br />
(2003). L. H. Pinborg et al., J. Cereb. Blood Flow Metab.<br />
23, 985 (2003).<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
day1<br />
Parallel Session 2: NEUROSCIENCE I
36 Introduction:<br />
WarSaW, poland May 26 – 29, 2010<br />
Qualitative and quantitative assessment of florbetapir F-18 PET ( 18 F-AV45) amyloid<br />
deposition PET imaging - validation by pathology. Preliminary report.<br />
Romanowicz G. (1) , Saha K. (2) , Krautkramer M. (2) , Joshi A. (2) , Pontecorvo M. (2) , Clark C. (2) , Carpenter A. (2) , Skovronsky D. (2) .<br />
(1) Gdański Uniwersytet Medyczny, Poland<br />
(2) Avid Radiopharmaceuticals Inc..<br />
greg@amg.gda.pl<br />
Various methods for analyzing amyloid<br />
brain PET scans have been proposed and tested.<br />
The lack of reliable truth standards has complicates<br />
the validation and implementation of these methods,<br />
and investigators have relied on theoretical modeling<br />
and clinical diagnoses as surrogates for true<br />
pathology. We applied three methods for assessing<br />
florbetapir F18 PET (18F-AV45) amyloid images: a<br />
semiquantitative visual read, a mean SUVr quantitation<br />
based on VOIs, and a novel automated histogram<br />
based quantitative approach. Each method<br />
was validated by comparison with amyloid burden<br />
measured at post-mortem.<br />
Methods: 6 subjects (3 men; 3 women; mean age at<br />
imaging 76y (47-86); diagnosis at enrollment, 1 MCI,<br />
4 AD, 1 PDD) with a life expectancy of < 6 months<br />
had a 10 minute PET scan 50 minutes after IV injection<br />
of 10 mCi of florbetapir F 18. Images were reconstructed<br />
by iterative technique with 4i/16s and 3<br />
mm FWHM post-reconstruction Gaussian filter. For<br />
visual assessment (VR) an experienced reader rated<br />
florbetapir cortical uptake intensity (VR score) on a<br />
5 point scale ranging from 0, (no difference in uptake<br />
between cortex and cerebellum), to 4 (uptake<br />
in all cortical brain regions significantly higher vs.<br />
both cerebellum and white matter). For the SUVr<br />
technique, PET images were spatially normalized by<br />
12 parameter affine registration to Talairach/MNI<br />
space and counts extracted from six regional VOIs<br />
(frontal, temporal, precuneus, parietal, anterior<br />
cingulated and posterior cingulated). Average standardized<br />
uptake value ratios (SUVr) were calculated<br />
with cerebellum as reference. The values for the six<br />
cortical regions were averaged to generate a global<br />
SUVr. For the histogram based analysis image data<br />
were processed automatically to generate a128 bin<br />
count histogram. The first order derivative Gaussian<br />
(FWHM= 3mm) convolved histogram curve was<br />
searched in the intensity direction to estimate separation<br />
of high/low intensity areas. The high/low intensity<br />
curve area ratio (CAR) was calculated to estimate<br />
specific amyloid binding. After the patient’s<br />
death (mean interval from imaging 43 days (range<br />
12-158)) their brain was evaluated for of β-amyloid<br />
deposition using immunohistochemistry (IHC) and<br />
by neuritic plaque rating (modified CERAD method).<br />
imaging life<br />
CAR score, VR score and SUVr were compared with<br />
IHC/CERAD using Spearman’s (ρ) or Pearson’s correlation<br />
coefficient (r) as appropriate.<br />
Results: A strong correlation was obtained between<br />
each measure of PET amyloid binding and both<br />
measures of amyloid deposition at autopsy (VR and<br />
IHC (ρ=0.88), VR and CERAD (ρ =0.92); SUVr and<br />
IHC (r=0.89), SUVr and CERAD (ρ=0.93); CAR and<br />
IHC (r=0.97), CAR and CERAD (ρ =0.64)).<br />
Conclusions: The results confirm that florbetapir F<br />
18 PET imaging provides relevant in vivo estimate of<br />
brain amyloid pathology irrespectively of the choice<br />
of image assessment method. The novel histogram<br />
based method is particularly interesting because it<br />
is quantitative and does not require fitting images<br />
to a template or reorientation of images, kinetic data<br />
acquisition, input functions or drawing / applying<br />
regions of interest.<br />
Acknowledgement: This work is supported by AVID<br />
Radiopharmaceuticals Inc. We would also like to<br />
thank A.S. Fleisher, J.A. Schneider, T.G. Beach, B.J.<br />
Bedell, S.P. Zehntner and M. Mintun for their contribution<br />
to the work.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
In-vivo imaging of a mouse traumatic brain injury model using dual-isotope quantitative<br />
spect/ct<br />
Máthé D. (1) , Szigeti K. (2) , Fekete K. (3) , Horváth I. (2) , Benyó Z. (3) .<br />
(1) CROmed Ltd,<br />
(2) Nanobiotechnology and In Vivo Imaging Centre Semmelweis University Faculty of Medicine,<br />
(3) Semmelweis University Faculty of Medicine.<br />
domokos.mathe@gmail.com<br />
Introduction: Using a standardized mouse neurotrauma<br />
model we aimed at determining the role<br />
of high-resolution SPECT/CT in detecting and<br />
quantifying the volumetric and functional extent of<br />
blood-brain barrier disruption. We chose the freezing<br />
trauma model because of its reproducibly standard<br />
damage.<br />
Methods: Mice were subjected to a standardized<br />
freezing method transcranially using a cooled<br />
needle tip. In the presented initial studies, we compared<br />
the imaging pattern of the animals at equally 5<br />
hours post the freezing trauma. We used a dedicated,<br />
quantitative multiplexed multipinhole SPECT imaging<br />
system for laboratory animals. X-ray CT of the<br />
structures was also performed together with SPECT<br />
data acquisition.<br />
We correlated BBB disruption and blood perfusion<br />
with quantitative imaging of the decrease in glial<br />
and neuronal potassium uptake. We applied the validated<br />
intravenous tracer 99mTc-DTPA to detect the<br />
disruption of the BBB. Blood perfusion of the brain<br />
was assessed using the also validated tracer 99mTc-<br />
HMPAO. A radioactive isotopic potassium analogue,<br />
201Tl was used to track K+ uptake changes quantitatively.<br />
201Tl ions were passed through the BBB by<br />
means of diethyl-dithiocarbamate (DDC) complex<br />
that redistributes to ionic 201Tl after being taken<br />
up in brain tissues.<br />
Uptake volumes (in mm3) and total brain as well as<br />
lesion radioactivity values (in kBq) were evaluated<br />
on 3D reconstructed brain images of treated mice<br />
(n=5 per group) and a non-treated group. Besides<br />
imaging of single tracers (3 groups), simultaneous<br />
multi-channel imaging was used in two other groups<br />
of mice having received 99mTc-DTPA plus 201Tl-<br />
DDC or, 99mTc-HMPAO plus 201Tl-DDC.<br />
After imaging, histological control of the brain<br />
trauma size and localization was performed in the<br />
formaldehyde-fixed brains of all animals.<br />
Results: The uptake of 99mTc-DTPA correlated well<br />
with the size and localization of the lesion whereas<br />
the cold spot of the lesion at the perfusion image<br />
was evident in all animals having received 99mTc-<br />
HMPAO. However the cold spot was surrounded by<br />
an area of increased perfusion as compared to the<br />
same area in control animals. When comparing with<br />
201Tl-DDC images, the penumbra effect became evident,<br />
especially in the animals imaged with 99mTc-<br />
HMPAO and 201Tl-DDC in the same time. The<br />
area of non-active glial and neuronal potassium uptake<br />
was significantly larger than the non-perfused<br />
area and the hyper-perfused area co-localized with<br />
the edge of the disappeared neural potassium uptake<br />
volumes in 4 animals out of 5. SPECT/CT identified<br />
the dislocation of brain due to increased intracranial<br />
pressure in all treated animals.<br />
Conclusions: In vivo whole-animal imaging using<br />
quantitative SPECT is a very promising method to<br />
dissect different activation patterns and regulation<br />
of different mechanisms behind the events following<br />
neurotrauma (and consequently stroke too). Using<br />
a unique dual-isotopic approach to detect multiple<br />
events in the same time in the same animals, the size<br />
and presence of a penumbral region where perfusion<br />
is elevated but neural (both glial and neuronal) K+<br />
utilization is decreased, could be identified.<br />
Acknowledgement: We are grateful for Dr. Jürgen<br />
Goldschmidt (Magdeburg) and Roberto Pasqualini<br />
(Orsay) for valuable advice and kind hints in 201Tl-<br />
DDC application and preparation.<br />
References:<br />
1. Goldschmidt et al. NeuroImage 49 (2010) 303–315<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
YIA applicant<br />
day1<br />
Parallel Session 2: NEUROSCIENCE I
38 Introduction:<br />
WarSaW, poland May 26 – 29, 2010<br />
Molecular analysis of adaptive immune function through microscopic and mesoscopic<br />
imaging<br />
Stein J. .<br />
University of Bern, Switzerland<br />
jstein@tki.unibe.ch<br />
Cell migration is of central importance<br />
during development, cancer metastasis and the<br />
functioning of the immune system. A powerful<br />
approach to dissect molecular mechanisms during<br />
cell trafficking on a single cell level requires the<br />
adaptation of microscopy techniques to anesthetized<br />
animals, usually mice.<br />
Twophoton microscopy (2PM) was developed to<br />
examine the molecular mechanisms governing<br />
transmigration through endothelium and within<br />
tissue. Here, a brief overview is given over the<br />
techniques and potential applications of 2PM in the<br />
field of lymphocyte trafficking.<br />
imaging life<br />
The overall internal organization of organ<br />
microenvironments, such as B cell follicles and<br />
blood microvessels in lymph nodes, has thus far<br />
been mainly determined by two-dimensional tissue<br />
sectioning, whereby three-dimensional information<br />
is lost. Optical Projection Tomography (OPT) and<br />
selective plane illumination (SPIM) are recently<br />
developed mesoscopic imaging approaches to dissect<br />
the overall organization of specimen of 1-15 mm<br />
diameter. Their applications in lymphoid structure<br />
analysis will be discussed.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Magnetic resonance imaging – from structure to molecular interactions<br />
Rudin M. .<br />
ETH and University of Zürich, Switzerland<br />
rudin@biomed.ee.ethz.ch<br />
Magnetic resonance imaging (MRI) yields images<br />
characterized by high spatial resolution and<br />
unsurpassed soft-tissue contrast. The latter is<br />
the consequence of the fact that the MRI signals<br />
depends on multiple parameters such a various<br />
relaxation rates, water diffusivity, proton exchange<br />
reactions, which are tissue specific. By choice of<br />
experimental parameters contrast can be varied to<br />
highlight structures of interest. Paramagnetic or<br />
superparamagnetic contrast agents can be used to<br />
further enhance specific structures. It is therefore<br />
not surprising that today MRI has become one of the<br />
most important modalities for structural imaging.<br />
Yet MRI provides information beyond mere anatomy.<br />
The analysis of dynamic signal changes - e.g. during<br />
administration of a contrast agent - yields relevant<br />
quantitative information on physiological processes<br />
such as blood flow, vascular permeability, or renal<br />
function. Probably the most important physiological<br />
MRI application is functional MRI (fMRI), which<br />
has become an indispensable tool for studying<br />
brain function, or more precisely the hemodynamic<br />
response to neuronal activity, under normal and<br />
pathological conditions. fMRI measures local<br />
hemodynamic changes in the CNS that are linked to<br />
neural activity through neurovascular coupling.<br />
More recently, MRI has tapped into the field of<br />
molecular imaging. By coupling the MRI contrast<br />
agent to a targeting moiety, molecular information<br />
can be derived at high spatial resolution. Yet the<br />
MRI molecular imaging approach suffers from two<br />
limitations. MRI is insensitive due to the small<br />
quantum energy involved in the process, typically<br />
concentrations have to be in the micromolar range<br />
to induced chances detectable by MRI. This can be<br />
in part be accounted for by increasing the relaxivity<br />
of MRI reporters by increase of the payload or by<br />
using physiological amplification. The second<br />
limitation is that MRI contrast agents are in<br />
general bulky, which renders target accessibility<br />
difficult. Straightforward molecular targets that<br />
can be reached by MRI contrast agents are those<br />
expressed on the endovascular side. On the other<br />
hand the efficiency of MRI probes, similar to that<br />
of fluorescent probes, can be modulated through<br />
the molecular interaction with the target. This<br />
potentially allows discriminating target-bound from<br />
free floating probe, thereby enhancing the contrastto-background<br />
ratio. An attractive application of<br />
targeted MRI imaging are studies of cell trafficking.<br />
As many cells are rather tolerant to the amount of<br />
contrast agent they can carry, sensitivity appears<br />
to be less an issue. In fact there are some reports,<br />
that under favorable conditions single cells might be<br />
detected.<br />
The lecture will discuss the various aspects of MRI with<br />
focus on molecular and cellular imaging applications.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
day1<br />
Parallel Session 3: TECHNOLOGY
40<br />
WarSaW, poland May 26 – 29, 2010<br />
Imaging modalities: PET and SPECT<br />
Ziegler S. .<br />
TU Munich, Department of Nuclear Medicine, Germany<br />
sibylle.ziegler@tum.de<br />
Nuclear medical imaging methods, positron emission<br />
tomography (PET) and single photon emission<br />
computed tomography (SPECT), utilize the detection<br />
of gamma rays leaving the body after a radioactive<br />
tracer has been administered in vivo. The choice<br />
of tracer substance as well as radio-nuclide for labelling<br />
depends on the biological process of interest<br />
and the organ which is imaged. While electronic<br />
collimation is used in PET, mechanical collimators<br />
made of high-Z materials need to be employed in<br />
SPECT imaging. Depending on the imaging situation,<br />
these collimators can be designed for parallel,<br />
imaging life<br />
diverging, or converging projection. Gamma ray detection<br />
in either modality is accomplished by scintillation<br />
detectors or semiconductor detectors, as in<br />
more recent developments. Raw data are projections<br />
of the activity distribution, which is reconstructed<br />
using analytical or statistical algorithms. Sensitivity<br />
of PET allows detecting pico-molar tracer amounts<br />
in vivo and current technology offers mm (PET) or<br />
sub-mm (SPECT) spatial resolution. Quantitative<br />
measurement of activity concentration in vivo is the<br />
basis for more advanced dynamic studies including<br />
biokinetic modelling.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
in vivo fluorescence kinetic imaging for improved contrast and studies of temporal and<br />
quantitative biodistribution<br />
Mansfield J. (1) , Agarwal A. (2) , Curtis A. (2) , Krucker T. (2) .<br />
(1) Cambridge Research & Instrumentation,<br />
(2) Novartis Institutes for BioMedical Research.<br />
jmansfield@cri-inc.com<br />
Introduction: In vivo fluorescence imaging has<br />
added an easy and economical modality to the rapidly<br />
growing field of molecular imaging. It offers<br />
the possibility to perform experiments analogous<br />
to bioluminescence imaging through fluorescent<br />
proteins, but at longer and more efficient wavelengths.<br />
A further distinction is the translational<br />
and research aspects enabling the imaging of fluorophore-labelled<br />
biologics (e.g., antibodies, peptides,<br />
siRNA) and activatable reagents. One unique<br />
aspect limiting the sensitivity of in vivo fluorescence<br />
methodologies is the confounding effect of<br />
tissue autofluorescence, which can be addressed<br />
through the proper use of spectral imaging [1,2].<br />
However, like other molecular imaging modalities,<br />
reagent-based in vivo fluorescence imaging also<br />
has to contend with sensitivity and contrast problems<br />
due to non-specific signals and long wash-out<br />
times, both limiting the detection of specifically<br />
bound reagent and preventing accurate determination<br />
of uptake rates.<br />
Methods: A kinetic imaging modality, Dynamic<br />
Contrast Enhancement, or DyCETM, that combines<br />
rapid imaging (up to 15 frames/sec monochrome<br />
or 10 sec/frame multispectrally) with an advanced<br />
data processing methodology was developed. When<br />
combined with analysis software, these allow determination<br />
of (1) the rates of change of the intensity<br />
of the fluorophore in each pixel of the image and<br />
(2) the rate of uptake and wash-out in the animal.<br />
Mice were injected with a near-infrared fluorescent<br />
agent (IgG antibody) that was taken up in the liver<br />
and imaged for 80 minutes following injection at<br />
a rate of 1 multispectral dataset per minute. Each<br />
timepoint’s data were unmixed and kinetic data<br />
and “movies” assembled from these.<br />
Results: By utilizing the uptake and wash-out rate<br />
information, a much higher contrast image of the<br />
accumulating fluorophore was obtained in a much<br />
shorter period of time (minutes and hours vs. days).<br />
In addition, body compartment data determined<br />
from the kinetic data can provide information on<br />
the temporal distributions of a fluorescent agent<br />
during the experiment and can act as inputs for<br />
rate-of-change or body compartment models.<br />
Conclusions: This broadly applicable temporalbiodistribution<br />
methodology can be used, for<br />
example, to differentiate between the rate of liver<br />
uptake vs. the rate of tumor uptake and quantitate<br />
each signal relative to general body and/or bladder<br />
distribution. This information can then be<br />
combined with multispectral imaging and used to<br />
quantitate the biodistribution of multiple fluorophores<br />
simultaneously, each without interference<br />
from autofluorescence. When combined with<br />
models of peripheral, tumor, blood and wash-out<br />
(bladder) distributions, this kinetic imaging data<br />
can be transformed into a physiologically based<br />
pharmacokinetic model of agent distribution that<br />
provides an estimate of the pK values between the<br />
various compartments. Potentially such a method<br />
can also be used to establish optimal drug treatment<br />
schedules aiding drug discovery and development.<br />
References:<br />
1. Levenson, Mansfield, Cytometry A. 2006 Aug;<br />
69(8):748-58.<br />
2. Tam et al., Mol Imaging. 2007 Oct-Dec;6(4):269-76.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
day1<br />
Parallel Session 3: TECHNOLOGY
42 Introduction:<br />
WarSaW, poland May 26 – 29, 2010<br />
Cerenkov radiation imaging of a xenograft murine model of mammary carcinoma<br />
Boschi F. (1) , Calderan L. (1) , D’ambrosio D. (2) , Marengo M. (2) , Fenzi A. (1) , Calandrino R. (3) , Sbarbati A. (1) , Spinelli A. E. (3) .<br />
(1) University of Verona,<br />
(2) S. Orsola – Malpighi University Hospital,<br />
(3) S. Raffaele Scientific Institute.<br />
federico@anatomy.univr.it<br />
2-[18F]fluoro-2-deoxy-D-glucose<br />
( 18 F-FDG) is a well known radiotracer for the in<br />
vivo studies of several diseases. In a previous paper<br />
[1] we showed that the positrons emitted by 18 F-FDG,<br />
travelling into tissues faster than the speed of light<br />
in the same medium, are responsible of Cerenkov<br />
Radiation (CR) emission which is prevalently in the<br />
visible range. The purpose of this work was to show<br />
that Cerenkov radiation escaping from tumour tissues<br />
of small living animals injected with 18 F-FDG<br />
can be detected with optical imaging (OI) techniques<br />
using a commercial optical instrument equipped<br />
with charged coupled detectors.<br />
Methods: In order to demonstrate as a proof of<br />
principle the possibility of imaging tumours using<br />
CR we studied an experimental model of mammary<br />
carcinoma named BB1. BB1 tumours were obtained<br />
by subcutaneous injection of BB1 cells, which are<br />
epithelial cells, from spontaneous mammary carcinomas<br />
of FVB transgenic mice for HER-2/neuT<br />
oncogene. The BB1 carcinomas exhibit histopatological<br />
and vascular features very similar to those<br />
of the parent spontaneous tumours. The BB1 mouse<br />
tumour model was well explained by Galiè and coworkers<br />
[2] and will not be described here.<br />
The images show a comparison between images acquired pre injection (left image) and 1 hour after 18F-<br />
FDG injection for two mice. White arrows indicate the position of the tumour masses.<br />
imaging life<br />
Mice injected with 18 F-FDG or saline solution underwent<br />
dynamic OI acquisition and a comparison<br />
between images were performed. Multispectral analysis<br />
of the radiation was used to estimate the deepness<br />
of the source of Cerenkov light. Small animal<br />
PET images were also acquired in order to compare<br />
the 18 F-FDG bio-distribution measured using OI<br />
and PET scanner.<br />
Results: The first Cerenkov in vivo whole body images<br />
of tumour bearing mouse and the measurements<br />
of the emission spectrum (560-660 nm range) were<br />
presented. Brain, kidneys and tumour were identified<br />
as a source of visible light in the animal body:<br />
the tissue time activity curves reflected the physiological<br />
accumulation of 18 F-FDG in these organs.<br />
The identification is confirmed by the comparison<br />
between CR and 18 F-FDG images.<br />
Conclusions: These results will allow the use of<br />
conventional optical imaging devices for the in<br />
vivo study of the cancer glucose metabolism and<br />
the assessment, for example, of anti-cancer drugs.<br />
Moreover this demonstrates that 18 F-FDG can be<br />
employed as it is as bimodal tracer for PET and OI<br />
techniques.<br />
References:<br />
1. Spinelli A E et al; Phys.<br />
Med. Biol. 55(2):483-<br />
495 (2010)<br />
2. Galiè M et al;<br />
C a r c i n o g e n e s i s .<br />
26:1868-1878 (2005)
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
A system for 4D (3D+Kinetics) molecular imaging in bioluminescence and fluorescence<br />
Maitrejean S. (1) , Kyrgyzov I. (1) , Bonzom S. (1) , Levrey O. (1) , Le Masne Q. (1) , Hernandez L. (1) , Raphael B. (2) .<br />
(1) Biospace Lab,<br />
(2) CEA/DSV/ I2BM / SHFJ / LIME.<br />
smaitrejean@biospacelab.com<br />
Introduction: Several technologies and systems are<br />
now capable of delivering tri-dimensional data in Bioluminescence<br />
and Fluorescence imaging. However, all<br />
are based on sequential acquisitions, and therefore any<br />
of them allow the production of real kinetic data in<br />
3D. In this work we demonstrate a new device which<br />
is able to acquire Bioluminescence and Fluorescence<br />
data from several views simultaneously, allowing the<br />
reconstruction of tri-dimensional images while keeping<br />
all kinetic properties of the acquisition.<br />
Methods: Multiple views of Bioluminescence and Fluorescence<br />
data are acquired simultaneously using a photon<br />
counting device (Photon ImagerTM) in which a<br />
specific add-on with four mirrors is installed. This device<br />
(named 4Views) allows the concurrent acquisition<br />
of the ventral, dorsal, right, and left views of the animal<br />
in a single image. The size and intensity of the four subimages<br />
(i.e. the four views) are corrected by taking the<br />
true optical path into account. The corrected photon<br />
counting data are recorded in a list mode file with time<br />
information (43 frame/s) as can be seen in Fig1.<br />
In a second step a micro video projector is used to<br />
project a moving spot on the animal. For each position<br />
of the spot, the<br />
height of the animal<br />
is calculated<br />
by triangulation<br />
and a map of the<br />
surface of the animal<br />
is produced.<br />
As the chosen<br />
reconstruction<br />
Fig1: simultaneous acquisition of four views<br />
in bioluminescence imaging.<br />
method is based<br />
on the finite elements<br />
method,<br />
the volume of the animal is represented by a tetrahedral<br />
mesh (about 30 000 tetrahedrons) using the Delaunay<br />
algorithm, while the surface is approximated<br />
by triangles, using a marching cube method. Then, the<br />
forward problem is solved for given light sources that<br />
are placed at the nodes of tetrahedrons and the light<br />
intensities on the surface of the triangles are computed.<br />
The forward problem is based in this first version on a<br />
diffusion model with average constant absorption and<br />
diffusion parameters. In a next version, a registration of<br />
the surface of the animal with an anatomical atlas will<br />
allow to use optical parameters associated with each<br />
organ. In the following step measured data is extracted<br />
from the list mode file and mapped on the triangulated<br />
surface. Since the detected events are stored separately,<br />
any time interval from 22 ms (one frame) up to the<br />
total scan duration can be used to create the data. In<br />
the last step of the process, the inner light sources are<br />
estimated as the result of the inverse problem using a<br />
least square criterion with a Tikhonoff regularization<br />
term. This regularisation term is chosen as an entropic<br />
term in order to favour connected solution. The two<br />
last steps can be performed using any time interval of<br />
the list mode file and therefore 3D kinetic data can be<br />
computed for times scales larger than 22 ms.<br />
Results: The validity of the method has been first tested<br />
using light beads (Microtek) inside a half cylinder of a<br />
scattering material (delrin). It has been demonstrated<br />
that two light beads as close as three millimetres could<br />
be separated, at a depth of one centimetre. A second<br />
set of tests has been realised on an animal (nude mice)<br />
by placing the light beads in the rectum of the animal.<br />
On the second image (Fig 2) , two beads 9 mm far from<br />
each other were placed in the rectum. It was possible to<br />
reconstruct the two positions of the light sources. The<br />
distance between the two reconstructed sources is 9.77<br />
mm in good agreement.<br />
Fig2: Reconstruction of two light sources based<br />
on the four views data of fig1.<br />
Conclusions: 3D optical reconstruction is known to<br />
be approximate, but can give useful and satisfactory<br />
results in a large number of applications. We have<br />
demonstrated that this four view approach is able to<br />
provide 3D kinetic molecular imaging data with a<br />
spatial accuracy similar to other methods.<br />
Acknowledgement: This work was supported in part<br />
by the DIMI and ENCITE networks.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
day1<br />
Parallel Session 3: TECHNOLOGY
44 Magnetic<br />
WarSaW, poland May 26 – 29, 2010<br />
The alignment of target-specific lipoCEST MRI contrast agents<br />
Langereis S. (1) , Burdinski D. (1) , Pikkemaat J. (1) , Gruell H. (1) , Huskens J. (2) .<br />
(1) Philips Research Europe,<br />
(2) University of Twente.<br />
sander.langereis@philips.com<br />
resonance imaging (MRI) offers a unique<br />
combination of advantages such as the recording<br />
of contrast enhanced and anatomical images with<br />
a high spatial resolution, while avoiding the use of<br />
ionizing radiation. MRI for imaging sparse molecular<br />
epitopes on diseased cells is hampered by its low<br />
sensitivity, which can potentially be overcome with<br />
liposomal chemical exchange saturation transfer (lipoCEST)<br />
contrast agents (CAs).1-3 In this case, MR<br />
detection is based on the saturation of the intraliposomal<br />
water signal with a selective radiofrequency<br />
pulse. Water exchange across the liposomal membrane<br />
causes partial saturation of the bulk water<br />
signal and, as a consequence, negative contrast enhancement<br />
in the MR image. For in vivo applications,<br />
it is crucial to achieve large intraliposomal chemical<br />
shifts of the water protons, as larger shifts allow for<br />
better lipoCEST contrast enhancement, reduce the<br />
interference with background magnetization transfer<br />
effects, and allow for frequency-based multiplexing.<br />
Large chemical shift differences have been<br />
obtained upon aspherical deformation of liposomes<br />
encapsulating a chemical shift agent in response to<br />
osmotic shrinkage, and the additional incorporation<br />
of amphiphilic, paramagnetic lanthanide complexes<br />
within the liposomal bilayer.<br />
The direction of the chemical shift is governed by<br />
the alignment of the aspherical liposomes in the external<br />
magnetic field, which in turn is dictated by<br />
the sign of the magnetic anisotropy of the incorporated<br />
amphiphilic lanthanide complex. The use of<br />
lipoCEST CAs as targeted probes for molecular MRI<br />
applications entails their specific binding and immobilization<br />
at the target site, for example, the surface<br />
of a biological structure or a cell. To maximize the<br />
imaging life<br />
attractive interactions, such aspherical liposomes<br />
will tend to align with the target structure (Scheme<br />
1).4 This enforced orientation may, however, be<br />
different from the magnetic alignment. As a consequence,<br />
the chemical shift of the intraliposomal<br />
water of the bound lipoCEST CA may differ from<br />
that of the unbound CA. It is therefore essential<br />
to understand the interplay between the preferred<br />
magnetic and the enforced mechanical alignment of<br />
such aspherical lipoCEST CAs. Herein, we address<br />
the alignment change of such aspherical liposomes<br />
upon multivalent binding to a target surface, which<br />
was studied by using routine CEST MR methods.4<br />
References:<br />
Fig1.: Reorientation of aspherical<br />
lipoCEST contrast agents upon<br />
binding to a target surface with<br />
respect to an external magnetic<br />
field (B0).4<br />
1. Aime, S.; Delli Castelli, D.; Terreno, E. Angew. Chem. Int.<br />
Ed. 2005, 44, 5513-5515.<br />
2. Terreno, E.; Cabella, C.; Carrera, C.; Delli Castelli, D.;<br />
Mazzon, R.; Rollet, S.; Stancanello, J.; Visigalli, M.; Aime,<br />
S. Angew. Chem. Int. Ed. 2007, 46, 966-968.<br />
3. Langereis, S.; Keupp, J.; van Velthoven, J. L. J.; de Roos,<br />
I. H. C.; Burdinski, D.; Pikkemaat, J. A.; Grüll, H. J. Am.<br />
Chem. Soc. 2009, 131, 1380-1381.<br />
4. Burdinski, D.; Pikkemaat, J. A.; Emrullahoglu, M.;<br />
Costantini, F.; Verboom, W.; Langereis, S.; Grüll, H.;<br />
Huskens, J. Angew. Chem. Int. Ed. 2010, 49, 2227-2229.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Lanthanide-based in vivo luminescence imaging<br />
Petoud S. .<br />
CNRS, France<br />
spetoud@pitt.edu<br />
Introduction: Fluorescence and luminescence<br />
are detection techniques that possess important<br />
advantages for bioanalytical applications and<br />
biologic imaging: high sensitivity, versatility and<br />
low costs of instrumentation. A common characteristic<br />
of biologic analytes is their presence in<br />
small quantities among complex matrices such as<br />
blood, cells, tissue and organs. These matrices<br />
emit significant background fluorescence (autofluorescence),<br />
limiting detection sensitivity.<br />
The luminescence of lanthanide cations has several<br />
complementary advantages over the fluorescence<br />
of organic fluorophores and semiconductor<br />
nanocrystals, such as sharp emission bands for<br />
spectral discrimination from background emission,<br />
long luminescence lifetimes for temporal<br />
discrimination and strong resistance to photobleaching.<br />
In addition, several lanthanides emit<br />
near-infrared (NIR) photons that can cross deeply<br />
into tissues for non-invasive investigations and<br />
that result in improved detection sensitivity due<br />
to the absence of native NIR luminescence from<br />
tissues and cells. The main requirement to obtain<br />
lanthanide emission is to sensitize them with an<br />
appropriate chromophore.<br />
Methods: An innovative concept for such sensitization<br />
of lanthanide cations is proposed herein;<br />
the current limitation of low quantum yields<br />
experienced by most mononuclear lanthanide<br />
complexes is compensated for by using larger<br />
numbers of lanthanide cations and by maximizing<br />
the absorption of each discrete molecule,<br />
thereby increasing the number of emitted photons<br />
per unit of volume and the overall sensitivity<br />
of the measurement. To apply this concept, we<br />
are developing a family of dendrimer-naphthalimide<br />
ligands that are able to incorporate several<br />
lanthanide cations. Polyamidoamine (PAMAM)<br />
dendrimers have been chosen as a basis for these<br />
complexes because the oxygen atoms of the amido<br />
groups located along their branches can bind<br />
and protect the lanthanide cations inside the<br />
dendrimer core.1,2 Derivatives of naphthalimide<br />
groups, required for the sensitization of the lanthanide<br />
cations, are located at the branch termini.<br />
Our synthetic approach allows facile modification<br />
of the dendrimer complex for control over<br />
photophysical properties and solubility. It also<br />
provides for the attachment of different types<br />
of targeting agents such as peptides, oligonucleotides<br />
or proteins, as well as other sensing agents,<br />
to provide functionality to these compounds in a<br />
broad range of applications.<br />
Results: In this paper, we will describe several<br />
examples of luminescent polymetallic lanthanide<br />
complexes based on dendrimers. We will also<br />
present examples of their applications as reporters<br />
and sensors for biologic imaging in living cells<br />
and small animals.<br />
References:<br />
1. J. P. Cross, M. Lauz, P. D. Badger, S. Petoud, Journal of<br />
the American Chemical Society, 2004, 126, 16278.<br />
2. D. R. Kauffman, C. M. Shade, H. Uh, A. Star and S. Petoud,<br />
Nature Chemistry 2009, 1, 500.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
day1<br />
Parallel Session 4: PROBES - supported by COST
46<br />
WarSaW, poland May 26 – 29, 2010<br />
New perspectives for imaging molecules and metabolism in vivo<br />
Gruetter R. .<br />
University of Lausanne and Geneva, Switzerland<br />
rolf.gruetter@epfl.ch<br />
Magnetic resonance imaging is subjected to continuous<br />
advances and discoveries, much of which are lead<br />
by either improved data acquisition techniques and/<br />
or higher magnetic fields or the detection of novel<br />
principles/contrast mechanisms altogether. This presentation<br />
will highlight on one hand the possibility<br />
to detect contrast agents at very low concentrations<br />
using a new approach to MR, based on hyperpolarized<br />
media using dissolution DNP. The potential<br />
will be demonstrated especially for long-lived nuclei<br />
with long T1, such as Lithium-6, Yttrium-89 and<br />
N-15, but also C-13 will be illustrated. The ability to<br />
detect low-concentration nuclei or rare spin nuclei<br />
imaging life<br />
opens new possibilities for molecular imaging. On<br />
the other side, for imaging molecules (metabolism)<br />
recent advances have allowed to attain in rodent<br />
brain a spatial resolution of below 1umol at 14.1<br />
Tesla that matches or even exceeds that possible by<br />
nuclear imaging modalities, in particular PET. The<br />
quantitative nature of the MR spectroscopic imaging<br />
approach allows insights into cellular biochemistry<br />
and metabolism that complements the capabilities<br />
of PET and SPECT and opens new windows on<br />
characterizing disease evolution and treatment opportunities,<br />
as will be illustrated with the example of<br />
ischemia and cancer, among others.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
In vivo biodistribution of radiolabeled matrix metalloproteinase-2 activatable cell<br />
penetrating peptides<br />
Van Duijnhoven S. (1) , Robillard M. (2) , Nicolaij K. (1) , Gruell H. (1) .<br />
(1) University of Technology Eindhoven, The Netherlands<br />
(2) Philips Research Laboratories. The Netherlands<br />
s.m.j.v.duijnhoven@tue.nl<br />
Introduction: Activatable cell penetrating peptides<br />
(ACPPs) are a new class of promising molecular<br />
imaging probes for the visualization of proteolytic<br />
activity in vivo [1-3] . The cell penetrating function of<br />
a polycationic peptide is efficiently blocked by intramolecular<br />
electrostatic interactions with a polyanionic<br />
peptide. Proteolysis of a cleavable linker<br />
present between the polycationic cell penetrating<br />
peptide and the polyanionic peptide affords dissociation<br />
of both domains and enables the activated<br />
cell penetrating peptide to enter cells. Fluorescently<br />
labeled ACPPs cleavable by matrix metalloproteinase-2<br />
(MMP-2) have been reported as specific<br />
probes for MMP-2 expressing tumors in mice [1-3] .<br />
Here, we developed MMP-2 activatable dual isotope<br />
radiolabeled ACPPs and assessed their in vivo<br />
biodistribution in HT-1080 tumor-bearing mice.<br />
These probes enabled us to discriminate activated<br />
from intact ACPP.<br />
Methods: MMP-2 activatable and non-activatable<br />
cell penetrating peptides (ACPP and non-ACPP, respectively)<br />
containing an n-terminal tyrosine were<br />
prepared by Fmoc solid-phase peptide synthesis,<br />
site specifically conjugated with DOTA chelate succinimidyl<br />
ester at the c-terminus, purified by HPLC,<br />
and characterized by LC-MS. Furthermore, a DOTAconjugated<br />
cell penetrating peptide (CPP) was synthesized<br />
as positive control. Nude mice were injected<br />
subcutaneously with approximately 3.0 x 10 6 MMP-2<br />
positive HT-1080 fibrosarcoma cells. When the<br />
tumors reached a size of 8-50 mm 3 , the mice (n=6<br />
per probe) were used for in vivo studies. Therefore,<br />
the cell penetrating peptide and polyanionic peptide<br />
of ACPP or non-ACPP (60 nmol) were labeled<br />
with 177 Lu and 125 I, respectively, analyzed by iTLC<br />
and HPLC, injected into the tail vein, and in vivo<br />
biodistribution was determined 24h post-injection.<br />
Results: Radiolabeled ACPP (>98% radiochemical<br />
purity for both 177 Lu and 125 I) showed a significant<br />
~3-fold increase in tumor uptake relative to a negative<br />
control peptide with a scrambled linker (t-test,<br />
p
YIA applicant<br />
48 Introduction:<br />
WarSaW, poland May 26 – 29, 2010<br />
Bioresponsive MRI contrast agents based on self-assembling β-cyclodextrin nanocapsules<br />
Martinelli J. (1) , Fekete M. (1) , Tei L. (1) , Botta M. (1) .<br />
Università del Piemonte Orientale “A. Avogadro”, Italy<br />
jonathan.martinelli@unipmn.it<br />
One of the most exciting research area<br />
in the development of MRI contrast agents is the design<br />
of responsive or “smart” probes, whose performance<br />
is modulated by changes in physiological environment<br />
such as pH, partial oxygen pressure, metal<br />
ion concentration, enzyme activity etc. We have designed<br />
and synthesized a new type of nanosized Gdbased<br />
MRI probe containing disulfide bonds, that<br />
can be activated (i.e. switched on or off) under reducing<br />
conditions like those where specific enzymes<br />
or high radical concentrations are associated with a<br />
disease state (e.g. tumors, strokes etc.). The activation<br />
of the agent is signaled by a large change in the<br />
relaxation properties.<br />
Methods: The macromolecular architecture of the<br />
agent is based on nanocapsules prepared from perthiolated<br />
β-cyclodextrins via oxidation of the thiol<br />
groups to form S-S bridges.1 The assembly was<br />
carried out in the presence of either an equimolar<br />
amount or an excess of Gd-benzyl-AAZTA2 as the<br />
MRI-active paramagnetic complex, able to form<br />
inclusion adducts with the cyclodextrin buildingblocks<br />
and thus being “trapped” inside the capsules<br />
during their formation. After purification of the<br />
nanomaterials and removal of the external Gd-complexes<br />
by prolonged dialysis, the macromolecular<br />
systems were characterized by analytical and NMR<br />
relaxometric techniques. Reduction kinetic experiments<br />
were carried on by monitoring the variation<br />
in the longitudinal relaxation rate vs. time upon addition<br />
of tris(2-carboxyethyl)phosphine (TCEP)3 as<br />
a reducing agent able to cleave the disulfide bonds<br />
between the CD units.<br />
Results: High relaxivity nanoparticles made up of several<br />
β-CD units were formed which include in the inner<br />
core a relatively large number of Gd-chelates. The<br />
ICP analyses and NMRD profiles confirmed that a<br />
significant amount of complex was caged within the<br />
macromolecular structures. The relaxivity is as high<br />
as 22 mM-1 s-1 at 20 MHz and 25 °C for the system<br />
prepared with a 5:1 complex/CD ratio. Dynamic light<br />
scattering measurements also showed that the size of<br />
the nanocapsules prepared in the presence of the Gdcomplex<br />
is sensibly bigger than in its absence (120-<br />
200 nm vs. 30 nm). Following addition of TCEP and<br />
imaging life<br />
cleavage of the S-S bridges, a significant decrease (ca.<br />
30%) in the water proton relaxation rate was observed.<br />
Conclusions: The high relaxivity values measured for<br />
the Gd-loaded nanocapsules imply a high permeability<br />
of water through the cyclodextrin units of the surface<br />
shell. Upon disruption of the nanoparticles following<br />
the cleavage of the disulfide bonds between<br />
the CD units by the reducing agent TCEP, the complexes<br />
are released and originate an equilibrium between<br />
the free form and their adduct with the monomeric<br />
CDs. This is signaled by a remarkable decrease<br />
in the relaxivity as a consequence of the shortening<br />
of the reorientational correlation time τR.<br />
According to these data, our β-cyclodextrin nanocapsules<br />
containing Gd-complexes appear to be<br />
promising as MRI contrast agents responsive to<br />
reducing biological environments.<br />
Acknowledgement: This work is supported by the<br />
Regione Piemonte (Italy) as part of the NanoIGT<br />
project.<br />
References:<br />
1. Jones, L. C.; Lackowski, W. M.; Vasilyeva, Y.; Wilson, K.;<br />
Chechik, V. Chem. Commun. 2009, 1377-1379.<br />
2. Aime, S.; Calabi, L.; Cavallotti, C.; Gianolio, E.; Giovenzana,<br />
G. B.; Losi, P.; Maiocchi, A.; Palmisano, G.; Sisti, M. Inorg.<br />
Chem. 2004, 43, 7588-7590.<br />
3. Burns, J. A.; Butler, J. C.; Moran, J.; Whitesides, G. M. J.<br />
Org. Chem. 1991, 56, 2648-2650.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Photochemical activation of endosomal escape of MRI-Gd-agents in tumor cells<br />
Gianolio E. (1) , Arena F. (1) , Hogset A. (2) , Aime S. (3) .<br />
(1) Centro di Imaging Molecolare,<br />
(2) PCI Biotech AS Laboratories,<br />
(3) Molecular Imaging Center, Torino Italy.<br />
eliana.gianolio@unito.it<br />
Introduction: The cellular uptake of xenobiotics often<br />
procedes through the entrapment into endosomes. As<br />
recently reported1,2, in the case of cellular labeling with<br />
Gd-based complexes, the confinment into endosomal<br />
vesicles negatively affects the attainable relaxation enhancement<br />
of water protons. In fact it has been shown<br />
that, upon increasing the number of Gd(III) per cell, a<br />
quenching effect on the observed relaxivity takes place.<br />
It is the consequence of the fact that the term |R1end<br />
– R1cyt| is > than the water exhange rate between the vesicular<br />
and cytosolic compartments. In this communication<br />
we report an efficient method for endosomal escape<br />
of paramagnetic Gd(III) chelates that yields to a marked<br />
improvement of the efficiency in cellular labeling.<br />
Methods: The Photosensitizer TPPS2a (LumiTrans®)<br />
and the Lumisource® lamp were provided by PCI Biotech<br />
AS laboratories (Oslo, Norway). For cellular labeling,<br />
ca. 3-4×106 HTC,K562, NEURO2A and C6 cells<br />
were incubated for 18 hours at 37°C with different concentrations<br />
(5-100mM) of Gd-HPDO3A in the absence<br />
and in the presence of the Photosentisizer (2µl/ml). After<br />
this incubation time cells were washed three times<br />
and incubated for additional 4 hours at 37°C. Then the<br />
cells containing the Photosentisizer were exposed to LumiSource<br />
light for 5 minutes. Then cells were detached,<br />
washed and transferred into glass capillaries for registraion<br />
of MR-images on a Bruker Avance300 spectrometer<br />
operating at 7.1T.<br />
K562 cells<br />
B<br />
K562 cells<br />
A<br />
C<br />
D<br />
E<br />
F<br />
G<br />
R1obs (s -1 )<br />
10<br />
9<br />
8<br />
7<br />
6<br />
5<br />
4<br />
3<br />
2<br />
1<br />
0,0 5,0x10 9<br />
1,0x10 10<br />
Number of Gd 3+ / cell<br />
1,5x10 10<br />
Fig.1: A) T 1 -weighted spin echo images of K562 cells labeled with Gd-HPDO3A. Phantoms E, F<br />
and G contain cells treated with the PCI technology while phantoms B, C, and D contain cells<br />
simply labeled by pynocitotic uptake. B) Observed relaxation rates of cells (HTC stars; NEURO-2a<br />
circles; C6 triangles) labelled with Gd-HPDO3A with endosomic (black symbols) distribution as<br />
a function of the number of Gd(III) found in each cell.<br />
Results: The cellular labeling has been pursued<br />
by pynocitosis (18h at 37°C) at different concentration<br />
of Gd-HPDO3A in the presence and in<br />
the absence of PCI treatment. As shown in the<br />
figure 1A, a marked enhancement in the labeling<br />
efficiency has been observed upon application<br />
of photochemical stimulus to cells entrapping<br />
Gd-HPDO3A and TPPS2a. This considerable<br />
gain in signal intensity achieved when cells are<br />
processed with PCI tehnology is due to the release<br />
of Gd-units from endosomes to cytosol. As<br />
shown in Fig. 1B, the “quenching” effect on the<br />
relaxivity of cells processed with PCI technology<br />
is reached when the number of Gd-HPDO3A per<br />
cell is ca. One order of magnitude higher than the<br />
number causing the same effect when the paramagnetic<br />
complexes are confined into endosomes.<br />
Thus, on going from the endosome-entrapped to<br />
cytoplasm-entrapped Gd(III), the paramagnetic<br />
loading can be several times higher thus allowing<br />
a marked improvement in the MRI detection of<br />
labelled cells.<br />
Conclusions: The PCI methodology appears an<br />
excellent route to pursue the endosomal escape of<br />
Gd-HPDO3A molecules entrapped by pynocitosis<br />
in different types of cells. It as been shown that<br />
it allows to exploit high payload of Gd-HPDO3A<br />
before the quenching effect becomes detectable.<br />
Fig. 1: A) T1-weighted spin echo<br />
Neuro<br />
images of K562 cells Neuro_lumi labeled with<br />
Gd-HPDO3A. Phantoms Htc E, F and G<br />
contain cells treated Htc_lumi with the PCI<br />
C6<br />
technology while phantoms C6_Lumi B,C and<br />
D contain cells simply labeled by<br />
pynocitotic uptake. B) Observed<br />
relaxation rates of cells (HTC stars;<br />
NEURO-2a circles; C6 triangles)<br />
labelled with Gd-HPDO3A with<br />
endosomic (black symbols) or<br />
cytoplasmatic (red symbols)<br />
distribution as a function of the<br />
number of Gd(III) found in each cell.<br />
References:<br />
1. Terreno, E et al., Magnetic<br />
Resonance in Medicine,<br />
2006, 55, 491-497.<br />
2. Strijkers G.J. et al. 2009,<br />
61, 1049-58.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
day1<br />
Parallel Session 4: PROBES - supported by COST
50 Education<br />
WarSaW, poland May 26 – 29, 2010<br />
and Research Experience:<br />
Degree in Medicine and Surgery at the Catholic University of Rome (Italy).<br />
Membership of the College of Physicians and Surgeons of Rome (Italy).<br />
Specialization in Neurology at the Catholic University of Rome (UCSC).<br />
Post-graduate research at the laboratory of muscular disease of the neurological department at the Catholic<br />
University of Rome (UCSC).<br />
PhD in Neuroscience at the Neuroscience Department of the Catholic University of Rome (UCSC) within a<br />
joint collaboration with the department of Neuroimmunology of the Max Planck Institute for Neurobiology<br />
(Martinsried, Germany).<br />
Post doctoral position at the Max Planck Institute of Neurobiology, department of Neuroimmunology<br />
(Martinsried, Germany).<br />
Group leader position at the Institute for Multiple Slerosis Research (IMSF) of the Georg-August Universität<br />
of Göttingen.<br />
Dissertation: Visualization of antigen presentation and T cell activation after treatment with high doses of<br />
soluble antigen.<br />
Selected references:<br />
• I. Bartholomäus, N. Kawakami, F. Odoardi, C. Schläger, D. Miljkovic, J.W. Ellwart., W.E.F Klinkert., C. Flügel-Koch, T.B.<br />
Issekutz, H. Wekerle, A. Flügel. Effector T cell interactions with meningeal vascular structures in nascent autoimmune<br />
lesions, Nature. 2009 Nov 5; 462 (7269):94-8.<br />
• W. Dammermann+, B. Zhang+, M. Nebel+, C. Cordiglieri+, F. Odoardi, T. Kirchberger, N. Kawakami, J. Dowden, F.<br />
Schmid, K. Dornmair, M. Hohenegger, A. Flügel*, A.H. Guse*, B.V.L. Potter* (2009) NAADP mediated Ca2+ signaling via<br />
type 1 ryanodine receptor in T cells revealed by a synthetic NAADP antagonist, PNAS, 2009 Jun 30; 106 (26): 10678-83.<br />
+,* equal contribution.<br />
• Odoardi F, Kawakami N, Klinkert WE, Wekerle H, Flügel A. Blood-borne soluble protein antigen intensifies T cell activation<br />
in autoimmune CNS lesions and exacerbates clinical disease. Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18625-30.<br />
• Flügel A, Odoardi F, Nosov M, Kawakami N. Autoaggressive effector T cells in the course of experimental autoimmune<br />
encephalomyelitis visualized in the light of two-photon microscopy. J Neuroimmunol. 2007 Nov;191(1-2):86-97.<br />
• Odoardi F, Kawakami N, Li Z, Cordiglieri C, Streyl K, Nosov M, Klinkert WE, Ellwart JW, Bauer J, Lassmann H, Wekerle H,<br />
Flügel A. Instant effect of soluble antigen on effector T cells in peripheral immune organs during immunotherapy of<br />
autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):920-5.<br />
• Kawakami N, Nägerl UV, Odoardi F, Bonhoeffer T, Wekerle H, Flügel A. Live imaging of effector cell trafficking<br />
and autoantigen recognition within the unfolding autoimmune encephalomyelitis lesion. J Exp Med. 2005 Jun<br />
6;201(11):1805-14.<br />
imaging life<br />
Francesca Odoardi
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Immune surveillance and autoimmunity: how encephalitogenic T cells enther their target organ<br />
Odoardi F. .<br />
Max Planck Institute of Neurobiology, Germany<br />
odoardi@neuro.mpg.de<br />
Introduced in the immunological field in 2002<br />
two-photon microscopy is the method of choice<br />
for visualizing living cells in their anatomical<br />
compartment because it allows to image deep<br />
in the tissue with negligible phototoxicity and<br />
photobleaching. We applied this technique in order<br />
to visualize in living Lewis rat the fate of genetically<br />
labeled MBP specific effector T cells in the menigeal<br />
vessels during the initial phase of experimental<br />
autoimmune encephalomyelitis, a classical model of<br />
multiple sclerosis. We observed that the incoming<br />
cells remained in close association with pial blood<br />
vessels, crawling on surfaces within the outline of<br />
the vessels. This behavior was specific to the CNS:<br />
in peripheral organs, for example in peripheral<br />
nerves, muscle or subcutaneous tissue, MBP T<br />
cells mainly rolled along the inner surface of the<br />
vessels. The crawling was completely abolished by<br />
the treatment with anti VLA-4 and LFA-1 antibodies.<br />
After diapedesis, the cells continued their scan on<br />
the abluminal vascular surface and the underlying<br />
leptomeningeal (pial) membrane. Here they<br />
established contact with local meningeal phagocytes<br />
and these interactions were crucial to induce the<br />
production of proinflammatory and to trigger<br />
tissue invasion.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
day1<br />
<strong>ESMI</strong> Plenary Lecture 2 by Francesca Odoardi
52 Introduction:<br />
WarSaW, poland May 26 – 29, 2010<br />
Exendin-4 derivatives labeled with radiometals for the detection of insulinoma: a “from<br />
bench to bed approach”<br />
Wild D. (1) , Wicki A. (1) , Mansi R. (1) , Béhé M. (1) , Keil B. (1) , Bernhardt P. (1) , Christofori G. (1) , Ell P. J. (1) , Reubi J. C. (1) , Maecke H. (1) .<br />
(1) University of Freiburg, Department of Nuclear Medicine<br />
damian.wild@uniklinik-freiburg.de<br />
Strong overexpression of glucagonlike<br />
peptide-1 (GLP-1) receptors in human insulinoma<br />
provides an attractive target for imaging.<br />
We have shown that GLP-1 receptor SPECT/CT<br />
using a Lys(Ahx-DOTA)NH2 C-terminal extended<br />
Exendin-4 derivative labeled with 111In shows<br />
high sensitivity in the detection of hardly detectable<br />
insulinoma [1]. For obvious reasons 111In<br />
is not an ideal nuclear imaging probe label. We<br />
therefore aimed at the development of 99mTc-<br />
(SPECT/CT) and 68Ga-, 64Cu-(PET/CT) labeled<br />
peptides. In addition we extended our clinical<br />
studies with a DTPA-modified peptide for higher<br />
specific activity labeling with 111In.<br />
Methods: Internalisation, biodistribution and<br />
imaging studies were performed in the Rip1Tag2<br />
mouse model and the corresponding cell line.<br />
The Results were compared with the “gold standard”<br />
Lys40(Ahx-DOTA-111In)NH2-Exendin-4.<br />
Kidney blocking was studied with poly-glutamic<br />
acid and Gelofusine. Clinical data were obtained<br />
with the 111In-labeled DTPA-analog.<br />
Results: The tumor uptake of Lys40(Ahx-DOTA-<br />
68Ga)NH2-Exendin-4 was very high, at 205±59<br />
%IA/g (1h pi) and was very similar to Lys40(Ahx-<br />
DOTA-111In) NH2-Exendin-4. > 90% of this<br />
uptake could be blocked by the preinjection of<br />
cold peptide. Normal organs showed much lower<br />
uptake resulting in a high lesion-to-background<br />
ratio. Kidney uptake was high and comparable<br />
to the tumor uptake. Lys40(Ahx-HYNIC-99mTc/<br />
EDDA)NH2-Exendin-4 shows distinctly lower<br />
tumor but also normal tissue uptake. Tumors<br />
with 1-3.2 mm in size could be visualised easily<br />
by SPECT and PET.<br />
The kidney uptake could be reduced by 49-78%<br />
using poly-glutamic acid, Gelofusine or a combination<br />
of both.<br />
Clinical studies using SPECT/CT with Lys40(Ahx-<br />
DTPA-111In)NH2-Exendin-4showed 100% sensitivity<br />
in the localisation of benign insulinoma<br />
of the first consecutive 13 patients. Some of the<br />
localisations such as an ectopic insulinoma could<br />
imaging life<br />
only be localised with SPECT/CT. Due to the long<br />
residence time in the tumor intraoperative localisation<br />
with an endoscopic gamma probe was possible<br />
even 2 weeks i.p..<br />
Conclusions: These very promising pharmacokinetic<br />
data show that the two new imaging probes<br />
are good candidates for clinical translation: Especially<br />
the 99mTc-labeled peptide may increase<br />
the availability and distribution of the method<br />
whereas the 68Ga derivative may even allow to<br />
image and localise very small lesions<br />
Acknowledgement: Oncosuisse grant No OSC-<br />
01778-08-2005 and grants from the Novartis<br />
Foundation and Swiss National Science Foundation<br />
are gratefully achnowledged.<br />
References:<br />
1. Wild D, Macke H, Christ E, Gloor B, Reubi JC. Glucagonlike<br />
peptide 1-receptor scans to localize occult<br />
insulinomas. N Engl J Med. 2008;359(7):766-768.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Assessment of HIF transcriptional activity in a mouse tumor model using GPI anchored avidin–<br />
a novel protein reporter for in vivo imaging<br />
Lehmann S. (1) , Garcia E. (2) , Blanc A. (2) , Schibli R. (2) , Keist R. (1) , Rudin M. (1) .<br />
(1) Animal imaging center,<br />
(2) Paul Scherrer Institute, Villigen, Switzerland.<br />
lehmann@biomed.ee.ethz.ch<br />
Introduction: With the emergence of multimodal<br />
imaging approaches genetic reporters, which can be<br />
flexibly combined with multiple imaging methods,<br />
are highly attractive. Here we present the feasibility<br />
of using glycosylphosphatidylinositol anchored avidin<br />
(av-GPI) (1) as a novel reporter for multimodal<br />
in vivo imaging. Expressed on the extracelluar side<br />
of cell membranes, av-GPI can be targeted with<br />
biotinylated imaging probes. In this study, we employed<br />
av-GPI to read out on the activity of hypoxia<br />
inducible factors (HIFs) in tumors. Induced by tumor<br />
hypoxia to mediate the adaptation of cells to<br />
low oxygen tensions these transcription factors play<br />
an important role in cancer progression. Typically,<br />
the expression of HIF in human cancer patients is<br />
associated with more aggressive tumor phenotypes<br />
and poor patient prognosis. Imaging HIF activity<br />
in live tumors hence provides an important tool to<br />
study the mechanisms leading to its activation in<br />
cancer.<br />
Methods: Mouse C51 cells were stably transfected<br />
with pH3SVG, a reporter construct driving the<br />
expression of avidin-GPI from a minimal SV40<br />
promoter and 3 hypoxia response element (HRE),<br />
bound by HIF, from the human transferrin gene<br />
(2). To monitor HIF activity in vivo, pH3SVG transfected<br />
C51 cells were subcutanouesly implanted into<br />
Balb/C nude mice. 10 days after tumor inoculation,<br />
mice received an i.v. injection of alexa-594-biocytin<br />
and were imaged using fluorescence reflectance<br />
imaging.<br />
Results: Fluorescence stainings of av-GPI expressing<br />
cells demonstrated that this protein is specifically expressed<br />
on the extracellular side of cell membranes.<br />
Moreover, upon pharmacological activation of HIF,<br />
we observed a shift in fluorescence indicative of<br />
an increased expression of av-GPI in fluorescent<br />
activated cell sorting (FACS) experiments involving<br />
pH3SVG transfected cells. In vivo fluorescence<br />
imaging showed a specific uptake of a biotinylated<br />
dye (alexa-594-biocytin) in the tumor from 60 minutes<br />
after contrast injection, whilst there was no<br />
accumulation of an unbiotinylated control probe<br />
(alexa-594-cadaverine). On ex vivo tissue sections<br />
alexa-594 biocytin was found to co-localize with<br />
zones positive for pimonidazole, a commonly used<br />
hypoxia marker (3) but also showed staining in regions<br />
devoid of pimonidazole uptake. In additional<br />
experiments, biotinylated 67Ga-DOTA was shown<br />
to specifically label avidin expressing cells in vitro.<br />
Conclusions: Overall, we demonstrate the utility<br />
of av-GPI as a reporter for in vivo imaging of HIF<br />
transcriptional activity in an optical, fluorescence<br />
reflectance approach. In vitro binding studies with<br />
67Ga-DOTA showed a high specificity of the probe<br />
in targeting av-GPI in cells, which implies that<br />
this reporter can indeed be combined with different<br />
imaging modalities. Its application in SPECT is<br />
currently being tested.<br />
References:<br />
1. Pinaud, F., King, D., Moore, H.-P. & Weiss, S. (2004)<br />
Bioactivation and Cell Targeting of Semiconductor<br />
CdSe/ZnS Nanocrystals with Phytochelatin-Related<br />
Peptides. Journal of the American Chemical Society<br />
126: 6115-6123<br />
2. Wanner, R. M., et al. (2000) Epolones induce<br />
erythropoietin expression via hypoxia-inducible<br />
factor-1 alpha activation. Blood 96: 1558-65<br />
3. Raleigh, J. A., et al. (1998) Hypoxia and vascular<br />
endothelial growth factor expression in human<br />
squamous cell carcinomas using pimonidazole as a<br />
hypoxia marker. Cancer Res 58: 3765-8<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
YIA applicant<br />
day1<br />
Plenary Session on Excellent and Late Breaking Abstracts
YIA applicant<br />
54 Introduction:<br />
WarSaW, poland May 26 – 29, 2010<br />
A leukocyte ligand of vascular adhesion protein-1 as an imaging tool in PET<br />
Autio A. (1) , Saanijoki T. (1) , Sipilä H. (1) , Jalkanen S. (2) , Roivainen A. (3) .<br />
(1) Turku PET Centre,<br />
(2) MediCity Research Laboratory, National Public Health Institute,<br />
(3) Turku PET Centre, Turku Centre for Disease Modeling.<br />
akauti@utu.fi<br />
Vascular adhesion protein-1 (VAP-1)<br />
is both an endothelial glycoprotein and a semicarbazide-sensitive<br />
amine oxidase (SSAO) enzyme playing<br />
a critical role in leukocyte trafficking to the sites of<br />
inflammation. Although VAP-1 was identified more<br />
than 15 years ago, the leukocyte ligand has remained<br />
unknown until very recently. Last year it was shown<br />
that Siglec-10 (sialic acid-binding immunoglobulinlike<br />
lectin) expressed on a subpopulation of lymphocytes<br />
can bind to VAP-1 and serve as its substrate [1].<br />
According to phage display screening and structural<br />
modeling also Siglec-9 expressed on granulocytes<br />
and monocytes interacts with VAP-1. In this study,<br />
we investigated a Siglec-9 peptide as a potential imaging<br />
tool in positron emission tomography (PET).<br />
Methods: A cyclic peptide binding to recombinant<br />
human VAP-1 was conjugated with DOTA-chelator<br />
through PEG-linker and 68Ga-labeled for PET<br />
studies as previously described [2]. The interaction<br />
between VAP-1 and 68Ga-Siglec-9 peptide<br />
was evaluated in vitro in human plasma samples<br />
possessing different SSAO levels. The VAP-1 specificity<br />
was further tested with competition assay in<br />
mice bearing melanoma xenografts by PET imaging<br />
and autoradiography. In vivo imaging of inflammation<br />
was examined in a rat model. All in vivo<br />
studies were confirmed by ex vivo measurements.<br />
Standardized uptake value<br />
a Tumor<br />
b Tumor<br />
c<br />
500<br />
P
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Clinical translation of ex vivo sentinel lymph node mapping for colorectal cancer using<br />
invisible near-infrared fluorescence light<br />
Hutteman M. (1) , Choi H. S. (2) , Mieog S. (1) , Van Der Vorst J. (1) , Ashitate Y. (2) , Kuppen P. (1) , Löwik C.W.G.M. (1) , Van De Velde C. (1) ,<br />
Frangioni J. (2) , Vahrmeijer A. (1) .<br />
(1) Leiden University Medical Center,<br />
(2) BIDMC / Harvard Medical School.<br />
m.hutteman@lumc.nl<br />
Introduction: Sentinel lymph node (SLN) mapping<br />
in colorectal cancer may have prognostic and therapeutic<br />
significance, however, currently available<br />
techniques are not optimal. We hypothesized that<br />
the combination of invisible near-infrared (NIR)<br />
fluorescent light and ex vivo injection could solve<br />
remaining problems in the field.<br />
Methods: The FLARE imaging system was used<br />
for real-time identification of SLNs after injection<br />
of the lymphatic tracer HSA800 in the colon and<br />
rectum of (n = 4) pigs. A total of 32 SLN mappings<br />
were performed in pigs, in vivo and ex vivo after oncologic<br />
resection, using an identical injection technique.<br />
Guided by these results, SLN mappings were<br />
performed in ex vivo tissue specimens of 6 colorectal<br />
cancer patients undergoing resection (Figure 1).<br />
Results: Using NIR fluorescent imaging, lymph<br />
flow could be followed in real-time from the injection<br />
site to the SLN. Pre-clinically, in pigs, the SLN<br />
was identified in 32/32 (100%) SLN mappings in<br />
both colon and rectum, under both in vivo and ex<br />
COLON<br />
RECTUM<br />
Color<br />
Fig1.: NIR Fluorescence-Guided SLN Mapping in Patients with Colorectal Cancer<br />
vivo conditions. Clinically, SLNs were identified in<br />
all patients (n = 6) using the ex vivo strategy (Figure<br />
1). No false negatives were found. SLNs were<br />
identified within 5 minutes after injection of the<br />
fluorescent dye.<br />
Conclusions: The current study shows proof of<br />
principle that ex vivo NIR fluorescence-guided SLN<br />
mapping can provide high-sensitivity, rapid, and accurate<br />
identification of SLNs in colon and rectum.<br />
This will permit optimized, non-FDA-approved NIR<br />
fluorescent lymphatic tracers to be translated immediately<br />
to the clinic.<br />
NIR Fluorescene Color-NIR Merge<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
YIA applicant<br />
day1<br />
Plenary Session on Excellent and Late Breaking Abstracts
YIA applicant<br />
56<br />
WarSaW, poland May 26 – 29, 2010<br />
Development of strategies for in vivo MRI and Optical Imaging of neural stem cells distribution<br />
for the treatment of traumatic spinal cord injury<br />
Lui R. (1) , Merli D. (1) , Libani I. V. (1) , Madaschi L. (1) , Marra F. (1) , Marfia G. (1) , Carelli S. (1) , Clerici M. S. (2) , Gorio A. (3) ,<br />
Lucignani G. (1) , Ottobrini L. (1) .<br />
(1) University of Milan,<br />
(2) University of Milan and Don Gnocchi Foundation IRCCS,<br />
(3) University of Milan and Humanitas IRCCS, Rozzano, Milan.<br />
ramona.lui@unimi.it<br />
Introduction: The use of adult stem cells in cell-mediated<br />
therapies is an area of considerable interest within<br />
tissue regeneration research. However, important<br />
parameters such as the distribution of the injected<br />
cells, cell survival, target organ localisation, cell proliferation<br />
and differentiation cannot be evaluated in<br />
vivo. Here we propose multiple labelling protocols<br />
for in vivo visualisation by MRI, and Optical fluorescence<br />
imaging of murine neural stem cells (mNSC)<br />
originating from the subventricular zone of the adult<br />
murine brain in spinal cord injury animal models.<br />
Methods: mNSC were isolated and cultured as<br />
described[1]. Cells were directly labelled for 24 hours<br />
with 200 μg Fe/ml of SPIOs (Endorem®) in presence<br />
of different amount of Protamine Sulphate (PS) (ratio<br />
Fe/PS 1:0,025; 1:0,05) and immediately analysed<br />
for viability, iron content (Perl’s Staining and spectrophotometer<br />
analysis), morphology, staminality<br />
and differentiation capability. Labelled cells were<br />
injected into the tail vein of a spinal cord injury<br />
murine model and followed by MRI for a month to<br />
visualize their distribution. Initial cell distribution<br />
was also followed with scintigraphy after cell labelling<br />
with 111Indium-oxine (60 μCi/106 cells). Cells<br />
localization, distribution e viability, over time, were<br />
analysed in vivo with CCD camera after injection of<br />
mNCS infected with a viral vector expressing Luciferase<br />
under a PGK promoter (PLW vector).<br />
Results: mNSC incubated for 24 with 200 μg Fe/ml<br />
Endorem® did not show significant differences in<br />
terms of viability and proliferation rate between labelled/non-labelled<br />
cells in presence or absence of<br />
different amount of PS[2]. The percentage of viable<br />
cells was 85% for Fe/PS 1:0.025 ratio, and 77% for<br />
Fe/PS 1:0.05 ratio compared to the 95% of the control.<br />
On the contrary, the percentage of iron-positive<br />
cells increased in proportion to the PS content in the<br />
medium. In particular we obtained 94,5% of ironpositive<br />
cells in the samples incubated with Fe/PS<br />
1:0.025 ratio and 99% iron-positive cells in the samples<br />
incubated with Fe/PS 1:0.05 ratio. The iron content<br />
increased from 110 pg Fe/cell to 210 pg Fe/cell<br />
increasing PS concentration. In both cases, labelled<br />
cells were able to give rise to floating neurospheres<br />
imaging life<br />
as observed by optical microscopy after further 5<br />
days of culture, demonstrating their maintenance<br />
of the self-renewal capability. Immune fluorescence<br />
analysis for Nestin confirmed these data. Differentiation<br />
capability was also maintained as confirmed<br />
by β-TubulinIII and GFAP expression. Scintigraphic<br />
techniques confirmed initial distribution to lung,<br />
spleen and liver while MRI showed iron signal due<br />
to stem cell localization into the lesion site at 21 and<br />
28 days after injection. Neural stem cells, infected<br />
with the viral vector PLW, were detected up to one<br />
week after i.v. injection within the lesion of injured<br />
mice. Infected cells intramedullary injected as control<br />
were detected at the same timepoint as well.<br />
Conclusions: These results showed that adult neural<br />
stem cells can be efficiently labelled with different<br />
molecules without significantly perturbing physiological<br />
stem cell features and self-renewal capability.<br />
This labelling protocols can be applied for<br />
the in vivo visualisation by MRI, scintigraphy, and<br />
Luminescence imaging of the distribution of stem<br />
cells after their transplantation into murine model<br />
of disease.<br />
Acknowledgement: this work is supported by CAR-<br />
IPLO Foundation grant. Dr Lui R is supported by a<br />
fellowship from the Doctorate School of Molecular<br />
Medicine, University of Milan.<br />
References:<br />
1. Bottai D et al. Mol Med (2008) 14:634-644<br />
2. Politi LS et al. Neuroradiology (2007) 49:523–534
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Validation of bone marrow-derived stromal cell graft position by colocalisation of histology,<br />
bioluminescence and magnetic resonance imaging.<br />
De Vocht N., Van Der Linden A. .<br />
Universiteit Antwerpen – Bio Imaging Lab<br />
nathalie.devocht@ua.ac.be<br />
Introduction: The use of stem cell transplantation<br />
as a therapeutic tool to treat neurodegenerative disorders<br />
(e.g. traumatic brain injury, stroke, multiple<br />
sclerosis) has gained increasing interest over the<br />
last decade. However, a profound knowledge of cell<br />
implant migration, differentiation and survival will<br />
be necessary to understand the physiological mechanisms<br />
involved in regeneration of injured brain tissue.<br />
For this, the development of multimodal cell<br />
imaging techniques, both in vivo and post-mortem,<br />
is currently of highest importance.<br />
Methods: We optimised a multimodal labelling<br />
strategy for bone marrow-derived stromal cells<br />
(BMSC), based on (i) genetic modification with<br />
both the eGFP and Luciferase reporter genes, and<br />
(ii) endocytic uptake of blue fluorescent magnetite-containing<br />
micron-sized particles (MPIO).<br />
This combined labelling strategy allows unambiguous<br />
identification of cell localisation, survival<br />
and differentiation using pre-mortem bioluminescence<br />
/ magnetic resonance imaging (BLI/MRI)<br />
and post-mortem histological analysis.<br />
Results: For this study, we labelled Luciferase/<br />
eGFP-expressing BMSC (BMSC-Luc/eGFP, Bergwerf<br />
et al. 2009) with 1.63 µm fluorescent (Glacial<br />
Blue) MPIOs from Bangs Laboratories. MPIO labelling<br />
of BMSC-Luc/eGFP did not influence their<br />
phenotypic properties and self-renewal capacity.<br />
In order to evaluate the suitability of these MPIO<br />
particles for in vivo multimodal imaging, we implanted<br />
4 x 105 MPIO labelled (n = 15) or unlabelled<br />
(n = 15) cells by stereotactic injection in the<br />
right hemisphere (DV: 2mm beneath the dura; ML:<br />
2mm; AP: -2mm) of syngeneic male FVB mice (10-<br />
12 weeks old). Survival of unlabelled and MPIOlabelled<br />
MSC-Luc/eGFP implants was monitored<br />
during 2 weeks by BLI, which demonstrated equal<br />
survival of both cell populations. Moreover, T2-<br />
and T2*-weighted MR images clearly demonstrated<br />
the presence of iron oxide particles in mouse<br />
brain. Additionally, combined immunohistochemistry<br />
and fluorescence microscopy was able to confirm<br />
cell identity and the presence of MPIO particles<br />
within BMSC-Luc/eGFP grafts.<br />
Conclusions: We here demonstrate that combining<br />
three labelling strategies allows unambiguous identification<br />
of MSC following implantation in mouse<br />
brain. The MPIO-labelling allows for pre-mortem<br />
MRI detection of cell implant localisation. In addition,<br />
BMSC survival was followed up using BLI up<br />
to two weeks post-injection. Finally, the combination<br />
of eGFP expression and MPIO-labelling allows<br />
for discrimination of cell implants (eGFP+/MPIO+)<br />
from inflammatory cells (green background fluorescence/MPIO-)<br />
and free particles (eGFP-/MPIO+),<br />
enabling an improved qualitative histological analysis<br />
of cell implantation.<br />
Acknowledgement: This work was supported in part<br />
by: (i) the EC-FP6-NoE funded DiMI (ii) the Flemish<br />
government-funded IWT-SBO BRAINSTIM<br />
Project and (iii) the FWO Flanders.<br />
References:<br />
1. Bergwerf I, De Vocht N, et al., BMC Biotechnology<br />
2009; 9:1<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
day1<br />
Plenary Session on Excellent and Late Breaking Abstracts
DAY<br />
2
• <strong>ESMI</strong> Plenary Lecture 3: Theodorus W.J. Gadella Jr. (Amsterdam, The Netherlands)<br />
New probe-based strategies for quantitative microscopy of signaling dynamics in single cells<br />
Chairs: Vasilis Nziachristos (Munich, Germany) , Bengt Långström (Uppsala, Sweden)<br />
• Parallel Session 5: Neuroscience II<br />
Chairs: Markus Rudin (Zürich, Switzerland), Veerle Baekelandt (Leuven, Belgium),<br />
Mathias Hoehn (Cologne, Germany)<br />
• Parallel Session 6: Cardiovascular I – together with ESR<br />
Chairs: Tony Lahoutte (Mons, Belgium), Nicolas Grenier (Bordeaux, France)<br />
• Parallel Session 7: Probes II – together with EANM<br />
Chairs: Frédéric Dollé (Orsay, France), Denis Guilloteau (Tours, France)<br />
• Parallel Session 8: Gene and Cell Based Therapies – together with CliniGene<br />
Chairs: Ludwig Aigner (Salzburg, Austria), Cornel Fraefel (Zürich, Switzerland)<br />
• <strong>ESMI</strong> Plenary Lecture 4: Hans-Jürgen Wester (Munich, Germany)<br />
Molecular imaging of CXCR4 receptors<br />
Chairs: Adriana Maggi (Milano, Italy), Adriaan Lammertsma (Amsterdam, The Netherlands)<br />
• Plenary Session on Current Contribution of Imaging Technologies to Drug Development<br />
Chairs: Adriana Maggi (Milano, Italy), Adriaan Lammertsma (Amsterdam, The Netherlands)<br />
Day 2 - Friday May 28, 2010
60<br />
WarSaW, poland May 26 – 29, 2010<br />
Chairman of section of Molecular Cytology, Director Centre for Advanced Microscopy<br />
Swammerdam Institute for Life Sciences, University of Amsterdam, The Netherlands<br />
www.mc.bio.uva.nl<br />
Dr. Gadella is founder/director of the Centre for Advanced Microscopy (CAM) at the University of Amsterdam<br />
and full professor in Molecular Cytology chairing a group of 25-30 scientists including 4 assistant<br />
professors. The CAM and chairgroup are positioned within the Swammerdam Institute for Life Science at<br />
the Science Faculty of the University of Amsterdam and fully integrated within the Netherlands Institute for<br />
Systems Biology founded in 2007. Dr Gadella personally supervises a research team on spatiotemporal cell<br />
signaling. His team wants to understand how cells can achieve and maintain a local signal in order to drive<br />
morphogenesis, to define new cytoskeletal anchorage or vesicle-docking sites. The focus is on signal flow<br />
across and in the plane of the membrane of living mammalian cells. To this end genetic encoded fluorescent<br />
biosensors are employed and the in situ molecular interactions between signaling molecules including phospholipid-second<br />
messengers, receptors, G-proteins and downstream targets are analyzed. By multiparameter<br />
imaging approaches several signaling events are visualized and quantified simultaneously in individual living<br />
cells with sub-second temporal and submicron spatial resolution. The in situ cellular imaging research<br />
heavily depends on advanced bioimaging. To this end advanced automated microscopy approaches such<br />
as fluorescence resonance energy transfer (FRET) microscopy (including bleaching-, spectral-, ratio- and<br />
fluorescence lifetime-imaging approaches), fast live cell microscopy (including spinning disk, line-scanning<br />
and controlled light exposure confocal microscopy, and total internal reflection microscopy (TIRF)), and<br />
photochemical microscopy approaches such as photoactivation, uncaging, fluorescence recovery after photobleaching<br />
(FRAP), fluorescence loss in photobleaching microscopy (FLIP), fluorescence correlation spectroscopy<br />
(FCS), cross-correlation (FCCS), lifetime-correlation (FCLS) have been implemented developed<br />
and applied to quantifying cell signalling phenomena. Currently, the palette of advanced imaging instrumentation<br />
is expanded with superresolution localization microscopy approaches such as PALM and STORM.<br />
The research group is funded from university resources (roughly 40%), national grant agencies (NWO-ALW,<br />
CW, FOM and STW) and several international grants (ESF and EU-FP6/7 projects including integrated projects,<br />
STREPs and TMR programs).<br />
The Gadella lab has numerous (inter)national collaborations in the field of signal transduction (Dr. C. Hoffman,<br />
Univ. Würzburg; M. Wymann, Univ. Basle; K. Jalink, NKI Amsterdam) and collaborations on probe<br />
development (dr. C. Schultz, EMBL Heidelberg; dr. K. Lukyanov & D. Chudakov, Moscow) and collaborations<br />
on advanced light microscopy (prof. van Noorden (AMC); dr. A. Houtsmuller, Erasmus MC; dr. H.<br />
Gerritsen, Utrecht; dr. Dobrucki, Univ. Krakow; prof. M. Carmo Fonseca, Lisbon). In 2007 prof Gadella<br />
was elected president of the Netherlands Society for Advanced Microscopy. Recently he was appointed as<br />
national coordinator of the advanced light microscopy activities of the Netherlands for the new large EU<br />
infrastructure (ESFRI) programme EuroBioimaging that recently entered the startup phase.<br />
imaging life<br />
Theodorus W.J. Gadella Jr.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
New probe-based strategies for quantitative microscopy of signaling dynamics in single cells<br />
Gadella T.W.J. jr, Goedhart J., Van Weeren L., Crosby, K., Hink M.A.<br />
Section of Molecular Cytology and Centre for Advanced Microscopy, Swammerdam Institute for Life Sciences & Netherlands Institute for Systems Biology,<br />
University of Amsterdam, Science Park 904, NL-1098 XH Amsterdam.<br />
Th.W.J.Gadella@uva.nl<br />
Since the cloning of the green fluorescent protein<br />
from Aequoria victoria, numerous fluorescence<br />
microscopy applications have been described in<br />
the literature. By exploiting the spectroscopic axis<br />
in microscopy (excitation/emission wavelength,<br />
fluorescence lifetime) utilizing spectral variants<br />
of GFP colocalization and FRET applications<br />
were enabled. In the other direction, the spectroscopical<br />
axis in microscopes can also be used to<br />
obtain novel GFP variants with optimized properties.<br />
Here we report a screening method that,<br />
in addition to fluorescence intensity, quantifies<br />
the excited state lifetime of a fluorescent protein,<br />
providing a direct measure for the quantum yield<br />
of the fluorescent protein. The novel approach<br />
was used to screen a library of cyan fluorescent<br />
protein (CFP) variants yielding the brightest cyan<br />
fluorescent protein variant described thus far<br />
which we dubbed mTurquoise. mTurquoise has a<br />
marked increased quantum yield of 0.84, and a<br />
seriously increased lifetime of 3.7 ns. Because of<br />
its monoexponential decay and high R0 for FRET<br />
to SYFP2 (5.7 nm), it is the preferred donor in<br />
FRET studies. In addition, the lifetime screening<br />
method also yielded several other CFP lifetime<br />
variants with identical spectra. It is demonstrated<br />
that three spectrally identical CFP variants can<br />
be separated in single FLIM experiment in living<br />
cells and their distribution & molecular stoichiometry<br />
can be quantified. The triple unmixing<br />
technique using the new lifetime variants can be<br />
combined with spectral separation of other GFP<br />
color variants with a great potential for multiparameter/multiplexed<br />
imaging.<br />
We apply the different probes for the study of<br />
GPCR-triggered signaling in single mammalian<br />
cells. The design of a Gq FRET sensor reporting<br />
on activation by endogenous expressed receptors,<br />
multiparametric imaging of lipid-derived second<br />
messengers, PtdInsP2-dependent PLC translocation,<br />
and RhoGEF activation using a variety of<br />
FRET-, ratio imaging- and TIRF-microscopic applications<br />
will be presented.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
day2<br />
<strong>ESMI</strong> Plenary Lecture 3 by Theodorus Gadella
62<br />
WarSaW, poland May 26 – 29, 2010<br />
Potential to use transgenic animals for imaging of neurological diseases<br />
Aigner L. .<br />
Institute of Molecular Regenerative Medicine, Paracelsus Medical University, Austria<br />
ludwig.aigner@pmu.ac.at<br />
Transgenic animal models represent an elegant and<br />
innovative tool to image the multitude of events<br />
including degenerative, inflammatory and regenerative<br />
responses in the brain. However, there are<br />
currently no transgenic animal models that would<br />
image specifically one or another neurological<br />
disease. Typically, a transgenic reporter animal<br />
highlights the activity of a gene promoter that is<br />
specifically active in one or another cell type during<br />
a certain physiological process, upon response<br />
to injury, along the course of neurodegeneration<br />
or during a regenerative response. Thus, transgenic<br />
animal models allow the imaging of physiological<br />
and pathophysiological responses that are<br />
associated with neurological / neurodegenerative<br />
diseases, but not the disease itself. For example,<br />
currently available models allow the elucidation of<br />
several aspects of neurodegeneration: 1) Inflammatory<br />
events can be visualized using transgenic<br />
animals with the TLR2 promoter controlling the<br />
expression of reporter genes; herein, these reporters<br />
are up-regulated in response to the onset<br />
imaging life<br />
of an inflammatory response hand in hand with<br />
endogenous TLR2 and microglial activation (Lalancette-Hebert,<br />
Gowing et al. 2007). 2) Reactive<br />
gliosis may be pictured using GFAP-reporter mice<br />
as a result of stroke in living animals (Cordeau,<br />
Lalancette-Hebert et al. 2008). 3) Hypoxia might<br />
be imaged due to the application of models like<br />
the HRE-GFP transgenic animals where cells that<br />
suffer from oxygen deprivation express reporter<br />
proteins induced by low-oxygen-responsive transcription<br />
factors (Berchner-Pfannschmidt, Frede<br />
et al. 2008). 4) Neuroplasticity after brain ischemia<br />
comprises the recovery of dendritic structure, and<br />
this event may be imaged using transgenic models<br />
with fluorescent proteins expressed throughout a<br />
distinct cell population and including the cellular<br />
protrusions (Li and Murphy 2008). 5) Neurogenesis<br />
and the migration of young neurons can be<br />
visualized using DCX-promo luciferase mice. This<br />
presentation will provide a summary and an overview<br />
on the current state of transgenic models in<br />
the field of neurological diseases.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Specific cell labeling with imaging reporters in vivo by viral vectors: the challenges<br />
Reumers V. (1) , Ibrahimi A. (2) , Toelen J. (2) , Aelvoet S. A. (1) , Van Den Haute C. (1) , Debyser Z. (2) , Baekelandt V. (1) .<br />
(1) Neurobiology and Gene Therapy, Katholieke Universiteit Leuven,<br />
(2) Molecular Virology and Gene Therapy, Katholieke Universiteit Leuven. From MoSAIC, the Molecular Small Animal Imaging Center, K.U.Leuven, Belgium<br />
Veerle.Baekelandt@med.kuleuven.be<br />
Viral vectors are extremely efficient tools for gene<br />
transfer into living cells. We are using lentiviral<br />
vectors and adeno-associated viral (AAV) vectors<br />
for stable overexpression and suppression of gene<br />
expression in rodent brain. Stereotactic injection<br />
of these viral vectors into different brain regions<br />
of mouse and rat brain induces overexpression or<br />
inhibition of disease-related genes, which can be<br />
used for target validation, functional genomics and<br />
generation of disease models. We have invested<br />
over the last years into reporter gene technology<br />
and non-invasive imaging in rodent brain. We have<br />
optimized bioluminescence imaging to monitor<br />
gene expression in mouse brain and to track<br />
neuronal stem cell migration and differentiation.<br />
In order to specifically target certain neuronal cell<br />
populations we have recently developed conditional<br />
lentiviral and AAV viral vectors based on Cremediated<br />
recombination. Application of these viral<br />
vectors in specific cre-transgenic mouse strains<br />
allows to specifically label endogenous neural stem<br />
cells in the subventricular zone or dopaminergic<br />
cells in the substantia nigra. This approach holds<br />
promise to non-invasively follow up endogenous<br />
neurogenesis and neurodegeneration over time.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
day2<br />
Parallel Session 5: NEUROSCIENCE II
YIA applicant<br />
64<br />
WarSaW, poland May 26 – 29, 2010<br />
Optimization of an MRI method to measure microvessel density: application to monitor<br />
angiogenesis after stroke<br />
Boehm-Sturm P. (1) , Adamczak J. (1) , Farr T. D. (1) , Jikeli J. (2) , Kallur T. (1) , Hoehn M. (1) .<br />
(1) MPI for Neurological Research in Cologne, Germany<br />
(2) Center of Advanced European Studies and Research in Bonn.<br />
philipp.boehm-sturm@nf.mpg.de<br />
Introduction: Angiogenesis is the growth of new vessels<br />
from an existing vascular network and is highly<br />
upregulated following ischemia. Increases in microvessel<br />
density (MVD) have been reported to occur<br />
in the peri-infarct zone of stroke patients, which was<br />
correlated with increased survival time [1]. Steadystate-contrast-enhanced<br />
(SSCE) MRI provides<br />
the ability to monitor MVD in vivo. To do so, the<br />
changes in relaxivities ΔR2/ΔR2* due to an i.v. injection<br />
of a paramagnetic blood pool contrast agent are<br />
evaluated by spin-echo (SE) and gradient-echo (GE)<br />
imaging, and the MVD index Q=ΔR2/(ΔR2)2/3 is<br />
mapped [2,3]. However, noise in the MR images can<br />
significantly distort the results of the method. Therefore,<br />
the goal of this study is to optimize the SSCE<br />
MRI parameters in simulations in order to find a<br />
noise-resistant protocol. We aim to apply the method<br />
to monitor angiogenesis after stroke in rats and to<br />
validate this by immunohistochemistry.<br />
Left: simulated relative error in Q (in %) over TESE and TEGE at a fixed noise level; the arrow indicates the optimal set of TEs. Right: lesion in SE<br />
image 48 h after MCAO (a) and Q at 7 days prior (b), and 7 (c), and 14 days (d) post MCAO of the same animal. Arrow indicates an area with high Q<br />
value. Typical RECA (red)/BrdU (green) (e) and Hoechst(blue)/RECA(red)/laminin (green) (f) fluorescence microscopy images close to the infarct.<br />
Methods: Q-maps were simulated for different levels<br />
of noise and echo times TESE/TEGE of the SE/<br />
GE images. Male Wistar rats (n=7) were scanned<br />
with SSCE MRI 7 days prior, and 7 and 14 days post<br />
60 min transient MCAO. An SE image was acquired<br />
48 h post MCAO to depict the lesion extent. Rats<br />
received Bromodeoxyuridine (BrdU) injections between<br />
3-7 days post MCAO in order to label proliferating<br />
cells. Following the final SSCE MRI scan<br />
at 14 days, animals were perfused and brain sections<br />
stained for BrdU, rat endothelial cell antigen<br />
(RECA), and laminin.<br />
imaging life<br />
Results: The simulations revealed that the error in<br />
Q is minimal for a TESE of 30-40 ms and a TEGE of<br />
10-15 ms. Areas with increased Q could be detected<br />
close to the infarct in a few of the rats as early as 7<br />
days and in most of the rats at 14 days post MCAO.<br />
BrdU/RECA double staining was established to<br />
identify newly formed endothelial cells and laminin<br />
staining confirmed the presence of an intact basement<br />
membrane in the vessels.<br />
Conclusions: Our results show that scanner noise<br />
can severely limit the capabilities of SSCE MRI but<br />
a set of optimal scan parameters can minimize this<br />
problem. The method has been shown to monitor<br />
potential changes of the microvasculature longitudinally<br />
and non-invasively in the ischemic rat brain.<br />
It will in the future allow to study neo-angiogenesis<br />
in the course of (stem)cell-based therapies after cerebral<br />
lesions.<br />
Acknowledgements: Generous supply of ENDOREM<br />
by Drs. C. Corot and P. Robert is gratefully acknowledged.<br />
This work was supported in part by grants from<br />
the European Union under FP6 program (StemStroke,<br />
LSHB-CT-2006-037526), and under FP7 program<br />
(ENCITE, 201842), and an Alexander von Humboldt<br />
Research Fellowship to TDF.<br />
References:<br />
1. Krupinski et al, Stroke (1994) 25:1794-1798;<br />
2. Jensen et al., MRM (2000) 44:224–230;<br />
3. Wu et al., NMR Biomed (2004) 17:507–512
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
MRI study of intra-arterial bone marrow-derived macrophage administration after acute<br />
focal ischemic stroke in rats<br />
Riou A. (1) , Chauveau F. (1) , Cho T.H. (1) , Nataf S. (2) , Berthezene Y. (1) , Nighoghossian N. (1) , Wiart M. (1) .<br />
(1) CREATIS-LRMN : CNRS UMR5220, INSERM U630, Univ. Lyon1, INSA-Lyon, France<br />
(2) CNRS UMR5220, INSERM U630.<br />
adrien.riou@live.fr<br />
Introduction: In the past few years numerous studies<br />
have been published to assess if cell-based therapy<br />
after stroke can enhance long-term recovery. It<br />
is well established that cerebral ischemia results in<br />
a complex inflammatory cascade that mainly involves<br />
cells from the mononuclear phagocyte system1,<br />
although the beneficial or deleterious effect<br />
of this activation following stroke is still a matter<br />
of controversy. Furthermore, therapeutic benefits<br />
gained from cell-based therapy depend on migration<br />
and localization of grafted cells within the target<br />
tissue that is closely related to the cell delivery<br />
route2 and therapeutic time window3 chosen for<br />
the therapy. The aim of this study was to assess the<br />
feasibility of in vivo early intra-arterial (IA) bone<br />
marrow-derived macrophage (BMDM) administration<br />
for acute focal ischemic stroke treatment, using<br />
multiparametric magnetic resonance imaging<br />
(MRI).<br />
Methods: BMDM were obtained from a sacrificed<br />
littermate of recipient rats by flushing out one<br />
hindlimb. Bone marrow cells were then seeded on<br />
uncoated flasks at 5 x 105 cells/ml in medium supplemented<br />
with murine macrophage-colony stimulating<br />
factor and flt3 ligand (mM-CSF and flt3L at<br />
10ng/ml) for one week. At day 6, cells were labeled<br />
with anionic superparamagnetic nanoparticles<br />
overnight (AMNP, CNRS UMR 7612, Paris, France,<br />
[Fe]=1mM). Male Sprague Dawley rats (250 to 350g,<br />
n=17) were subjected to 1-h intraluminal transient<br />
middle cerebral artery occlusion (tMCAO) (n=12)<br />
or sham procedure (n=5). IA administration of<br />
AMNP-labeled cells was performed at the time of<br />
reperfusion in all tMCAO animals and in 3 shams<br />
animals (4 million in 1-ml except for one sham: 1<br />
million in 1-ml). Ischemia / reperfusion and cell<br />
injection were monitored by transcranial laser doppler<br />
flowmetry. MRI was performed on a Bruker<br />
Biospec 7T/12cm magnet at D0 just after cells administration<br />
and from D1 to D9. The MR exam included<br />
T2-, T2*-, diffusion- and perfusion-weighted<br />
imaging and multi-echo 3D imaging. Animals<br />
were sacrificed after completion of the MRI exams<br />
and brains were prepared for immunohistological<br />
analysis with Prussian blue for iron detection and<br />
Ox-42 for macrophage detection.<br />
Results: IA administration in tMCAO group lead to<br />
heterogeneous results: 3 rats died following injection,<br />
2 had cells detectable only in the temporalis<br />
muscle and 7 had cells detectable in the ipsilateral<br />
parenchyma but with heterogeneous patterns: 3 had<br />
a widespread persistent hypointense signal distribution,<br />
while 4 had only few local spots of signal<br />
loss on follow-up scans. Furthermore, IA administration<br />
in the sham group caused lesion formation<br />
on follow-up scans in all injected animals (n=3),<br />
even when cell number was decreased, as opposed<br />
to the non-injected sham rats that did not have any<br />
lesions. Immunohistological analysis is in progress<br />
to ascertain iron-labeled macrophage localization.<br />
Conclusions: Our results were consistent with that<br />
of previous studies2, 4 showing that IA delivery<br />
route efficiently brought a large number of cells to<br />
the brain soon after transplantation, but severely<br />
increased mortality. More importantly, lesions observed<br />
in the sham group (undemonstrated to date<br />
to our knowledge) suggested that this high mortality<br />
rate resulted from cell embolisation in cerebral<br />
vessels leading to formation or worsening of the<br />
ischemic lesion. This result points out a serious limitation<br />
for the translation of this cell delivery route<br />
into the clinics.<br />
References:<br />
1. Huang J, et al. Surg Neurol.;66:232-45 (2006).<br />
2. Li L, et al. J Cereb Blood Flow Metab (2009).<br />
3. de Vasconcelos Dos Santos A, et al. Brain Res.1306:149-<br />
58 (2010).<br />
4. Walczak P, et al. Stroke. 2008;39:1569-74 (2008).<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
day2<br />
Parallel Session 5: NEUROSCIENCE II
YIA applicant<br />
66<br />
WarSaW, poland May 26 – 29, 2010<br />
Inactivated paramagnetic tissue plasminogen activator predicts thrombolysis outcome<br />
following stroke<br />
Gauberti M. (1) , Montagne A. (1) , Vivien D. (1) , Orset C. (1) .<br />
INSERM U919 SP2U Serine protease and pathophysiology of the neurovascular unit, France<br />
gauberti@cyceron.fr<br />
Introduction: Ischemic stroke is the third leading<br />
cause of death in developed countries. Despite numerous<br />
clinical trials, tissue plasminogen activator<br />
(tPA) induced thrombolysis remains the only treatment<br />
of the acute phase. However there is growing<br />
body of evidences that parenchymal tPA has deleterious<br />
effects including increased risk of intra cranial<br />
hemorrhages and neurotoxicity. To limit these side<br />
effects, only rigorously selected patients (onset of<br />
symptoms < 4.5 hrs, age < 85 hrs, etc.) benefit from<br />
thrombolysis, with more than 90% of patients being<br />
untreated. In previous in vitro studies we showed<br />
that vascular tPA can cross the intact blood brain<br />
barrier (BBB) by Low Density Lipoprotein Receptor<br />
Protein (LRP) mediated transcytosis [1]. Accordingly,<br />
increasing data of the literature suggest that<br />
BBB specific permeability to tPA could be critical for<br />
brain outcome following thrombolysis [2] [3].<br />
Figure 1. Ex-vivo NIRF brain imaging of fluorescent tPA and albumin<br />
administered at 1 or 4 hours after permanent middle cerebral artery<br />
occlusion in mice. Unlike albumin which has the same molecular<br />
weight, tPA can cross the BBB at 4 hours post ischemia.<br />
Results: Here in a model of permanent middle cerebral<br />
artery occlusion in mice, we show that intravenous<br />
tPA aggravates ischemic lesion size and<br />
BBB permeability if administrated at 4 hours but<br />
not at 1 hour after ischemia. In parallel, although<br />
BBB remains impermeable to albumin, we provide<br />
evidences both by microscopic epifluorescence and<br />
near infrared fluorescence (NIRF) brain imaging of<br />
a passage of tPA across the BBB only when administrated<br />
at 4 hours post ischemia. Using MRI and inactivated<br />
paramagnetic tPA as molecular probe, we<br />
imaging life<br />
are tempting to demonstrate that such type of brain<br />
imaging could allow us to pre-select stroke patients<br />
who would not be susceptible to haemorrhagic transformations<br />
following rtPA-induced thrombolysis.<br />
Conclusions: Non invasive imaging of inactivated<br />
paramagnetic tPA could allow clinicians to include<br />
stroke patients for thrombolysis with objective brain<br />
imaging data independently of the time post-stroke<br />
onset. As long as the BBB remains impermeable to<br />
tPA, thrombolysis seems safe.<br />
References:<br />
1. Benchenane et al.; Circulation 111:2241-2249 (2005).<br />
2. Benchenane et al.; Stroke 38:1036 (2005).<br />
3. Roussel et al.; Thromb Haemost. 102:602-608 (2009).
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Matrix metalloproteinase-9 – a possible therapeutic target in intractable epilepsy<br />
Wilczynski G. .<br />
Nencki Institute, Poland<br />
g.wilczynski@nencki.gov.pl<br />
Introduction: Temporal lobe epilepsy (TLE) is a<br />
chronic, devastating, pharmacologically intractable<br />
disease in which aberrant synaptic plasticity<br />
plays a major role. Recently, MMP-9, a matrix<br />
metalloproteinase, has been implicated in synaptic<br />
plasticity, long-term potentiation and learning and<br />
memory formation. We asked, whether MMP-9<br />
might play a pathogenic role in epileptogenesis.<br />
Methods: High resolution light- and electronmicroscopic<br />
immunocytochemistry, in situ hybridization,<br />
in situ zymography; use of transgenic<br />
animals; antibody microarrays<br />
Results: Our study revealed MMP-9 as a novel<br />
synaptic enzyme, and a key pathogenic factor<br />
in two distinct animal models of TLE: kainateevoked-epilepsy<br />
and pentylenetetrazole (PTZ)<br />
kindling-induced epilepsy. In particular, sensitivity<br />
to PTZ-induced epileptogenesis is decreased<br />
in MMP-9 knockout (KO) mice, whereas it is<br />
increased in MMP-9-overexpressing rats. Moreover,<br />
confocal- and immunoelectron-microscopic<br />
analyses demonstrated that MMP-9 associated<br />
with hippocampal dendritic spines bearing asymmetric<br />
(excitatory) synapses. In addition, both<br />
MMP-9 protein levels as well as its enzymatic activity<br />
became strongly increased upon seizures.<br />
Furthermore, MMP-9-deficiency diminished seizure-evoked<br />
pruning of dendritic spines, and it<br />
decreased aberrant synapse formation following<br />
mossy-fibers sprouting.<br />
We then asked whether MMP-9 could play an important<br />
role also in human intractable epilepsy.<br />
Accordingly, we have studied the expression and<br />
localization of MMP-9 in samples of human epileptic<br />
brain tissue, obtained upon surgical treatment<br />
of childhood intractable epilepsy. By antibody<br />
microarrays, we found MMP-9, but none of<br />
the other seven MMPs studied, to be consistently<br />
upregulated in epileptic lesions, as compared to<br />
autopsy brain tissue. By immunohistochemistry<br />
of epileptic tissue, increased MMP-9 localized<br />
specifically to affected neurons.<br />
Conclusions: Taken together, the aforementioned<br />
results suggest that the synaptic pool of MMP-9 is<br />
critically involved in the sequence of events that underlie<br />
epileptogenesis, both in rodents and humans.<br />
Therefore, the enzyme should be considered as a<br />
candidate target for therapeutic pharmacological<br />
intervention.<br />
Acknowledgement: The work was supported by<br />
Polish-Norwegian Research Grant<br />
References:<br />
1. Wilczynski et al., Important role of matrix<br />
metalloproteinase 9 (MMP-9) in epileptogenesis. J Cell<br />
Biol 180: 1021-1035, 2008.<br />
2. Konopacki et al., Synaptic localization of seizureinduced<br />
matrix metalloproteinase-9 mRNA.<br />
Neuroscience; 150:31-39, 2007<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
day2<br />
Parallel Session 5: NEUROSCIENCE II
68<br />
WarSaW, poland May 26 – 29, 2010<br />
Potentials of new contrast agents for vascular molecular imaging in patients<br />
Douek P., Boussel L., Sigovan M., Cannet E. .<br />
Creatis, Hopital Louis Pradel, Lyon University, France<br />
philippe.douek@creatis.univ-lyon1.fr<br />
Introduction: Atherosclerosis is a diffuse and<br />
multisystem, chronic inflammatory disorder<br />
involving vascular, metabolic, and immune systems<br />
leading to plaque instability and / or vascular<br />
trombosis. The traditional risk assessment relies on<br />
clinical, biological and conventional imaging tools.<br />
However, they fall short in predicting near future<br />
events particularly in patients with unstable carotid<br />
artery disease or coronary artery disease. The plaque<br />
instability is dictated in part by plaque morphology,<br />
which in turn is influenced by pathophysiologic<br />
mechanisms at the cellular and molecular level.<br />
In current clinical practice, anatomic imaging<br />
modalities such as intravascular ultrasound, highresolution<br />
magnetic resonance imaging can identify<br />
several morphologic features supporting the unstable<br />
plaque, but give little or no information regarding<br />
molecular and cellular mechanisms. optical imaging,<br />
PET, Molecular MR imaging, or more recently<br />
spectral CT may identify some of these molecular<br />
and cellular processes.<br />
Methods: We aimed to review<br />
1) the role of relevant biological, factors and<br />
advances in atherosclerosis biology, that illuminate<br />
key biological aspects of atherosclerosis, including<br />
macrophage activity, protease activity, lipoprotein<br />
presence, apoptosis, and angiogenesis<br />
imaging life<br />
2) imaging agent chemistry (nanotechnology,<br />
chemical biology screens)<br />
3) recent advances in the field of molecular<br />
imaging that have led to the development of novel<br />
paramagnetic and superparamagnetic targeted<br />
contrast agents that bind exclusively to cells such as<br />
macrophages, or molecules such as albumin, fibrin,<br />
angiogenesis markers... with either PET, MR, US or<br />
CT .and<br />
Results: 4) a few clinically promising applications of<br />
molecular imaging for high-risk atherosclerosis and<br />
its potential for current and emerging treatments in<br />
clinical trials.<br />
Conclusions: A multimodal assessment of plaque<br />
instability involving the combination of systemic<br />
markers, high resolution imaging and molecular<br />
imaging targeting inflammatory and thrombotic<br />
components and the potential of new drugs<br />
targeting plaque stabilization may lead to a new<br />
stratification of the atherothrombotic risk and to<br />
a better prevention of atherothrombotic stroke or<br />
myocardial infarction.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Protease specific nanosensors in atherosclerosis<br />
Schellenberger E. .<br />
Charité Berlin, Germany<br />
eyk.schellenberger@charite.de<br />
Introduction: Atherosclerosis and especially the<br />
consequences of rupture of atherosclerotic plaques<br />
are the foremost cause of death in industrialized<br />
societies. Up to date the identification of vulnerable<br />
atherosclerotic plaques prone to rupture has not been<br />
solved for the clinics. The pathological processes<br />
leading to destabilization of such plaques are highly<br />
complex and involve inflammatory action and<br />
pathological tissue remodeling of the extracellular<br />
matrix performed by proteases. Therefor the imaging<br />
of specific protease activity by high resolution<br />
MR imaging could be an important tool to find<br />
dangerous plaques that need urgent treatment.<br />
Results: Optical imaging with activatable fluorescent<br />
smart probes has become the modality of choice<br />
for experimental in vivo detection of protease<br />
activity. Recently we introduced a novel highrelaxivity<br />
nanosensors that are suitable for in vivo<br />
imaging of protease activity by MRI. Upon specific<br />
protease cleavage, the nanoparticles rapidly switch<br />
from a stable low-relaxivity stealth state to become<br />
adhesive, aggregating high-relaxivity particles.<br />
To demonstrate the principle, we chose a cleavage motif<br />
of matrix metalloproteinase 9/2 (MMP-9 and MMP-2),<br />
proteases that important during the destabilization of<br />
the extracellular matrix of plaques. Based on clinically<br />
tested very small iron oxide particles (VSOP), the<br />
MMP-9-activatable protease-specific iron oxide<br />
particles (PSOP) have a hydrodynamic diameter of<br />
only 25 nm. PSOP are rapidly activated, resulting in<br />
aggregation and increased T2*-relaxivity of the particles.<br />
Conclusions: PSOP could be useful sensors for the<br />
in vivo identification of vulnerable plaques in the<br />
future.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
day2<br />
Parallel Session 6: CARDIOVASCULAR I - together with ESR
YIA applicant<br />
70<br />
WarSaW, poland May 26 – 29, 2010<br />
Imaging of inflamed carotid artery atherosclerotic plaques with the use of 99mTc-HYNIC-<br />
IL-2 scintigraphy in the end-stage renal disease patients<br />
Opalinska M. (1) , Hubalewska-Dydejczyk A. (2) , Stompor T. (3) , Krzanowski M. (4) , Mikołajczak R. (5) , Garnuszek P. (5) ,<br />
Karczmarczyk U. (6) , Maurin M. (5) , Rakowski T. (7) , Sowa-Staszczak A. (2) , Glowa B. (2) .<br />
(1) Nuclear Medicine Unit, Chair and Department of Endocrinology, Jagiellonian University Medical School, (2) Nuclear Medicine Unit, Chair and Department of<br />
Endocrinology, Jagiellonian University Medical School, (3) Chair and Department of Nephrology, Hypertesiology and Internal Medicine, University of Warmia<br />
and Mazury, (4) Chair and Department of Nephrology, Jagiellonian University Medical School, (5) Radioisotope Center POLATOM, (6) Departament of Radiopharmaceuticals,<br />
National Medicines Institute, (7) 2nd Cardiology Clinic, Institute of Cardiology, Jagiellonian University Medical School.<br />
mkal@vp.pl<br />
Introduction: Cardiovascular diseases are the main<br />
cause of death in developed countries. In some patients’<br />
populations, including those with end-stage<br />
renal disease (ESRD), cardiovascular related mortality<br />
is 30 times higher compared to the general<br />
population.<br />
Such a high cardiovascular mortality is associated<br />
with significantly accelerated atherosclerosis in<br />
ESRD mainly due to intense inflammatory state.<br />
Therefore serum concentrations of inflammatory<br />
agents that promote atherosclerosis are often used<br />
to evaluate the cardiovascular risk.<br />
The histological studies of the atherosclerotic<br />
plaque revealed that at least 20% of inflammatory<br />
cells within unstable plaque comprise lymphocytes<br />
T, which contain receptors for interleukin 2 (IL-2);<br />
those receptors can be identified by scintigraphy<br />
with radiolabeled IL-2.<br />
Methods: 28 patients (13 men, 15 women, aged 55,2<br />
± 9,6, 17 on peritoneal dialysis, 11 on hemodialysis)<br />
underwent scintigraphy with the use of 99mTc-<br />
HYNIC-IL-2. In all cases ultrasound examination<br />
of the carotid arteries was performed to obtain information<br />
about localization and morphology of<br />
atherosclerosis plaques and intima-media thickness<br />
(IMT) measurement. Furthermore, levels of selected<br />
proinflammatory factors, atherogenic markers and<br />
calcium-phosphate balance parameters were measured.<br />
Finally, target/non-target (T/nT) ratio of IL-2<br />
uptake in atherosclerotic plaques confirmed by carotid<br />
USG with IMT, presence of calcifications in<br />
atherosclerotic plaques and concentration of the<br />
measured agents were compared.<br />
Results: Increased 99mTc-IL-2 uptake in atherosclerotic<br />
plaques previously visualized by neck ultrasound<br />
in 38/41 (91%) cases was detected. Median<br />
T/nT ratio of focal 99mTcIL-2 uptake in atherosclerotic<br />
plaque was 2,35 (range 1,23– 3,63, average 2,35<br />
± 0,70). Mean IMT value on the side of plaque assessed<br />
in scintigraphy was 0,79 ± 0,18 mm (median<br />
0,8, range 0,5 – 1,275).<br />
imaging life<br />
No statistically significant association was found<br />
between 99mTc-IL-2 T/nT ratio and mean value<br />
of either IMT or classical cardiovascular risk factors.<br />
Inversely, proportional dependence between<br />
scintigraphy results and hemoglobin concentration<br />
(R = - 0,21, p = 0,02) was found. Furthermore, relationships<br />
between T/nT ratio and homocysteine (R<br />
= 0,22, p = 0,037), ApoB (R = 0,31, p = 0,008), ApoB/<br />
ApoA-I ratio (R= 0,29, p= 0,012) and triglycerides<br />
concentration (R = 0,26, p = 0,021) were detected.<br />
Lower T/nT ratio in patients with better parameters<br />
of nutrition state (hemoglobin, albumin, adiponectin)<br />
in comparison with patients with worse nutritional<br />
parameters (3,20 ± 0,5 vs 2,16 ± 0,68, p =<br />
0,025) was revealed as well as the difference between<br />
values of T/nT ratio in groups of patients with values<br />
of ApoB, sCD40L and ADMA above and below median<br />
(3,18 ± 0,52 vs 2,16 ± 0,68 p = 0,031). An interesting<br />
relationship between T/nT ratio in atherosclerotic<br />
plaques with and without calcifications (2,35 ±<br />
0,68 vs 1,924 ± 0,55 p = 0,088) was observed.<br />
Conclusions: Scintigraphy with the use of labeled<br />
IL-2 can be a tool for inflamed atherosclerotic (vulnerable)<br />
plaque visualization within common carotid<br />
arteries in ESRD patients. Quantitative results<br />
of the carotid arteries scintigraphy with labeled IL-2<br />
correlate with serum concentration of selected cardiovascular<br />
risk markers<br />
Acknowledgement: This work is supported by the<br />
Polish Committee for Scientific Research (KBN)<br />
within Research Project 2 P05B 003 28<br />
References:<br />
1. Annovazzi A et al; 99mTc-interleukin-2 scintgraphy for<br />
the in vivo imaging of vulnerable atheroslerotic plaque.<br />
Eur J Nucl Med Mol Imaging 2006; 33: 117 – 126.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Uptake of 68 Ga-Chloride in Atherosclerotic Plaques of LDLR -/- ApoB 100/100 Mice<br />
Silvola J. (1) , Laitinen I. (2) , Sipilä H. (1) , Laine J. (3) , Leppänen P. (4) , Ylä-Herttuala S. (4) , Knuuti J. (1) , Roivainen A. (5) .<br />
(1) Turku PET Centre, University of Turku,<br />
(2) Nuklearmedizinische Klinik der TU Muenchen, Technische Universitaet Muenchen,<br />
(3) Department of Pathology, Turku University Hospital,<br />
(4) A.I. Virtanen Institute, University of Kuopio,<br />
(5) Turku Centre for Disease Modelling, University of Turku.<br />
jmuhau@utu.fi<br />
Introduction: Atherosclerosis is an inflammatory<br />
disease in which monocytes/macrophages have essential<br />
role in the development of plaques. Radiogallium<br />
has been used for decades for in vivo imaging<br />
of inflammation. 68Ga is a positron emitter with a<br />
half-life of 68 min and it is suitable for PET imaging.<br />
Purpose of this study was to explore the uptake of<br />
68Ga-chloride in atherosclerotic plaques in mice.<br />
Methods: Uptake of intravenously administered<br />
68Ga-chloride (17 ± 2 MBq) was investigated in<br />
9 atherosclerotic LDL-/-ApoB100/100 mice and<br />
6 control mice at 3 hours after injection. LDL-/-<br />
ApoB100/100 mice were kept in on a high fat, Western-type<br />
diet for 3-4 months, starting at 7 months<br />
of age. Control mice were fed with regular chow.<br />
The biodistribution of the tracer was evaluated, and<br />
aortic cryosections were further analysed by digital<br />
autoradiography. Subsequently, the autoradiographs<br />
were combined with histological and immunohistological<br />
analysis of sections [1].<br />
Results: According to the autoradiography analysis,<br />
the radioactivity uptake in atherosclerotic plaques was<br />
higher compared to healthy vessel wall (ratio 1.8 ± 0.2,<br />
P = 0.0002) and adventitia (ratio 1.3 ± 0.2, P = 0.0011).<br />
Some 68Ga-radioactivity was also detected in calcified<br />
regions of plaques. Autoradiography signal<br />
co-localized with macrophages as demonstrated by<br />
Mac-3 immunohistochemistry. In both mice strains,<br />
the highest level of radioactivity was found in the<br />
urine and blood.<br />
Conclusions: We observed a moderate but significantly<br />
higher 68Ga-chloride uptake in the aortic<br />
plaques of atherosclerotic mice. While the uptake of<br />
68Ga-chloride was promising in this animal model,<br />
the slow blood clearance may limit the usability of<br />
68Ga-chloride in clinical imaging of atherosclerotic<br />
plaques.<br />
Acknowledgement: The study was conducted within<br />
the Finnish Centre of Excellence in Molecular Imaging<br />
in Cardiovascular and Metabolic Research, supported<br />
by the Academy of Finland, University of Turku, Turku<br />
University Hospital and Åbo Akademi University.<br />
This work was further funded by the Finnish Foundation<br />
for Cardiovascular Research, Instrumentarium<br />
Foundation and the Drug Discovery Graduate School.<br />
References:<br />
1. Haukkala J et al; Eur J Nucl Med Mol Imaging. 36:2058–<br />
2067 (2009)<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
day2<br />
Parallel Session 6: CARDIOVASCULAR I - together with ESR
YIA applicant<br />
72<br />
WarSaW, poland May 26 – 29, 2010<br />
Hybrid imaging using dual energy µCT and FMT for characterization of atherosclerotic<br />
plaques in ApoE -/- mice<br />
Gremse F. (1) , Rix A. (2) , Bzyl J. (1) , Lederle W. (1) , Schulz R. (2) , Perkuhn M. (3) Schober A. (3) , Weber C. (3) , Kiessling F. (1) .<br />
(1) Department of Experimental Molecular Imaging, Medical Faculty, RWTH Aachen University,<br />
(2) Chair for Biological Imaging, Technical University Munich, Germany,<br />
(3) Department of Diagnostic Radiology, Medical Faculty, RWTH Aachen University,<br />
(4) Institute of Molecular Cardiovascular Research RWTH Aachen University, Germany.<br />
fgremse@ukaachen.de<br />
Introduction: To evaluate the ability of combined<br />
µCT and fluorescence mediated tomography (FMT)<br />
to characterize early and late stages in atherosclerotic<br />
plaque formation.<br />
Methods: Three groups of ApoE -/- mice were<br />
scanned by dual energy µCT and FMT. Iodine<br />
based blood pool CT contrast agent and a fluorescent<br />
probe for active cathepsins were used. CT and<br />
FMT datasets were fused using automated marker<br />
detection and registration. Group 1 consisted of 5<br />
mice with an age of more than 40 weeks fed with<br />
normal chow. Group 2 included 6 mice (age < 20<br />
weeks) with 12 weeks of cholesterol diet and group 3<br />
consisted of 5 mice (age
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Long circulating emulsion based ct contrast agents<br />
De Vries A. (1) , Custers E. (2) , Lub J. (2) , Nicolay K. (1) , Gruell H. (1) .<br />
(1) Eindhoven University of Technology, The Netherlands<br />
(2) Philips Research, Eindhoven, The Netherlands<br />
A.d.Vries@tue.nl<br />
Introduction: With X-ray and CT moving forward<br />
into the interventional care, such as stent placement,<br />
balloon dilatation, vascular surgery, and electrophysiological<br />
procedures, there is a need for contrast<br />
agents that have long circulation times [1]. Previously,<br />
we prepared iodinated emulsion-based CT contrast<br />
agents that remain in the blood pool for several hours<br />
[2]. The primary blood clearance occurs via uptake in<br />
the reticuloendothelial system (RES), which is known<br />
to be dose dependant. Here, we tested if circulation<br />
times of these iodinated emulsions can possibly be extended<br />
by a co-injection with liposomes to slow down<br />
RES uptake of the contrast agents. We co-injected the<br />
iodinated emulsion (radiolabeled with 111 Indium) together<br />
with liposomes (radiolabeled with 177 Lutetium)<br />
and investigated the biodistribution of iodinated nanoparticles<br />
and liposomes by in vivo CT and γ-counting.<br />
Methods: Liposomes were prepared using DPPC,<br />
cholesterol and DOTA-DSPE (mol ratio 65.7/33.3/1)<br />
and were radiolabeled with 177 Lutetium. Iodinated<br />
nanoparticles were prepared using 2% w/w PBD-<br />
PEO (with 1 mol% PBD-PEO-DOTA) and 20% w/v<br />
3,7-dimethyloctyl 2,3,5-triiodobenzoate and were<br />
radiolabeled with 111 Indium. Swiss mice were used<br />
in the study, in which 2 mL/kg body weight of iodinated<br />
contrast agent (113 mgI/mL) together with<br />
2 mL/kg body weight of a) physiological salt (n=5)<br />
(control) or b) liposomes (n=5) was injected, leading<br />
to an injected dose of 225 mg I/kg body weight.<br />
Helical CT scans were acquired pre-injection (reference)<br />
and up to 3 hours post-injection using a<br />
dedicated small animal SPECT/CT system (nano-<br />
SPECT/CT ® , Bioscan). The uptake of 177 Lutetium<br />
and 111 Indium in dissected organs was measured<br />
using a γ-counting wizard.<br />
Results: Fig. 1 shows the Hounsfield Unit (HU)<br />
increase of blood after the injection of emulsion<br />
and emulsion together with liposomes as a function<br />
of time. The blood half life increased by 40<br />
minutes to t ½ =116 min when liposomes were coinjected<br />
(t ½ =77 min for pure emulsion; blood half<br />
time was derived from a single-exponential fit).<br />
The CT and biodistribution data (γ-counting)<br />
showed that when co-injecting liposomes, the<br />
emulsion particles are taken up in a lower degree<br />
by the spleen as compared to the control group.<br />
Conclusions: Circulation times of the iodinated<br />
emulsions as CT contrast agents can be further<br />
extended when co-injecting liposomes. The liposomes<br />
are likely taken up by the RES system,<br />
thereby slowing down the clearance of the iodinated<br />
emulsion in a dose dependant manner. As<br />
liposomes are well tolerated with little toxicity at<br />
high doses, the above strategy can be exploited to<br />
formulate well tolerated long circulating iodinated<br />
contrast agents without increasing the administered<br />
iodine dose.<br />
Delta Hounsfield Units<br />
120<br />
100<br />
80<br />
60<br />
40<br />
20<br />
References:<br />
Emulsion<br />
Emulsion + Liposomes<br />
0<br />
0 25 50 75 100 125 150 175 200<br />
Time (min)<br />
1. Vera DR, Mattrey RF; Acad Rad. 9(7):784-792 (2002)<br />
2. de Vries, A. et al. Biomaterials, submitted (2010)<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
YIA applicant<br />
day2<br />
Parallel Session 6: CARDIOVASCULAR I - together with ESR
74<br />
WarSaW, poland May 26 – 29, 2010<br />
Application of microfluidics to the ultra-rapid preparation of fluorine-18 and carbon-11<br />
labelled compounds<br />
Miller P. .<br />
Imperial College London, UK<br />
philip.miller@imperial.ac.uk<br />
Introduction: The advantages associated with the<br />
miniaturisation of chemical reactions have been<br />
recognised for well over a decade now. Such benefits<br />
include controlled and predicable mixing regimes,<br />
efficient heat transfer, reduced reagent consumption,<br />
small reaction volumes (nL-µL), improved safety<br />
and enhanced processing capabilities. Microfluidic<br />
reactors, the devices used to perform and process<br />
small scale chemical reactions, contain enclosed<br />
microchannels typically 10-500 µm in diameter and<br />
can be fabricated from a wide range of materials including<br />
various polymers, silicon and glass (figure<br />
1). The use of microfluidic reactors for rapid synthesis<br />
with the short-lived isotopes 11C (t1/2 = 20.4<br />
min) and 18F (t1/2 = 109 min), commonly used in<br />
positron emission tomography, has been recognised<br />
since 2003. Interest in the application of microfluidics<br />
to PET radiosynthesis has come about primarily<br />
because miniaturised reaction systems have the<br />
potential to address several key challenges in PET<br />
radiochemistry, including increasing the speed,<br />
imaging life<br />
reducing the scale and improving the processing of<br />
radiolabelling procedures.[1,2] This talk will provide<br />
a succinct and critical overview, to the nonspecialist,<br />
of the emerging and developing field of<br />
using microfluidics for the rapid preparation of 11C<br />
and 18F labelling compounds.<br />
Acknowledgement: PWM is grateful to the EPSRC<br />
for the award of a Life Sciences Interface fellowship<br />
(EP/E039278/1).<br />
References:<br />
Figure 1<br />
1. P. W. Miller, J. Chem. Technol. Biotechnol. 2009, 84,<br />
309. [2] P. W. Miller, A. J. deMello and A. D. Gee, Curr.<br />
Radiopharmaceuticals.accepted for publication.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Radioligand for in vivo measuring neurotransmitters release<br />
Halldin C. (1) , Finnema S. (1) , Varrone A. (1) , Farde L. (1) .<br />
Karolinska Institutet, Sweden<br />
christer.halldin@ki.se<br />
Introduction: This report deals with an overview<br />
of radioligands useful for in vivo measuring<br />
neurotransmitter release. In particular this will<br />
be exemplified by a PET-study evaluating the<br />
effect of (±)-fenfluramine- induced serotonin<br />
release on the binding of the selective serotonin<br />
5-HT1B receptor radioligand [11C]AZ10419369 in<br />
cynomolgus monkeys. In a classical displacement<br />
paradigm after bolus administration of radioligand<br />
fenfluramine caused a dose-dependent reduction in<br />
specific binding ratios. The aim of this study was to<br />
confirm our previous findings by using a bolus plus<br />
continuous infusion approach in monkey.<br />
Materials and Methods: A total of 18 PET<br />
measurements were conducted using a bolus plus<br />
infusion paradigm of [11C]AZ10419369 in three<br />
cynomolgus monkeys. On six of the nine experimental<br />
days a baseline measurement was followed by a<br />
displacement measurement in which fenfluramine<br />
(1.0 or 5.0 mg/kg) was infused i.v. between 80 and<br />
85 minutes after the bolus radioligand injection.<br />
On three of the nine experimental days a baseline<br />
measurement was followed by a pretreatment<br />
measurement in which fenfluramine (5.0 mg/kg)<br />
was infused i.v. between 30 and 25 minutes before<br />
the bolus radioligand injection. Emission data were<br />
acquired for 125 or 155 minutes using the HRRT<br />
PET-system. For determination of the fenfluramine<br />
effect the binding potential (BPND) was calculated<br />
for different time frames with the cerebellum as<br />
reference region.<br />
Results: Administration of fenfluramine had no<br />
evident effect on radioactivity in the cerebellum.<br />
After administration of fenfluramine (1.0 and 5.0<br />
mg/kg), the respective binding potentials decreased<br />
in the occipital cortex by 19% (7-34%) and 47% (40-<br />
57%) in the displacement paradigm, and by 39%<br />
(32-45%) in the pretreatment paradigm (5.0 mg/kg).<br />
Conclusions: This study confirms that the 5-HT1Bligand<br />
[11C]AZ10419369 is sensitive to endogenous<br />
serotonin levels in vivo.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
day2<br />
Parallel Session 7: PROBES II - together with EANM
76<br />
WarSaW, poland May 26 – 29, 2010<br />
18f-tracers for amyloid plaques<br />
Guilloteau D. .<br />
CHRU Tours, INSERM Imaging and Brain, France<br />
denis.guilloteau@univ-tours.fr<br />
As documented by the increasing literature, PET<br />
imaging using probes binding to amyloid plaques<br />
represents a major opportunity to investigate<br />
early symptoms and prodromal phase of AD, and<br />
in other hand to follow up the efficiency of new<br />
treatment.<br />
The most well-known tracer used for this molecular<br />
imaging is the [11C]-PIB. Numerous studies with<br />
PIB have demonstrated that the properties of this<br />
tracer permit the visualization and the quantification<br />
of amyloid deposits, but its [11C] labelling limits<br />
considerably its potential use due to its short half-life.<br />
A strong effort have been performed by different<br />
groups in order to develop a tracer labelled with [18F]<br />
for amyloid plaques. Several 18F amyloid binding<br />
compounds belonging to different families have<br />
been described. Of these 18F-AV-45 (Florbetapir)<br />
is most advanced in clinical development (end of<br />
imaging life<br />
Phase III) but Phase I / II clinical results have also<br />
been reported on 18F-FDDNP, 18F-Flumetametamol,<br />
18F-BAY94-9172 (AV-1). We will present these<br />
results and discuss the similarities and differences<br />
regarding the specificity and the sensitivity of the<br />
brain uptake.<br />
Some results obtained with [18F]-FDDNP and<br />
([18F]-AV45 in our University Hospital will be<br />
presented.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Chelators for radiocopper: biological/pharmacokinetic differences of [Tyr 3 ,Thr 8 ]octreotide<br />
conjugates<br />
Abiraj K. (1) , Fani M. (2) , Tamma M. L. (1) , Reubi J. C. (3) , Barnard P. (4) , Schibli R. (5) , Dilworth J. (6) , Maecke H. (2) .<br />
(1) University Hospital of Basel, Switzerland<br />
(2) University Hospital of Freiburg, Germany<br />
(3) University of Bern, Switzerland<br />
(4) University of Melbourne,<br />
(5) ETH Zurich,<br />
(6) University of Oxford.<br />
keelaraa@uhbs.ch<br />
Introduction: Copper-64 has attracted great deal<br />
of attention as radioisotope for targeted positron<br />
emission tomography (PET) and radionuclide therapy<br />
due to its dual decay characteristics (β+: 17.4%;<br />
E β+max= 653 keV; β-: 39%; E β-max= 579 keV),<br />
favorable half life (t1/2=12.7 h) and increased availability.1<br />
Owing to the instability of copper complexes<br />
under ‘in vivo’ condition, continuous efforts<br />
are being made to develop bifunctional chelators<br />
(BFC’s) which can form stable copper complexes for<br />
labeling of biomolecules.1-3 In the present study,<br />
we conjugated [Tyr3,Thr8]octreotide (TATE), to<br />
four different chelating systems, radiolabeled with<br />
64Cu and evaluated the biological/pharmacokinetic<br />
differences of these radioconjugates.<br />
Methods: The BFC’s DOTA(tBu)3 and<br />
NODAGA(tBu)3 are commercially available whereas<br />
CB-TE2A(tBu) and PHENDAM were synthesized<br />
using suitable synthetic methodologies. TATE was<br />
synthesized on solid phase using standard Fmoc<br />
strategy and coupled to each BFC. The conjugates<br />
were labeled with 64Cu using 0.1 M ammonium<br />
acetate buffer (pH 8.0) under different labeling<br />
conditions. Receptor affinity measurements were<br />
performed using radioligand assays and autoradiographic<br />
methods. The radiolabeled conjugates were<br />
evaluated in vitro and in vivo in tumor-bearing nude<br />
mice, using the HEK-sst2 cell line. Imaging studies<br />
were performed using a clinical PET/CT camera.<br />
Results: Synthesis of orthogonally protected crossbridged<br />
cyclam-based BFC (CB-TE2A(tBu)) allows<br />
facile conjugation to targeting biomolecules such<br />
as peptide on solid phase. Synthesis of PHENDAM<br />
provides a new N4-macrocyclic ligand for conjugation<br />
to biomolecule and subsequent labeling with<br />
64Cu. All the conjugates (DOTA-TATE, NODAGA-<br />
TATE, PHENDAM-TATE and CB-TE2A-TATE)<br />
showed high binding affinity to somatostatin receptor<br />
subtype-2 (sst2) with IC50 values ranging from<br />
0.6 nM to 2.5 nM. The labeling of NODAGA-TATE<br />
could be performed at room temperature (radiolabeling<br />
yield >97% at specific activity of >20 GBq/<br />
µmol) whereas other conjugates required elevated<br />
temperature. All the radioconjugates showed substantially<br />
high and receptor mediated uptake by<br />
HEK-sst2 cells. Biodistribution studies with nude<br />
mice showed high uptake of the radioconjugates in<br />
HEK-sst2 xenografts at 1h p.i. (64Cu-DOTA-TATE:<br />
20.29±2.74%, 64Cu-NODAGA-TATE: 29.39±4.13%,<br />
64Cu-PHENDAM-TATE: 16.97±1.46%, and 64Cu-<br />
CB-TE2A-TATE: 19.34±2.55% ID/g). The radioactivity<br />
in tumor persisted at 4h p.i., but 24h p.i. data<br />
showed fast washout in case of all the conjugates.<br />
Compared to 64Cu-DOTA-TATE, the other three<br />
radioconjugates showed improved pharmacokinetics.<br />
High in vivo stability of radiometal complex in<br />
case of 64Cu-NODAGA-TATE and 64Cu-CB-TE2A-<br />
TATE was apparent from their low uptake in liver<br />
and blood at all time points. Interestingly, 64Cu-<br />
PHENDAM-TATE showed fast washout from the<br />
kidneys resulting in high tumor-to-kidney ratio at<br />
early time points. The PET/CT images acquired at<br />
8 h p.i. clearly delineated the tumor and showed images<br />
in accordance with the biodistribution data.<br />
Conclusions: Among four different chelating systems<br />
evaluated, 64Cu-NODAGA-TATE and 64Cu-<br />
CB-TE2A-TATE showed superior in vivo stability<br />
of the radiocopper complex. The study infers that<br />
triazacyclononane and cross-bridged cyclam based<br />
chelating systems might be ideal for 64Cu labeling<br />
of biomolecules intended to be used in targeted PET<br />
imaging and radionuclide therapy but PHENDAM<br />
may be a new 64Cu chelating system of interest for<br />
protein labeling.<br />
Acknowledgement: Swiss National Science Foundation,<br />
European Molecular Imaging Laboratories<br />
(EMIL), COST BM0607.<br />
References:<br />
1. Shokeen W et al; J. Acc. Chem. Res. 42: 832-841 (2009)<br />
2. Boswell C A et al; J. Med. Chem. 47: 1465-1474 (2004)<br />
3. Prasanphanich A F et al; PNAS 104: 12462-12467<br />
(2007)<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
YIA applicant<br />
day2<br />
Parallel Session 7: PROBES II - together with EANM
78<br />
WarSaW, poland May 26 – 29, 2010<br />
[ 11 C]SOMADAM: potential sert ligand for pet studies and comparison with [ 11 C]MADAM<br />
Gourand F. (1) , Emond P. (2) , Bergström J. P. (3) , Takano A. (3) , Gulyas B. (3) , Guilloteau D. (2) , Barré L. (1) , Halldin C. (3) .<br />
(1) CEA/DSV CI-NAPS, France<br />
(2) INSERM U930-Université François Rabelais de Tours CHRU Bretonneau, France<br />
(3) Karolinska Institutet, Sweden<br />
gourand@cyceron.fr<br />
Introduction: Although [ 11 C]MADAM is an<br />
appropriate PET radioligand for the visualization<br />
and quantification of SERT in vivo, metabolite<br />
analysis in human and non-human plasma samples<br />
using HPLC separation have shown that [ 11 C]<br />
MADAM was rapidly metabolized. 1,2<br />
A possible metabolic pathway is the S-oxidation<br />
which could lead to SOMADAM and SO 2 MADAM.<br />
In vitro evaluation of these two potential metabolites<br />
have shown that SOMADAM exhibited a good<br />
affinity for SERT and a good selectivity for SERT<br />
over NET and DAT. 3 In view of its in vitro biological<br />
properties, SOMADAM has been labelled with<br />
carbon-11 and evaluated as a potential radioligand<br />
for in vivo quantification of SERT in the monkey<br />
brain using PET.<br />
Methods: The labeling of [ 11 C]SOMADAM is based<br />
on the N-alkylation reaction of the N-desmethyl<br />
precursor using [ 11 C]methyl triflate in acetone.<br />
Comparative PET imaging studies in cynomolgus<br />
monkey with [ 11 C]MADAM and [ 11 C]SOMADAM<br />
were carried out and plasma samples were analyzed<br />
using reverse phase HPLC.<br />
Results: The incorporation of [ 11 C]methyl triflate to<br />
[ 11 C]SOMADAM was in the range of 50% and after<br />
purification by reverse phase HPLC, [ 11 C]SOMADAM<br />
was obtained with a radiochemical purity higher<br />
than 99%. PET imaging studies in monkey using<br />
[ 11 C]SOMADAM showed 1) a rapid and high brain<br />
uptake and 2) an homogenous distribution of the<br />
imaging life<br />
radioactivity. A rapid washout in all regions was<br />
observed, indicating a high non-specific binding. As<br />
it has already been shown in previous PET studies,<br />
the radioactivity accumulation of [ 11 C]MADAM is<br />
consistent with the known densities of SERT sites.<br />
HPLC analysis of plasma samples obtained after<br />
either [ 11 C]MADAM or [ 11 C]SOMADAM injection<br />
gave radiochromatograms with a similar profile<br />
where all the radioactive metabolites detected were<br />
more hydrophilic than the parent compound. After<br />
[ 11 C]MADAM injection, one radioactive species has<br />
been identified as [ 11 C]SOMADAM and the fraction<br />
was approximatively 5% at 4 min and 1% at 15 min.<br />
Conclusions: From PET imaging studies in<br />
monkey, it appears that [ 11 C]SOMADAM does not<br />
present any advantages over [ 11 C]MADAM, either<br />
in terms of brain kinetics and specific binding.<br />
Nevertheless, [ 11 C]SOMADAM has been identified<br />
in plasma sample as a minor labeled metabolite of<br />
[ 11 C]MADAM.<br />
References:<br />
1. Halldin C et al; Synapse. 58:173-183 (2005)<br />
2. Lundberg J et al; J Nucl Med. 46:1505-1515 (2005)<br />
3. Vercouillie J et al; Bioorg Med Chem Lett. 16:1297-<br />
1300 (2006)
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
MR imaging of extracellular redox by a thiolsensitive Gd(III)-DO3A derivative<br />
Menchise V. (1) , Gianolio E. (2) , Digilio G. (3) , Cittadino E. (2) , Napolitano R. (2) , Fedeli F. (2) , Catanzaro V. (2) , Aime S. (2) .<br />
(1) Institute for Biostructures and Bioimages (CNR) c/o Molecular Biotechnology Center University of Turin, Italy<br />
(2) Department of Chemisty IFM & Center for Molecular Imaging, University of Turin, Italy<br />
(3) Department of Environmental and Life Sciences, University of Eastern Piedmont “A. Avogadro”, Alessandria, Italy<br />
valeria.menchise@unito.it<br />
Introduction: The characterization of the microenvironment<br />
around and within tumors is of great<br />
importance to evaluate the invasiveness of cancers<br />
and to predict resistance to radio- and chemotherapy.<br />
Severe hypoxia and acidosis has been related<br />
to aggressive cell phenotype, poor clinical outcome<br />
and low likelihood of patient survival. 1 More reducing<br />
microenvironment conditions are related<br />
to increased cancer cell proliferation and increased<br />
resistance to chemotherapies. Any method for the<br />
imaging of the parameters characterizing the tumor<br />
microenvironment would be therefore of immense<br />
value for the characterization/grading of the tumor<br />
and for the choice and calibration of therapies. We<br />
have recently described a series of Gd-DO3A based<br />
compounds that exploit exofacial protein thiols<br />
(EPTs) to be taken up by cells. The most effective<br />
of these compounds, named Gd-L1A, can reach an<br />
intracellular concentration as high as 1.2x10 10 Gd<br />
atom per single cell. 2 The fact that the uptake of Gd-<br />
L1A by cells is proportional to the amount of EPTs<br />
makes it an interesting candidate as a probe for the<br />
MR molecular imaging of the extracellular redox<br />
microenvironment.<br />
Methods: In labeling experiments, cells grown to a<br />
confluence of 80% were subjected to a 4 hours incubation<br />
with Gd-L1A (0.5 to 3mM) at 37 °C, washed<br />
three times, mechanically harvested and finally subjected<br />
to mineralization and quantitative analysis of<br />
Gd(III) by a relaxometric assay. MR images were acquired<br />
on mice grafted with B16 tumor before and after<br />
intratumor/intramuscle injection of Gd-L1A using<br />
a T1-weighted multislice multiecho protocol (TR/TE<br />
250/7.7) on an ASPECT spectrometer operating at 1T.<br />
Results: Uptake experiments of GdL1A carried<br />
out on B16 melanoma cells treated with chemicals<br />
known to block EPTs have shown that the extent of<br />
Gd uptake increases with the concentration of free<br />
EPTs on the cell membrane. Imaging of EPTs has<br />
been performed in an animal tumor model obtained<br />
by inoculating about 1 million of B16 melanoma<br />
cells subcutaneously in B57Bl/6 mice. Gd-L1A has<br />
been delivered to tumor areas in these mice models<br />
and signal enhancement monitored over time and<br />
compared to that found in non-tumor bearing tissue.<br />
Gd-DO3A has been used as a control.<br />
A significant signal enhancement has been found in<br />
the tumor area of mice treated with Gd-L1A, with<br />
wash-out kinetics of the contrast agent consistent<br />
with its internalisation by tumor cells.<br />
Conclusions: These results show that Gd-L1A is<br />
suitable to image EPTs, that are in turn sensitive and<br />
responsive to the extracellular redox.<br />
Acknowledgement: This work is supported by FP6<br />
Project NMP4-CT-2006-026668 (MediTrans) and by<br />
Regione Piemonte (PIIMDMT)<br />
References:<br />
1. Tatum et al. Int J Radiat Biol., 82: 699-757 (2006)<br />
2. Digilio G. et al., Chem. Commun. 893–895 (2009)<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
day2<br />
Parallel Session 7: PROBES II - together with EANM
80<br />
WarSaW, poland May 26 – 29, 2010<br />
Everything but not cell replacement with somatic neural stem cell transplantation<br />
Pluchino S. .<br />
San Raffaele Scientific Institute Milano, Italy<br />
pluchino.stefano@hsr.it<br />
Introduction: Since the first transplant of stem cells<br />
into the spinal cord of rodents in which an acute demyelinating<br />
lesion was induced, we have witnessed<br />
a spur of experimental cell-based transplantation<br />
approaches aimed at fostering biological and molecular<br />
mechanisms underlying CNS repair. Theories<br />
assuming that very little renewing potential is<br />
identified within the adult CNS have been contravened,<br />
new promising sources of myelinogenic cells<br />
for transplantation purposes have been characterized,<br />
and new cell-replacement strategies have been<br />
proposed and established. A better understanding of<br />
the dynamics of endogenous remyelination has been<br />
achieved, and insights concerning the process of remyelination<br />
driven by site-specific myelin-forming<br />
cell transplantation have been discovered.<br />
Methods: Some major limitations have – however –<br />
not been overcome yet:<br />
(i) the limited amount of highly myelinating cells<br />
that can be grown in vitro and<br />
(ii) the limited migratory capacity of myelinating<br />
cells once transplanted. Somatic stem cells might<br />
represent therefore an alternative and promising area<br />
of investigation with some potential in its essence.<br />
Results: New hopes have been recently raised by the<br />
encouraging preliminary results obtained by transplanting<br />
CNS-derived NPCs and bone marrow mesenchymal/stromal<br />
stem cells in rodents with experimental<br />
MS. However, most of the results with stem<br />
cells as therapeutic weapons for MS have consistently<br />
challenged the sole and limited view that stem cells<br />
therapeutically work exclusively throughout cell replacement.<br />
Indeed, the transplantation of somatic<br />
(non-hematopoietic) stem cells promotes substantial<br />
CNS repair via a number of bystander mechanisms,<br />
mainly exerted by undifferentiated stem cells releasing<br />
in vivo a milieu of tissue-trophic and immune<br />
modulatory molecules, whose release is likely to be<br />
temporally and spatially orchestrated by specific<br />
(micro)environmental cues. These molecules are indeed<br />
are pleiotropic and redundant in nature as well<br />
as ‘constitutively’ secreted by stem cells. In this view,<br />
the therapeutic plasticity of stem cell can be viewed<br />
imaging life<br />
as the capacity of stem cells to adapt their fate and<br />
function(s) to specific environmental needs occurring<br />
as a result of different pathological conditions.<br />
Conclusions: While further studies are certainly required<br />
to assess the overall safety, efficacy and in vivo<br />
therapeutic plasticity of NPCs, the great challenge for<br />
any future human application of NPC-based protocols<br />
in MS will be to develop more reliable and reproducible<br />
approaches optimizing both (tissue) trophic<br />
as well as immune regulatory capacities of stem cells<br />
for functional and anatomical rescuing of myelin architecture<br />
in MS patients.<br />
Detailed review of the most recent data on the highly<br />
peculiar immune regulatory stem cell signature will<br />
be here provided.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Mesenchymal stem cell transplantation: an option to promote remyelination?<br />
Aigner L. .<br />
Institute of Molecular Regenerative Medicine, Paracelsus Medical University Salzburg, Austria<br />
ludwig.aigner@pmu.ac.at<br />
Mesenchymal stem cells (MSCs) have been<br />
used previously in a number of animal models<br />
for neurological / neurodegenerative diseases.<br />
Moreover, clinical studies that are using MSCs for<br />
therapy of CNS diseases are currently ongoing. In<br />
animal models, systemic or local transplantation<br />
of MSCs provided functional improvement. The<br />
therapeutic effects of MSCs are derived from their<br />
immuno-modulatory activity and from the fact<br />
that MSCs secrete a number of neuroprotective<br />
cytokines. Moreover, there is evidence that MSCs<br />
might be able to influence the pool of endogenous<br />
stem or progenitor cells. Along this line, we have<br />
recently demonstrated that MSCs secrete activities<br />
that promote oligodendroglial fate and differentiation<br />
of neural progenitors (Rivera et al., 2006).<br />
Here, we will present data on the effects of MSC<br />
transplantation on endogenous spinal cord<br />
progenitors after spinal cord injury. Like in the<br />
in vitro situation, the presence of MSCs in the<br />
lesioned spinal cord promoted oligodendroglial and<br />
inhibited astroglial differentiation of endogenous<br />
progenitors. This supports the possibility of use<br />
MSC transplantation for strategies to remyelinate<br />
axons in the diseased CNS.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
day2<br />
Parallel Session 8: GENE and CELL based therapies - together with CliniGene
82<br />
WarSaW, poland May 26 – 29, 2010<br />
Viral vector-mediated transcriptional targeting of dendritic cells for antigen-specific<br />
tolerance induction in EAE/MS.<br />
Dresch C. .<br />
Univesity of Zürich, Switzerland<br />
cdresch@vetvir.uzh.ch<br />
Introduction: The cause of multiple sclerosis (MS)<br />
is unknown and the pathogenic processes leading<br />
to disease development is incompletely understood.<br />
Current knowledge supports a T cell<br />
mediated autoimmune pathogenesis targeting myelin<br />
components or myelin-producing cells. Immunization<br />
of susceptible animals with myelin<br />
antigens or transfer of myelin antigen-reactive T<br />
cells induces experimental autoimmune encephalomyelitis<br />
(EAE), an inflammatory disorder of<br />
the CNS which closely resembles MS. Because the<br />
ethiology of MS is not yet completely understood,<br />
there is no curative treatment available at present.<br />
Methods: The aim of this project was to induce permanent,<br />
antigen-specific tolerance in EAE/MS. The<br />
strategy includes the ex vivo modification of autologous<br />
hematopoietic stem cells (HSC) with lentiviral<br />
vectors that express antigens involved in EAE/MS<br />
from a dendritic cell-specific promoter. After reinfusion,<br />
the modified HSC will give rise to all cells<br />
of the immune system including antigen expressing<br />
dendritic cells. As lentivirus vectors mediate the genomic<br />
integration of transgenes in HSC, there is a<br />
constant supply of antigen expressing “steady-state”<br />
dendritic cells. We hypothesized that the stable<br />
antigen presentation by these cells in thymus and<br />
periphery in a non-inflammatory condition would<br />
tolerize self-reactive T cells and, therefore, prevent/<br />
revert disease development.<br />
Results: We demonstrated the effectiveness of this<br />
strategy for inducing myelin oligodendrocyte glycoprotein<br />
(MOG)-specific tolerance in an EAE<br />
model in mice. We show the efficient deletion of<br />
MOG specific T cells in chimeras that received HSC<br />
transduced with a MOG-expressing lentivirus vector.<br />
Also, 0% of mice which received HSC transduced<br />
with the MOG-expressing lentivirus vector<br />
developed EAE upon induction (clinical score 0),<br />
while 100% of mice that received BM cells transduced<br />
with a GFP-expressing control lentivirus vector<br />
developed EAE.<br />
Conclusions: We confirmed the potential of lentivirus<br />
vectors that transcriptionally target transgene<br />
imaging life<br />
expression to dendritic cells for antigen-specific<br />
tolerance induction in autoimmune diseases. This<br />
strategy completely prevented MOG induced EAE<br />
in mice. We will further investigate the mechanisms<br />
of vector mediated tolerance induction, in particular<br />
the involvement of regulatory T cells and cytokines.<br />
The strategy presented here is particularly promising<br />
for clinical applications. Moreover, these tools<br />
will also prove useful for studying disease mechanisms<br />
and for addressing fundamental questions in<br />
immunity and tolerance.<br />
Acknowledgement: Swiss-MS Society.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Delivery of a bioluminescent transgene to a tumor via bone marrow engraftment and local<br />
control of gene expression by non invasive local hyperthermia<br />
Fortin P. Y. (1) , Lepetit-Coiffe M. (1) , Genevois C. (1) , Debeissat C. (1) , Quesson B. (1) , Moonen C. (1) , Couillaud F. (1) .<br />
(1) University of Bordeaux/CNRS, France<br />
py.fortin@imf.u-bordeaux2.fr<br />
Introduction: The success of a gene therapy strategy<br />
depends on several parameters including the<br />
right choice of therapeutic gene, efficient delivery<br />
method and reliable control of gene expression. In<br />
the present study, we investigate an in vivo strategy<br />
to deliver a transgene around a tumor and to control<br />
the expression of the transgene. This strategy<br />
includes bone marrow engraftment of genetically<br />
engineered cells into a wild type mouse to create<br />
a chimera with nucleated circulating blood cells<br />
(CBC) expressing the firefly luciferase (lucF) reporter<br />
gene under the transcriptional control of a<br />
thermosensitive promoter. Later on, a subcutaneous<br />
tumor is induced and as part of the physiological<br />
inflammatory process, CBC accumulate into<br />
and around the tumor. Finally, lucF expression<br />
detected by bioluminescence imaging (BLI) is<br />
induced “on demand” by local hyperthermia using<br />
MR guided high-intensity focused ultrasound<br />
(MRgHIFU).<br />
Methods: Bone marrow cells (BMCs) were obtained<br />
from homozygote C57/BL6 (CD45.2) transgenic<br />
mice (NLF-1) containing the lucF transgene under<br />
transcriptional control of the heat shock protein 70<br />
(Hspa1b) promoter. BMCs were transplanted into<br />
a congenic mouse (CD45.1) pre-treated with Busilvex®,<br />
an injectable form of busulfan (2 busulfan IP<br />
injections, 25 mg/Kg) to induce medullar aplasia.<br />
The level of engraftment was measured 2 months<br />
later by measuring CD45.1/CD45.2 ratio using Fluorescence<br />
Activated Cell Sorting (FACS). Carcinoma<br />
Mouse Tumor 93 (CMT-93, ATCC) were implanted<br />
subcutaneously (2 millions cells) to generate a tumor<br />
on the left leg. Tumors were heated (44°C, 8<br />
min) for local gene activation using either a water<br />
bath or MRgHIFU. LucF expression was evaluated<br />
in vivo 6 hours post heating by BLI.<br />
Results: After 2 months, about 80% of engrafted<br />
mice exhibited more than 65% of CBC from the<br />
donor mouse as demonstrated by FACS. CMT-93<br />
cells implanted into engrafted mice formed tumors<br />
ranging from 5 and 10 mm in one month. Tumors<br />
heated (44°C, 8 min) by dipping the tumor-bearing<br />
leg into a water bath, in mice exhibiting more<br />
than 65% of engraftment, induced lucF activation<br />
and transient light emission 6 hours later. Light<br />
emission was found in and around the tumor, for<br />
about 50% of the mice. The remaining mice did<br />
not exhibit any light emission. A week later lightemitting<br />
mice did not produce light anymore.<br />
They were heated again (44°C, 8 min) but using<br />
the MRgHIFU device. Six hours later, light emission<br />
was found around the heated focal region corresponding<br />
to both tumors and the surrounding<br />
region (n = 15). Light emission was also detected<br />
in an additional location (n = 6) corresponding to<br />
head and apical region of bone both on ipsi and<br />
contralateral legs.<br />
Conclusions: The bioluminescent chimera mice<br />
express the lucF reporter under transcriptional<br />
control of a thermosensitive promoter in hematopoietic<br />
cells. This model allows for studying<br />
gene delivery to tumor using circulating blood cells.<br />
Local gene expression was induced “on demand”<br />
by local hyperthermia. MRgHIFU heating reveals<br />
both expected (inside and around the tumor) and<br />
unexpected (contralateral leg) activation patterns<br />
further to be explored.<br />
Acknowledgement: This work was supported in<br />
part by Diagnostic Molecular Imaging and the<br />
Conseil Régional d’Aquitaine.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
day2<br />
Parallel Session 8: GENE and CELL based therapies - together with CliniGene
YIA applicant<br />
84<br />
WarSaW, poland May 26 – 29, 2010<br />
Dendritic cell labelling with paramagnetic nanoparticles and 111 In-oxine for in vivo magnetic<br />
resonance imaging and scintigraphic imaging<br />
Martelli C. (1) , Borelli M. (1) , Rainone V. (1) , Ottobrini L. (1) , Degrassi A. (2) , Russo M. (2) , Texido G. (3) , Pesenti E. (2) , Fiorini C. (4) ,<br />
Clerici M. (5) , Trabattoni D. (1) , Lucignani G. (1) .<br />
(1) University of Milan ,<br />
(2) Nerviano Medical Sciences,<br />
(3) Pharmacology Department, BU Oncology, Nerviano Medical Sciences, Nerviano, MI,<br />
(4) Politecnico of Milan,<br />
(5) University of Milan and on Gnocchi Foundation.<br />
cristina.martelli@unimi.it<br />
Introduction: Better understanding of the biology<br />
and the role of dendritic cells (DCs) in regulating<br />
immune responses is driving the development of innovative<br />
anti-neoplastic DC based immunotherapies<br />
both at clinical and pre-clinical levels [1] . The aim of<br />
this study is the development and the evaluation of a<br />
tumour-specific DC vaccine, tested on a transgenic<br />
murine model of breast cancer (MMTV-v-Ha-Ras).<br />
MRI and SPET methodologies were tested for their<br />
feasibility in showing the migration to local draining<br />
lymph nodes (DLNs) of DC, properly labelled<br />
with paramagnetic nanoparticles (MNPs, Endorem ® )<br />
or 111 In-oxine [2] .<br />
Methods: Total bone marrow cells were extracted<br />
from wt mice. DC differentiation was studied by<br />
flow cytometry; at the 6 th day of culture DCs were<br />
labelled with commercial MNPs (200 ugFe/ml, for<br />
16h). Labelling efficiency was checked by optical<br />
microscopy after Perl’s staining and relaxometric<br />
analysis. Tumour lysates from breast cancer lesions<br />
of transgenic mice were used to load immature DCs<br />
(iDCs), and maturation was monitored by flow cytometry.<br />
Stimulatory activity of Ag-loaded DCs and<br />
migratory ability were evaluated in vitro. MNP labelled<br />
and Ag loaded DCs were then injected into<br />
the footpad of a transgenic tumour bearing mice.<br />
The same cells were labelled after antigen loading<br />
with 111 In-Oxine (30 uCi/10 6 cells). MRI and SPET<br />
imaging were performed at 4, 24 and 48h after cells<br />
injection. MRI was performed on a 7T Bruker Pharmascan<br />
instrument, and MSME and FLASH sequences<br />
were used. SPET imaging was carried out<br />
with a new prototype of gamma camera developed<br />
within an European Project by Politecnico of Milano.<br />
Ex vivo Perl’s staining and gamma counting of<br />
explanted DLNs was performed to validate imaging<br />
data and DC migration.<br />
Results: Perl’s staining showed constant iron content<br />
of DCs in all the experiments. Mean Iron<br />
content was 240 pg/cell. DCs labelling with 111 Inoxine<br />
showed a very high efficiency (83%). Vitality<br />
was not significantly affected by both labelling<br />
strategies. Labelling with MNPs did not affect DC<br />
imaging life<br />
immune-phenotype or functionality, as demonstrated<br />
by CD86 and CD83 expression levels, T-cell proliferation<br />
and INF-γ production. Migration assays<br />
showed that Ag-loaded DCs were able to migrate<br />
in the presence of stimulatory chemokines (6Ckine<br />
and MIP3β). MRI evidenced the presence of an hypointense<br />
signal in both axillary and popliteal LN,<br />
in relation to the injection site, 4h after cell injection.<br />
Signal was visible up to 24 h after DC injection.<br />
Perl’s staining of LN sections after in vivo injection<br />
of labelled DCs loaded with the antigens, showed<br />
the presence of iron within the node, indicating that<br />
mature and labelled DCs migrate in vivo from the<br />
site of injection to the DLN. SPET imaging demonstrated<br />
as well DCs migration from the injection<br />
site to the DLN. Ex vivo analysis of different organs<br />
showed a statistically significant higher signal within<br />
the LN omolateral to the injection site in comparison<br />
with the controlateral one.<br />
Conclusions: Labelling protocols do not perturb<br />
DC physiology and functionality. Dynamic in vivo<br />
MRI and SPET imaging monitoring of DCs distribution<br />
will shed light on the fundamental parameters<br />
responsible for anti-neoplasic efficacy [3] , while<br />
the use of clinically approved MNPs and tracers will<br />
speed up the transfer from pre-clinical studies to<br />
clinical trials.<br />
Acknowledgement: this work is supported by the FP6<br />
funded Hi-CAM project (LSHC-CT-2006-037737),<br />
PRIN (20082NHWH9) and AIRC (IG2009-9311)<br />
and by fellowships from the Doctorate School of<br />
Molecular Medicine, University of Milan.<br />
References:<br />
1. de Vries IJ et al. Nature Biotech, 2005,23(11):1407-<br />
1413<br />
2. Baumjohann D et al. Eur. J. Immunobiology 2006; 36:<br />
2544-2555<br />
3. Lucignani G et al. TRENDS in Biotechnology 2006;<br />
24(9): 410-418
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
The type 2 cannabinoid receptor as a new PET reporter gene for the brain<br />
Vandeputte C. (1) , Evens N. (1) , Toelen J. (1) , Deroose C. (1) , Ibrahimi A. (1) , Verbruggen A. (1) , Debyser Z. (1) , Bormans G. (1) ,<br />
Baekelandt V. (1) , Van Laere K. (1) .<br />
(1) K.U. Leuven, Belgium<br />
caroline.vandeputte@med.kuleuven.be<br />
Introduction: Reporter genes play an important role<br />
in the understanding of gene expression and function<br />
in living subjects. However, for the brain no<br />
successful PET reporter systems are available with<br />
low endogenous background gene expression and<br />
good blood-brain-barrier (BBB) penetration of the<br />
PET probe. The aim of this study was to develop<br />
a new PET reporter gene system which can be applied<br />
to the brain. The type 2 cannabinoid receptor<br />
(CB 2 ) has a very low brain expression in physiological<br />
conditions and CB 2 PET radioligands crossing<br />
the BBB were recently developed.<br />
Methods: We constructed lentiviral (LV) and<br />
adeno-associated viral vector (AAV) transfer plasmids<br />
encoding human CB 2 , harboring a point mutation<br />
at position 80 (D80N) referred to as CB 2 (D80N),<br />
as such or in combination with enhanced green fluorescent<br />
protein (eGFP) or firefly luciferase (FLuc).<br />
Rats were stereotactically injected with either 5 µl of<br />
AAV-eGFP-T2A-CB 2 (D80N) in the right striatum<br />
and 5 µl of AAV control vector in the left striatum<br />
or 5 µl of AAV-fLuc-T2A-CB 2 (D80N) in the right<br />
striatum. At different time points (6, 13, 18, 73, 96<br />
and 252 days) after stereotactic injection of the<br />
AAV, a CB 2 selective carbon-11 labeled radioligand<br />
[ 11 C]GW405833 was injected intravenously and<br />
dynamic µPET images (Focus 220, Siemens) were<br />
acquired. BLI scans were performed at 16, 58 and<br />
281 days after surgery. Time-activity curves (TAC)<br />
and parametric binding potential maps were determined.<br />
The animals were sacrificed and perfused<br />
and double immunohistochemical staining against<br />
CB 2 and eGFP of the brain slices was performed.<br />
Results: The observed CB 2 binding potential increased<br />
over time and reached a maximum in right<br />
striatum between 18 and 58 days after vector injection<br />
in the brain. The time-activity curves persistently<br />
expressed an increased uptake in right<br />
striatum compared to control left striatum and<br />
cerebellum. Immunohistochemical analysis showed<br />
colocalization of both CB 2 and eGFP in right striatum.<br />
In contrast, only eGFP expression was seen in<br />
the contralateral hemisphere.<br />
Conclusions: We have successfully developed a new<br />
PET reporter gene system consisting of a lentiviral<br />
or an adeno-associated viral vector expressing<br />
the CB 2 receptor as the reporter gene which can be<br />
quantified for several months.<br />
Acknowledgement: We gratefully acknowledge the<br />
financial support by the European Commission for<br />
EC-FP6-STREP-STROKEMAP, BRAINSTIM SBO-<br />
IWT-060838, DIMI LSHB-CT-2005-512146 and<br />
the K.U. Leuven Center of Excellence ‘MoSAIC’<br />
(Molecular Small Animal Imaging Center).<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
YIA applicant<br />
day2<br />
Parallel Session 8: GENE and CELL based therapies - together with CliniGene
86<br />
WarSaW, poland May 26 – 29, 2010<br />
Department of Nuclear Medicine , Klinikum rechts der Isar<br />
Technische Universität München, Ismaninger Straße 22<br />
D-81675 München, Germany<br />
Phone: +49-(0)89-4140-4586, Fax: +49-(0)89-4140-4841<br />
Graduation:<br />
1981-1985 Study of Chemistry, University of Cologne<br />
1992-1996 Diploma and PhD, Radiochemistry,<br />
Res. Center Juelich, Germany<br />
1995-1997 Scientific Assistant, Department of Nuclear Medicine,<br />
Technische Universität München (TUM)<br />
1997-2004 Research Associate, Department of Nuclear Medicine (TUM)<br />
Academic Appointments<br />
since 2003 five national and international offers (W3 Radiopharm. Chem. , C4 Bioinorg. and Radiopharm.<br />
Chem., C3 Radiopharm. Chem., Assoc. Prof. for Radiology, Assoc. Prof. for Radiat. Oncol.). Since 2004<br />
Professor for Radiopharmaceutical Chemistry at the TU München, Faculty of Medicine)<br />
Scientific Focus<br />
Development of specific molecular probes for the non-invasive imaging of diseases, new strategies for<br />
production of radiopharmaceuticals, radionuclide therapy, tissue selective targeting of imaging probes and<br />
therapeutic compounds, transfer of genomic and proteomic information into new imaging methods.<br />
imaging life<br />
Hans-Jürgen Wester
Molecular imaging of CXCR4 receptors<br />
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Wester H.J. (1) , Demmer O. (2) , Dijkgraaf I. (1) , D´Alessandria C. (1) , Kessler H. (2) .<br />
(1) Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany<br />
(2) Institute for Advanced Study, Technische Universität München, Lichtenbergstrasse 4, 85747 Garching, Germany<br />
H.J.Wester@lrz.tu-muenchen.de<br />
Chemokines play a key role in tumor metastasis and are<br />
also involved in tumor growth. The receptor subtype<br />
CXCR4 has been found to be highly expressed in >30<br />
different types of cancer. Similar to the homing of hematopoietic<br />
progenitor and stem cells, the chemokine<br />
receptor subtype CXCR4 and its endogenous ligand,<br />
the stromal cell derived factor 1-alpha (SDF1-alpha or<br />
CXCL12), have been found to be responsible for “hijacking”<br />
circulating tumor cells in organs and tissues<br />
expressing CXCL12. In primary tumors, expression<br />
and binding of CXCL12 to CXCR4 promotes tumor<br />
proliferation and activates cell migration. In addition,<br />
CXCL12 induces recruitment of progenitor cells, which<br />
allows for tumor angiogenesis. It has been demonstrated<br />
that CXCR4 gene expression in mammary cancer<br />
cells is coregulated by Her2/neu, and also activated by<br />
HIF-1-alpha, implicating hypoxia-induced metastasis.<br />
A high CXCR4 density has also been reported for cancer<br />
stem cells. Consequently, CXCR4 directed therapies<br />
are currently under development aiming to inhibit<br />
tumor growth and metastasis by blocking CXCL12<br />
binding to CXCR4 using antibodies, large and small<br />
peptides as well as small molecules. CXCR4-directed<br />
PET probes should be useful tracers for monitoring<br />
those CXCR4-directed therapies in the future, i.e. for<br />
patient selection, therapy planning and monitoring<br />
response and may also independently allow for imaging<br />
the ´metastatic potential` of primary tumors.<br />
Antibodies, radiolabeled SDF, medium sized peptides<br />
and newly developed cyclic CXCR4 peptides antagonists<br />
are currently assessed as probes for monitoring<br />
CXCR4 expression or CXCR4 targeted therapies<br />
using metastasizing tumor models in rodents.<br />
With the aim to develop suitable radiolabeled probes to<br />
image CXCR4 receptor expression, we initially started<br />
with the evaluation of 4-[ 18 F]Fluorobenzoyl-TE14011-<br />
Me. Initial experiments showed unfavourable in vitro<br />
characteristics and low labelling yields. Using a similar<br />
approach by Hanoka et al (2006), Ac-TZ14011<br />
(Acetyl-Arg 1 -Cit 6 -Arg 7 -Lys 8 (In-DTPA)-T140-amide),<br />
labelled with In-111, showed high uptake in liver and<br />
kidney of tumor bearing mice reached, whereas tumor<br />
uptake was only negligible.<br />
Exploiting our experience in the development of small<br />
peptides, i.e. on cyclic RGD- pentapetides as high affinity<br />
ligand for the alpha(v)beta(3) integrin, we focussed<br />
our research on small CXCR4-binding pentapeptides.<br />
We have synthesized approximately 150<br />
monomeric and dimeric peptides and evaluated their<br />
binding characteristics on Jurkat cells and transfected<br />
CMS5 cells stably expressing the hCXCR4 receptor.<br />
Selected candidates were labelled with 123,125 I-iodine,<br />
18 F-fluorine and 68 Ga-gallium and investigated in nude<br />
mice bearing CMS5/CXCR4+ fibrosacoma and metastasizing<br />
OH-1 SCLC tumors. Based on c(Gly-D-Tyr-<br />
Orn-Arg-NaI), 4-fluorobenzoylated and 2-fluoropropionylated<br />
versions showed IC 50 of 11±2 nM and 35±1<br />
nM ( 125 I-CXCL12 as competitor), and radioiodinated<br />
c(Gly-D-Tyr-Arg-Arg-NaI) exhibited an IC 50 of 4nM.<br />
We could demonstrate that N-methylated peptides<br />
showed an improved IC 50 when compared to the nonmethylated<br />
analogues. A variety of linkers were investigated<br />
allowing for conjugation of chelators without<br />
affecting the affinity of the entire molecule. The<br />
DOTA-Ahx-Asp (Ahx= aminohexanoic acid) conjugate<br />
of a cxclic D-Orn-peptide version showed an IC 50<br />
of 38nM (with free chelator) and 13.7nM after complexation<br />
with indium. A variety of dimers were synthesized,<br />
the linkers and linker length optimized and<br />
the generated constructs assessed. C4-C16 dicarbonic<br />
acid spacers showed a continuously increasing affinity<br />
in the series C4 (6.6nM) – C10 (2.3nM), whereas<br />
longer spacers were unsuitable. The first of a series of<br />
promising 68 Ga-labeled peptides is renally excreted<br />
leading to high tumor-to-background contrast and<br />
high contrasting small animal PET-imaging approx.<br />
1h post injection.<br />
Compared to the other CXCR4-probes described,<br />
the small cyclic peptides developed offer significant<br />
advantages and will allow for broadening state-ofthe-art<br />
high contrast peptide receptor imaging to<br />
another important class of GPCRs.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
day2<br />
<strong>ESMI</strong> Plenary Lecture 4 by Hans-Jürgen Wester
88<br />
WarSaW, poland May 26 – 29, 2010<br />
Evaluation of the temporal window for drug delivery following ultrasound mediated<br />
membrane permeability enhancement<br />
Yudina A. (1) , Lepetit-Coiffé M. (1) , Moonen C. (1) .<br />
Laboratoire IMF CNRS UMR 5231 / Université Bordeaux 2, France<br />
anna@imf.u-bordeaux2.fr<br />
Introduction: Ultrasound (US)-mediated delivery<br />
is a new therapeutic option to locally facilitate the<br />
passage of drugs through cell plasma membrane<br />
by reversibly altering its permeability[1] possibly<br />
via the formation of pores that are known to spontaneously<br />
reseal within a short time – seconds to<br />
minutes[2]. However under certain conditions the<br />
effects of US for drug delivery last for hours after<br />
the exposure[3]. The present work is the first in<br />
vitro attempt to confirm and quantitatively assess<br />
the temporal window for the US-mediated intracellular<br />
drug delivery by live-cell imaging.<br />
Methods: Cell-impermeable optical chromophores<br />
with fluorescence intensity increasing 100-1000<br />
fold upon intercalation with nucleic acids served<br />
as smart agents for reporting cellular uptake. Opticell<br />
chambers with a monolayer of C6 cells were<br />
subjected to ultrasound in the presence of microbubbles<br />
followed by varying delays between<br />
0 and 24 hours before addition of Sytox Green<br />
optical contrast agent. Micro- and macroscopic<br />
fluorescence imaging was used for qualitative and<br />
quantitative analysis.<br />
Results: Strong enhancement of the fluorescence<br />
signal upon binding to nucleic acids allowed efficient<br />
visualization of the local effect of US on internalization<br />
of cell-impermeable intercalating dyes.<br />
Up to 25% of viable cells showed uptake of contrast<br />
agent with a half time of 8 hours, with cellular uptake<br />
persisting even at 24 hours (Figure 1). Only<br />
cells exposed to ultrasound showed the effect.<br />
imaging life<br />
Conclusions: Optical imaging showed that temporal<br />
window of increased membrane permeability is<br />
much longer than previously suggested. This may<br />
have important repercussions for in vivo studies in<br />
which membrane permeability may be temporally<br />
separated from drug administration to better adapt<br />
to pharmacokinetic / pharmacodynamic properties<br />
of the drug or drug carrier.<br />
Acknowledgement: This work is supported by the<br />
EC-project FP7-ICT-2007-1-213706 SonoDrugs and<br />
Foundation InNaBioSanté-project ULTRAFITT. Microscopy<br />
was performed in the Bordeaux Imaging<br />
Center of the Neurosciences Institute of the University<br />
of Bordeaux II.<br />
References:<br />
Figure 1. In the absence of US<br />
only occasional cells with the<br />
compromised membrane show<br />
the uptake of cell-impermeable<br />
Sytox green (A). However the<br />
effects of the US on membrane<br />
permeability can last up to<br />
24h (B), with the fluorescence<br />
intensity increasing as the time<br />
between US application and<br />
fluorophore administration<br />
shortens (C-F).<br />
1. Hernot S, Klibanov AL; Adv Drug Deliv Rev. 60(10):1153-<br />
66 (2008)<br />
2. van Wamel A et al.; J Control Release. 112(2):149-55<br />
(2006)<br />
3. Hancock HA et al. Ultrasound Med Biol. 35(10):1722-36<br />
(2009)
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Integrisense: a novel near-infrared fluorescent probe for α v β 3 integrin and its applications in<br />
drug discovery<br />
Sur C. (1) , Lin S.A. (1) , Gleason A. (1) , Kossodo S. (1) , Pickarski M. (1) , Coleman P. (1) , Rajopadhye M. (2) , Duong L. T. (1) , Yared W. (2) ,<br />
Peterson J. (2) , Bednar B. (1) .<br />
(1) Merck Research Laboratories, Westpoint US<br />
(2) ViSen Medical.<br />
cyrille_sur@merck.com<br />
Introduction: The α v β 3 integrin belongs to the superfamilly<br />
of dimeric transmembrane cell adhesion<br />
receptors involved in critical biological processes<br />
such as cell-to-cell, and cell-to-extracellular<br />
matrix binding. As these activities are central to<br />
pathological conditions such as inflammation and<br />
tumor progression, the RGD-binding α v β 3 integrin<br />
has been considred as clinically-relevant biomarkers<br />
of these disease states. Although, RDG peptides<br />
have been developed for PET and SPECT imaging,<br />
the operating cost of these modalities limits their<br />
widespread deployment in drug discovery teams. In<br />
contrast optical molecular imaging allows the noninvasive<br />
monitoring and quantification of fluorescent<br />
probes in vivo with less expensive equipment<br />
that can be installed at multiple research sites. In<br />
order to take full advantage of the rich biology of integrins,<br />
a partnership has been established between<br />
Merck Research Laboratories and VisEn Medical to<br />
develop a novel near-infrared (NIR) fluorescent integrin<br />
probe, IntegriSense TM . The pharmacological<br />
and biological characterization of IntegriSense TM ,<br />
a peptidomimetic antagonist-based molecule with<br />
improved specificity and binding affinity will be<br />
presented together with research applications in the<br />
oncology and atherosclerosis research fields.<br />
Methods: The in vitro cell biology and pharmacological<br />
profiling of IntegriSense TM were conducted<br />
with recombinant HEK-293 cells expressing α v β 3<br />
and included confocal microscopy for cellular localization<br />
and flow cytometry for binding and kinetic<br />
constant determination. In vivo pharmacodynamics<br />
and tumor localization studies were performed<br />
in female NU/NU mice bearing different human<br />
tumor xenografts. IntegriSense TM NIR fluorescent<br />
signal was acquired with a Fluorescent Molecular<br />
Tomography imaging system (FMT2500). The potential<br />
application of IntegriSense TM in atherosclerosis<br />
was evaluated in apolipoprotein E-deficient<br />
(ApoE-/-) and human cholesteryl ester transfer<br />
protein (CETP) knockin/LDL receptor-deficient<br />
(C57BL/6-Tg(CETP)-Ldlrtm1) mice. Transgenic<br />
as well as control C57Bl/6 mice were fed a cholesterol<br />
enriched diet (9% fat, 0.15% cholesterol) to<br />
induce atherosclerosis. IntegriSense TM NIR signal<br />
was measured in vivo 24 and 48 hours after probe<br />
injection and its localization in inflamed aortas was<br />
further evaluated by ex-vivo imaging and histology.<br />
Results: Integrisense-680 has absorption/emission<br />
spectra centered at 674nm/692nm and an extinction<br />
coefficient of 2.02x10 5 M -1 cm -1 . Binding of IntegriSense<br />
TM to HEK-293 stably expressing recombinant<br />
human α v β 3 yielded a Kd of 4.2±0.6 nM and<br />
a dissociation constant koff of 1.08x10 -4 s -1 . Plasma<br />
pharmacokinetic analysis revealed a two compartmental<br />
profile with t1/2 of 6 min and 210 min corresponding<br />
to clearance of free and bound IntegriSense<br />
TM , respectively. Biodistribution studies in<br />
mice with xenograft tumors showed a specific uptake<br />
of IntegriSense TM by tumor cells and supported<br />
using IntegriSense TM to monitor tumor growth in<br />
animal models.<br />
In vivo measurements with FMT2500 in mice atherosclerosis<br />
models detected a longitudinal increase in<br />
IntegriSense TM fluorescence in the thorax area that<br />
was three to five fold higher when compared with<br />
control animals. This NIR signal originated from<br />
atherosclerotic lesions in the aortic arch, carotid,<br />
and subclavian arteries as confirmed by ex vivo imaging<br />
of the dissected vessels and histopathology.<br />
Conclusions: This report demonstrated that the α v β 3<br />
integrin optical reporter, IntegriSense TM developed<br />
by Merck and VisEn partnership can be used as a<br />
molecular imaging biomarker for in vivo imaging<br />
studies. For instance, IntegriSense TM can be used to<br />
monitor tumor growth as well as to detect inflammation<br />
in atherosclerosis plaques. The ability of<br />
this biomarker to report on several important cellular<br />
and physiological functions makes it a tool of<br />
choice to evaluate preclinically the therapeutic potential<br />
of novel anticancer and atherosclerosis drugs.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
day2<br />
Plenary Session on current contribution of IMAGING TECHNOLOGIES to DRUG DEVELOPMENT
90<br />
WarSaW, poland May 26 – 29, 2010<br />
Harnessing the power of bioluminescence to cross the in vitro–in vivo divide<br />
Watson J. (1) , Klaubert D. (1) , Biserni A. (2) , Ciana P. (2) , Maggi A. (2) , Allard S. (1) .<br />
(1) Promega<br />
(2) TOP (Transgenic Operative Products)srl<br />
John.watson@promega.com<br />
Introduction: Bioluminescence imaging is accomplished<br />
by sensitive detection of light emitted following<br />
chemical reaction of the luciferase enzyme<br />
with substrate. The imaging process in animal<br />
models requires a reporter construct that leads to<br />
production of luciferase enzyme. The most commonly<br />
used reporter for this purpose is a construct<br />
that can express firefly luciferase (1). Data will be<br />
presented that shows how a number of biomarkers<br />
can be measured using bioluminescence in vitro,<br />
including caspase-3/7, ATP and transcriptional<br />
activation. We will also describe the in vivo characterization<br />
of VivoGlo Caspase-3/7 Substrate, a<br />
modified firefly luciferase substrate that in apoptotic<br />
cells is cleaved by caspase-3 to liberate aminoluciferin,<br />
which can be consumed by luciferase<br />
to generate a luminescent signal. Evidence will be<br />
shown illustrating the possibility to merge a line of<br />
reporter mice (repTOP) engineered for the ubiquitous<br />
expression of the luciferase reporter gene<br />
(2-4) and the modified luciferase substrate, Vivo-<br />
Glo Caspase-3/7 Substrate, to measure molecular<br />
apoptotic events in whole living animals. We will<br />
also demonstrate that this substrate can be used<br />
to non-invasively observe the apoptotic affects of<br />
chemotherapy several days before they are able to<br />
be detected by traditional methods (5).<br />
Methods: In this study, liver apoptosis was induced<br />
in luciferase reporter mice by a single i.p. injection<br />
of D-galactosamine (D-GalN; 800mg/kg) and<br />
Lipopolysaccharide (LPS; 100mg/kg) (6). Six hours<br />
after LPS/D-GalN or vehicle administration, mice<br />
were treated i.p. with increasing doses (17-150mg/<br />
kg) of the VivoGlo Caspase-3/7 substrate (Z-<br />
DEVD-Aminoluciferin, Sodium Salt) and subjected<br />
to the bioluminescence in vivo imaging procedure.<br />
Results: The in vivo imaging data obtained clearly<br />
showed a dose-dependent increase of photon<br />
emission in the hepatic area of mice treated with<br />
D-GalN/LPS. No photon emission was observed in<br />
organs not affected by the apoptotic treatment. A<br />
complete analysis of pro-apoptotic effects induced<br />
by the treatment was carried out by ex vivo imaging<br />
acquisition of photon emission in several dissected<br />
imaging life<br />
tissues. This investigation confirmed that light<br />
emission observed in vivo was produced selectively<br />
by liver and adipose tissues. Western blot analysis<br />
and the measure of Caspase-3/7 enzymatic activity<br />
fully supported in vivo imaging data.<br />
Conclusions: The work here shows the power of<br />
a modified luciferin substrate such as VivoGlo<br />
Caspase-3/7 Substrate to detect apoptotic cells in<br />
living animals, providing an important advancement<br />
over current imaging methodologies based<br />
on fluorescence, nuclear or magnetic resonance<br />
including: virtually no background, high sensitivity<br />
and simple instrumentation needed for the in vivo<br />
imaging measurement of the Caspase-3/7 activity.<br />
The present application carried out in reporter<br />
mice genetically engineered to develop specific<br />
cancers will open the way to novel, more predictive<br />
approaches for the study of anti-cancer treatments<br />
that will enable researchers to measure drug efficacy<br />
in space and time, providing relevant information<br />
to be rapidly translated to human therapy.<br />
References:<br />
1. Zinn, KR et al; ILAR Journal. 49:103-115 (2008)<br />
2. Ciana, P et al; Nat. Med. 9:82-86 (2003)<br />
3. Maggi, A and Ciana, P; Nat. Rev. Drug Discov. 4:249-255<br />
(2005)<br />
4. Maggi, A et al; Trends Pharmacol. Sci. 25:337-342<br />
(2004)<br />
5. Hickson, J et al; Cell Death Differ. doi:10.1038/<br />
cdd.2009.205 (2010)<br />
6. Nakama, T et al; Hepatology. 33:1441-1450 (2001)
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
In vivo imaging in drug discovery: the example of application in the development of novel<br />
estrogenic compounds.<br />
Biserni A. (1) , Rando G. (2) , Ciana P. (2) , Komm B. (3) , Maggi A. (2) .<br />
(1) TOP (Transgenic Operative Products)srl,<br />
(2) University of Milan,<br />
(3) Wyeth Research .<br />
andrea.biserni@top-mice.com<br />
Introduction: Intracellular Receptor (IR) signalling<br />
is temporally organized at different levels: at the<br />
cellular level, post-translational modification and<br />
proteolysis were shown to be responsible for IRdependent<br />
recruitment of co-regulators and proteins<br />
of the transcriptional apparatus necessary to<br />
modulate IR activity in time. At the whole organism<br />
level, circadian rhythms and pulsatility of hormone<br />
release may be responsible for maintaining<br />
a state of activity of IR that is critical for hormone<br />
action. With hormone therapy, the reinstatement<br />
of the receptor oscillatory activity may be a key element<br />
for achieving the desired beneficial effect. To<br />
date, the lack of appropriate models to study the<br />
response to pharmacological treatments in time<br />
has been a limiting factor in the study of spatiotemporal<br />
activity of drugs. The availability of the<br />
ERE-Luc reporter mouse model where the application<br />
of BLI-based imaging methodologies allows<br />
one to study estrogen receptor activity in living animals,<br />
opens the way to a more in-depth analysis of<br />
the effect of estrogen therapy (ET). The aim of this<br />
study was to set up a protocol for the study of ET<br />
and SERM (Selective Estrogen Receptor Modulator)<br />
therapies to verify their ability to efficaciously<br />
restore the effects of the natural endocrine state in<br />
reproductive and non reproductive organs.<br />
Methods: The study was carried out in the ERE-Luc<br />
reporter mouse model where the luciferase reporter<br />
gene is expressed under the transcriptional control<br />
of an ER responsive promoter. In this model, MARs<br />
(Matrix Attachment Regions) insulator sequences<br />
flanking the transgene guarantee a ubiquitous and<br />
tightly regulated expression of the biosensor making<br />
it suitable for pharmacological studies. In the present<br />
study, we treated ovariectomized, female mice with<br />
CE (3 mg/kg/day), raloxifene (RAL; 10 mg/kg/day)<br />
and bazedoxifene (BZA, 10 mg/kg/day) for 21 days.<br />
To measure ER state of activity, mice were subjected to<br />
in vivo imaging. Photon emission was measured by the<br />
use of a segmentation algorithm enabling the automatic<br />
quantification of photon emission in different body regions<br />
of mouse images. At the end of the study a further<br />
analysis was carried out on tissue extracts by luciferase<br />
enzymatic assay.<br />
Results: In the initial analysis, we evaluated the<br />
effect of each treatment in the genital, hepatic,<br />
abdominal area and limbs at 0, 3, 7, 14 and 21d.<br />
CE had a major effect in the genital and hepatic<br />
areas shown by a significant increase of ER activity.<br />
As expected the effect of SERMs was significant<br />
in the skeletal (limbs) where ER activity<br />
started to be significantly increased only after<br />
day 14. In the body areas affected by treatments,<br />
we observed time-dependent changes: i.e. in the<br />
liver CE activity decreased with time, while in<br />
the limbs ER activity was shown to increase with<br />
the time of exposure to SERMs. This observation<br />
prompted us to perform a more in-depth analysis<br />
of ER activity by measuring photon emission<br />
daily. This second analysis demonstrated that ER<br />
activity oscillates in time with a period and amplitude<br />
that is tissue specific and is differentially<br />
affected by the hormonal treatments. Furthermore,<br />
the analysis of ER oscillation revealed that<br />
ovariectomy does not fully disrupt the fluctuation<br />
observed in intact, cycling mice indicating<br />
the existence of mechanisms other than circulating<br />
hormone responsible for ER transcriptional<br />
activity. The treatments evaluated partially restored<br />
the physiological oscillatory behavior of<br />
the receptor.<br />
Conclusions: Our study: Provides evidence for a<br />
novel, long paced, oscillatory activity of ERs that is<br />
independent of ovarian function. This oscillatory<br />
ER activity may be relevant for the whole body homeostatic<br />
control and may be of relevance for the<br />
identification of safer and more efficacious therapies.<br />
Points to the importance of whole animal imaging<br />
for drug development and for the study spatio-temporally<br />
drug activity on targets.<br />
Novel protocols for a wider application of BLI to<br />
the study of molecular events in vivo should be<br />
developed.<br />
Acknowledgement: Grants from: NoE DIMI<br />
LSHB-CT-2005-512146; IP CRESCENDO LSHM-<br />
CT-2005-018652), National Institutes of Health<br />
(RO1AG027713), and Wyeth Pharmaceutical Co.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
day2<br />
Plenary Session on current contribution of IMAGING TECHNOLOGIES to DRUG DEVELOPMENT
DAY<br />
3
• <strong>ESMI</strong> Plenary Lecture 5: Jagat Narula (Irvine, USA)<br />
Molecular Imaging of unstable coronary plaques<br />
Chairs: Uwe Haberkorn (Heidelberg, Germany), Helmut Maecke (Freiburg, Germany)<br />
• Parallel Session 9: Cardiovascular II<br />
Chairs: Klaas Nicolay (Eindhoven, The Netherlands), Michael Schäfers (Münster, Germany)<br />
• Parallel Session 10: Cancer II – together with COST action BM0607<br />
Chairs: Marion de Jong (Rotterdam, The Netherlands), Fabian Kiessling (Aachen, Germany)<br />
• Plenary Session and Closing Ceremony<br />
Chairs: John Clark (Edinburgh, UK), Bertrand Tavitian (Orsay, France)<br />
Day 3 - Friday May 29, 2010
94<br />
WarSaW, poland May 26 – 29, 2010<br />
imaging life<br />
Jagat Narula<br />
Jagat Narula MD, PhD, FACC, FRCP [Edin, Hon]<br />
Professor of Medicine and Chief, Division of Cardiology<br />
Director, Memorial Heart & Vascular Institute<br />
Medical Director, Edwards Lifesciences Center for Advanced Cardiovascular Technology<br />
University of California, Irvine School of Medicine<br />
Jagat Narula completed his cardiology training in India at the All India Institute of Medical Sciences, Delhi,<br />
and relocated to Massachusetts General Hospital and Harvard Medical School in 1989. After fellowships in<br />
heart failure, transplantation, and cardiovascular imaging, he joined the Massachusetts General cardiology<br />
faculty. In 1997, he moved to Hahnemann University School of Medicine in Philadelphia. At Hahnemann,<br />
he was the Thomas J. Vischer Professor of Medicine, Chief of Division of Cardiology, and Vice-Chairman<br />
of Medicine. He joined University of California, Irvine in 2003 as Professor of Medicine Chief, Division<br />
of Cardiology, and Associate Dean for Research. Dr. Narula is involved in clinical and basic research in<br />
the fields of heart failure and atherosclerosis, with major emphasis on development of novel noninvasive<br />
imaging techniques. He has made vital contributions to the imaging of apoptotic cell death in heart<br />
muscle, and to the imaging of atherosclerotic plaques that are vulnerable to rupture. His research is not<br />
limited by any one imaging modality; and uses integrated imaging approaches for better identification<br />
of cardiovascular pathology. His research is funded, in part, by grants from the National Institutes of<br />
Health. Dr. Narula has authored more than 700 research publications or presentations and edited 25 books<br />
and journal supplements. He has been awarded “Best Young Investigator” on several occasions by the<br />
Cardiovascular Council, the Society of Nuclear Medicine, and the American Society of Nuclear Cardiology.<br />
He serves on various committees of the American Heart Association. He is the editor-in-chief of the Journal<br />
of the American College of Cardiology- Imaging. He has also been an Associate Editor of the Journal of<br />
the American College of Cardiology and the Founder Editor of Heart Failure Clinics of North America.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Molecular imaging of unstable coronary plaques<br />
Narula J. .<br />
University of California, USA<br />
narula@uci.edu<br />
Sudden cardiac death and acute myocardial infarction<br />
often occur as the first manifestation of coronary<br />
artery disease. Otherwise asymptomatic individuals<br />
with subclinical atherosclerosis almost always<br />
have a classic risk-factor profile and it is essential<br />
that they are identified before the occurrence of an<br />
acute coronary event. The ability to recognize such<br />
individuals requires the development of noninvasive<br />
strategies that can localize unstable atherosclerotic<br />
lesions. Plaques that are vulnerable to rupture demonstrate<br />
distinct histological characteristics, including<br />
large plaque and necrotic core volumes covered<br />
by attenuated fibrous caps and extensive remodeling<br />
of the vessel at the lesion site. The morphologic features<br />
can be characterized by CT angiography and<br />
magnetic resonance imaging.<br />
In addition to characteristic morphological profile,<br />
monocyte-macrophage infiltration of the fibrous<br />
cap is one of the strongest determinants of plaque<br />
instability, and amenable to molecular inaging. After<br />
crossing the intimal border, infiltrating monocytes<br />
express receptors for chemoattractants (such as<br />
MCP-1 or adhesion molecules), and subsequently develop<br />
scavenger receptors in the subintimal layers for<br />
ingestion of oxidized LDL. Although multiple cellular<br />
processes can be targeted for the identification of<br />
plaque inflammation only a few molecular imaging<br />
strategies have been successfully employed for clinical<br />
imaging. The inflammatory cells in plaques have<br />
high metabolic activity. In contrast to granulocytes,<br />
which carry a supply of glycogen to provide energy<br />
for their phagocytic activities, the macrophages in<br />
an atheroma require exogenous glucose for their<br />
metabolism. Incidental uptake of a glucose analog,<br />
[18F]-FDG, commonly used to characterize malignant<br />
tumors, has been demonstrated in the aorta,<br />
carotid arteries and, rarely, the coronary vessels of<br />
patients with tumors. Carotid endarterectomy specimens<br />
have demonstrated that uptake correlates with<br />
macrophage content, and is reduced in patients<br />
treated with statins. A prospective study has demonstrated<br />
that FDG uptake can be seen in the coronary<br />
arteries if background FDG uptake in the myocardium<br />
is adequately suppressed. Following coronary<br />
interventions, intense FDG uptake has been seen at<br />
the sites of stent implantations in patients with acute<br />
coronary events; no uptake was observeat the stent<br />
sites in patients with stable disease. Concurrent CT<br />
angiography was performed in these patients for precise<br />
anatomical localization of FDG uptake on PET<br />
imaging. Another clinical approach with molecular<br />
imaging has utilized radiolabeled annexin A5 to<br />
target apoptotic macrophages in the atherosclerotic<br />
lesions. A large proportion of macrophages in the<br />
attenuated fibrous caps of vulnerable and ruptured<br />
plaques undergo apoptosis. The annexin uptake in<br />
the carotid vessels has been predominantly seen in<br />
symptomatic carotid disease. Annexin imaging of<br />
coronary vessels has not been attempted. Various other<br />
molecules targeting evolution of receptors such as<br />
MCP-1 and scavenger receptors, as well as those targeting<br />
the products of inflammation such as metalloproteinases<br />
are being successfully employed for the<br />
imaging of atherosclerosis in experimental models.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
day3<br />
<strong>ESMI</strong> Plenary Lecture by Jagat Narula
96<br />
WarSaW, poland May 26 – 29, 2010<br />
Advances in contrast-enhanced MRI of the mouse heart<br />
Strijkers G. .<br />
Biomedical NMR Eindhoven, The Netherlands<br />
g.j.strijkers@tue.nl<br />
Introduction: In preclinical cardiovascular research<br />
using mouse models, MRI has proven to<br />
be the imaging modality of choice for studying<br />
cardiac pathology. This is mainly thanks to its<br />
high temporal and spatial resolution, enabling<br />
accurate determination of cardiac functional<br />
parameters.<br />
MRI contrast agents are used to differentiate between<br />
viable and infarct myocardium. Recently, it<br />
has become possible to use MR contrast agents for<br />
the evaluation of the mouse myocardial perfusion<br />
status. Molecular MR imaging techniques are being<br />
developed, allowing contrast agents to specifically<br />
target disease markers, providing additional<br />
information about the infarction. The use of contrast<br />
agents in the mouse myocardium requires innovative<br />
mouse cardiac MRI techniques to quantify<br />
contrast agent kinetics and concentration in the<br />
myocardium.<br />
Results: In this presentation I will present recent<br />
advances in the contrast-enhanced MR imaging of<br />
the mouse heart.<br />
First, I will discuss new MR technology, which enables<br />
the assessment of mouse myocardial perfusion.<br />
This methodology involves intravenous injection of<br />
an MRI contrast agent, after which the first pass of<br />
the contrast agent through the heart is monitored<br />
in a time-series of images. The combination of the<br />
high heart rate (400-600 bpm), small heart size (5-6<br />
mm left ventricle (LV) diameter) and fast systemic<br />
blood circulation time (4-5 s) require a very fast<br />
imaging protocol while preserving adequate spatial<br />
resolution to visualize the regional myocardial inflow<br />
of the contrast agent.<br />
Secondly, I will discuss recent advances in the T1<br />
quantification of the mouse myocardium, which<br />
enables quantification of contrast agent concentration.<br />
The T1 quantification method uses a combination<br />
of 3D IntraGate FLASH steady-state imaging<br />
together with DESPOT1 analysis. The 3D IntraGate<br />
FLASH makes use of a navigator echo that retrospectively<br />
triggers the acquisition to the heartbeat<br />
and respiration cycle.<br />
imaging life<br />
Acknowledgement: Grant sponsor: Dutch Technology<br />
Foundation STW, applied science division of<br />
NWO and the Technology Program of the Ministry<br />
of Economic Affairs; Grant numbers: 07952 and<br />
10191. Grant sponsor: European Union Network of<br />
Excellence Diagnostic Molecular Imaging; Grant<br />
number: 512146 (LSHB-CT-2005-512146).
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Molecular imaging of α v β 3 integrin expression with 18 F-galacto-RGD after experimental<br />
myocardial infarction: comparison with left ventricular remodeling and function.<br />
Saraste A. (1) , Sherif H. (1) , Nekolla S. (1) , Weidl E. (1) , Higuchi T. (1) , Reder S. (1) , Tapfer A. (1) , Botnar R. (1) , Wester H. J. (1) ,<br />
Schwaiger M. (1) .<br />
Technische Universität München, Germany<br />
antti.saraste@utu.fi<br />
Introduction: Myocardial infarction (MI) and subsequent<br />
left ventricular (LV) remodeling are the<br />
most frequent cause for development of chronic<br />
heart failure. Expression of α v β 3 integrin receptors<br />
is increased early after MI as part of the healing<br />
process. Poor infarct healing can contribute to progressive<br />
LV remodeling. 18 F-galacto-RGD (RGD) is<br />
a PET tracer that binds to α v β 3 integrin receptors.<br />
We studied whether molecular imaging of myocardial<br />
RGD uptake early after MI can predict longterm<br />
LV remodeling in rat.<br />
Methods: Wistar rats underwent permanent left<br />
coronary artery (LCA) ligation to induce myocardial<br />
infarction (MI) or sham operation. One week<br />
post-MI, rats were imaged with a small animal PET<br />
scanner after injection of 13N ammonia to define<br />
perfusion defect area, and 90 minutes post injection<br />
of RGD in order to measure α v β 3 integrin expression.<br />
Myocardial RGD uptake (%ID/cc) in the<br />
infarcted (defect area) and remote myocardium<br />
were measured in co-registered polar maps. Cardiac<br />
magnetic resonance imaging (MRI) with 1.5T<br />
scanner, small animal coil and ECG triggering was<br />
used to measure LV remodeling and function repeatedly<br />
1 week and 12 weeks post-MI.<br />
Results: One week after LCA ligation, RGD uptake<br />
was significantly higher in the defect area than<br />
in the remote myocardium of MI rats and in controls<br />
(0.2±0.05 vs. 0.06±0.03 and 0.07±0.04 %ID/<br />
cc, respectively, p20% increase in EDV, early RGD uptake<br />
in the defect area was 29% lower than in rats with<br />
less than
98<br />
WarSaW, poland May 26 – 29, 2010<br />
Existing and emerging animal models mimicking cardiovascular disease and their relevance<br />
for molecular imaging<br />
Schäfers M. .<br />
European Institute for Molecular Imaging – EIMI, University of Münster<br />
schafmi@uni-muenster.de<br />
Appropriate animal models, mimicking the pathology<br />
of cardiovascular human diseases is essential<br />
for progress in the field of cardiovascular research<br />
and for the transfer of preclinical results into the<br />
clinical setting. In principle, a variety of animal<br />
species can be used in cardiovascular research. Although<br />
larger animal such as pigs (a classical model<br />
for myocardial infarction) are used in cardiovascular<br />
research, the focus has been shifted to small<br />
imaging life<br />
animal models such rats and mice recent years.<br />
Animal models of cardiovascular diseases can rely<br />
both on genetic manipulations or surgical interventions<br />
and do nowadays cover the wide spectrum<br />
of cardiovascular human diseases. In this talk, examples<br />
for relevant human cardiovascular diseases,<br />
myocardial infarction and atherosclerosis, already<br />
being studied by small animal imaging is given.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Imaging of Matrix Metalloproteinase Activity in Vulnerable Human Carotid Plaques with<br />
Multispectral Optoacoustic Tomography<br />
Razansky D. (1) , Harlaar N. J. (1) , Hillebrands J. L. (2) , Taruttis A. (1) , Herzog E. (1) , Zeebregts C.J. (2) , Van Dam G. M. (2) ,<br />
Ntziachristos V. (1) .<br />
(1) Technical University of Munich and Helmholtz Center Munich, Germany<br />
(2) University Medical Center Groningen, The Netherlands.<br />
tdr@tum.de<br />
Introduction: The indication for a carotid endarterectomy<br />
is nowadays mainly based on symptomatology<br />
or, alternatively, on the degree of stenosis in<br />
carotid arteries (>80%). Those indications however<br />
do not provide an accurate assessment of plaque<br />
vulnerability and therefore only a small percentage<br />
of patients do actually benefit from the surgical intervention<br />
by preventing a major cerebro-vascular<br />
event especially in the asymptomatic group [1].<br />
High activity levels of tissue biomarkers, such as<br />
cathepsins, integrins, and matrix metalloproteinases<br />
(MMPs), have been associated with atherosclerotic<br />
plaque instability, thus can potentially be<br />
used for highly specific diagnosis [2]. While fluorescent<br />
tagging of such molecules has been amply<br />
demonstrated, no imaging method has so far been<br />
shown capable of resolving inflammation-associated<br />
tags with high fidelity.<br />
Methods: We showcase herein the ability to resolve<br />
activation of common probes sensitive to matrix<br />
metallo-proteinases with unprecedented image<br />
quality and resolution utilizing multi-spectral optoacoustic<br />
tomography (MSOT) [3], thus revealing<br />
atherosclerotic activity. Human carotid plaque specimens<br />
from patients were incubated ex vivo with<br />
an MMP-sensitive activatable fluorescent probe<br />
(MMPsense 680TM) directly after endarterectomy.<br />
The specimen were subsequently imaged using an<br />
MSOT scanner capable of simultaneous high resolution<br />
visualization of morphology and molecular<br />
activity with better than 200 micron resolution.<br />
Results: MSOT analyses identified heterogeneous<br />
MMP activity throughout the plaques, revealing<br />
hot and cold spot regions indicative of relatively<br />
high and low MMP activity respectively. The results<br />
from intact specimen corresponded well with<br />
epi-fluorescence images made on thin cryosections.<br />
Elevated MMP activity in the hot spot regions resolved<br />
was further confirmed by in situ zymography,<br />
accompanied by increased macrophage influx.<br />
Results from both MSOT investigations and histological<br />
sections confirmed that most of the plaque<br />
formation activity occurs, as expected, close to the<br />
bifurcation area of the carotid artery.<br />
Conclusions: We show, for the first time to our<br />
knowledge, the ability of multispectral optoacoustic<br />
tomography to deliver volumetric images of activatable<br />
molecular probe distribution deep from optically<br />
opaque tissues. High resolution mapping of MMP<br />
activity in the vulnerable plaque of human carotid<br />
specimen was demonstrated. This ability directly relates<br />
to clinical potential as it can allow highly specific<br />
visualization and staging of plaque vulnerability<br />
in atherosclerosis during surgical intervention or by<br />
intravascular or potentially non-invasive imaging;<br />
thus impacting therapeutic clinical decision.<br />
Acknowledgement: This research was partially supported<br />
by the German Research Foundation (DFG)<br />
Research Grant (RA 1848/1), ERC Senior Investigator<br />
Award, and the Medizin Technik BMBF award for<br />
excellence in medical innovation.<br />
References:<br />
1. Chambers BR et al; Cochrane Database Syst Rev.<br />
2:CD001923 (2000).<br />
2. Libby P.; Inflammation in atherosclerosis. Nature.<br />
420:868-874 (2002).<br />
3. Razansky D et al.; Nature Phot. 3:3525-3529 (2009).<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
day3<br />
Parallel Session 9: CARDIOVASCULAR II
100<br />
WarSaW, poland May 26 – 29, 2010<br />
c-Jun N-terminal kinase promotes inflammation at atherosclerosis-prone sites by enhancing<br />
expression and activity of NF-κB transcription factors<br />
Evans P. (1) , Cuhlmann S. (1) , Van Der Heiden K. (1) , Haskard D. (1) , Krams R. (1) , Gsell W. (1) , Carlsen H. (2) , Jones H. (1) .<br />
(1) Imperial College London,<br />
(2) University of Oslo, Norway.<br />
paul.evans@imperial.ac.uk<br />
Introduction: Atherosclerosis is a chronic inflammatory<br />
disease of arteries that causes heart attack or<br />
stroke. Early lesions contain monocytes and T lymphocytes<br />
which are recruited from the circulation<br />
to activated vascular endothelial cells (ECs). This<br />
process relies on NF-κB transcription factors which<br />
induce pro-inflammatory molecules (e.g. VCAM-1)<br />
in ECs. Atherosclerosis develops predominantly at<br />
branches and bends of arteries that are exposed to<br />
low, oscillatory shear stress (frictional force exerted<br />
by flowing blood on ECs). We previously demonstrated<br />
that c-Jun N-terminal kinase (JNK), a MAP<br />
kinase, is activated in ECs at atherosusceptible but<br />
not atheroprotected sites (Chaudhury et al 2010).<br />
Here we combined in vitro studies with molecular<br />
imaging techniques in murine models to study the<br />
function of JNK in arterial EC.<br />
Methods: We studied the function of JNK by<br />
performing microarray analysis of cultured<br />
ECs treated with a pharmacological JNK inhibitor.<br />
En face immunostaining was used to determine<br />
the expression of particular proteins in<br />
ECs at atheroprotected and atherosusceptible<br />
sites of murine arteries. In addition, we assessed<br />
NF-κB transcriptional activity in murine<br />
arteries of transgenic NF-κB-luciferase reporter<br />
mice by measuring luminescence using an ultrasensitive<br />
camera (Xenogen). Inflammation<br />
was also assessed by F18-FDG PET/CT imaging<br />
of murine arteries and identification of<br />
CD68-positive macrophages by immunostaining.<br />
Results: Transcriptome profiling of cultured ECs<br />
treated with a pharmacological inhibitor revealed<br />
that JNK functions as a positive regulator of NFκB<br />
transcription factors. This observation was<br />
confirmed by silencing of JNK1 and ATF2 (a<br />
downstream transcription factor) which led to<br />
reduced NF-κB expression in cultured ECs. We<br />
validated our findings by studying ECs in the aorta<br />
of wild-type and JNK1-/- mice. En face immunostaining<br />
revealed that EC expression of NF-κB<br />
and VCAM-1 and accumulation of CD68-positive<br />
macrophages was enhanced at atherosusceptible<br />
imaging life<br />
compared to atheroprotected sites in wild-type<br />
mice. Genetic deletion of JNK1 suppressed NF-κB<br />
and VCAM-1 expression at the atherosusceptible<br />
site, indicating that JNK1 positively regulates<br />
NF-κB expression and inflammation. Similarly,<br />
studies of transgenic NF-κB-luciferase mice revealed<br />
that NF-κB activity in ECs was enhanced<br />
at atherosusceptible compared to atheroprotected<br />
sites. To determine whether a causal relationship<br />
exists between shear stress and vascular inflammation<br />
we altered blood flow in the murine carotid<br />
artery by placing a flow altering cuff. We<br />
observed that low, oscillatory shear stress enhanced<br />
JNK activity, increased the expression of<br />
NF-κB and VCAM-1, promoted the accumulation<br />
of macrophages and enhanced arterial uptake of<br />
F18-FDG.<br />
Conclusions: We conclude that JNK1-ATF2 signalling<br />
promotes EC activation and inflammation<br />
at atherosusceptible sites exposed to low, oscillatory<br />
shear stress by enhancing NF-κB expression.<br />
Our findings illuminate a novel level of cross-talk<br />
between the NF-κB and JNK signalling pathways<br />
that may influence the spatial distribution of atherosclerotic<br />
lesions.<br />
Acknowledgement: Funded by the European Union<br />
FP6 NoE DiMI (LSHB-CT-2005-512146) and British<br />
Heart Foundation.<br />
References:<br />
1. Chaudhury et al. 2010 Arterioscler. Thromb. Vasc. Biol.<br />
30(3):546-53.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Absolute Quantification in Small Animal Pinhole Gated Myocardial Perfusion SPECT<br />
Goethals L. (1) , Devos H. (1) , Vanhove C. (1) , De Geeter F. (1) , Lahoutte T. (1) .<br />
(1) VUB Brussels, Belgium<br />
lode.goethals@vub.ac.be<br />
Introduction: Previously, our group has demonstrated<br />
the feasibility of absolute quantification using SPECT<br />
[1] imaging by incorporating a CT derived non-uniform<br />
attenuation correction (AC) map and a triple energy<br />
scatter window correction in the reconstruction<br />
algorithm of SPECT images. In this study we apply<br />
these techniques to the rat myocardium, which has a<br />
size below the resolution of our imaging system, thus<br />
suffering from a partial volume effect, which results in<br />
an underestimation of the activity concentration in the<br />
target tissues. To compensate for this underestimation<br />
we performed ultrasound imaging prior to SPECT imaging<br />
to determine myocardial wall thickness. We then<br />
derived a recovery coefficient (RC) from phantom studies<br />
to correct for the partial volume effect.<br />
Methods: SPECT/CT scans were performed in 9<br />
healthy Wistar rats 30 min after injection of 99mTc-<br />
Tetrofosmin. Prior to SPECT/CT imaging, 2D cardiac<br />
ultrasound images were acquired in the midventricular<br />
segments to determine diastolic and systolic<br />
myocardial wall thickness. After SPECT/CT imaging,<br />
animals were sacrificed and 6 midventricular segments(anterior-anterolateral-inferolateral-inferiorinferoseptal-anteroseptal)<br />
of the left ventricle were<br />
excised and counted in a gamma well counter. Using<br />
6 midventricular ROI’s in AMIDE, the effect of scatter<br />
correction (SC) and attenuation correction (AC) was<br />
determined in every midventricular segment.<br />
The activity in every ROI was expressed in Curie per<br />
gram (taking into account the density of myocardial tissue<br />
of 1,055 Kg/L). These image-derived activities were<br />
compared to the ex vivo activity concentrations<br />
counted in the gamma counter. To correct for<br />
the partial volume effect, a RC was determined from<br />
a phantom study. All values obtained after AC and SC<br />
were corrected by this RC and compared to the ex vivo<br />
counting data.<br />
Results: AC leads to a significant increase in counts in<br />
every midventricular segment, whilst SC results in a<br />
decrease in counts in every midventricular segment.<br />
The combination of both S and AC leads to a significant<br />
increase in counts in the inferior midventricular segment<br />
(paired Student’s T test, p < 0,05).<br />
After combined AC and SC, there remains a vast underestimation<br />
of activity in the myocardium, compared<br />
to the ex vivo data. Incorparation of a recovery<br />
coefficient derived from the phantom study, alleviates<br />
this problem: in the sub 5mm region, a RC of Y<br />
= 17,252 . X (with X = myocardial size in mm, Y = RC<br />
in %) was derived from the phantom studies. Dividing<br />
the combined AC and SC values by a RC derived<br />
from the average wall thickness (diastolic + systolic<br />
/ 2) leads to an adequate estimation of activity, correlating<br />
well with the ex vivo data. Use of the diastolic<br />
thickness as source of the RC leads to an overestimation<br />
of activity, use of the systolic thickness<br />
as a source of the RC leads to an underestimation<br />
of activity on the non-gated images. Use of the appropriate<br />
RC on the corresponding gated images also<br />
leads to an adequate estimation of activity on images.<br />
Conclusions: Combining attenuation, scatter and<br />
partial volume effect corrections in small animal<br />
myocardial perfusion SPECT allows for non invasive<br />
absolute quantification of myocardial perfusion.<br />
Acknowledgement: Researh at ICMI is funded by the<br />
Interuniversity Attraction Poles Program - Belgian<br />
State - Belgian Science Policy. Tony Lahoutte is a Senior<br />
Clinical Investigator of the Research Foundation - Flanders<br />
(Belgium) FWO. Lode Goethals is a PhD fellow of<br />
the research foundation – Flanders (Belgium) -FWO.<br />
References:<br />
1. Improved quantification in single-pinhole and<br />
multiple-pinhole SPECT using micro-CT information.<br />
Vanhove C, Defrise M, Bossuyt A, Lahoutte T. Eur J Nucl<br />
Med Mol Imaging. 2009 Jul;36(7):1049-63.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
YIA applicant<br />
day3<br />
Parallel Session 9: CARDIOVASCULAR II
102<br />
WarSaW, poland May 26 – 29, 2010<br />
Cancer imaging<br />
Haberkorn U. .<br />
University Heidelberg, Germany<br />
Uwe.Haberkorn@med.uni-heidelberg.de<br />
Increased metabolism has been found to be one<br />
of the most prominent features of malignant<br />
tumors. This property led to the development of<br />
tracers for the assessment of glucose metabolism<br />
and amino acid transport and their application for<br />
tumor diagnosis and staging. Prominent examples<br />
are fluorodeoxyglucose, methionine and tyrosine<br />
analogs which have found broad clinical application.<br />
Since quantitative procedures are available these<br />
imaging life<br />
techniques can also be used for therapy monitoring.<br />
Another approach may be based on the noninvasive<br />
detection of apoptosis with tracers for<br />
phosphytidyl-serine presentation and/or caspase<br />
activation as surrogate marker for therapeutic<br />
efficacy. Finally, the use and development of<br />
specific ligands to target structures overexpressed<br />
in tumor tissue may be a valuable tool for diagnosis<br />
and novel therapeutic interventions.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Controlled drug delivery under image guidance<br />
Gruell H. (1) , Langereis S. (1) , De Smet M. (2) , Sanches P. (2) , Hijnen N. (2) , Rossin R. (1) , Bohmer M. (1) , Keupp J. (1) , Tiemann K. (3) ,<br />
Heijman E. (1) .<br />
(1) Philips Research,<br />
(2) Eindhoven University of Technology,<br />
(3) University Hospital Münster.<br />
holger.gruell@philips.com<br />
Introduction: Focused ultrasound (FU) is an excellent<br />
method for local triggered drug delivery<br />
using either pressure or temperature sensitive delivery<br />
systems. Temperature sensitive liposomes<br />
(TSLs) as drug carriers are promising to maximize<br />
delivery of drugs to tumors that are heated<br />
slightly above body temperature using FU. Besides<br />
heating, the pressure pulses of ultrasound<br />
waves can be exploited to disrupt microbubbles,<br />
which can lead to formation of transient pores in<br />
the endothelial wall. The latter is termed sonoporation<br />
and was shown to mediate cellular uptake<br />
of therapeutic agents. Either way, imaging based<br />
method to visualize, follow, and control drug delivery<br />
in-vivo are of importance to establish more<br />
quantitative treatment protocols.<br />
Methods: TSLs of different lipid compositions<br />
and a release temperature slightly above body<br />
temperature were loaded with T1, CEST or fluorinated<br />
MRI contrast agents and the drug doxorubicin.<br />
MRI was used to assess the signal change<br />
upon heating the TSLs from T=310 K to T=315 K<br />
using FU. For pressure induced drug delivery, microbubbles<br />
were injected into tumor bearing mice.<br />
Tumor and muscle tissues were treated with FU.<br />
Subsequently, radiolabeled albumin was injected<br />
and the extravasation in tumor and muscle tissue<br />
was followed and quantified using single photon<br />
computed tomography (SPECT).<br />
Results: Focused ultrasound is used to locally<br />
heat tissue, while MRI provides spatial and temperature<br />
control of the process. Co-encapsulation<br />
of drugs and MRI contrast agents allows to image<br />
the drug carrier system as well as to quantify<br />
release of drugs under hyperthermia conditions<br />
with MRI, making this modality the perfect<br />
choice for temperature induced drug delivery<br />
under image guidance. The temperature of drug<br />
release but also contrast properties can be tuned<br />
by nature and composition of the phospholipid<br />
bilayer. The rapid release of drugs and contrast<br />
agents can be explained by the formation of transient<br />
pores in the lipid membrane upon heating.<br />
For pressure induced drug delivery, the cavitation<br />
of microbubbles by ultrasound creates transient<br />
pores in the endothelial layer allowing macromolecules<br />
to efficiently extravasate. This effect<br />
is found to be more pronounced in muscle tissue<br />
than in tumors. In healthy muscle tissue the<br />
intact endothelial layer prevents extravasation of<br />
macromolecules while the leaky and premature<br />
vasculature in tumors is more permeable for macroscopic<br />
compounds.<br />
Conclusions: Focused Ultrasound allows to noninvasively<br />
trigger drug delivery in vivo, either using<br />
a local heating or focused pressure pulses in<br />
combination with suited drug delivery vehicles.<br />
The drug delivery process can be planned, controlled<br />
and followed using diagnostic imaging<br />
modalities such as MRI or ultrasound in combination<br />
with smart drug delivery vehicles. Above<br />
approach allows local non-invasive image guided<br />
treatment of a tissue that potentially leads to an<br />
improvement of the therapeutic window or even<br />
enables delivery of completely different classes of<br />
drugs such as siRNA or plasmid DNA.<br />
Acknowledgement: This project was funded in<br />
part by the EU Project Sonodrugs (NMP4-LA-<br />
2008-213706)<br />
References:<br />
1. Langereis et al., J. Am. Chem. Soc. 131, 1380 (2009).<br />
2. De Smet et al. J. Contr. Release 143, 120 (2010).<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
day3<br />
Parallel Session 10: CANCER II - together with COST
104<br />
WarSaW, poland May 26 – 29, 2010<br />
Comparative biodistribution of twelve gastrin/CCK2 receptor targeting peptides<br />
De Jong M. .<br />
Erasmus MC Rotterdam, The Netherlands<br />
m.hendriks-dejong@erasmusmc.nl<br />
Introduction: Molecular targeted radionuclide cancer<br />
therapy is becoming of increasing importance,<br />
especially for disseminated diseases. Systemic chemotherapies<br />
often lack selectivity; targeted radionuclide<br />
therapy has important advantages as the<br />
radioactive cytotoxic unit of the targeting vector is<br />
specifically directed to the cancer, sparing normal<br />
tissues. The basis of COST Action BM0607 is the<br />
great potential of targeted radionuclide therapy<br />
using a variety of vectors and radionuclides. This<br />
Action brings together the different disciplines involved<br />
and provides a reliable and rapid means for<br />
developing new (fundamental) knowledge, method<br />
standardization and products.<br />
Minigastrin and CCK analogs have been developed<br />
for radionuclide imaging and therapy of CCK2R<br />
expressing tumors. One project in COST Action<br />
BM0607 aims to select the optimal gastrin/CCK<br />
analogs for targeting MTC and SCLC expressing<br />
the CCK2R. In the present study, twelve DOTA-<br />
conjugated analogues were labeled with In-111<br />
and their in vitro and in vivo CCK2R targeting<br />
properties were studied in nude mice with CCK2R<br />
expressing A431 tumors.<br />
Methods: All peptides were labeled with In-111<br />
at high specific activity. Receptor affinity and internalization<br />
were tested in vitro using CCK2Rtransfected<br />
A431 tumor cells. Mice with CCK2Rtransfected<br />
A431 tumors in the left flank and with<br />
mock-transfected A431 tumors in the right flank<br />
received radiolabeled peptide intravenously for<br />
imaging and biodistribution studies.<br />
Results: All peptides demonstrated high receptor affinity<br />
and receptor-specific internalization in vitro<br />
and tumor targeting in the CCK2R expressing tumor<br />
in vivo. Tumor uptake at 1 h p.i. ranged from<br />
2.53 ± 0.47 %ID/g for CP07 to 13.3 ± 4.9 %ID/g for<br />
CP10, whereas uptake at 4 h p.i. ranged from 1.88 ±<br />
1.12 %ID/g to 9.90 ± 2.0 %ID/g, respectively. Uptake<br />
in non-target tissues was low for all peptides, except<br />
for high kidney uptake for CP10 and CP11. Highest<br />
tumor-to-kidney ratios (3-5) were obtained with<br />
the gastrin analogues CP01, CP02, CP03 and CP09.<br />
imaging life<br />
Conclusions: All peptides showed good CCK2Rmediated<br />
tumor-targeting in vitro and in vivo,<br />
with low uptake in non-target organs except for<br />
the kidneys in some cases. CP01, CP04 and CP05<br />
displayed favorable in vivo characteristics, combing<br />
high tumor uptake with low kidney retention.<br />
Acknowledgement: This study is part of COST Action<br />
BM0607
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Targeting cancer stem cells using radiolabeled Sonic Hedgehog<br />
Tworowska I. (1) , Delpassand E. S. (1) , Sims-Mourtada J. (1) .<br />
(1) RadioMedix Housten, USA<br />
itworowska@radiomedix.com<br />
Introduction: Sonic Hedgehog (SHH) is an extracellular<br />
signalling protein involved in embryo<br />
development and morphogenesis [1]. Constitutive<br />
activation of the hedgehog pathway is observed in<br />
several types of cancers [2], especially in the most<br />
aggressive cancer stem cells and it is associated<br />
with their chemo/radiation resistance [3]. This<br />
work reports results on characterization of the SHH<br />
conjugates and their application to the cancer imaging<br />
using positron emission tomography (PET).<br />
Methods: 6xHis-tagged recombinant SHH<br />
(19.5kDa) with terminal NH2 group was conjugated<br />
to the DOTA (1,4,7,10-Tetraazacyclododecane-N,N’,N’’,N’’’-tetraacetic<br />
acid) in phosphate<br />
buffer and purified by dialysis. Alternatively<br />
SHH ligand was coupled to the maleimido-monoamide-DOTA<br />
chelator through thiol group of<br />
cysteine. Protein conjugates were further characterized<br />
using MALDI-MS and HPLC. Radiolabeling<br />
of the DOTA-SHH was performed in 0.1M<br />
NH4OAc (pH=4.4) using 68GaCl3 eluted from<br />
68Ge/68Ga generator (iThemba). In vitro bioactivity<br />
was evaluated by cellular uptake studies of<br />
the radiolabeled ligand in the several cancer cell<br />
lines and enriched stem cancer-cells population<br />
(mammospheres).<br />
Results: DOTA-SHH was obtained with total<br />
yield of 74%-89%. Reaction proceeded with radiochemical<br />
purity of >98% and specific activity<br />
of 3.38E+05 MBq/g, (theoretical specific activity<br />
= 3.64E+11 MBq/gram) as assessed by radio-TLC<br />
and radio-HPLC. 68Ga-DOTA-SHH have shown<br />
high affinity to Patched receptors (PTCH) in cancer<br />
cells (BT-474, MDA-MB-231, MCF-7) and its<br />
cellular uptake correlates with PTCH receptor expression<br />
levels. Cellular uptake of the SHH conjugates<br />
in the presence of the hedgehog pathway inhibitor,<br />
cyclopamine, was reduced by more than<br />
50%. Competitive uptake studies in the presence<br />
of the cold SHH, have also shown reduced cellular<br />
uptake by approximately 90%. In vitro uptake<br />
of 68Ga-DOTA-SHH was approximately 12-fold<br />
higher in cancer stem-cells (MCF-7 cultures)<br />
compared to the total cell population.<br />
Conclusions: Our studies have shown that 68Ga<br />
DOTA-SHH conjugates have potential application<br />
to non-invasive imaging of cancer, especially<br />
the most aggressive cancers. This is<br />
the first report on application of radiolabeled<br />
SHH conjugates for identification of the cancer<br />
stem-cell from the total tumor population.<br />
SHH conjugates may be also useful to evaluate<br />
new therapies targeting cancer stem-cells.<br />
References:<br />
1. Hammerschmidt M., Brook A., McMahon A.P., Trends<br />
Genet., (1997), 13, 14-2.<br />
2. Beachy P.A., Karhadkar S.S., Berman D.M., Nature (2004),<br />
432, 324-331; Mullor JL, Sánchez P, Altaba A.R., Trends<br />
Cell Biol.,(2003), 12 (12): 562–9.<br />
3. Al-Hajj M., Becker M.W., Wicha M., Weissmann I., Clarke<br />
M.F., Curr. Opin. Genet. Dev., (2004), 14(1), 43-47<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
day3<br />
Parallel Session 10: CANCER II - together with COST
YIA applicant<br />
106<br />
WarSaW, poland May 26 – 29, 2010<br />
Evaluation of the photosensitizer Bremachlorin for photodynamic treatment of breast<br />
cancer bone metastasis.<br />
Van Driel P. (1) , Que I. (1) , Snoeks T. (1) , Mol I. (1) , Xie B. (1) , Keereweer S. (1) , Kaijzel E. (1) , Löwik C.W.G.M. (1) .<br />
Leiden University Medical Center<br />
tpieter_v_driel@hotmail.com<br />
Introduction: Photodynamic therapy (PDT) is a<br />
promising treatment for tumors in which harmless<br />
light is used for the irradiation of nontoxic photosensitizers<br />
to create highly toxic reactive oxygen<br />
species for the destruction of certain tumors. In<br />
this study, the photosensitizer Bremachlorin TM<br />
(Brema Pharma Int.), derived from the seaweed<br />
spirulina, consisting of the compounds Chlorin e6,<br />
Purpurin 5 and Chlorin p6, was evaluated for PDT<br />
of breast cancer derived bone metastasis.<br />
Methods: The uptake of Bremachlorin in the human<br />
breast cancer cell line MDA-MB231 luc<br />
D3H2LN was quantitatively measured with flow<br />
cytometry and visualized with confocal laser scan<br />
microscopy. Cell viability after photodynamic<br />
treatment was measured with a luciferase assay<br />
and colorimetric MTS cell proliferation assay to<br />
identify the cytotoxic potential of Bremachlorin<br />
on these cells.The tumor cells were injected in the<br />
bone marrow cavity in femurs of immunodeficient<br />
mice to form osteolytic tumors. In vivo effects of<br />
PDT with Bremachlorin were followed by whole<br />
body bioluminescent imaging (BLI).<br />
Results: Flow cytometry analysis showed<br />
Bremachlorin uptake by the tumor cells was (close<br />
to) 100%. Also, fluorescent signal increased with<br />
an increasing dose of Bremachlorin. Complete<br />
cell death in vitro was already achieved after an<br />
incubation time of 5 hours with a concentration<br />
of 2 mg/l Bremachlorin. In vivo BLI experiments<br />
showed the partial or total eradication of the osteolytic<br />
tumors after a single pulse treatment of<br />
imaging life<br />
Bremachlorin-treated animals. In case of partial<br />
cure, the tumors were successfully eradicated by a<br />
second PDT treatment<br />
Conclusions: Our in vitro results show the tumor<br />
selective uptake of the photosensitizer Bremachlorin<br />
and its cytotoxic effects on the human<br />
breast cancer cells. Furthermore, with whole body<br />
BLI we show that PDT treatment of Bremachlorin-treated<br />
animals is an interesting therapy to<br />
eradicate aggressive tumors deep down in bone<br />
marrow. These results are very promising and<br />
interesting for future clinical use of photodynamic<br />
treatment of tumors with the photosensitizer<br />
Bremachlorin.<br />
Acknowledgement: Dhr. H. Vink and Andrei Reshetnickov<br />
from Brema Pharma
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
In vivo targeting of HEK-hsst 2/3/5 Xenografts by 111 in-labeled [(DOTA)Ser 1 ,Leu 8 ,trp 22 ,Tyr 25 ]-SS-<br />
28 in SCID mice<br />
Maina T. (1) , Tatsi A. (1) , Marsouvanidis I. P. (1) , Krenning E. P. (2) , De Jong M. (2) , Nock B.A. (1) .<br />
(1) IRRP, NCSR “Demokritos”,<br />
(2) Dept. of Nuclear Medicine, EMC Rotterdam.<br />
maina_thea@hotmail.com<br />
Introduction: Radiolabeled pansomatostatin-like<br />
analogs are expected to enhance the diagnostic<br />
sensitivity and to expand the clinical indications<br />
of currently applied sst 2 -specific radioligands<br />
(like OctreoScan ® ) [1,2]. We have previously reported<br />
on [(DOTA)Ser 1 ,Leu 8 ,trp 22 ,Tyr 25 ]SS-28<br />
displaying a high affinity for all five hsst 1-5 . In<br />
mice, the 111 In-radioligand showed specific uptake<br />
in AR4-2J tumors which express the rat sst 2<br />
[3]. We were further interested to investigate the<br />
ability of [( 111 In-DOTA)Ser 1 ,Leu 8 ,trp 22 ,Tyr 25 ]SS-<br />
28 to target human sst x expressing tumors in vivo.<br />
Methods: HEK-293 cells stably transfected with<br />
one of the hsst 2A , the hsst 3 or the hsst 5 were cultured<br />
in a humidified-5% CO 2 atmosphere at 37 0 C<br />
in DMEM GLUTAMAX-I supplemented with<br />
10%FBS, 100 U/mL penicillin / 100 µg/ml µg/mL<br />
streptomycin and 400 µg/mL G418. Cells were<br />
cropped, suspended in PBS and cell-suspension<br />
was equally divided in Eppendorf tubes (1 – 2 x<br />
10 7 cells, 150 mL). Inoculation was performed<br />
by subcutaneous injection of a cell suspension<br />
bolus in the left flank of young SCID mice. After<br />
10-18 days well-palpable tumor masses developed<br />
at the inoculation site and biodistribution<br />
experiments were performed. On the day of<br />
the experiment the radioligand was injected as<br />
a bolus (100 µL, 2 µCi) in the tail vein, alone or<br />
together with a high excess sst x -binding peptide<br />
(blocker). Animals were sacrificed in groups of<br />
four at 4 h postinjection (pi) and tissues were<br />
excised, weighed and counted in a gamma-counter.<br />
Values were calculated as percent injected<br />
dose per gram (%ID/g) tissue and are expressed<br />
as mean ± SD.<br />
Results: [( 111In-DOTA)Ser 1 ,Leu8 ,trp22 ,Tyr 25 ]SS-28<br />
showed significant and specific uptake in the hsst - 2A<br />
positive HEK implants of 4.43 ± 1.5%ID/g vs. 0.49 ±<br />
0.0%ID/g block (50 µg Tate) at 4 h pi (the previously<br />
+ reported values in the rsst -AR4-2J tumor, were<br />
2<br />
9.35 ± 1.31%ID/g and 0.35 ± 0.0%ID/g, respectively<br />
[3]). Equally high and specific uptake was displayed<br />
+ in the hsst -HEK xenografts with a 4.88 ± 1.1%ID/g<br />
3<br />
vs. 0.52 ± 0.05%ID/g block at 4 h pi (100 µg Demo-<br />
+ Pan 2 [2]). Preliminary values in the hsst -HEK<br />
5<br />
xenografts were slightly inferior (
poster
• MI in Cancer Biology – Visualisation of Extra- and Intracellular Processes 114<br />
Poster number P001 – P012<br />
• Imaging in Drug Development 126<br />
Poster number P013 – P022<br />
• Cancer from Bench to Bedside – Translational Research in Oncology 136<br />
Poster number P023 – P030<br />
• Imaging in Cardiovascular Disease: from Bench to Bedside 144<br />
Poster number P031 – P033<br />
• Molecular Neuroimaging: from Bench to Bedside 147<br />
Poster number P034 – P047<br />
• Imaging-guided Gene and Cell based Therapies 161<br />
Poster number P048 – P057<br />
• Probe Design – Innovative Approaches to Smart Contrast Agents 171<br />
Poster number P058 – P069<br />
• Technology – Technical Advances in MI Instrumentation 183<br />
Poster number P070 – P078<br />
• Imaging in Endocrine Diseases 192<br />
Poster number P079 – P083<br />
• MI of Infection and Inflammation 197<br />
Poster number P084 – P091<br />
• Imaging for Targeted Therapy 205<br />
Poster number P092 – P096<br />
• MI Data Analysis Methods 210<br />
Poster number P097 – P104<br />
• Late Breaking Abstracts 218<br />
Poster number P105 – P107<br />
Poster Session
110<br />
WarSaW, poland May 26 – 29, 2010<br />
Guided Poster Sessions – Poster Walks 1 to 7<br />
Guided Poster Session 1, Day 1: Thursday May 27, 2010 from 14:30 to 16:00<br />
Poster Walk 1: Imaging Cancer Biology – P001 to P012 & P105 to P106<br />
Co-Chairs: Fabian Kiessling (Aachen, Germany), Markus Rudin (Zürich, Switzerland)<br />
Poster Walk 2: Technology & Data Analysis Methods – P070 to P078 & P097 to P104<br />
Co-Chairs: Serge Maitrejean (Paris, France), Adriaan Lammertsma (Amsterdam, The Netherlands)<br />
Poster Walk 3: Molecular Neuroimaging – P034 to P047 & P107<br />
Co-Chairs: Sabina Pappata (Naples, Italy), Andreas Jacobs (Muenster, Germany)<br />
Poster Walk 4: Probe Design – P058 to P069<br />
Co-Chairs: Frédéric Dollé (Orsay, France), Helmut Maecke (Freiburg, Germany)<br />
Guided Poster Session 2, Day 2: Friday May 28, 2010 from 14:30 to 16:00<br />
Poster Walk 5: Imaging in Cancer & Drug Development – P013 to P022 & P023 to P030<br />
Co-Chairs: Peter Brader (Graz, Austria), NN<br />
Poster Walk 6: Imaging in Other Diseases – P031 to P033 & P079 to P083 & P084 to P091<br />
Co-Chairs: Bertrand Tavitian (Orsay, France), Nicolas Grenier (Bordeaux, France)<br />
Poster Walk 7: Imaging-guided Gene and Cell based and Targeted Therapies –<br />
P048 to P057 & P092 to P096<br />
Co-Chairs: Ludwig Aigner (Salzburg, Austria), NN<br />
imaging life
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
overview poster presentations – per title<br />
MI in CANCER BIOLGY<br />
In vivo MRI multicontrast kinetic analysis of intracellular trafficking of liposomes 114<br />
Diffusion-weighted MRI for differentiation of breast lesions at 3.0 Tesla: a new biomarker for breast imaging 115<br />
Imaging tumour apoptosis with 68Ga-labelled AnnexinA5 derivatives early after cancer therapy 116<br />
68 Ga-RGD-based PET tracers for imaging αν β 3 expression: a comparative study 117<br />
Influence of anaesthetics on tumor tracer uptake in radiopeptide receptor imaging (PRI) and radionuclide therapy (PRRT) 118<br />
Optical imaging of oral squamous cell carcinoma and cervical lymph node metastasis using near-infrared fluorescent<br />
probes in a mouse model – a pilot study 119<br />
Spectral unmixing of red and green luciferases for in vivo bioluminescence imaging 120<br />
High resolution redox imaging of intact cells by rxYFP, a ratiometric oxidation- sensitive fluorescent protein<br />
Assessment of antiangiogenic therapy effects in preclinical tumour models: Implementation of a novel contrast -<br />
121<br />
enhanced 3 D scanning technique and comparison to established ultrasound imaging protocols<br />
Influence of the BMP pathway on cell cycle regulation and its differentiation inducing potential on brain<br />
122<br />
tumor initiating cells 123<br />
A near infrared fluorescent-based method for imaging breast cancer induced osteolysis 124<br />
Near infrared fluorescent probes for whole body optical imaging of 4T1-luc2 mouse breast cancer development<br />
and metastasis 125<br />
IMAGING in DRUG DEVELOPMENT<br />
Improved animal models to study tumor growth and spontaneous metastases: bioluminescence imaging<br />
characterization of the HT-29 human colorectal cancer cell line<br />
Development of dorsal skin-fold window chamber for the analysis of blood vessel modifications induced by<br />
126<br />
electropermeabilization<br />
Characterization and evaluation of a tumor specific RGD optical probe for time-domain near-infrared<br />
127<br />
fluorescence imaging 128<br />
18F labeling of insulin via click chemistry<br />
Whole-body distribution, pharmacokinetics and dosimetry of radioiodinated fully humanized anti-VAP-1<br />
129<br />
antibody – a PET imaging study of rabbits 130<br />
Pharmacological characterization of iodine labeled adenosine kinase inhibitors<br />
Determining the nasal residence time of protein-polymer conjugates for nasal vaccination using a novel<br />
131<br />
imaging technique 132<br />
Nanotubes as mutli-modality vehicles for imaging and therapy of cancer 133<br />
Early assessment of temozolomide treatment efficacy in glioblastoma using [ 18F]FLT PET imaging 134<br />
Sensitive time-gated FRET microscopy of G-Protein coupled receptors using suicide enzymes, lanthanide cryptates and<br />
fluorescent ligands 135<br />
CANCER from BENCH to BEDSIDE<br />
Selection of a nanobody scaffold with low renal retention 136<br />
In vitro assessment of androgen mediated uptake of 18F-FDG, 11C-choline and 11C-acetate in prostate cancer 137<br />
Comparison of two 68Gallium-labeled octreotide analogues for molecular PET(CT) imaging of neuroendocrine tumours 138<br />
Real time per operative optical imaging for the improvement of tumour surgery in an in vivo micro-metastases model 139<br />
Fluorescence imaging modalities for imaging gastrointestinal tumor models<br />
Assessment of effectiveness and toxicity of the therapy with somatostatin analogue labelled 90Y-DOTATATE in<br />
140<br />
patients with non-functional pancreatic neuroendocrine tumours (PNT)<br />
Intra operative near-infrared fluorescent imaging of colorectal liver metastases using clinically available Indocyanine<br />
141<br />
Green in a syngene rat model 142<br />
Molecular imaging of resistance to EGFR tyrosine kinase inhibitors by 18F-FLT PET/CT and its reversal in non small cell<br />
lung cancer 143<br />
MI in CARDIOVASCULAR DISEASE<br />
Synchronised Cardiac and Lung CT in Rodents Using the Mobile CT Scanner LaTheta 144<br />
Molecular imaging of neurovascular inflammation in a mouse model of focal cerebral ischemia using Ultra small<br />
Superparamagnetic Particles of Iron Oxide (USPIOs) targeted to vascular cell adhesion molecule-1 (VCAM-1) 145<br />
Scintigraphy with the use of 123I-IL-2: a new promising tool for cardiovascular risk assessment in patients with high<br />
cardiovascular risk 146<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
poStEr
112<br />
WarSaW, poland May 26 – 29, 2010<br />
imaging life<br />
NEUROIMAGING from BENCH to BEDSIDE<br />
MEMRI-DTI study of focal transient ischemia in immature rat brain 147<br />
A clinically relevant model of in situ embolic stroke in the anesthetized monkey (macaca mulatta): long-term<br />
electrophysiological and mri analyses 148<br />
Automated radiosynthesis of [ 18F]MPPF derivatives for imaging 5-HT receptors 1A<br />
The vitamine E analogue CR6 protects against the long-term microstructure damage induced by MCA occlusion: a<br />
149<br />
longitudinal Diffusion Tensor Imaging study 150<br />
Design and synthesis of fluorescent probes for serotonin 5-HT1A receptors 151<br />
Comparative evaluation of cerebral blood flow in a rat model of cerebral ischemia using 15O-H 0 positron emission<br />
2<br />
tomography and 99mTc-HMPAO single-photon emission tomography<br />
Comparison of dopamine transporter density in Parkinson’s disease patients with and without autonomic dysfunction<br />
152<br />
using F-18 FP-CIT PET/CT 153<br />
Synthesis of tosylate and mesylate precursors for one-step radiosynthesis of [ 18F]FECNT 154<br />
Sex differences inDopamine D Receptor Occupancy in the Amygdala using AMPT with PET and [ 2 18F]fallypride 155<br />
Manual versus automatic delineation of VOIs for analysis of nuclear medicine images 156<br />
PET Amyloid and Tau Ligand [18F]FDDNP uptake in early Alzheimer disease<br />
Cryogenic brain injury as a model of brain trauma: Use of GFAP-luc mice to assess GFAP expression as an indication<br />
157<br />
of neural injury 158<br />
Plaque burden in the APPPS1 mouse picked up with diffusion kurtosis magnetic resonance imaging 159<br />
In vivo Imaging of Rat Glioma using the TSPO-ligand [ 18F]DPA-714 160<br />
GENE and CELL based THERAPIES<br />
A novel 19F MRI-based migration assay: application to primary human dendritic cells<br />
In vivo magnetic resonance imaging reveals altered migration of endogenous neural progenitor cells following<br />
161<br />
cuprizone-induced central nervous system demyelination 162<br />
Evolution pathways of compartmentalization and distribution of labeling iron-oxide particles in tumor tissue 163<br />
Acupuncture Works on Endorphins via Activating Stretch-Activated Cation Channels 164<br />
Labeling protocols for MRI and optical imaging of human muscle cells precursors 165<br />
Studying molecular processes in-vivo: A framework for quantifying variability in molecular MRI 166<br />
Clinically applicable cell tracking by MRI in cartilage repair using Superparamagnetic Iron Oxide (SPIO)<br />
Labeling of HUVEC with different iron oxide particles: An in vitro study about incorporation, distribution,<br />
167<br />
retention and toxicity<br />
Visualization of aberrant migration in the YAC 128 mouse model for Huntington’s disease by in situ labelling of<br />
168<br />
neural progenitor cells with iron oxide particles 169<br />
Optimization of in vitro radiolabeling of mesenchymal stem cells with 18F-fluorodeoxyglucose 170<br />
PROBE DESIGN<br />
Responsive MRI contrast agent for specific cell imaging of inhibitory, GABAergic neurons 171<br />
Novel ultrasound contrast agents for drug delivery 172<br />
Methods to study the interaction between aptamer probes and cell surface biomarkers 173<br />
MRI intelligent contrast agents as enzyme responsive nanosystems 174<br />
Standardization of molecular PBCA-microbubbles for routine use 175<br />
Novel Gd(III)-based probes for MR molecular imaging of matrix metalloproteinases 176<br />
Functionalization of nanoparticles for molecular imaging; a covalent approach<br />
Comparison of different chelating systems for the synthesis of Ga-68 labelled peptides for molecular imaging using<br />
177<br />
RGD-peptides as model compound 178<br />
GdDOTA-PIB: a potential MRI marker for Alzheimer’s disease<br />
A comparative study of the self-elimination of para-aminobenzyl alcohol and hemithioaminal-based linkers.<br />
179<br />
Application to the design of Caspase-3 sensitive pro-fluorescent probes 180<br />
Olefin Metathesis for the functionalization of superparamagnetic nanoparticles<br />
Pyridine-based lanthanide complexes : towards bimodal agents operating as near infrared luminescent and<br />
181<br />
MRI reporters 182<br />
TECHNOLOGY<br />
Delivery of multiple F-18 tracers from a single automated platform (FASTlab TM synthesizer) 183<br />
Monte-carlo modelling of a silicon detector insert combined with a PET scanner 184<br />
Autofluorescence corrected multispectral red-shifted fluorescent protein tomography 185
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Acquiring the sample surface from co-registered FMT/MR measurements of a murine tumor model 186<br />
fDOT/ PET/CT imaging of biological processes in tumors 187<br />
Deep tissue molecular imaging with fluorescent biomarkers using multispectral optoacoustic tomography.<br />
A simulation study 188<br />
Microfluidic [ 11C]-carbonylation reactions for the rapid synthesis of radiolabelled compounds for PET 189<br />
Boosting image quality in low-dose RC-gated 5D cone-beam micro-CT 190<br />
Methodological approach using microscopy for quantitative evaluation of neo-angiogenesis and tumour<br />
progression in pre-clinical cancer models 191<br />
ENDOCRINE DISEASES<br />
Changes of heart stroke volume index established by 99mTc MIBI GSPECT scintigraphy after radioiodine treatment<br />
of patients with subclinical hyperthyroidism 192<br />
PET/CT investigations with 68Ga-DOATATE in neuroendocrine tumors - first clinical experience 193<br />
Influence of number of subsets and iterations of Ordered Subsets Expectation Maximization (OSEM 3D Flash)<br />
reconstruction on quantitative assessment of small and medium detected lesions in SPECT study with used in<br />
99mTc[EDDA/HYNIC]Octreotate for patients with GEP-NET 194<br />
The precise localization of metastatic lesion with used SPECT/CT with CoDe system after 131I – MIBG therapy in patients<br />
with disseminated pheochromocytoma 195<br />
Multimodal in vivo imaging of pancreatic beta-cells via antibody mediated targeting of beta-cell tumors 196<br />
INFECTION and INFLAMMATION<br />
6-[ 18F]Fluoro-PBR28, a novel TSPO 18 kDa radioligand for imaging neuroinflammation with PET 197<br />
Neuroinflammation is increased in the brain of ageing corpulent (JCR:LA-cp) rats: a positron emission tomography study 198<br />
Detection of inflammatory diseases by NIRF imaging with specific probes targeting leukotriene receptor CysLT R 1 199<br />
PET imaging of Hypoxia by 18F-Fluoromisonidazole ([ 18F]FMISO) to detect early stages of experimental arthritis<br />
Intracellular [<br />
200<br />
64Cu]PTSM and extracellular [ 64Cu]DOTA-antibody labelling of ovalbumin-specific Th1 cells for in vivo PET<br />
investigations of Th1 cell trafficking in OVA-specific lung inflammation 201<br />
[ 18F]DPA-714, [ 18F]PBR111 and [ 18F]FEDAA1106: Radiosyntheses on a TRACERLAb FX-FN synthesizer<br />
In vivo near-infrared fluorescence imaging of lung matrix metalloproteinases in an acute cigarette smoke-induced<br />
202<br />
airway inflammation model in different mice strains<br />
Development and pre-clinical evaluation of a novel class of<br />
203<br />
18F labelled PET ligands for evaluation of PBR/TSPO<br />
in the brain 204<br />
Local administration of adeno-associated virus into the mammary gland ductules 205<br />
TARGETED THERAPY<br />
Copper-64- and Gallium-68- NODAGA-conjugated bombesin antagonists as new PET tracers 206<br />
A novel indocyanine green nanoparticle probe for non invasive fluorescence imaging in vivo<br />
Evaluation and optimization of the concept of an antibody directed enzyme-prodrug therapy using noninvasive<br />
207<br />
imaging technologies 208<br />
A novel [ 18F] PET imaging agent for the epidermal growth factor receptor 209<br />
MI DATA ANALYSIS METHODS<br />
Structural methods in subcellular image analysis 210<br />
In vivo-post mortem multimodal image registration in a rat glioma model 211<br />
Feasibility and success of Independent Component Analysis of resting state fmri data from the rat 212<br />
A fast and robust acquisition scheme for CEST experiments<br />
Binding potential estimation in 11C-PE2I PET brain striatal images: impact of partial volume correction under<br />
213<br />
segmentation errors<br />
Automated quantification scheme based on an adapted probabilistic atlas based segmentation of the brain basal<br />
214<br />
nuclei using hierarchical structure-wise registration 215<br />
VHISTdiff - comparing workflow histories (VHIST/VINCI) 216<br />
Fast matrix-free method for fluorescence imaging 217<br />
Late Breaking<br />
PET and MRI studies applied on characterization of Fisher/F98 rat glioma model 218<br />
Non-invasive “E2F sensing” system for monitoring DNA damage alteration induced by BCNU<br />
Multi-tracer PET imaging of a mouse model of Alzheimer´s disease to assess microglial activation related to ageing<br />
219<br />
and anti-inflammatory treatment 220<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
poStEr<br />
Poster Session
P-001<br />
114<br />
WarSaW, poland May 26 – 29, 2010<br />
In vivo MRI multicontrast kinetic analysis of intracellular trafficking of liposomes<br />
Aime S. , Delli Castelli D. , Dastrù W. , Terreno E. , Cittadino E. , Torres E. , Mainini F. , Spadaro M. .<br />
University of Torino, Italy<br />
silvio.aime@unito.it<br />
Introduction: Liposomes are mainly used in the<br />
pharmaceutical field as drug delivery systems.<br />
Despite their large use, there is still a lack of<br />
information about the interaction between the<br />
nanovesicles and the cells in tumor environments<br />
and their intracellular fate after the cellular uptake.<br />
Most of the information on this topic comes out from<br />
in vitro cellular studies that are not always reliable<br />
models for mimicking the in vivo system. The aim<br />
of this work is the visualisation of the metabolic<br />
pathway of these vesicles directly in vivo by means<br />
of MRI. Since MRI does not provide enough spatial<br />
resolution to directly observe events at subcellular<br />
level, we have developed a multicontrast analysis<br />
that provides indirect evidence about the uptake<br />
and the intracellular trafficking of the nanovesicles.<br />
The method relies on the peculiarity of nanovesicles<br />
encapsulating paramagnetic Ln(III)-based complexes<br />
that may act as T1, T2, and CEST agents. In order to<br />
account for the observed MRI data, a kinetic model<br />
able to describe the underlying biological processes<br />
has been developed. The fit of the data provides a<br />
rough estimate of the kinetic constants for each<br />
process considered in the model.<br />
Methods: Non targeted, stealth or pH-sensitive,<br />
liposomes encapsulating paramagnetic<br />
lanthanide(III) complexes were prepared and in vitro<br />
characterized. The liposomes were locally injected in<br />
B16 melanoma tumor xenografted on C57 mice. The<br />
temporal evolution of T1, T2 and CEST MR contrast<br />
was followed at 7 T until 48 h post-injection.<br />
Results. The evolution over time is different among<br />
the three contrast modes (T1,T2, CEST). The process<br />
taking place (cellular uptake, intracellular release,<br />
esocytosis, and wash out) have been modeled and<br />
rough estimates for the kinetic constants have been<br />
determined upon the simultaneous interpolation of<br />
all the data. Moreover, the intracellular trafficking of<br />
stealth vs pH sensitive liposomes has been compared.<br />
The comparison among the evolution of the three<br />
contrast modalities for the two different liposomes<br />
is quite different. In particular, the maximum T1<br />
contrast was observed at 5hrs post injection while for<br />
the stealth one it occurs at 24hrs post injection.<br />
imaging life<br />
Conclusions: The MRI multicontrast analysis<br />
developed in this work represents an innovative way<br />
to get deeper insight into the in vivo detection of<br />
sub-cellular process. In particular, the intracellular<br />
trafficking of two liposomal formulations (pHsensitive<br />
and conventional stealth) of great relevance<br />
in the field of drug delivery have been compared. The<br />
kinetic analysis revealed that both liposomes are taken<br />
up quite fast from Tumor Associated Macrophages<br />
but the intracellular release of the imaging<br />
reporters is much faster for the pH sensitive one.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Diffusion-weighted MRI for differentiation of breast lesions at 3.0 Tesla: a new biomarker for<br />
breast imaging<br />
Bogner W. , Gruber S. , Pinker K. , Grabner G. , Moser E. , Trattnig S. , Stadelbauer A. , Helbich T. .<br />
Department of Radiology, Vienna, Austria<br />
thomas.helbich@akhwien.at<br />
Introduction: To compare the diagnostic quality of<br />
different diffusion weighting schemes with regard<br />
to apparent diffusion coefficient (ADC) accuracy,<br />
ADC precision, and diffusion-weighted image<br />
(DWI) contrast-to-noise ratio (CNR) for different<br />
types of lesions and breast tissue. Based on these<br />
assessments a new biomarker for breast imaging<br />
will be defined.<br />
Materials and Methods: Institutional Review Board<br />
approval and written, informed consent were<br />
obtained. Fifty-one patients with histopathologic<br />
correlation or follow-up were included in this study<br />
on a 3.0 Tesla MR scanner. There were 112 regions<br />
of interest (ROIs) drawn in 24 malignant, 17 benign,<br />
20 cystic, and 51 normal tissue regions. ADC maps<br />
were calculated for combinations of ten different<br />
diffusion-weightings (b-values), ranging from 0<br />
to 1250 s/mm². Differences in ADC among tissue<br />
types were evaluated. The CNR of lesions on DWI<br />
was compared for all b-values. A repeated measure<br />
ANOVA was used to assess lesion differentiation.<br />
Results: ADC (mean±SD x10-3mm²/s) values<br />
calculated from b=50 and 850 s/mm² were<br />
0.99±0.18, 1.47±0.21, 1.85±0.22, and 2.64±0.30<br />
for malignant, benign, normal, and cystic tissue,<br />
respectively. An ADC threshold of 1.25 x10-3mm²/s<br />
allowed discrimination of malignant from benign<br />
lesions with a diagnostic accuracy of 95% (p
P-003<br />
116<br />
WarSaW, poland May 26 – 29, 2010<br />
Imaging tumour apoptosis with 68Ga-labelled AnnexinA5 derivatives early after cancer<br />
therapy<br />
De Saint-Hubert M. (1) , Bauwens M. (1) , Devos E. (1) , Deckers N. (2) , Reutelingsperger C. (2) , Verbruggen A. (1) , Mortelmans L. (1) ,<br />
Mottaghy F. (3) .<br />
(1) KULeuven, Heverlee, Belgium<br />
(2) University Maastricht, The Netherlands<br />
(3) RWTH Aachen, Germany<br />
marijke.desainthubert@med.kuleuven.be<br />
Introduction: Molecular imaging of apoptosis offers<br />
a direct and early measurement of response to<br />
cancer therapy which allows a fast decision making<br />
in cancer treatment. One of the early characteristics<br />
of apoptosis is externalization of phosphatidylserine<br />
(PS) on cell membranes. Annexin V<br />
(AnxA5) binds with a high affinity to membranebound<br />
PS. Due to suboptimal imaging quality of<br />
99m Tc labelled AnxA5 we aimed to specifically label<br />
AnxA5 with an emerging radioisotope, 68 Ga, allowing<br />
Positron Emission Tomography (PET).<br />
Methods: We radiolabelled AnxA5 with 68 Ga using<br />
two mutated forms of AnxA5 with a single cysteine<br />
residue at position 2 or 165, respectively Cys2-<br />
AnxA5 and Cys165-AnxA5, allowing site-specific<br />
coupling of 68 Ga-Dota-maleimide. In vitro cell<br />
binding of both radiotracers was studied in healthy<br />
and anti-Fas treated Jurkat cells. Biodistribution<br />
and pharmacokinetics were studied with µPET in<br />
healthy mice and in a hepatic apoptosis model (anti-Fas<br />
Ab treated) up to 60 min p.i.. Daudi (Burkitt<br />
lymphoma) tumour bearing mice were scanned<br />
before and after treatment with combined chemotherapy<br />
(125 mg/g Endoxan) and radiotherapy (10<br />
Gy/tumour) using µPET and µMRI. Tracer uptake<br />
was measured and imaged ex vivo using autoradiography<br />
and correlated to histological evidence of<br />
apoptosis (TUNEL).<br />
Results: 68 Ga-Dota-maleimide labelling yield was at<br />
least 98% and coupling yield of 68 Ga-Dota-maleimide<br />
to Cys2-AnxA5 and Cys165-AnxA5 was ~70%.<br />
Labelling and purification took about 60 min, with<br />
a final radiochemical purity of at least 98%. In vitro<br />
binding of 68 Ga-Cys2-AnxA5 and 68 Ga-Cys165-<br />
AnxA5 to anti-Fas treated tumour cells was 5 times<br />
higher compared to normal cells.<br />
Dynamic PET images in normal mice revealed that<br />
both tracers showed a fast clearance from the blood<br />
towards the kidneys, with no significant change in<br />
biodistribution from 30 min p.i. on. Dissection data<br />
confirmed clearance was mainly via the urinary tract.<br />
imaging life<br />
Dynamic PET images of anti-Fas treated animals<br />
revealed a major shift of radioactivity from the<br />
kidneys to the (apoptotic) liver for both 68 Ga-<br />
Cys2-AnxA5 and 68 Ga-Cys165-AnxA5. Compared<br />
to normal mice anti-Fas treated animals showed a<br />
7 to 9 times higher liver uptake (for respectively<br />
68 Ga-Cys2-AnxA5 and 68 Ga-Cys165-AnxA5) as<br />
compared to healthy animals. Autoradiography<br />
images confirm the higher uptake in anti-Fas<br />
treated livers, corresponding to TUNEL positive<br />
cells.<br />
MRI-PET fusion images allowed clear delineation<br />
of each tumor. Using this technique, we noted that<br />
the post-therapy SUV values significantly exceeded<br />
those prior to therapy. The absolute tumour uptake<br />
of 68 Ga-Cys2-AnxA5 and 68 Ga-Cys165-AnxA5<br />
was respectively only 0.5 ± 0.1 % ID/g and 1.0 ±<br />
0.3 % ID/g and significantly increased to 1.5 ± 0.2<br />
% ID/g and 1.6 ± 0.1 % ID/g after therapy. Autoradiography<br />
confirms an increased activity in<br />
treated tumors with several regions showing 10-20<br />
times higher uptake compared to the tumor uptake<br />
prior to treatment while other regions were<br />
found relatively unaffected. The same heterogeneous<br />
distribution of apoptosis was observed with<br />
TUNEL stainings.<br />
Conclusions: 68 Ga-Cys2-AnxA5 and 68 Ga-<br />
Cys165-AnxA5 can be prepared with a high yield<br />
and within a reasonable time period. Apoptosis<br />
targeting capacity was clearly demonstrated in<br />
a model of hepatic apoptosis. PET-MRI fusion<br />
images demonstrated a higher tumor uptake after<br />
cancer therapy, indicating that 68 Ga-AnxA5<br />
may be useful for the early evaluation of tumor<br />
therapy.<br />
Acknowledgement: This work was financially<br />
supported by the European Union through the<br />
grant Euregional PACT II by the Interreg IV program<br />
of Grensregio Vlaanderen-Nederland (IVA-<br />
VLANED-1.20).
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
68 Ga-RGD-based PET tracers for imaging αν β 3 expression: a comparative study<br />
Dumont R. (1) , Maecke H. (1) , Haubner R. (2) , Behe M. (1) , Weber W. (1) , Fani M. (1) .<br />
(1) University Clinic Freiburg, Germany<br />
(2) Medical University Innsbruck, Austria<br />
rebecca.dumont@uniklinik-freiburg.de<br />
Introduction: The integrin α ν β 3 is a cellular adhesion<br />
molecule that is frequently expressed on<br />
malignant tumors and acts as an important receptor<br />
affecting tumor angiogenesis, local invasiveness,<br />
and metastatic potential. For imaging of the<br />
α ν β 3 integrin, cyclic pentapeptides containing the<br />
tripeptide sequence arginine-glycine-aspartate<br />
(RGD) have been developed. These peptides specifically<br />
bind to α ν β 3 in its activated state and recent<br />
clinical trials have shown that PET imaging<br />
with radiolabelled RGD peptides allows quantitative<br />
determination of activated α ν β 3 integrin in<br />
patients with various malignant tumors [1,2]. Development<br />
of a 68 Ga-RGD-based tracer would be<br />
of great clinical utility given the increasing clinical<br />
importance of oncologic PET imaging and the excellent<br />
imaging properties and availabilty of 68 Ga.<br />
Thus, we developed [ 68 Ga]-DOTA-c(RGDfK) [3]<br />
and most recently [ 68 Ga]-NODAGA-c(RGDfK)<br />
[4]. The aim of this study was to compare the<br />
tracer properties in a U87MG human glioblastoma<br />
xenograft model.<br />
Methods: The conjugate DOTA-c(RGDfK) was<br />
synthesised according to the literature [3]. An<br />
alternative head-to-tail cyclization protocol of<br />
the linear RGDfK was followed for the conjugate<br />
NODAGA-c(RGDfK) using a 50% solution<br />
of 1-propanephosphonic acid cyclic anhydride<br />
(T3P), triethylamine, and 4-di(methylamino)pyridine<br />
(DMAP). The two conjugates NODAGAc(RGDfK)<br />
and DOTA-c(RGDfK) were labelled<br />
with 68 Ga in sodium acetate buffer 0.2 N, pH 4.0<br />
using the Modular-Lab PharmaTracer module by<br />
Eckert & Ziegler. Biodistribution studies were performed<br />
in balb-c nude mice bearing subcutaneous<br />
U87MG human glioblastoma xenografts 1 h postinjection<br />
of the radiotracers (600 pmol / 4 MBq /<br />
mouse). To evaluate specificity of the compounds,<br />
blocking studies were done with an excess of the<br />
commercially available c(RGDfV). Static images<br />
were concurrently accquired with a microPET Focus<br />
small animal scanner and all results were evaluated<br />
comparatively.<br />
Results: Both conjugates were labelled with 68 Ga<br />
with radiochemical purity > 97% and specific activity<br />
of 8-10 MBq/nmol at room temperature<br />
(NODAGA-c(RGDfK)) or elevated temperatures<br />
(DOTA-c(RGDfK)). The biodistribution profile<br />
of the two radio-conjugates was similar. However,<br />
[ 68 Ga]-NODAGA-c(RGDfK) showed faster blood<br />
clearance and higher tumor uptake compared to<br />
[ 68 Ga]-DOTA-c(RGDfK) (5.2 ± 1.4 %IA/g vs 3.5 ±<br />
0.8 %IA/g) and improved tumor-to-blood and tumor-to-kidney<br />
ratios (27.7 ± 7.0 vs 9.2 ± 1.1 and 2.6<br />
± 0.3 vs 1.6 ± 0.1, respectively). Specificity of both<br />
tracers was demonstrated by successful blocking of<br />
tumor uptake in the presence of excess c(RGDfV),<br />
present on both biodistribtion and imaging studies.<br />
PET imaging quantitatively confirmed tumor targeting<br />
and biodistribution results of both conjugates.<br />
Conclusions: Compared to [ 68 Ga]-DOTA-c(RGDfK),<br />
the superior labelling conditions and in vivo profile<br />
of [ 68 Ga]-NODAGA-c(RGDfK) make this<br />
compound a compelling radiotracer candidate<br />
for use in PET imaging of α ν β 3 -expressing tumors.<br />
References:<br />
1. Haubner R et al., PLoS Med. 2:e70 (2005)<br />
2. Beer AJ et al., Clin Cancer Res. 12:3942-9 (2006)<br />
3. Decristoforo C et al., Eur J Nucl Med Mol Imaging.<br />
35:1507-1515 (2008)<br />
4. Knetsch P et al., J Label Compd Radiopharm. 52: S413<br />
(2009)<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-004<br />
poStEr<br />
MI in CANCER BIOLGY
P-005<br />
118<br />
WarSaW, poland May 26 – 29, 2010<br />
Influence of anaesthetics on tumor tracer uptake in radiopeptide receptor imaging (PRI) and<br />
radionuclide therapy (PRRT)<br />
Haeck J. , De Poel M. , Bijster-Marchand M. , Verwijnen S. , De Swart J. , Bernsen M. , De Jong M. .<br />
Erasmus Medical Centre, Oegstgeest, The Netherlands<br />
j.haeck@erasmusmc.nl<br />
Introduction: Neuro-endocrine tumors originating<br />
from various organs are known to over express somatostatin<br />
receptors (SSR) on the cell membrane (1).<br />
PRI and PRRT enable selective imaging and treatment<br />
of tumor cells over expressing SSR using radiolabelled<br />
somatostatin analogues, e.g. the SPECT<br />
tracer 111In-DTPA-octreotide. In experimental studies,<br />
in vivo imaging and measurement of tracer uptake<br />
in tumors and in normal organs is generally<br />
performed in anaesthetised laboratory animals. Different<br />
methods of anaesthesia are used according to<br />
the possibilities, experience and common practice<br />
in a laboratory. However, in many in vivo experiments<br />
the influence of changes in physiology due to<br />
anaesthetics is not taken into account. The aim of<br />
the current study was to determine the influence of<br />
different anaesthetics on bio-distribution of radioactive<br />
111In-DTPA-octreotide, a somatostatin analogue,<br />
5<br />
in rats bearing SSR positive tumors.<br />
Methods: Lewis rats (n=8) were inoculated with 0.5<br />
million CA20948 (SSR-positive) pancreatic tumor<br />
cells in the flank. The tumors were grown to approximately<br />
1.5 cm2 3<br />
2<br />
before imaging. Prior to i.v. injection<br />
of the radiolabelled peptide (50 MBq in 0.4 1 µg) the<br />
animals were anaesthetized with either inhalant-an-<br />
0<br />
aesthetic isoflurane (n=4) or a mixture of injectable<br />
anaesthetics consisting of sufentanil (300µg/kg) and<br />
medetomidine (300µg/kg) injected intra-peritoneally<br />
(n=4). The rats were kept under anaesthesia during 1h<br />
tracer circulation and subsequent SPECT/CT imaging.<br />
After imaging the rats were euthanized and tumor and<br />
organs were removed to study the peptide biodistribution<br />
ex-vivo. Biodistribution was performed at 3h p.i.<br />
Results: A significantly higher tumor uptake of<br />
111 In-DTPA-octreoscan was found when the rats<br />
were anaesthetized with isoflurane in comparison<br />
to medetomidine/sufentanil (figure 1), p
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Optical imaging of oral squamous cell carcinoma and cervical lymph node metastasis using<br />
near-infrared fluorescent probes in a mouse model – a pilot study<br />
Keereweer S. (1) , Mol I. (2) , Snoeks T. (2) , Kerrebijn J. (1) , Van Driel P. (2) , Xie B. (2) , Kaijzel E. (2) , Baatenburg De Jong R. J. (1) ,<br />
Löwik C.W.G.M. (2) .<br />
(1) Erasmus Medical Center, Rotterdam, The Netherlands<br />
(2) Leiden University Medical Center, The Netherlands<br />
s.keereweer@erasmusmc.nl<br />
Introduction: In head and neck cancer surgery, intra-operative<br />
assessment of the tumor-free margin<br />
is critical to completely remove the tumor, thereby<br />
improving the prognosis of the patient. Currently,<br />
this mostly relies on visual appearance and palpation<br />
of the tumor. However, optical imaging techniques<br />
provide real-time visualization of the tumor,<br />
warranting intra-operative, image-guided<br />
surgery. The use of the near-infrared (NIR) light<br />
spectrum offers two additional advantages: increased<br />
tissue penetration of light and an increased<br />
signal-to-background-ratio of contrast agents. We<br />
performed a pilot study to assess the possibilities<br />
of optical imaging of oral squamous cell carcinoma<br />
and cervical lymph node metastasis using<br />
near-infrared fluorescent probes in a mouse model.<br />
A<br />
B<br />
Fig1. A. Bioluminescence image of oral carcinoma and cervical<br />
lymph node metastasis. B. Fluorescence image showing increased<br />
signal of Prosense680TM in the tongue and cervical lymph nodes.<br />
Methods: An oral tumor model was developed using<br />
luciferase-bearing OSC19 (human oral squamous<br />
cell carcinoma) cells that were injected directly into<br />
the tongue of 8 Balb/C nu/nu female mice. Tumor<br />
progression was followed by bioluminescence imaging<br />
(BLI) using the IVIS-100 (Caliper LS) and by<br />
inspection of the tongue. At day 21, different NIR<br />
fluorescent probes were systemically injected, targeting<br />
cathepsins (Prosense680TM, VisEn Medical),<br />
matrix metalloproteinases (MMPsense 680TM,<br />
VisEn Medical), increased glucose uptake (800CW<br />
2-DG, LI-COR) and increased epidermal growth<br />
factor expression (800CW EGF, LI-COR) of the tumor.<br />
Fluorescence imaging of the mouse and organs<br />
(after surgical removal) was performed using the<br />
Maestro (CRi) and Odyssey (LI-COR). A control<br />
group of 8 Balb/C nu/nu mice without tumor was<br />
used to compare light intensity between healthy and<br />
cancer tissue.<br />
Results: After 7 days, oral squamous cell carcinoma<br />
was established in all 8 mice. After 11 days, all<br />
mice had developed cervical lymph node metastasis,<br />
which was confirmed by a BLI signal (figure 1,A).<br />
The primary tumor and cervical lymph node metastases<br />
were successfully detected by the use of all NIR<br />
fluorescent probes, with increased tumor-to-control<br />
ratios that varied per probe (figure 1,B).<br />
Conclusions: This preliminary study shows the establishment<br />
of an oral squamous cell carcinoma<br />
mouse model, which progress could be followed by<br />
bioluminescence. Moreover, real-time visualization<br />
of the primary tumor and cervical lymph node metastases<br />
was achieved by fluorescence imaging using<br />
various NIR fluorescent probes. This technique<br />
can be used for intra-operative, image-guided surgery,<br />
which could improve complete removal of oral<br />
squamous cell carcinoma.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-006<br />
poStEr<br />
MI in CANCER BIOLGY
WarSaW, poland May 26 – 29, 2010<br />
P-007 Spectral unmixing of red and green luciferases for in vivo bioluminescence imaging<br />
120<br />
Mezzanotte L. (1) , Kaijzel E. (2) , Michelini E. (1) , Que I. (2) , Calotti F. (2) , Hoeben R. (2) , Roda A. (1) , Löwik C. W.G.M. (2) .<br />
(1) University of Bologna, Bologna, Italy<br />
(2) Leiden University Medical Center, Leiden, The Netherlands<br />
laura.mezzanotte@libero.it<br />
Introduction: Amongst the numerous luciferase reporter<br />
genes cloned from different animal species<br />
and mutated to achieve different emission properties<br />
only a few have been employed for in vivo bioluminescence<br />
imaging (BLI). Good thermostability, high<br />
and stable photon emission and codon optimization<br />
of the luciferase gene are required (1,2). Moreover,<br />
spectral overlap prevents them from being measured<br />
simultaneously. Recently, spectral unmixing<br />
methodologies have been employed to unmix and<br />
quantify signals from images obtained from the<br />
collection of light emitted from proteins with different<br />
emission spectra (3,4). Here we investigated<br />
the combined use of green click beetle luciferase<br />
(CBG99, max. emission 537nm) and a red codonoptimized<br />
mutant of P.pyralis (Ppy-RE8, max emission<br />
618nm) for in vivo BLI purposes.<br />
Methods: Both in vitro and in vivo studies were carried<br />
out to analyse the different luciferases. Lentiviruses<br />
expressing Red Ppy-RE8 and Green CBG99<br />
luciferase reportergenes were generated and human<br />
embryonic kidney (Hek293) cells were subsequently<br />
Fig1.: CBG99 and PpyRE8 expressing cells were mixed in different<br />
ratios and measured in vitro (a) and in vivo at 540nm (c) and<br />
620nm (d).The graph (b) shows the max. emission peaks of the<br />
different luciferases.<br />
imaging life<br />
transduced to express the different variants of luciferase.<br />
Cell population of red and green emitting<br />
were mixed in different proportions and BLI measurements<br />
were carried out in a plate luminometer<br />
with appropriate filters.<br />
In addition, Hek293 cells co-expressing the mentioned<br />
luciferases were imaged using the IVIS Spectrum system<br />
(Caliper LS) by collecting BLI signals at different<br />
wavelengths. Finally, the cells expressing Ppy-RE8 or<br />
Green CBG99 were injected subcutaneously into immunodeficient<br />
mice and BLI imaging was performed<br />
in vivo using the same system. Signals from the two<br />
luciferases were unmixed using Living Image 3.2<br />
software.<br />
Results: Both in vitro as in vivo results demonstrated<br />
the feasibility to use Red Ppy-RE8 and Green CBG99<br />
luciferase reporter genes, simultaneously. These luciferase<br />
variants demonstrated to be a good couple for<br />
dual luciferase applications employing the same substrate<br />
luciferin. Using a pair of band pass filter (535nm<br />
and 628nm) contributions of red- and green-emitting<br />
luciferases can be calculated using a luminometer.<br />
Confirmative results were obtained using the Living<br />
image software to spectrally unmix the images composed<br />
by the signals of the two different luciferases and<br />
obtained from both in vitro and in vivo experiments.<br />
Conclusions: The possibilities of a combined use of<br />
the selected red and green luciferases have been demonstrated.<br />
Preliminary in vivo data envisage the future<br />
application of these couple of luciferases for monitoring<br />
of multiple events simultaneously by means of bioluminescence<br />
imaging.<br />
References:<br />
Branchini BR et al. Anal Biochem. 2010 Jan 15;396(2):290-7.<br />
Mezzanotte L, et al. Mol Imaging Biol. 2009,Nov 25.<br />
Gammon ST, et al. Anal Chem. 2006 Mar 1;78(5):1520-7.<br />
Michelini E, et al. Anal Chem. 2008 Jan 1;80(1):260-7.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
High resolution redox imaging of intact cells by rxYFP, a ratiometric oxidation- sensitive<br />
fluorescent protein<br />
Pani G. , Maulucci G. , Mele M. , Labate V. , Panieri E. , De Spirito M. .<br />
Catholic University Medical School, Rome, Italy<br />
gpani@rm.unicatt.it<br />
Introduction: Plasmid encoded redox sensitive<br />
fluorescent probes promise to pave new avenues<br />
for realt time imaging of oxidative signaling in live<br />
cells. We have recently shown that rxYFP, a redoxsensitive<br />
variant of the Yellow Fluorescent Protein,<br />
can be used ratiometrically to construct high resolution<br />
redox maps of live cells. Confocal analysis of<br />
cell fluorescence at two excitation wavelenghts allows<br />
in fact to monitor, voxel by voxel, the distribution<br />
of the probe between its reduced and oxidised<br />
states, while normalizing fror probe concentration<br />
and photobleaching.<br />
Methods: rxYFP was transiently transfected in 293T<br />
human kidney carcinoma and B16F10 murine melanoma<br />
cells plated on glass bottom dishes (IbiDi).<br />
Cell fluorescence was analysed by confocal microscopy<br />
at two different excitation wavelengths (450<br />
and 488nm) and fluorescence ratios calculated by a<br />
dedicated software and converted into pseudocolors<br />
to construct redox-based cell maps.<br />
Results: By imaging cells based on rxYFP distribution<br />
between reduced and oxidised states, we were<br />
able to confirm that, in human and murine malignant<br />
cells, the nucleus is significantly more reduced than<br />
the cytosol; additionally, simple deconvolution of redox<br />
images constructed with untargeted rxYFPallows<br />
to identify hypereduced perinuclear spots that correspond<br />
to mitochondria, as further confirmed by the<br />
use of a mitochondrially targeted form of the probe.<br />
In 2D scans, the cell border of adherent cells consistently<br />
appears to be significantly more oxidised than<br />
the inner cytosol, while 3D cell reconstruction oxidation<br />
is polarized towards the bottom of the cells; finally,<br />
in a spontaneously migrating cell the leading edge<br />
appears to me more oxidised than the trailing one.<br />
Conclusions: This set of obserbations suggests, in<br />
keeping with our previous biochemical studies, that<br />
integrin signaling and cuytoskeleton rearrangement<br />
are associated with increased prooxidant activity, with<br />
relevant implications for cell invasion and metastasis.<br />
Acknowledgement: Work partially supported by DiMI<br />
FP6 European NoE DiMI (LSHB-CT-2005-512146)<br />
References:<br />
1. Maulucci G, Labate V, Mele M, Panieri E, Arcovito G,<br />
Galeotti T, Østergaard H, Winther JR, De Spirito M and<br />
Pani G High resolution imaging of redox signaling<br />
in live cells through an oxidation-sensitive yellow<br />
fluorescent protein Sci. Signal. 1, pl3 (2008).<br />
2. Maulucci G, Pani G, Labate V, Mele M, Panieri E, Papi M,<br />
Arcovito G, Galeotti T, De Spirito M. 2009 Investigation<br />
of the spatial distribution of glutathione redox-balance<br />
in live cells by using Fluorescence Ratio Imaging<br />
Microscopy. Biosens Bioelectron. 25:682-687.<br />
3. Maulucci G, Pani G, Fusco S, Papi M, Arcovito G, Galeotti<br />
T, Fraziano M, De Spirito M. 2009 Compartmentalization<br />
of the redox environment in PC-12 neuronal cells. Eur<br />
Biophys J. in press<br />
4. P. Chiarugi, G. Pani , E. Giannoni, L. Taddei, R. Colavitti,<br />
G. Raugei, M. Symons, S. Borrello, T. Galeotti, and G.<br />
Ramponi 2003 Reactive oxygen species as essential<br />
mediators of cell adhesion:The oxidative inhibition of a<br />
FAK tyrosine phosphatase is required for cell adhesion<br />
J. Cell. Biol. 161, 933-944<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-008<br />
poStEr<br />
MI in CANCER BIOLGY
122<br />
WarSaW, poland May 26 – 29, 2010<br />
P-009 Assessment of antiangiogenic therapy effects in preclinical tumour models: Implementation<br />
of a novel contrast - enhanced 3 D scanning technique and comparison to established<br />
ultrasound imaging protocols<br />
Rix A. , Lederle W. , Bzyl J. , Gaetjens J. , Fokong S. , Grouls C. , Kiessling F. , Palmowski M. .<br />
Helmholtz Institute for biomedical engineering , Aachen, Germany<br />
arix@ukaachen.de<br />
Introduction: Assessment of antiangiogenic therapy<br />
effects in rodent tumours plays an important role<br />
in drug development. Different ultrasound imaging<br />
protocols are described, predominantly using 2 D<br />
contrast-enhanced techniques. However, a limitation<br />
of 2 D scans is the reduced reproducibility of<br />
the data. Even if the acquired slice might be representative<br />
for the entire tumour, it will be impossible<br />
to find the identical slice position in longitudinal<br />
studies. In our study, we implemented a novel contrast-enhanced<br />
3 D scanning technique, evaluated<br />
its sensitivity and compared it to established 2 D<br />
and 3 D ultrasound imaging protocols.<br />
Methods: S.c epidermoid carcinoma xenografts in<br />
nude mice were scanned using a small animal ultrasound<br />
system (40 MHz). B-mode images with a<br />
low mechanical index and a slice thickness of 300<br />
µm were acquired and merged into a 3 D dataset.<br />
Prior to administration of the contrast agent, only<br />
one image was acquired per slice. During stable<br />
blood levels of polybutylcyanoacrylate-microbubbles,<br />
5 frames per slice were acquired (frame rate: 8<br />
Hz). The maximum intensity of each voxel per slice<br />
was recorded and compared to the pre-contrast<br />
dataset. To compare the potential role of this technique,<br />
a non contrast-enhanced 3 D Power Doppler<br />
scan (HF-VPDU: High frequency - volumetric<br />
power Doppler ultrasound [1]) and a 2 D dynamic<br />
contrast-enhanced scan (analyzed using the MIOT<br />
post-processing technique [2]) were performed.<br />
The sensitivity of all methods for assessing the antiangiogenic<br />
effects of SU11248 were examined at<br />
day 0, 1, 2 and 4 after treatment start. Tumour vascularisation<br />
was validated by determining the vessel<br />
density on corresponding histological sections.<br />
Mann-Whitney test was used for statistical analysis.<br />
Results: The novel 3 D contrast-enhanced imaging<br />
protocol could be applied to all animals successfully.<br />
The vascularisation of untreated control tumours<br />
slowly increased during the study, whereas<br />
a reduction was observed in tumours of treated<br />
animals. Differences in vascularisation between<br />
imaging life<br />
both groups were significant at day 1 (p
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Influence of the BMP pathway on cell cycle regulation and its differentiation inducing<br />
potential on brain tumor initiating cells<br />
Rudan D. (1) , Monfared P. (1) , Viel T. (1) , Hadamitzky M. (1) , Euskirchen P. (1) , Knödgen E. (1) ,tSchneider G. (1) , Jacobs A.H. (1,2) .<br />
(1) Max Planck Institute for Neurological Research, Cologne, Germany<br />
(2) European Institute for Molecular Imaging, , Germany<br />
daniel.rudan@nf.mpg.de<br />
Introduction: Glioblastoma multiforme is the<br />
most common type of brain tumor, and several alterations<br />
of the cell cycle and DNA repair mechanisms<br />
have led to increasing resistance against<br />
chemotherapy. Latest findings suggest that a subset<br />
of tumor cells, the brain tumor initiating cells<br />
(BTIC) with stem cell like properties, are responsible<br />
for initiation and maintenance of the disease.<br />
Approximately 1-1000 out of 1.000.000 cells<br />
within a glioma is a BTIC. These cells are thought<br />
to bring about relapse and metastasis through<br />
their tumorigenic potential and chemotherapeutic<br />
resistance1,2. Design of a specific therapeutic<br />
strategy against BTICs may improve overall survival<br />
and quality of life for patients with gliomas.<br />
The aim is to examine a novel, experimental therapy<br />
against malignant gliomas by differentiating<br />
their BTIC population. Building on our previous<br />
work3, where we demonstrated that BMP-7 treatment<br />
decreases the proliferation of Gli36ΔEGFR-<br />
LITG glioma cells up to 50% via a cell cycle arrest<br />
in G1 phase, we will further characterize and<br />
compare the effect of the BMP-pathway on cell<br />
cycle regulation of different glioma cell lines and<br />
“glioma stem cells”.<br />
Methods: We want to determine (i) whether BMP<br />
treatment, alone or in combination with state-ofthe-art<br />
chemotherapeutic agents, could be applied<br />
in a disease-tailored therapy against gliomas by<br />
depleting their BTIC pool and (ii) whether our<br />
reporter construct (LITG) can quantify the responses<br />
to such a treatment in culture and in vivo.<br />
Glioma cell lines, primary glioma cell cultures<br />
and BTICs with different genetic profiles are being<br />
utilized to analyze the influence of BMP-7<br />
and BMP pathway inhibitors on cell cycle regulating<br />
protein expression, cell viability and caspase<br />
activation as well as its differentiation-induction<br />
potential in culture. BTIC will be transduced<br />
with lentiviral reporter vectors to image changes<br />
in cell cycle regulation, differentiation status<br />
and BMP pathway activity non-invasively in vivo<br />
upon treatment.<br />
Results: Western blot data indicates that BMP-7<br />
treatment causes an arrest in cell cycle progression<br />
in the established glioma cell line A172 by influencing<br />
the expression of the key cell cycle regulators<br />
(p53�, p21�E2F-1�). Furthermore we have shown<br />
the differentiation-induction potential of BMP-7 on<br />
BTICs in culture optically and on the protein level.<br />
Upon BMP-7 treatment and respective growth-factor<br />
withdrawal the expression of the neural stem cell<br />
marker Mshi1 is clearly downregulated. Currently<br />
we focus on the design of a lentiviral reporter vector<br />
for imaging the observed BMP-Pathway reponses.<br />
Conclusions: Antagonizing the proliferative potential<br />
of BTICs by targeting the BMP pathway, thereby<br />
triggering cellular differentiation of malignant stem<br />
cells, could provide a promising means of improving<br />
the prognosis for patients with gliomas.<br />
Acknowledgement: This work is supported in part by<br />
the FP6 European NoE DiMI (LSHB-CT-2005-512146).<br />
References:<br />
1. Singh SK, Hawkins C,Clarke ID, Squire JA, Bayani J, Hide<br />
T, Henkelman RM, Cusimano MD, Dirks PB, Nature 432,<br />
396 (2004)<br />
2. Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda<br />
E, Broggi G, Brem H, Olivi A, Dimeco F, Vescovi AL,<br />
Bone morphogenetic proteins inhibit the tumorigenic<br />
potential of human brain tumour-initiating cells,<br />
Nature 444, 761 (2006)<br />
3. Klose A, Waerzeggers Y, Klein M, Monfared P, Vukicevic<br />
S, Kaijzel EL, Winkeler A, Löwik CW, Jacobs AH, Imaging<br />
bone morphogenetic protein induced cell cycle arrest<br />
in experimental gliomas, In Submission<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-010<br />
poStEr<br />
MI in CANCER BIOLGY
124<br />
WarSaW, poland May 26 – 29, 2010<br />
P-011 A near infrared fluorescent-based method for imaging breast cancer induced osteolysis<br />
Snoeks T. , Que I. , Mol I. , Kaijzel E. , Löwik C.W.G.M. .<br />
Leiden University Medical Center, The Netherlands<br />
t.j.a.snoeks@lumc.nl<br />
Introduction. In vivo bioluminescence imaging<br />
(BLI) of luciferase (Luc) expressing tumor cell lines<br />
has become a well accepted method to quantitatively<br />
follow tumor growth over time. Fluorescence<br />
imaging (FLI) can be used to visualize and quantify<br />
specific structures, molecules and even enzymatic<br />
activity using targeted dyes and enzyme activated<br />
smart probes. Two of such targeted fluorescent dyes<br />
are OsteoSense-680TM (VisEn Medical) and Bone-<br />
Tag-680TM (LI-COR Biosciences) both of which are<br />
directed specifically to bone.<br />
Traditionally, osteolytic lesions and subsequent bone<br />
loss are quantified using x-ray radiographs and μ-CT<br />
scans. These procedures are often time consuming<br />
and both methods possibly irradiate the animal limiting<br />
the number of repeated measurements.<br />
The aim of this study was to assess the possibility<br />
to quantify osteolysis by a loss of fluorescent signal<br />
after pre-labelling the skeleton with a bone-specific<br />
fluorescent probe. In this setup, we compared the<br />
performance of the two aforementioned commercially<br />
available bone specific fluorescent probes;<br />
OsteoSense-680TM and BoneTag-680TM.<br />
Fig1.: Decrease of fluorescence signal on osteolysis.<br />
Representative mouse labelled with BoneTag-680, imaged with<br />
the Pearl imager. A) Background FLI image before labelling<br />
with BoneTag-680. B-E) FLI images at day 2, 8, 19 and 42 after<br />
tumor cell inoculation in the right leg (*). F) Quantification of<br />
the fluorescent signal of the tumor bearing leg compared to<br />
the healthy leg.<br />
imaging life<br />
Methods. Immunodeficient mice received an intra<br />
venous injection with either OsteoSense-680 (2<br />
nmol, n=5) or BoneTag-680 (8 nmol, n=5). Three<br />
days after injection of the fluorescent probes the<br />
human breast cancer cell line MDA-BO2-Luc was<br />
inoculated in the femur bone marrow cavity of the<br />
right leg to form an osteolytic tumor. Tumor growth<br />
was followed by weekly BLI measurements using the<br />
IVIS Spectrum (Caliper LifeSciences) over a period<br />
of 6 weeks. Fluorescent data was obtained weekly using<br />
the IVIS Spectrum and at day 2, 8, 19 and 42 using<br />
the Pearl Imager (LI-COR Biosciences). In addition,<br />
μCT scans of each animal were made at day 21<br />
and 42 using the SkyScan-1076 μCT (SKYSCAN).<br />
Results. All inoculated mice developed a tumor in<br />
the right leg confirmed with BLI. Both bone specific<br />
probes remained detectable throughout the experiment,<br />
45 days after injection, in the healthy leg. The<br />
fluorescence signal decreased faster in the tumor<br />
bearing legs than in the healthy legs, this loss of signal<br />
could be quantified (Fig 1). The analysis of the<br />
x-ray and μCT data and the subsequent correlation<br />
between oslteolytic lesion size and the loss of fluorescence<br />
signal is still ongoing.<br />
Conclusions. Preliminary results show the possibility<br />
to follow osteolysis over time using an animal<br />
pre-labelled with a bone specific probe.<br />
Acknowledgement: Supported by the Dutch Cancer<br />
Society (Grant UL2007-3801)
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Near infrared fluorescent probes for whole body optical imaging of 4T1-luc2 mouse breast<br />
cancer development and metastasis<br />
Xie B. , Snoeks T. , Mol I. , Van Driel P. , Keereweer S. , Kaijzel E. , Löwik C.W.G.M. .<br />
Leiden University Medical Center , The Netherlands<br />
b.xie@lumc.nl<br />
Introduction: The rapid development of molecular<br />
imaging has improved early diagnosis and treatments<br />
for various diseases including cancer. The<br />
imaging modalities vary broadly in their sensitivitie,<br />
and the high sensitivity of optical imaging, especially<br />
near infrared fluorescent (NIRF) imaging,<br />
makes it an excellent experimental tool for imaging<br />
small animals like mice. NIRF light has advantages<br />
such as considerably low tissue absorption coefficient<br />
in the NIR region (700-900 nm) and low tissue<br />
autofluorescence so that deeper light penetration<br />
can be achieved. These advantages make NIR light<br />
ideal for whole body optical imaging. Furthermore,<br />
NIRF probes are becoming available for clinical applications,<br />
e.g. imaging-guided surgery. In the current<br />
work, we have implanted mouse mammary<br />
gland cancer cell line 4T1-luc2 in nude mice, and<br />
then assessed 2 commercially available NIRF probes<br />
in their ability and specificity of detecting tumor<br />
progression and metastasis by whole body FLI in<br />
comparison with BLI.<br />
Methods: The following NIRF probes were tested<br />
and validated on detecting the mouse mammary<br />
gland cancer cell line 4T1-luc2 both in vitro and in<br />
vivo: Prosense680 TM (VisEn Medical) and 800CW<br />
Figure: Upper panel shows BLI and FLI Prosense680TM imaging.<br />
Lower panel shows BLI and FLI Prosense680TM imaging of LNs.<br />
2-DG(LI-COR Biosciences). In vitro, studies included<br />
cell-based fluorescent assay by Odyssey measurements,<br />
flow cytometry analysis, and visualization<br />
of probe uptake by confocal laser scan microscopy<br />
analysis. In vivo, 20.000 4T1-luc2 cells were implanted<br />
into the upper mammary fat pad (MFP) of<br />
immunodeficient mice. BLI was used as an internal<br />
control to evaluate the luciferase expression level in<br />
tumor areas, and also for co-locolization of the NIRF<br />
probes. After time-dependent BLI and FLI measurements,<br />
thoracic cavities of mice bearing tumors<br />
were surgically opened and reimaged to reveal the<br />
metastasis of surrounding tissues and axial lymph<br />
nodes (LNs). Organs were quickly removed, and ex<br />
vivo BLI and FLI were performed. Tissues with positive<br />
signals were further analyzed by histochemistry.<br />
Results: Both tested probes could successfully visualize<br />
4T1-luc2 mouse breast cancer cells, both in<br />
vitro and in vivo. Our in vivo data showed that there<br />
was already a nice increase in the BLI signal 3 days<br />
after implanting 4T1-luc2 cells in the MFP of nude<br />
mice. We could also detect the tumor progression<br />
using the NIRF probes in intact animals. At the end<br />
of the experiment (18 days) the animals were surgically<br />
opened up, and we could clearly detect lung and<br />
axial LNs metastases, both by BLI and FLI. This was<br />
confirmed by ex vivo imaging and histochemistry.<br />
Conclusions: This preliminary study of 4T1-luc2<br />
mouse breast cancer indicates that the development<br />
and metastasis of cancer can not only be detected<br />
by BLI but also by FLI, using commercially available<br />
NIRF probes, especially after surgically opening<br />
up the animals. This should pave the way for realtime<br />
visualization of tumor tissues during operation,<br />
making radically removal of all tumor tissues and<br />
local metastases possible.<br />
Acknowledgement: This study is supported by the<br />
Dutch CTMM Project MUSIS<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-012<br />
poStEr<br />
MI in CANCER BIOLGY
126<br />
WarSaW, poland May 26 – 29, 2010<br />
P-013 Improved animal models to study tumor growth and spontaneous metastases:<br />
bioluminescence imaging characterization of the HT-29 human colorectal cancer cell line<br />
Fernández Y. , Miranda S. , López M.E. , Suárez L. , Céspedes M.V. , Mangues R. , Herance J. R. , Rojas S. , Abasolo I. ,<br />
Schwartz Jr S. .<br />
CIBBIM-Nanomedicina. Edifici Hospital General. Bioquímica, Barcelona, Spain<br />
yofernan@ir.vhebron.net<br />
Introduction: The main problem in the treatment of<br />
colorectal cancer (CRC) is not so much the eradication<br />
of the primary tumor, but rather the formation<br />
of incurable metastases. To improve survival of<br />
these patients, there is an urgent need for new treatment<br />
strategies. For this purpose, the development<br />
of reliable, reproducible, clinically-relevant and<br />
inexpensive mouse models that fulfill tumor progression,<br />
invasion and metastasis of human CRC is<br />
needed. A new era of modeling cancer metastasis<br />
involves the use of optical imaging technologies to<br />
monitor tumor growth and colonization after introduction<br />
of cancer cells into the animals. The purpose<br />
of this study was to characterize the behavior<br />
of the human colon cancer cell line HT-29 in a subcutaneous,<br />
experimental metastases and orthotopic<br />
mouse models using non-invasive bioluminescence<br />
imaging (BLI) technologies, thereby providing an<br />
additional method to study CRC disease.<br />
Methods: Luciferase expressing HT-29 cells were injected<br />
subcutaneously, into the left ventricle and orthotopically<br />
into the cecal wall of immunodeficient<br />
nude mice. The tumor growth and metastatic dissemination<br />
patterns were quantitatively and continuously<br />
followed up via BLI. Non-invasive monitoring<br />
of tumorigenicity and metastasis was also compared<br />
to the traditional assays of tumor volume, weight or<br />
histology. Ex vivo BLI and histological analyses were<br />
performed to further identify the exact nature and location<br />
of lesions. BLI results were also validated using<br />
the positron emission tomography (PET) imaging.<br />
Results: We show that BLI has been successfully<br />
used to monitor colorectal tumor growth and metastases<br />
in vivo, and even helps to identify new<br />
metastatic sites. In the subcutaneous mouse model,<br />
BLI production and traditional tumor volume<br />
measurements show a strong correlation, demonstrating<br />
that BLI is an appropriate method to noninvasively<br />
quantify tumor burden. The left cardiac<br />
ventricle injection resulted in colonic tumor<br />
colonies in most organs, including the skeletal<br />
system of mice. In orthotopic implants, locoregional<br />
tumor growth and distant metastases occur<br />
spontaneously and rapidly, closely resembling<br />
imaging life<br />
clinical human disease progression that includes<br />
lymphatic, hematogenous and celomic dissemination.<br />
Ex vivo BLI confirmed the localization of<br />
metastases and dictated which tissues were going<br />
to be analyzed by histopathology reducing the<br />
number of histology rounds required to eventually<br />
detect all the small micrometastases identified<br />
by BLI.<br />
Conclusions: Our findings show that BLI improves<br />
upon and refines traditional animal cancer<br />
models by using fewer animals, offering a rapid,<br />
sensitive and less invasive monitoring of early<br />
neoplastic growth and metastases. Moreover, it<br />
provides an accurate and temporal assessment in<br />
the same animal over time increasing the statistical<br />
power of the model. In conclusion, BLI is a<br />
powerful tool for high-throughput longitudinal<br />
monitoring of tumor load in small animals and<br />
allows the implementation of more advanced orthotopic<br />
tumor models in therapy intervention<br />
studies with almost the same simplicity as when<br />
measuring traditional ectopic models. The availability<br />
of these bioluminescent models are powerful<br />
and reliable tools with which to investigate<br />
metastatic human CRC and novel therapeutic<br />
strategies directed against it.<br />
Acknowledgement: We are grateful to the Spanish<br />
Ministry of Science and Innovation for supporting<br />
laboratory technician and pre-doctoral personal,<br />
and CIBER-BBN for funding the project.<br />
References:<br />
1. Taketo, M. M. & Edelmann, W.; Gastroenterology 136,<br />
780-98 (2009)<br />
2. Cespedes, M. V.; et al. Am J Pathol 170, 1077-85 (2007)<br />
3. Weissleder, R. & Pittet, M.; J. Nature 452, 580-9 (2008)<br />
4. O’Neill, et al.; J Pathol 220, 317-327 (2009)
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Development of dorsal skin-fold window chamber for the analysis of blood vessel<br />
modifications induced by electropermeabilization<br />
Golzio M. (1) , Bellard E. (1) , Markelc B. (2) , Cemazar M. (2) , Sersa G. (2) , Teissie J. (1) .<br />
(1) IPBS-CNRS, Toulouse, France<br />
(2) Institute of Oncology, Slovenia<br />
muriel.golzio@ipbs.fr<br />
Introduction: Recent developments in intravital microscopy<br />
(IVM) enable studies of tumour angiogenesis<br />
and microenvironment at the cellular level after<br />
different therapies. Preparation of skin fold chamber<br />
enables to follow fluorescent events on live animal.<br />
Electroporation/electropermeabilization, i.e. application<br />
of electric pulses to tissues, is a physical method<br />
for delivery of exogenous molecules. It is already used<br />
in clinical therapies of cancer, for electrochemotherapy<br />
of tumors (ECT). Its use was recently developed<br />
in electrogene therapy (EGT). In vivo, “electroporation”<br />
is associated with a blood -flow modifying effect<br />
resulting in decreased blood flow.<br />
The aim of our study was to observe directly on the<br />
living animal the effects of “electropermeabilization”<br />
on subcutaneous normal blood vessels by monitoring<br />
changes in morphology (diameter) and dynamics<br />
(vasomotricity, permeability and recovery).<br />
Methods: These parameters were measured using<br />
fluorescently labelled dextrans injected in the<br />
blood vessels observed via a dorsal skin fold window<br />
chamber, intravital digitized stereomicroscope,<br />
in vivo intravital biphoton microscopy and custom<br />
image analysis. A mathematical modelling gave access<br />
to the changes in permeability from the time<br />
lapse observation. Delivery of electric pulses was<br />
operated on the microscope stage directly on the<br />
animal under anaesthesia.<br />
Results: It resulted in immediate constriction of<br />
blood vessels that was more pronounced for arterioles<br />
(up to ~65%) compared to venules (up to ~20%).<br />
A rapid increase in vascular permeability was present<br />
that gradually decreased to basal (control) levels at<br />
1 h post-treatment. The decay of the high increase<br />
in vascular permeability was biphasic with an initial<br />
fast decrease, but was still present at 1h post-treatment.<br />
Furthermore, vasoconstriction of arterioles after<br />
“electropermeabilization” resulted in a “vascular<br />
lock” that remained for at least 6 minutes. This correlated<br />
approximately with the duration of decreased<br />
diameters of arterioles that lasted for 8 minutes.<br />
Conclusions: the results of our study provided<br />
direct in vivo monitoring of a vascular effect of<br />
electric pulses on normal vessels. The observed<br />
increase in permeability of vessels associated<br />
with delayed perfusion induced by electric pulses<br />
explains the improved delivery of molecules into<br />
tissues induced by this method after systemic<br />
delivery.<br />
Acknowledgement: CNRS, Region Midi Pyrenees,<br />
ARC, canceropole GSO, ANR “Cemirbio”, Slovenian<br />
French Proteus<br />
References:<br />
1. Cemažar M, Golzio M, et al. Current Pharmaceutical<br />
Design 12: 3817-3825. (2006).<br />
2. Marty M, et al. EJC 4(11): 3-13. (2006).<br />
3. Sersa G, et al. Br J Cancer; 98: 388-398 (2008).<br />
4. Golzio M., et al. Gene Therapy 11, S85-S91 (2004).<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-014<br />
poStEr<br />
IMAGING in DRUG DEVELOPMENT
128<br />
WarSaW, poland May 26 – 29, 2010<br />
P-015 Characterization and evaluation of a tumor specific RGD optical probe for time-domain<br />
near-infrared fluorescence imaging<br />
Mathejczyk J.E. (1) , Resch-Genger U. (2) , Pauli J. (2) , Dullin C. (3) , Napp J. (1) , Tietze L. F. (4) , Kessler H. (5) , Alves F. (1) .<br />
(1) Max-Planck Institute for Experimental Medicine, Göttingen, Germany<br />
(2) BAM Federal Institute for Materials Research and Testing, , Germany<br />
(3) University Medical Center Göttingen, Germany<br />
(4) University of Göttingen, Germany<br />
(5) Technical University of Munich, Germany<br />
jmathej@gwdg.de<br />
Introduction: RGD peptides provide useful tools<br />
for specific targeting of tumors overexpressing<br />
α ν β 3 integrins. We used a cyclic RGDfK peptide,<br />
coupled to the near-infrared fluorophore, Cy5.5,<br />
via an aminohexaonic spacer (RGD-Cy5.5) for<br />
functional imaging of α ν β 3 integrins on tumors in<br />
vivo. To assess the suitability and the achievable<br />
sensitivity of RGD-Cy5.5 for tumor imaging<br />
we characterized the spectroscopic properties<br />
of the optical probe and applied time-domain<br />
near-infrared fluorescence (NIRF) imaging for<br />
noninvasive and specific tumor targeting in vivo.<br />
Methods: Application-relevant properties like the<br />
fluorescence quantum yield, lifetime and the thermal<br />
stability of the cyclic RGDfK peptide coupled<br />
to Cy5.5 via an aminohexanoic acid spacer and its<br />
parent fluorophore, Cy5.5 were analyzed spectroscopically.<br />
For in vivo imaging, human α ν β 3 integrin-expressing<br />
glioblastoma cells, U87MG, were<br />
subcutaneously implanted into nude mice. Imaging<br />
was performed using the time-domain fluorescence<br />
imager, Optix MX2 (ART, Montreal, Canada).<br />
Results: RGD-Cy5.5 shows excellent spectroscopic<br />
properties making it a useful tool for in vivo NIRF<br />
imaging. Remarkable is the enhancement in fluorescence<br />
quantum yield of Cy5.5 in RGD-Cy5.5 increasing<br />
from 0.29 to 0.34. In vivo, the specificity<br />
of the RGD-Cy5.5-derived signals was confirmed<br />
by fluorescence lifetime measurements which were<br />
used to distinguish the probe signals from unspecific<br />
fluorescence. RGD-Cy5.5 binds selectively to<br />
glioblastoma with a maximum fluorescence intensity<br />
resulting 5 h after probe injection. The binding<br />
specificity was further confirmed by reduction<br />
of this fluorescence after application of an excess<br />
of unlabeled RGD peptides.<br />
Conclusions: Knowledge of the spectroscopic properties<br />
of fluorescent conjugates represents an important<br />
prerequisite for the successful application<br />
and sensitive detection of fluorescent probes in vivo.<br />
With RGD-Cy5.5, we developed a strongly emissive<br />
and stable optical probe for targeting α ν β 3 integrin<br />
receptors. Fluorescence lifetime measurements<br />
imaging life<br />
contributed to a further enhancement in detection<br />
sensitivity as compared to conventional steady state<br />
NIRF imaging in the intensity domain. Since the<br />
RGD probe contains an aminohexanoic acid spacer,<br />
that allows an easy and effective coupling with<br />
anti-cancer agents, this probe might be applied in<br />
oncology for therapeutic and diagnostic purposes.
18 F labeling of insulin via click chemistry<br />
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Paris J. , Mercier F. , Thonon D. , Kaisin G. , Lemaire C. , Goblet D. , Luxen A. .<br />
University of Liege, Belgium<br />
J.Paris@ulg.ac.be<br />
Introduction: As a positron emission tomography<br />
probe, a new 18 F-bearing insulin derivative was prepared<br />
by an original labeling method. This tracer was<br />
required as a radiolabelled active principle model<br />
compound to perform biodistribution imaging studies<br />
of new pulmonary administrable formulations.<br />
Methods: A 1,3-dipolar azide/alkyne cycloaddition<br />
(click chemistry) approach was developed for the<br />
mild and efficient linking of the radioactive probe<br />
onto insulin (Fig1).<br />
Gly A1 Insulin<br />
H2N CO2H H2N Phe B1<br />
NH 2<br />
As an initial step, native insulin had to be derivatized<br />
in order to present an accessible alkyne<br />
group at an appropriate position. For this, two of<br />
the three amino functions available on the molecule<br />
(Glycine A1 and Lysine B29) were first protected<br />
as N-Boc derivatives. An alkyne bearing<br />
prosthetic group could then be selectively grafted<br />
on the phenylanine B1 residue which does not<br />
interfere in the insulin-receptor binding process<br />
[1]. The final [ 18 F] fluorine insertion step was carried<br />
out by reacting this insulin derivative with<br />
the radioactive azide synthon 1-(azidomethyl)-<br />
4-[ 18 F]-fluorobenzene[2]under Cu(I) catalysis<br />
conditions.<br />
Results: The clickable 18 F azide 1-(azidomethyl)-4-<br />
-[ 18 F]-fluorobenzene was obtained in 65 minutes<br />
with good radiochemical yield (40-45% decay-corrected)<br />
and radiochemical purity (>90%) thanks to<br />
a fully automated preparation method developped<br />
on remote-controlled commercial radiosynthesis<br />
CO 2H<br />
BocHN CO 2H<br />
H 2N<br />
Boc 2 O<br />
Lys B29<br />
CO2H NHBoc<br />
O<br />
O<br />
O<br />
N<br />
O<br />
BocHN CO 2H<br />
HN<br />
O<br />
unit. Subsequent copper catalyzed click reaction on<br />
the alkyne bearing insulin derivative was performed<br />
at room temperature in less than 20 minutes with<br />
current radiochemical yields of 70-80% (decaycorrected).<br />
Conclusions: A mild and efficient radiolabelling<br />
strategy of insulin was succesfully developped using<br />
click chemistry. This radiotracer can now be incorporated<br />
in new inhalable pharmaceutical formulations<br />
for biodistribution imaging studies.<br />
CO2H NHBoc<br />
Acknowledgement: NeoFor and Keymarker research<br />
platforms from the BioWin projects of the Walloon<br />
Region are acknowledged for their financial support.<br />
References:<br />
Click<br />
[ 18 F]AzidoFB<br />
18F + TFA (deprotection)<br />
1. Guenther K.J. ; Yoganathan, S.; Garofalo, R.; Kawabata,<br />
T.; Strack, T.; Labiris, R.; Dolovich, M.; Chirakal, R. and<br />
Valliant, J.F., J.Med.Chem., 49: 1466-1474 (2006)<br />
2. Thonon, D. ; Kech, C. ; Paris, J. ; Lemaire, C. and Luxen,<br />
A.; Bioconjugate Chem., 20(4):817-823, (2009)<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
18 F<br />
N 3<br />
N<br />
N N<br />
HN<br />
O<br />
Insulin<br />
Fig1<br />
P-016<br />
poStEr<br />
IMAGING in DRUG DEVELOPMENT
130<br />
WarSaW, poland May 26 – 29, 2010<br />
P-017 Whole-body distribution, pharmacokinetics and dosimetry of radioiodinated fully<br />
humanized anti-VAP-1 antibody – a PET imaging study of rabbits<br />
Roivainen A. (1) , Autio A. (2) , Suilamo S. (2) , Mali A. (2) , Vainio J. (2) , Saanijoki T. (2) , Oikonen V. (2) , Luoto P. (2) , Teräs M. (2) , Karhi T. (2) ,<br />
Vainio P. (2) .<br />
(1) Academy of Finland/University of Turku, Finland<br />
(2) Turku PET Centre, Finland<br />
anne.roivainen@utu.fi<br />
Introduction: Vascular adhesion protein-1 (VAP-1)<br />
is an inflammation inducible endothelial glycoprotein<br />
[1]. It plays a key role in leukocyte trafficking<br />
and is a potential target for anti-inflammatory therapy.<br />
The antibody BTT-1023 is first-in-class, fully<br />
human monoclonal antibody to VAP-1. BTT-1023<br />
is potentially useful for the treatment of inflammatory<br />
diseases and in vivo imaging of inflammation.<br />
Positron emission tomography (PET) is powerful,<br />
non-invasive method particularly suitable for drug<br />
development because of its high sensitivity and ability<br />
to provide quantitative and kinetic data without<br />
sacrificing the animal. We assessed the usefulness<br />
of PET in evaluation of iodine-124 labeled antibody<br />
pharmacokinetics and distribution in rabbits.<br />
Methods: BTT-1023 was labeled with [ 124 I] using<br />
Chloramine-T method. Immunoreactivity of [ 124 I]<br />
BTT-1023 was verified in human VAP-1 transfected<br />
Chinese Hamster Ovary cells and by time-resolved<br />
immunofluorometric assay using human recombinant<br />
VAP-1. Ten rabbits were intravenously injected<br />
with [ 124 I]BTT-1023. PET/CT was obtained over the<br />
first 2 h after dosing and at 24, 48 and 72 h postinjection.<br />
Blood samples were collected during PET<br />
study to clarify in vivo stability and pharmacokinetics.<br />
As a final point, the human radiation dose estimates<br />
were extrapolated from rabbit information.<br />
Results: Binding of [ 124 I]BTT-1023 to hVAP-1<br />
transfected cells was app. 600-fold higher than<br />
in mock transfected controls. In rabbits, the radioactivity<br />
was distributed especially to liver and<br />
thyroid. Also heart and lungs showed some uptake<br />
whereas brain uptake was very low. Liver uptake<br />
is likely mediated, at least in a large part, by<br />
VAP-1, since the antigen is found on sinusoidal<br />
endothelia in the liver. Thyroid gland radioactivity<br />
is due to the de-iodination of [ 124 I] from the<br />
antibody. The plasma half-life of [ 124 I]BTT-1023<br />
was 58.3 h and clearance 7.8 mL/h/kg. [ 124 I]BTT-<br />
1023 showed good in vivo stability (80% of signal<br />
from intact antibody at 72 h after injection).<br />
The estimated human radiation dose resulting<br />
from [ 124 I]BTT-1023 was 3.66 mSv/MBq. Provided<br />
that thyroid gland uptake is blocked, the effective<br />
dose in a human adult of about 70 kg would<br />
imaging life<br />
decrease to 0.55 mSv/MBq, which is equivalent<br />
to 21 mSv from 35 MBq and 30 mSv from 50 MBq<br />
of [ 124 I]BTT-1023 PET.<br />
Conclusions: [ 124 I]BTT-1023 retained its biological<br />
activity to bind hVAP-1 also after radioiodination.<br />
This PET study of [ 124 I]-labeled VAP-1 targeting<br />
BTT-1023 antibody further elucidated whole-body<br />
distribution and pharmacokinetics of the therapeutical<br />
antibody, and supports clinical trials with [ 124 I]<br />
BTT-1023 at doses of 50 MBq or less.<br />
Acknowledgement: The study was conducted within<br />
the Finnish CoE in Molecular Imaging in Cardiovascular<br />
and Metabolic Research supported by the<br />
Academy of Finland, University of Turku, Turku<br />
University Hospital and Åbo Akademi University.<br />
Anu Autio is a PhD student supported by Drug Discovery<br />
Graduate School.<br />
References:<br />
1. Salmi M, Jalkanen S. Science. 257:1407-1409 (1992)
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Pharmacological characterization of iodine labeled adenosine kinase inhibitors<br />
Sihver W. (1) , Schulze A. (1) , Kaufholz P. (1) , Meyer A. (1) , Grote M. (2) .<br />
(1) Research Center Jülich, Germany<br />
(2) Hannover Medical School, Germany<br />
w.sihver@fz-juelich.de<br />
Introduction: The intracellular enzyme adenosine<br />
kinase (AK) catalyzes the phosphorylation of adenosine<br />
to adenosine monophosphate thus controlling<br />
the adenosine concentration. The inhibition of<br />
AK enhances the amount of adenosine, which is suggested<br />
to have neuroprotective, anticonvulsant, and<br />
antinociceptive effects [1,2] . Years ago, the non-nucleoside<br />
AK inhibitor ABT-702 has been investigated in<br />
vivo and in vitro [3,4] . In the present study the distribution<br />
of the radioiodine labeled adenosine kinase<br />
inhibitors [ 131 I]iodotubercidine ([ 131 I]IT) and [ 131 I]<br />
ABT-702 as well as the pharmacological behaviour<br />
of other known AK inhibitors (e.g. A134974) versus<br />
[ 131 I]IT was compared in rat brain. Furthermore the<br />
AK inhibiting strength of other halogenated ABT-<br />
702 derivatives was determined.<br />
Methods: The syntheses of [ 131 I]IT and [ 131 I]ABT-702,<br />
as well as the different halogenated ABT-702 derivatives<br />
were performed in house. Autoradiography was<br />
conducted using frozen rat brain sections. Binding<br />
competition was done with IT and ABT-702 vs. [ 131 I]<br />
IT. AK inhibition assays were performed with [ 3 H]<br />
adenosine and ATP using pig hippocampus cytosol.<br />
Results: Autoradiography showed generally high<br />
binding all over the brain, but more distinct in the<br />
hippocampus, outer layers of the cortex, and gray<br />
matter of cerebellum using [ 131 I]IT (10nM) compared<br />
to [ 131 I]ABT-702 (7 nM). [ 131 I]IT Binding could<br />
be blocked more than 90% with 5-IT and A134974,<br />
about 70% with tubercidine and 60% with ABT-702.<br />
[ 131 I]ABT-702 Binding could be blocked not even 50<br />
% with ABT-702, and even less with the other AK inhibitors.<br />
K i s of IT and ABT-702 were 20 nM and 850<br />
nM, respectively, in rat hippocampus vs. [ 131 I]IT.<br />
In the AK assays, A134974 and IT had the highest<br />
AK inhibition strength in hippocampal cytosol, followed<br />
by ABT-702 > I- ABT-702 > Cl- ABT-702 ><br />
F- ABT-702 with 78%, 62%, 42%, 30% and 21% inhibition,<br />
respectively.<br />
Conclusions: As a result of this study it is suggested<br />
that [ 131 I]IT and [ 131 I]ABT-702 binding represent<br />
AK distribution in rat brain. [ 131 I]IT appears to be<br />
the preferred ligand for in vitro binding compared<br />
H 2N<br />
N<br />
NH 2<br />
N<br />
I<br />
N N<br />
N<br />
X = Br: ABT-702<br />
X = I: I-ABT-701<br />
X = Cl: Cl-ABT-702<br />
X = F: F-ABT-702<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
N<br />
HO<br />
X<br />
O<br />
N N<br />
OH<br />
OH<br />
O<br />
5-Iodotubercidine (IT)<br />
to [ 131 I]ABT-702. ABT-702 Has recently shown<br />
beneficial therapeutic potential [3, 5] , but radioiodo-ABT-702<br />
seems to be unsuited as radiotracer.<br />
The AK inhibition strength was high both for IT<br />
and ABT-702, but low for the halogenated ABT-702<br />
derivatives. Since IT shows good in vitro behaviour<br />
as a radioligand as well as AK inhibitor, further experiments<br />
with [ 131 I]IT in vivo might be interesting.<br />
References:<br />
1. Kowaluk EA et al.; Expert Opin Investig Drugs.9:551-64<br />
(2000)<br />
2. Boison D; Drug News Perspect. 20:607-11 (2007)<br />
3. Jarvis MF et al.; J Pharmacol Exp Ther. 295:1156-64<br />
(2000)<br />
4. Kowaluk EA et al.; J Pharmacol Exp Ther. 295:1165-74<br />
(2000)<br />
5. McGaraughty S et al.; Curr Top Med Chem. 5:43-58 (2005)<br />
P-018<br />
poStEr<br />
IMAGING in DRUG DEVELOPMENT
WarSaW, poland May 26 – 29, 2010<br />
P-019 Determining the nasal residence time of protein-polymer conjugates for nasal vaccination<br />
using a novel imaging technique<br />
132<br />
Slütter B. (1) , Que I. (2) , Soema P. (1) , Hennink W. (3) , Kaijzel E. (2) , Löwik C.W.G.M. (2) , Jiskoot W. (1) .<br />
(1) Amsterdam Center for Drug Research (LACDR), The Netherlands<br />
(2) Leiden University Medical Center, The Netherlands<br />
(3) Utrecht Institute for Pharmaceutical Sciences (UIPS), The Netherlands<br />
bslutter@lacdr.leidenuniv.nl<br />
Introduction: Nasal administration of vaccines<br />
holds great promise as a painless alternative for the<br />
use of needles. Nonetheless, only one nasal vaccine<br />
is currently on the market (Flumist®). A major hurdle<br />
for successful nasal vaccination is the relatively<br />
short residence time of the vaccine in the nasal cavity,<br />
which hampers efficient uptake of the antigen<br />
through the nasal epithelium. Increasing the nasal<br />
residence time of the antigen is therefore an interesting<br />
approach to improve the efficacy of nasal<br />
vaccines. Here we investigated the possibility of extending<br />
the nasal residence time of a small antigen<br />
(ovalbumin, OVA) with a mucoadhesive polymer,<br />
trimethyl chitosan (TMC), using a novel live imaging<br />
technique1.<br />
Methods: A near-IR fluorescent probe (IR dye<br />
CW800) was covalently linked to OVA. TMC was<br />
either mixed with or conjugated to OVA using the<br />
SPDP method2. After nasal administration of the<br />
antigen to hairless mice, the fluorescence intensity<br />
in the nasal cavity was assessed using an IVIS Spectrum®<br />
and followed in time (Fig1).<br />
Results: We observed an exponential decay of fluorescence<br />
intensity after administration of OVA alone,<br />
whereas after co-administration of OVA with TMC<br />
or TMC-OVA conjugate fluorescence decay was delayed<br />
substantially.<br />
Conclusions: Using a live imaging technique we successfully<br />
studied the nasal residence time of a model<br />
subunit antigen. TMC prolongs the nasal residence<br />
time of OVA, either by mixing it with or conjugating<br />
it to the antigen.<br />
imaging life<br />
Fig1: Nasal residence time of OVA determined using<br />
fluorescent detection of OVA-IRdye CW 800. Intensity of<br />
fluorescence signal from the nasal cavity was measured<br />
in time and normalized for time point 0. n=3+/- SEM.<br />
References:<br />
1. Hagenaars et al. Role of trimethylated chitosan (TMC)<br />
in nasal residence time, local distribution and toxicity<br />
of an intranasal influenza vaccine. J Control Release.<br />
2010, in press.<br />
2. Slütter et al. Conjugation of ovalbumin to trimethyl<br />
chitosan improves immunogenicity of the antigen. J<br />
Control Release. 2010, in press.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Nanotubes as mutli-modality vehicles for imaging and therapy of cancer<br />
Tworowska I. (1) , Mackeyev Y. (2) , Sims-Mourtada J. (1) , Wilson L. J. (2) .<br />
(1) RadioMedix, Houston, USA<br />
(2) Rice University, Houston, USA<br />
itworowska@radiomedix.com<br />
Introduction: There is a growing interest in development<br />
of new radiolabeled nanocarriers for targeted<br />
delivery of isotopes. Nanotubes have been actively<br />
explored as new systems for delivery of anticancer<br />
drugs [1], fluorescent probes [2], genes [3], and peptides<br />
[4] to the target tissues. Previously reported<br />
synthesis of Gd-loaded US-tubes [5] and I 2 -modified<br />
US-tubes [6] have opened new possibilities in<br />
designing of contracts agents for MRI and CT. Here,<br />
we report on the synthesis of radiolabeled SWNT<br />
that can serve as vehicles for PET/SPECT imaging<br />
and cancer therapy.<br />
Methods: HiPco single-wall nanotubes (SWNTs)<br />
were chemically cut into US-tubes, using the established<br />
procedure [7], sonicated at RT in 0.5M<br />
HNO for 30min-2h. US-tubes were loaded with<br />
3<br />
radioisotopes: 177LuCl , 3 99mTcCl , 3 68GaCl , and cold<br />
3<br />
Re compounds (ReCl 5 , NH 4 ReO 4 , [NBu 4 ] + ReClO 4<br />
manually or using automated module for labelling,<br />
SmarTrace TM . The radiochemical yield was determined<br />
by radio-TLC and ICP-OES (Inductively<br />
coupled plasma optical emission spectrometry). Stability<br />
tests of labelled US-tubes were performed at<br />
RT for 1- 24h using 1M PBS, 0.1% FBS and transchelator<br />
(0.1M EDTA) to determine the desorption<br />
half-life of the labelled US-tubes.<br />
Results: Loading of US-tubes with 68 Ga was performed<br />
in 0.5M NH 4 OAc buffer at 90°C for 10<br />
min using 68 GaCl 3 eluted from 68 Ge/ 68 Ga generator<br />
(iThemba). Yield of the synthesis was found to be<br />
pH dependent with over 70% loading at pH=3.6- 4.1<br />
and to decrease drastically to 1% at pH51%. Yield of the reaction decreased<br />
to 1% in the absence of SnCl 2 , or when reduction<br />
proceeded after completion of labelling.<br />
Best 177 Lu loading of US-tubes was performed in<br />
0.1 M NH 4 OAc at pH=5.1 at 90°C for 20 min. The<br />
final yield of this synthesis was found to be >55%<br />
after repeated dialysis with 0.1M EDTA, pH=4.7.<br />
- )<br />
Loading of US-tubes with cold ReCl proceeded<br />
5<br />
in 0.6M NaOH at 90oC for 1h with final yield<br />
> 20%. Application of other Re compounds<br />
([NBu ] 4 + - ReClO and NH4ReO ) for modification<br />
4<br />
4<br />
of nanotubes gave products with yield higher than<br />
17% and approximately 0.4%, respectively.<br />
Conclusions: Our preliminary studies have shown<br />
that loading of US-tubes with imaging and therapeutic<br />
isotopes is feasible. Application of nanotubes<br />
in nuclear medicine may expand possibilities for<br />
development of new multi-modality agents for early<br />
detection and therapy of cancer.<br />
References:<br />
1. Tripisciano C., Kraemer K., Taylor A., Borowiak-Palen E.,<br />
Chem. Phys. Lett., 2009, 478, 200-205<br />
2. Wong Shi Kam N., Liu Z., Dai H., Angew. Chem. Int. Ed.,<br />
2006,45, 577-581<br />
3. Ramathan T, Fisher F.T., Ruoff R.S., Brinson L.C., Chem.<br />
Mater., 2005, 17, 1290-1295<br />
4. Kam N.W., Dai H., J. Am. Chem. Soc., 2005, 102, 6021-<br />
6026<br />
5. Mackeyev Y., Hartman K.B, Ananta J.S., Lee A.V., Wilson<br />
L.J., J. Am. Chem. Soc., 2009; 131(24): 8342–8343<br />
6. Ashcroft J.M, Hartman K.B., Kissel K.R., Mackeyev Y.,<br />
Pheasant S., Young S., Van der Heide P.A., Mikos A.,<br />
Wilson L.J., Advanced Materials, 2007, 19, 573-576<br />
7. Mickelson E.T., Huffman C.B., Rinzler A.G., Smalley R.E.,<br />
Hauge R.E., Margrave J.L., Chem Phys Lett, 1998, 296,<br />
188-194.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-020<br />
poStEr<br />
IMAGING in DRUG DEVELOPMENT
WarSaW, poland May 26 – 29, 2010<br />
P-021 Early assessment of temozolomide treatment efficacy in glioblastoma using [ 18 F]FLT PET<br />
imaging<br />
134<br />
Viel T. (1) , Backes H. (1) , Hadamitzky M. (1) , Monfared P. (1) , Rapic S. (1) , Rudan D. (1) , Schneider G. (1) , Neumaier B. (1) , Jacobs A.H. (1,2) .<br />
(1) MPI for Neurological Research, Köln, Germany<br />
(1,2) European Institute for Molecular Imaging – EIMI, University Muenster, Germany<br />
thomas.viel@nf.mpg.de<br />
Introduction: Temozolomide chemotherapy to radiation<br />
therapy is now the standard therapy for<br />
glioblastomas [1] . However there is considerable uncertainty<br />
with regard to the indication for and the<br />
chances of success of chemotherapy in affected patients.<br />
Standard Temozolomide treatment in clinic<br />
consists of 5 days treatment with 150-200 mg/m2 per<br />
day, repeated every 28 days. Treatment efficacy assessment<br />
is performed using MRI Imaging before treatment<br />
and after 3 cycles of treatment (meaning after<br />
3 months). Due to the rapid evolution of the disease<br />
(median survival of patient bearing glioblastoma is<br />
around 15 months), methods to assess TMZ efficacy<br />
early during treatment is needed. In several clinical<br />
studies [ 18 F]FLT PET imaging has been validated to<br />
assess proliferation of different types of tumors in<br />
vivo [2] , and could therefore be of interest for evaluation<br />
of TMZ during treatment of glioblastoma.<br />
The purpose of this study was to monitor the metabolic<br />
effects of temozolomide (TMZ) chemotherapy<br />
in malignant gliomas by means of repeated Positron<br />
Emission Tomography (PET) with [ 18 F]FLT.<br />
Methods: A glioma cell line, displaying a low resistance<br />
to TMZ (Gli36) was treated with two low<br />
doses of TMZ (25 and 50 µM). Two stable cell lines<br />
were obtained and characterized regarding their<br />
resistance to TMZ by growth and clonogenic assay.<br />
Resistant and sensitive cells were xenografted into<br />
nude mice. Mice were treated during five days with<br />
daily intra-peritoneal injection of 50 mg/kg of TMZ.<br />
Efficacy of TMZ treatment is followed using FLT<br />
imaging, before treatment as well as two and seven<br />
days after beginning of treatment.<br />
Results: Two stable cell lines resistant to TMZ were<br />
established (Gli36-25TMZ and Gli36-50TMZ). The<br />
EC50 for the induction of cytotoxicity cell death (as<br />
determined by growth assay) were 10 µM (Gli36), 110<br />
µM (Gli36-25TMZ) and 460 µM (Gli36-50TMZ). The<br />
EC50 for the prevention of clonogenic growth (as determined<br />
by clonogenic assay) were 10 µM (Gli36), 50<br />
µM (Gli36-25TMZ) and 325 µM (Gli36-50TMZ). In<br />
vivo, the TMZ treatment induced a strong reduction<br />
of Gli36 tumor volume, while Gli36-50TMZ continued<br />
to grow. Correlation between diminution of SUV in<br />
imaging life<br />
the tumor after two days of treatment (with regards to<br />
SUV before treatment) and diminution of tumor size<br />
seems to be observed so far (n=3 for each tumor type).<br />
Conclusions: Our results so far indicate that [ 18 F]FLT<br />
PET scan could be appropriate for an early evaluation<br />
of the response of Glioblastoma to TMZ chemotherapy.<br />
Acknowledgement: This work is supported in part<br />
by DiMI (LSHB-CT-2005-512146).<br />
References:<br />
1. Norden AD, Drappatz J, et al; Lancet Neurol. 7(12):1152-<br />
60 (2008).<br />
2. Ullrich RT, Zander T, et al; PLoS One. 3(12):e3908<br />
(2008).
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Sensitive time-gated FRET microscopy of G-Protein coupled receptors using suicide enzymes,<br />
lanthanide cryptates and fluorescent ligands<br />
Zwier J. (1) , Laget M. (1) , Cottet M. (2) , Durroux T. (2) , Mathis G. (1) , Trinquet E. (1) .<br />
(1) Cisbio Bioassays, Bagnols sur Cèze, France<br />
(2) Insitut de Génomique fonctionelle, France<br />
jzwier@cisbio.com<br />
Introduction: Donor crosstalk and non-specific fluorescence<br />
in classical biological FRET experiments<br />
using fluorescent proteins remains a major concern<br />
in high content screening. Using a time-gated microscope<br />
equipped with an intensified CCD camera<br />
[1], lanthanide cryptates and fluorescent-ligands it<br />
is possible to visualize G-protein coupled receptors<br />
(GPCR) labeled with the SNAP-tag® suicide enzyme<br />
at the cell membrane. Oligomerization of GPCR’s can<br />
be studied using time gated FRET without significant<br />
background. Using fluorescent ligands, binding<br />
and receptor trafficking can be imaged without ratiometric<br />
treatment of data.<br />
Methods: A bright terbium-cryptate (lumi4®-Tb)<br />
coupled to 0 6 -Benzylguanine is used to covalently<br />
label GPCR’s tagged with the SNAP-tag suicide enzyme<br />
developed by the laboratory of Kai Johnsson<br />
[2]. The luminescence of this lanthanide compound,<br />
which has a lifetime of about 2 ms, can be time-gated<br />
in such a way that all background fluorescence from<br />
the cells has decayed and only specific lanthanide or<br />
sensitized acceptor emission to either red or green<br />
emitting dyes can be detected. An in-house developed<br />
microscope equipped with an intensified CCD<br />
camera can monitor this luminescence. HEK/COS/<br />
CHO cells were either stably or transiently transfected<br />
with plasmids containing the SNAP-tagged GPCR<br />
under study and labeled with the benzylguanines of<br />
choice after which they are fixed.<br />
Results: Due to the significant Förster radius of 58<br />
A of the lumi4-Tb/red donor-acceptor couple, homodimerization<br />
of a GPCR can be monitored using<br />
a mix of the Tag-lite® reagent SNAP-Lumi4-Tb and<br />
SNAP-red wich results in a bright time gated sensitized<br />
emission image at 665 nm. These results confim<br />
the results obtained by dimerization assays [3]<br />
in standard plate readers.<br />
Due to the advantages of this technique it is also<br />
possible to visualize specific labeling of fluorescent<br />
ligands on the GPCR of interest. Using fluorescent<br />
ligands without the use of time gating gives significant<br />
contributions of non-specific binding. Since<br />
sensitized emission only occurs when donor and<br />
acceptor are in close proximity ligand receptor<br />
interactions were monitored for several GPCR’sligand<br />
couples including chemokine receptors.<br />
Conclusions: Time gated microscopy with terbiumcryptate<br />
is a convenient and novel way to avoid<br />
non-specific emission signals and to monitor FRET<br />
intensities showing genuine interactions between<br />
proteins and their ligands. This might become a<br />
powerful method to develop high content assays for<br />
drug evaluation.<br />
Acknowledgement: Tag-lite is a registered trademark<br />
of Cisbio bioassays. Lumi4 is a regis tered<br />
trademark of Lumiphore Inc. SNAP-tag is a registered<br />
trademark of New England Biolabs.<br />
References:<br />
1. Ghose S et al, J. Alloys and cmpds 451:35-37 (2008)<br />
2. Keppler A et al, Nature Biotechnology 21:86-89 (2003)<br />
3. Maurel D, Comps-Agrar L et al, Nature Methods 5:561-<br />
567 (2008)<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-022<br />
poStEr<br />
IMAGING in DRUG DEVELOPMENT
136<br />
WarSaW, poland May 26 – 29, 2010<br />
P-023 Selection of a nanobody scaffold with low renal retention<br />
D’huyvetter M. , Vaneycken I. , Tchouate Gainkam O. , Hernot S. , Caveliers V. , Xavier C. , Devoogdt N. , Lahoutte T. .<br />
Vrije Universiteit Brussel, Jette, Belgium<br />
mdhuyvet@vub.ac.be<br />
Introduction: Nanobodies are small (15kDa) antibody<br />
fragments, derived from heavy chain-only<br />
antibodies present in Camelidae. The structure<br />
consists of a scaffold and three CDR loops. The<br />
CDR loops determine the specificity of the nanobody.<br />
Nanobodies, labelled with a therapeutic<br />
radionuclide, could be used for the treatment of<br />
cancer. Unfortunately, the in vivo biodistribution<br />
shows high renal retention of radio-labeled nanobodies<br />
in the kidney cortex and this could result<br />
in an important kidney toxicity. However, during<br />
the in vivo screening of a large set of nanobodies<br />
we noticed that there is a wide variety in this kidney<br />
retention. This variability could be partially<br />
related to the amino acid sequence of the nanobody<br />
scaffold. In this study we aim to identify the<br />
nanobody scaffold with the lowest renal retention.<br />
Methods: The renal retention of 8 Nanobodies was<br />
evaluated in healthy Wistar rats. 99mTc labeling<br />
was performed using 99mTc-tricarbonyl (Isolink,<br />
Covedien). Dynamic planar imaging with a gamma<br />
camera was performed immediately after injection<br />
(100 frames of 30s). Three hours post injection an<br />
additional static image was acquired. Time activity<br />
curves of the kidney were generated using AMIDE.<br />
imaging life<br />
Results: We measured two distinct kinetic profiles:<br />
one showing a steadily increase in function of time<br />
and the other showing an initial peak (5 min p.i.)<br />
followed by a decrease. The highest renal activity<br />
measured at 1h p.i. was 46.8 % IA (range 41.6-53.3<br />
%IA), while the lowest was 11.3 % IA (range 10.1-<br />
13.2 %IA). At 3h p.i. we measured upto 69.3 %IA<br />
in the kidney for the group with a steadily increasing<br />
profile, while for the other group it remained<br />
low at 14.8 %IA.<br />
Conclusions: We identified a scaffold with low<br />
renal retention. The use of this scaffold for nanobody<br />
based targeted radionuclide therapy could<br />
significantly reduce kidney toxicity.<br />
Acknowledgement: The research at ICMI is funded<br />
by the Interuniversity Attraction Poles Program –<br />
Belgian State – Belgian Science Policy. Matthias<br />
D’huyvetter is funded by SCK-CEN/VUB.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
In vitro assessment of androgen mediated uptake of 18 F-FDG, 11 C-choline and 11 C-acetate in<br />
prostate cancer<br />
Emonds K. (1) , Swinnen J. (1) , Van Weerden W. (2) , Nuyts J. (1) , Mortelmans L. (1) , Mottaghy F. (3) .<br />
(1) KULeuven, Belgium<br />
(2) Josephine Nefkens Institute, The Netherlands<br />
(3) University Hospital Aachen, Germany<br />
Kimy.Emonds@med.kuleuven.be<br />
Introduction: Androgen deprivation is one of the<br />
first line palliative treatment approaches in recurrent<br />
prostate cancer. Although 18 F-FDG is mostly applied<br />
in oncological PET imaging, a low diagnostic performance<br />
has been shown for prostate cancer detection.<br />
Otherwise, both 11 C-choline and 11 C-acetate offer a<br />
higher diagnostic efficiency for PET detection of relapsing<br />
patients. With this study we aimed to evaluate the<br />
androgen dependency of the uptake of metabolic PET<br />
tracers ( 18 F-FDG, 11 C-choline and 11 C-acetate) in five<br />
different human prostate cancer cell lines, distinctive<br />
considering their androgen responsiveness, in order to<br />
define the most reliable tracer for treatment response<br />
assessment.<br />
Methods: Cell uptake experiments were performed with<br />
the prostate cancer cell lines LNCaP, PC346C, 22Rv1,<br />
PC346DCC and PC3, and the benign prostatic hyperplasia<br />
cell line BPH-1. Prior to the uptake experiments,<br />
cells were cultured in the presence of charcoal treated<br />
serum (native). In parallel cell cultures 10 -8 M R1881, 10 -<br />
10 M R1881, 10 -6 M bicalutamide or the combination of<br />
10 -10 M R1881 and 10 -6 M bicalutamide was added to the<br />
medium. The significant influence of androgens on the<br />
uptake of 18 F-FDG, 11 C-choline and 11 C-acetate in each<br />
prostate cancer cell line was evaluated using ANOVA<br />
and Tukey-HSD post-hoc analysis. The relative tracer<br />
uptake was evaluated in all prostate cancer cell lines<br />
with respect to the tracer uptake in BPH-1.<br />
Results: A significant increased 11 C-choline uptake is<br />
observed in the androgen responsive and unresponsive<br />
cell line, respectively PC346C and 22Rv1, grown in the<br />
presence of androgens (10 -8 M R1881). The same androgen<br />
concentration also caused a significant increase<br />
in 18 F-FDG uptake in LNCaP (androgen dependent)<br />
and 22Rv1. In both androgen unresponsive cell lines<br />
(PC3, PC346DCC) androgens did not significantly affect<br />
the uptake of these metabolic PET tracers. Unlike<br />
11 C-choline and 18 F-FDG, 11 C-acetate uptake was not<br />
influenced by androgen supplementation in any prostate<br />
cancer cell line.<br />
Compared to the tracer uptake in BPH-1, all prostate<br />
cancer cell lines showed a significant higher 11 C-acetate<br />
and 11 C-choline uptake. In contrast, a relative increased<br />
18 F-FDG uptake was only observed in PC346C and -DCC.<br />
Conclusions: 11 C-acetate uptake is androgen<br />
independent in every prostate cancer cell line,<br />
whereas a significant higher 11 C-choline and<br />
18 F-FDG uptake was established by androgens<br />
in respectively two (PC346C, 22Rv1) and three<br />
(LNCaP, PC346C, 22Rv1) human prostate cancer<br />
cell lines. Also, 11 C-acetate has the most<br />
clearly elevated uptake in all prostate cancer<br />
cell lines with respect to the benign prostatic<br />
hyperplasia cell line.<br />
The absent influence of androgens on 11 C-acetate<br />
uptake and the better differentiation of<br />
cancer from benign prostatic hyperplasia with<br />
this PET tracer compared to 11 C-choline and<br />
18 F-FDG, suggests a higher efficiency of 11 C-acetate<br />
PET for evaluation of treatment response.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-024<br />
poStEr<br />
CANCER from BENCH to BEDSIDE
138<br />
WarSaW, poland May 26 – 29, 2010<br />
P-025 Comparison of two 68 Gallium-labeled octreotide analogues for molecular PET(CT) imaging<br />
of neuroendocrine tumours<br />
Garcia C. , Woff E. , Muylle K. , Ghanem G. , Van der Linden B. , Vandormael S. , Rutten E. , Flamen P. .<br />
Institut Jules Bordet. Université Libre de Bruxelles, Brussels, Belgium<br />
camilo.garcia@bordet.be<br />
Introduction: PET(CT) using 68 Ga-labeled octreotide<br />
analogues is able to show the expression of<br />
somatostatin receptors (SSR) on gastroenteropancreatic<br />
neuro-endocrine tumours (GEP NET). The<br />
study aim was to compare the biodistribution and<br />
the tumour uptake intensity of two radiolabeled<br />
octreotide analogues, 68 Ga-DOTA-TOC ([DOTA-<br />
DPhe1,Tyr3]-octreotide) and 68 Ga-DOTA-TATE<br />
([DOTA-DPhe1,Tyr3]-octreotate).<br />
Methods: Octreo-PET(CT) was performed on 58<br />
patients: 29 patients using 68Ga-DOTA-TOC and<br />
29 patients using 68 Ga-DOTA-TATE. Standard Uptake<br />
Values (SUV) was measured in normal organs<br />
and in the lesions (SUVmax). Patient preparation,<br />
acquisition and image processing was standardized<br />
and identical in both subgroups. None of the<br />
patients had received any peptide therapy or radiolabeled<br />
peptide therapy before the study. The<br />
time delay between tracer injection and PET(CT)<br />
acquisition for respectively DOTA-TOC vs. DOTA-<br />
TATE patients was 95 min ± 0.01 vs. 100 min ± 0.01<br />
(p=NS); the mean injected tracer activity was 90.28<br />
MBq ± 46.62 vs. 88.8 MBq ± 21.09 (2.44 mCi ± 1.26<br />
vs. 2.40 mCi ± 0.57) (p=NS), and BMI 25.7 ± 3.71<br />
vs. 25.2 ± 3.6 (p=NS).<br />
imaging life<br />
Results: PET(CT) identified 107 tumor lesions: 52<br />
(49%) in the DOTA-TOC, and 55 lesions (51%) in<br />
the DOTA-TATE group. No significant differences<br />
of SUV(max) values were found in GEP NET lesions<br />
between DOTA-TATE and DOTA-TOC groups.<br />
Physiologic uptake in organs did not significantly<br />
differ between the 2 radiopharmaceuticals, except<br />
for the uptake of 68 Ga DOTA-TOC which was significantly<br />
lower in the head of pancreas than the<br />
uptake of 68 Ga DOTA-TATE (3.4 ± 1.5 vs. 4.6 ± 1.6)<br />
(P
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Real time per operative optical imaging for the improvement of tumour surgery in an in vivo<br />
micro-metastases model<br />
Keramidas M. , Josserand V. , Righini C. , Coll J. L.<br />
INSERM U823, Grenoble, France<br />
michelle.keramidas@ujf-grenoble.fr<br />
Introduction: In a wide range of cancer cases,<br />
surgery is the first therapeutic indication before<br />
radiotherapy and chemotherapy. In that<br />
way the prognostic strongly depends on the tumour<br />
removal exhaustiveness and in particular<br />
on metastases elimination.<br />
We developed a couple near-infrared fluorescent<br />
tracer / per operative detection system in<br />
order to improve tumour surgery efficacy.<br />
RAFT-c(RGD)4-Alexa 700 (Angiostamp®, Fluoptics)<br />
specifically bind to integrin αvß3, a<br />
receptor strongly expressed in angiogenesis<br />
and in many tumour types. The per-operative<br />
detection system (Fluobeam 700, Fluoptics) is<br />
a portative 2D fluorescent imager that can be<br />
used in white light environment and so, could<br />
be used directly during surgery to help the surgeon<br />
for tumour and metastases excision.<br />
We already demonstrated in animal models<br />
the very significant improvement in primary<br />
tumours resection: higher number of tumour<br />
nodules removed, sane margins on the removed<br />
fragments and surgery time divided by 2 (Keramidas<br />
M., British Journal of Surgery 2010).<br />
In the clinical situation, recurrence of cancer<br />
by metastases invasion after primary tumour<br />
surgery is a critical point. The aim of the present<br />
study is to evaluate the metastases resection<br />
impact on the survey. In order to proceed we<br />
first need to establish a suitable animal model<br />
of micro-metastases following primary tumour<br />
surgery. After calibration of the metastatic<br />
in vivo model, we will evaluate the survey of<br />
the twice-operated animals (metastases resection<br />
after primary tumour removal) versus the<br />
once-operated animals (only primary tumour<br />
removal).<br />
Methods: Luciferase positive tumour cells (TS/<br />
Apc-luc) are injected in the kidney capsule of<br />
nude mice and the primary tumour growth is<br />
followed by in vivo bioluminescence imaging.<br />
7 days after tumour cells implantation, the tumoral<br />
kidney is removed and the metastases<br />
development is followed by in vivo bioluminescence<br />
imaging. Then RAFT-c(RGD)4-Alexa<br />
700 is injected intravenously and twenty-four<br />
hours later the portative fluorescence detection<br />
system is used to assist the metastases excision.<br />
The possible recurrence of cancer is followed<br />
by in vivo bioluminescence imaging. Mice are<br />
sacrificed when they loose 10% of their weight.<br />
The mice survey is compared with the one of<br />
two control groups: in one group the mice don’t<br />
undergo the second surgery for metastases resection,<br />
and in a second group the mice don’t<br />
undergo any surgery and keep the primary kidney<br />
tumour.<br />
Results: Micro-metastases appear about 7 days<br />
after the primary tumour removal and soar up<br />
to 20 days after the first surgery. The metastases<br />
removal assisted by the RAFT-c(RGD)4-Alexa<br />
700 and the per operative fluorescence detection<br />
system significantly improved the mice<br />
survey (36 days).<br />
Conclusions: We developed an in vivo model of<br />
micro-metastases invasion following primary<br />
tumour surgery which is very relevant regarding<br />
to the clinical situation of head and neck<br />
or prostate cancer. The use of RAFT-c(RGD)4-<br />
Alexa 700 coupled with the portative device allows<br />
micro-metastases detection, significantly<br />
improve their resection and increase the mice<br />
survey.<br />
References:<br />
1. Intraoperative near-infrared image guided surgery for<br />
peritoneal carcinomatosis in a preclinical experimental<br />
model. M. KERAMDAS, V. JOSSERAND, RIGHINI C.A., WENK<br />
C., FAURE C. And COLL J.L. British Journal of Surgery,2010.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-026<br />
poStEr<br />
CANCER from BENCH to BEDSIDE
140<br />
WarSaW, poland May 26 – 29, 2010<br />
P-027 Fluorescence imaging modalities for imaging gastrointestinal tumor models<br />
Schulz P. , Cordula D. , Rexin A. , Wiedenmann B. , Groetzinger C. .<br />
Charite, Universitätsmedizin Berlin, Germany<br />
petra.schulz@charite.de<br />
Introduction: A number of peptide receptors have<br />
been found to be overexpressed in tumors of the GI<br />
tract. The overexpression of somatostatin receptors<br />
in neuroendocrine gastroenteropancreatic tumors<br />
has long been utilized for molecular imaging using<br />
radiolabelled somatostatin analogs in scintigrafic<br />
procedures. Other peptide GPCRs may therefore<br />
represent attractive new targets. The ongoing project<br />
is occupied in particular with the design of GPCR<br />
peptide ligands, which bind with high specificity to<br />
surface receptors of tumor cells. Pharmacologically<br />
optimized peptides could be used as vehicles for<br />
transport of contrast agents as well as therapeutics.<br />
Methods: The ongoing project follows four main<br />
goals: (1) The validation of GPCR peptides as tumor<br />
targets for the gastrointestinal tract (2) The identification<br />
of new peptide binding targets (3) The Optimization<br />
of peptide structures for imaging and targeted<br />
therapy and (4) the development of NIRF-probes<br />
and –techniques for a better diagnosis of tumors.<br />
NIRF probes are validated in established in vivo tumor<br />
models, including subcutaneous tumor models<br />
and in a number of orthotopic tumor models using<br />
planar and tomografic fluorescent imaging, micro<br />
CT and endoscopy for small animals. For monitoring<br />
and characterization of tumor growth of human cancer<br />
cells in nu/nu mice the bioluminescence imaging<br />
approach is utilized. For this purpose several stable<br />
cancer lines (colorectal, pancreatic, neuroendocrine),<br />
expressing the luciferase gene were established.<br />
Results: Currently, a number of peptide, antibody<br />
and small-molecule contrast agents are validated.<br />
Each tracer is characterized for its potency as a contrast<br />
agent by imaging with a 2-D fluorescence imaging<br />
system, which reveals target-to background<br />
ratios of the contrast agents, characteristic for target<br />
tissue specificity. Limitations of planar imaging<br />
systems are still the lack of depth resolution and<br />
difficult quantification. Currently we are therefore<br />
evaluating a fluorescence tomographic system with<br />
regard to deep tissue imaging and signal quantification.<br />
Tomograpic images also allow fusion with<br />
other imaging mmodalities such as CT to confirm<br />
the anatomical localization of the fluorescent signal.<br />
imaging life<br />
Conclusions: Although near-infrared radiation has<br />
a higher penetration depth than the visual light,<br />
scattering and absorption still prevent whole-body<br />
imaging. One potential application for the use of<br />
near-infrared optical agents in humans is therefore<br />
fluorescence-guided endoscopy. We are currently establishing<br />
a protocol for endoscopic imaging in mice<br />
with colorectal cancer with a rigid endoscopic device<br />
in combination with fluorescence-guided detection<br />
using a fiber endoscope.<br />
Acknowledgement: This work was supported by grant<br />
03IP614 from German ministry of research (BMBF)
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Assessment of effectiveness and toxicity of the therapy with somatostatin analogue labelled<br />
90Y-DOTATATE in patients with non-functional pancreatic neuroendocrine tumours (PNT)<br />
Sowa-Staszczak A. .<br />
Nuclear Medicin Unit, Krakow, Poland<br />
sowiana@gmail.com<br />
Introduction: Therapy with labelled somatostatin<br />
analogues is the modern approach to the patients<br />
with disseminated or unresectable NETs expressing<br />
somatostatin receptors (SSTR). Octreotate is<br />
the somatostatin analogue with very high affinity<br />
to the SSTR type 2, most commonly present in<br />
neuroendocrine tumours. In non-functional PNT,<br />
grading and systemic metastases have a significant<br />
impact on survival. Overall, the 5-year survival<br />
rate is about 33%. The chemotherapy is the most<br />
common treatment approach. The aim of the study<br />
was to assess the efficacy and toxicity of peptide<br />
receptor radionuclide therapy (PRRT) with the use<br />
of the high affinity somatostatin receptor subtype<br />
2 analogue, 90Y labelled Tyr3-octreotate, (90Y-<br />
DOTATATE) in non-functional pancreatic neuroendocrine<br />
tumours.<br />
Methods: 19 patients with metastatic NET were diagnosed<br />
in the Department of Endocrinology UJCM.<br />
5 patients with high proliferation index (Ki >20%, 4-<br />
negative SRS, tumour size 3-7cm) were directed to<br />
chemotherapy. 14 patients with positive SRS scan due<br />
to disseminated and/or unoperable PNTs (2 patients)<br />
were qualified to PRRT (6 men, 8 women, mean age 54,7<br />
years old, Karnofsky’s index > 70-100%). The size of the<br />
tumour was 2,3-12cm, Ki-67 was
142<br />
WarSaW, poland May 26 – 29, 2010<br />
P-029 Intra operative near-infrared fluorescent imaging of colorectal liver metastases using<br />
clinically available Indocyanine Green in a syngene rat model<br />
Van Der Vorst J. , Hutteman M. , Mieog J. , De Rooij K. , Kuppen P. , Kaijzel E. , Löwik C.W.G.M. , Van De Velde C. ,<br />
Vahrmeijer A. .<br />
Leiden University Medical Centre, The Netherlands<br />
j.r.van_der_vorst@lumc.nl<br />
Introduction: The survival of patients with colorectal<br />
carcinoma is mostly determined by the occurrence<br />
of distance metastases. When liver metastases occur,<br />
surgical resection can offer a 5-year survival of 35-<br />
40%. However, during resection, an adequate assessment<br />
of the extent of disease is limited, resulting in<br />
a high percentage of recurrence (40-50%). Ishizawa<br />
et al. reported that liver cancer could be identified<br />
using near-infrared (NIR) fluorescence and the clinically<br />
available indocyanine green (ICG) (1). However,<br />
the optimal dose of ICG and the interval between the<br />
administration of ICG and surgery is unclear.<br />
Methods: In the current study, the NIR probe ICG<br />
and the Mini-FLARE (Dr. J.V. Frangioni, Boston,<br />
USA) camera system were used. In 6 rats, 125,000<br />
CC531 cells were inoculated subcapsularly in<br />
three different lobes of the liver. After four weeks,<br />
tumors of approximately 3-5 mm diameter were<br />
present. In each rat, fluorescence was measured at<br />
24 and 48 hours post-injection of 0.04 mg (n = 3)<br />
or 0.08 mg (n = 3) ICG.<br />
Color<br />
Fig1: Intraoperative NIRF identification of colorectal liver metastases<br />
imaging life<br />
Results: In 6 rats, all colorectal liver metastases<br />
(n = 10) were intraoperatively identified using<br />
ICG and the Mini-FLARE camera system (Figure<br />
1). The fluorescent signal of the colorectal liver<br />
metastases was significantly higher than the signal<br />
of surrounding normal liver tissue (P < 0.001).<br />
No significant difference in mean signal to background<br />
ratio was found between imaging at 24 and<br />
48 hours post-injection. Furthermore, no significant<br />
difference in mean signal to background ratio<br />
was found between injection of 0.04 and 0.08 mg<br />
of ICG.<br />
Conclusions: This study demonstrated that colorectal<br />
liver metastases can be clearly identified during<br />
surgery using the clinically available NIRF probe<br />
ICG and the Mini-FLARE camera system. When<br />
the current intraoperative identification can be improved<br />
using this technique, resections can be performed<br />
more accurately and preoperatively missed<br />
metastases can be involved in surgical decision<br />
making during surgery.<br />
NIR Merge<br />
References:<br />
1. Ishizawa et al.; Cancer. 1;115(11):2491-504. (2009)
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Molecular imaging of resistance to EGFR tyrosine kinase inhibitors by 18F-FLT PET/CT and its<br />
reversal in non small cell lung cancer<br />
Zannetti A. (1) , Iommelli F. (1) , Lettieri A. (1) , Pirozzi G. (2) , Salvatore M. (3) , Del Vecchio S. (3) .<br />
(1) Institute of Biostructures and Bioimages, National Research Council, Naples, Italy<br />
(2) Department of Experimental Oncology, National Cancer Institute, Naples, Italy<br />
(3) Institute of Biostructures and Bioimages, National Research Council; Department of Biomorphological and Functional Sciences, University of Naples “Federico II”, Naples, Italy<br />
antonella.zannetti@ibb.cnr.it<br />
Introduction: Multiple molecular mechanisms<br />
may underlie the resistance to EGFR tyrosine kinase<br />
inhibitors (TKIs), including the occurrence<br />
of secondary mutations such as T790M in the kinase<br />
domain of EGFR, redundant lateral signalling<br />
or alterations of apoptotic program mainly due to<br />
dysregulation of Bcl-2 family members. The aim<br />
of our study was to test whether 18F-Fluorothymidine<br />
(18F-FLT) could detect EGFR TKI refractory<br />
tumors and identify the mechanisms underlying<br />
such resistance so that specific therapeutic strategies<br />
can be adopted in patients with non-small cell<br />
lung cancer (NSCLC).<br />
Methods: EGFR TKI sensitive and resistant<br />
NSCLC cells were evaluated for drug-induced<br />
apoptosis and growth arrest. Cells were also<br />
tested for inhibition of downstream signalling<br />
and expression or drug-induced upregulation<br />
of Bcl-2 family members. Nude mice bearing<br />
sensitive and resistant NSCLC were i.v. injected<br />
with 7.4 MBq of 18F-FLT and then subjected to<br />
microPET/CT (eXplore Vista Pre-Clinical PET<br />
Scanner GE Healthcare) before and after treatment<br />
with reversible or irreversible EGFR TKIs.<br />
Results: We found that NSCLC bearing T790M<br />
mutations showed a persistent high uptake<br />
of 18 F-FLT after treatment with reversible inhibitors<br />
and lack of growth arrest. Treatment<br />
of the same animals with irreversible inhibitors<br />
caused a reduction of 18F-FLT uptake in<br />
tumors indicating the reversal of T790M mutation-dependent<br />
resistance. Conversely, NSCLC<br />
cells that were resistant due to dysregulation of<br />
Bcl-2 family members became sensitive to EGFR<br />
TKIs when treatment included Bcl-2 inhibitors.<br />
Conclusions: Resistance to EGFR TKI may<br />
be caused by multiple mechanisms. Molecular<br />
imaging with 18F-FLT may contribute to the<br />
selection of patients that may benefit from<br />
treatment with irreversible EGFR TKI inhibitors.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-030<br />
poStEr<br />
CANCER from BENCH to BEDSIDE
P-031<br />
144<br />
WarSaW, poland May 26 – 29, 2010<br />
Synchronised Cardiac and Lung CT in Rodents Using the Mobile CT Scanner LaTheta<br />
Glowalla A. .<br />
Zinsser Analytic GmbH, Frankfurt, Germany<br />
a.glowalla@zinsser-analytic.com<br />
Introduction: Historically, in vivo CT images of<br />
the chest region of small animals were blurred and<br />
streaked due to movement artefacts caused by the<br />
heartbeat and breathing during scanning. However,<br />
synchronised Cardiac and Lung CT in rodents has the<br />
enormous potential to contribute greatly to research in<br />
heart and lung diseases. Using the mobile CT Scanner<br />
LaTheta, scanning artefacts are greatly reduced. Here<br />
we present scanning results of the chest region of mice<br />
and discuss their relevance in pre-clinical research.<br />
Methods: Manufacturers standard protocols for synchronised<br />
CT scanning were used to scan the chest<br />
region of anaesthetised mice with respiratory rates<br />
below 75bpm, as below:<br />
Synchronised CT scanning results for A) heart in systole phase<br />
and B) lung in mouse<br />
A) Cardiac Sync. Scan (systole + diastole)<br />
- scan range axial: heart, 15mm length<br />
- scan time: 13.1min<br />
B) Respiratory Sync. Scan<br />
- scan range axial: heart, 10mm length<br />
- scan time: 4.5min<br />
X-ray tube voltage: 50kV at 0.5mA; Pixel resolution:<br />
48um; Slice thickness: 192um; Contrast media: Iopamiron<br />
300, 1.5ml/h in 30g mouse given 10min.<br />
before scanning.<br />
imaging life<br />
A<br />
CT images were constructed using methods for reduction<br />
of motion artefacts and with focus on soft<br />
tissues.<br />
Results: CT images of heart (diastole and systole<br />
phases) and lung were acquired and reconstructed<br />
without common blurring and streaking effects.<br />
Conclusions: Synchronised scanning modes with<br />
LaTheta LCT -200 produce high-resolution CT<br />
cross-sections of heart and lung in living mice<br />
within a short time period. Similar methods are<br />
applicable also for rats. Since no additional sensor<br />
hardware is necessary, handling of the animal is as<br />
simple as for standard CT.<br />
The potential for the detection of lung diseases such<br />
as pulmonary fibrosis, pulmonary emphysema and<br />
also lung tumours has already been validated by<br />
manufacturer. With this technology LaTheta LCT<br />
-200 can also contribute to the studies of cardiovascular<br />
diseases in rodents.<br />
Acknowledgement:<br />
1. Manufacturer of LaTheta(TM): Aloka Co., Ltd., 6-22-1<br />
Mure, Mitaka-shi, Tokyo, 181-8622, Japan<br />
2. Distributor: Zinsser Analytic GmbH, Eschborner<br />
Landstr. 135, 60489 Frankfurt am Main, Germany<br />
B
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Molecular imaging of neurovascular inflammation in a mouse model of focal cerebral<br />
ischemia using Ultra small Superparamagnetic Particles of Iron Oxide (USPIOs) targeted to<br />
vascular cell adhesion molecule-1 (VCAM-1)<br />
Montagne A. (1) , Gauberti M. (1) , Orset C. (1) , Macrez R. (1) , Rubio M. (1) , Raynaud J. S. (2) , Vivien D. (1) , Maubert E. (1) .<br />
(1) Inserm U919 UMR 6232 CNRS Ci-Naps, Caen, France<br />
(2) Experimental Imaging, MRI unit. Research Division. GUERBET, Roissy CdG, France<br />
amontagne@cyceron.fr<br />
Introduction: Among several mechanisms, brain<br />
inflammation is thought to have critical functions<br />
in lesion progression during acute and<br />
subacute stages of ischemic stroke. Accordingly,<br />
anti-inflammatory strategies are neuroprotective<br />
in preclinical studies [1]. However, to date, all<br />
clinical trials with anti-inflammatory agents have<br />
failed to improve clinical outcome in acute ischemic<br />
stroke patients. New tools for non-invasive<br />
monitoring of inflammation following stroke are<br />
needed to select patients who are more susceptible<br />
to benefit from anti-inflammatory treatment.<br />
Vascular cell adhesion molecule 1 (VCAM-1), an<br />
endothelial adhesion molecule, is overexpressed<br />
in the injured brain and is therefore thought to be<br />
a good target for the molecular imaging of inflammatory<br />
processes [2]. The aim of this study was<br />
to investigate the use of targeted USPIOs against<br />
VCAM-1 to follow neurovascular inflammation in<br />
a mouse model of in situ thromboembolic stroke<br />
with recombinant tissue-type plasminogen activator<br />
(rt-PA) induced reperfusion [3].<br />
Results: Our present data confirm an increase of<br />
vascular cell adhesion molecule-1 (VCAM-1) immunoreactivity<br />
(-ir) in the ischemic brain with<br />
a peak at 24 hours post-ischemia. Interestingly,<br />
V-CAM-1-ir was significantly increased in late<br />
rt-PA-thrombolyzed animals (4 hours after clot<br />
formation) compared to early (20 minutes) or<br />
unthrombolyzed mice. These data suggest that<br />
inflammation could be involved in the deleterious<br />
clinical outcome reported with late rt-PA<br />
mediated thrombolysis. Targeted USPIOs against<br />
VCAM-1 showed numerous signal voids in the ipsilateral<br />
side by 7T magnetic resonance imaging<br />
(MRI) at 24 hours post-ischemia and the use of<br />
an antibody directed against polyethylene-glycol<br />
(USPIOs coating) confirmed histologically our<br />
MRI analysis.<br />
Conclusions: Our data indicate that non invasive<br />
imaging of VCAM-1 with targeted USPIOs allows<br />
reliable imaging of brain inflammation after<br />
stroke. Such molecular MRI approaches could be<br />
used to evaluate inflammatory processes in stroke<br />
patients and thus to adapt therapy on an individual<br />
basis. Furthermore, molecular imaging of<br />
VCAM-1 could also provide valuable clinical information<br />
in other diseases involving inflammatory<br />
processes (atherosclerosis, multiple sclerosis …).<br />
References:<br />
1. Machado L et al; Stroke. 40;3028-3033 (2009).<br />
2. Hoyte L et al; J Cereb Blood Flow Metab.1-10 (2010).<br />
3. Orset C et al; Stroke. 38;2771-2778 (2007).<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-032<br />
poStEr<br />
MI in CARDIOVASCULAR DISEASE
WarSaW, poland May 26 – 29, 2010<br />
P-033 Scintigraphy with the use of 123 I-IL-2: a new promising tool for cardiovascular risk assessment<br />
in patients with high cardiovascular risk<br />
146<br />
Opalinska M. (1) , Hubalewska-Dydejczyk A. (1) , Stompor T. (2) , Krzanowski M. (3) , Mikołajczak R. (4) , Sowa-Staszczak A. (1) ,<br />
Karczmarczyk U. (5) , Glowa B. (1) , Kuśnierz-Cabala B. (6) , Pach D. (1) , Sułowicz W. (3) .<br />
(1) Nuclear Medicine Unit, Department of Endocrinology, Jagiellonian University Medical School, Krakow, Poland (2) Chair and Department of Nephrology,<br />
Hypertesiology and Internal Medicine, University of Warmia and Mazury , Olsztyn, Poland (3) Chair and Department of Nephrology, Jagiellonian University<br />
Medical School, Krakow, Poland (4) Radioisotope Center POLATOM, Otwock-Swierk, Poland (5) Departament of Radiopharmaceuticals, National Medicines<br />
Institute, Warsaw, Poland (6) Chair of Clinical Biochemistry, Jagiellonian University Medical School, Krakow, Poland<br />
mkal@vp.pl<br />
Introduction: Cardiovascular diseases are the<br />
main cause of deaths in general population<br />
(0,28%/year) whereas in selected population like<br />
in end-stage renal disease patients, mortality<br />
reaches even 20%. More than half of the cardiovascular<br />
events occur among the patients without<br />
any previous symptoms of cardiovascular disease,<br />
when atherosclerotic plaques obliterate less than<br />
50% of arterial lumen.<br />
The majority of widely available methods of cardiovascular<br />
risk estimation are based on arterial<br />
lumen assessment, estimation of atherosclerotic<br />
plaque size or on intima-media complex measurements.<br />
It means that those methods may by imprecise<br />
in the identification of plaques of the highest<br />
risk of rupture. For that reason, the methods<br />
which enable the visualization and estimation of<br />
the intensity of inflammatory process within atherosclerotic<br />
lesions, seem to play the most promising<br />
diagnostic role.<br />
The histopathological studies of the atherosclerotic<br />
plaque have revealed that activated lymphocytes<br />
T, which contain IL-2 receptors on their surfaces,<br />
comprise at least 20 % of inflammatory cells in unstable<br />
plaques. Those receptors can be identified<br />
with the use of scintigraphy with labeled IL-2.<br />
Methods: 10 patients (5 women, 5 men, aged 62,4<br />
± 10,4), with the highest cardiovascular risk, were<br />
chosen from 67 peritoneal dialysis cohort patients.<br />
All of them underwent 123 I-IL2 scintigraphy, coronary<br />
calcium scoring by CT and common carotid<br />
artery intima-media thickness assessment by USG.<br />
The levels of some atherogenic, inflammatory and<br />
calcium-phosphate indicators were measured. Target/non-target<br />
ratio of 123 I-IL-2 uptake in atherosclerotic<br />
plaque confirmed by carotid artery USG<br />
with IMT, calcium score result and concentration<br />
measured agents were compared.<br />
Results: In the performed scintigraphies increased<br />
focal 123 I-IL-2 uptake in 16/16 (100%) atherosclerotic<br />
plaques previously visualized by neck ultrasound<br />
was detected. Mean T/nT ratio of focal 123 I-<br />
imaging life<br />
IL-2 uptake within atherosclerotic plaques was<br />
3,15 ± 0,54 (median 3,22, range 2,0 – 3,6). The<br />
levels of the inflammatory and atherogenic factors<br />
and IMT (mean 0,975 ± 0,337 mm) were increased<br />
in the majority of patients. High positive correlation<br />
between 123I-IL-2 uptake within atherosclerotic<br />
plaques and IMT in corresponding artery<br />
was observed (R = 0,92, p = 0,01). Significantly<br />
higher 123 I-IL-2 uptake on scintigraphy in patients<br />
who developed cardiovascular event during observation<br />
period (average 36 months), compared<br />
to patients without cardiovascular event, was revealed<br />
(3,45 ± 0,22 vs 2,91 ± 0,54, p = 0,046). No<br />
statistically significant association was found between<br />
123 I-IL-2 uptake and the levels of measured<br />
agents, calcium score or classical cardiovascular<br />
risk factors.<br />
Conclusions: Scintigraphy with the use of labeled<br />
123 I-IL-2 enables the visualization of inflamed<br />
atherosclerotic (vulnerable) plaque within common<br />
carotid arteries in end-stage renal disease<br />
patients.<br />
Quantitative results of the carotid arteries scintigraphy<br />
with 123 I-IL-2 correlate with the results of<br />
IMT and the risk of cardiovascular event during 3<br />
years of follow-up.<br />
Acknowledgement: This work is supported by the<br />
Polish Committee for Scientific Research (KBN)<br />
within Research Project 2 P05B 003 28<br />
References:<br />
1. Annovazzi A et al; 99mTc-interleukin-2 scintgraphy for<br />
the in vivo imaging of vulnerable atheroslerotic plaque.<br />
Eur J Nucl Med Mol Imaging 2006; 33: 117 – 126.<br />
2. Buyukhatipoglu H et al; Inflammation as a risk factor<br />
for carotid intimal-medial thickening, a measure of<br />
subclinical atherosclerosis in haemodialysis patients:<br />
the role of chlamydia and cytomegalovirus infection.<br />
Nephrology 2007; 12: 25 – 32.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
MEMRI-DTI study of focal transient ischemia in immature rat brain<br />
Dupont D. , Bogaert-Buchmann A. , Sebrie C. , Gillet B. .<br />
IR4M , UMR 8081 CNRS-Univ. Paris-Sud, ORSAY, France<br />
damien.dupont1@u-psud.fr<br />
Introduction: The aim of the study was to investigate<br />
anatomo-functional changes in immature rat brain<br />
after focal transient cerebral ischemia occurred<br />
when they were 7-day-old. The MRI study was carried<br />
out 14 days after ischemia by serial MEMRI<br />
combined with DTI.<br />
Methods: Focal ischemia was induced in P7 rats as<br />
previously described [1], and the size of the lesion<br />
was pointed out by DWI 3h after ischemia. MRI<br />
studies were carried out at 7T on P21 rats (n=5), 14<br />
days after focal transient ischemia and compared to<br />
normal P21 rats (n=5). DTI sequence used was DTI-<br />
EPI (2 b-values=500/1000s/mm2; 30 directions;<br />
resolution=0.156*0.156*1 mm3). For the MEMRI<br />
experiments, 160nl of a 50mM isotonic manganese<br />
chloride aqueous solution (pH=7.3) was injected<br />
in S1 at 1.5mm below the dura, at a rate of 20nl/<br />
min. T1-weighted experiments were achieved at 3,<br />
5, 7 and 24h post-injection, using 3D MP-RAGE<br />
sequence (resolution=0.156*0.156*0.5mm3; TR/<br />
TE=15/4.5ms, α=20°; Ti=1s). The manganese containing<br />
voxels were defined as hyper intense voxels<br />
and selected as those with a significant higher signal<br />
(p
148<br />
WarSaW, poland May 26 – 29, 2010<br />
P-035 A clinically relevant model of in situ embolic stroke in the anesthetized monkey (macaca<br />
mulatta): long-term electrophysiological and mri analyses<br />
Gauberti M. (1) , Guedin P. (1) , Etard O. (2) , Diependaele A.S. (2) , Chazalviel L. (3) , Lamberton F. (3) , Vivien D. (1) , Young A. (1) ,<br />
Agin V. (1) , Orset C. (1) .<br />
(1) INSERM, Caen, France<br />
(2) CHU Caen, France<br />
(3) CNRS, France<br />
gauberti@cyceron.fr<br />
Introduction: The lack of relevant stroke models in<br />
large animals is a limitation for the development of<br />
innovative therapeutic/diagnostic approaches. The<br />
aim of the present study was to develop an original<br />
and clinically relevant pre-clinical model of embolic<br />
stroke in the monkey.<br />
Methods: During full physiological and biochemical<br />
monitoring, six monkeys underwent enucleation,<br />
the right MCA was exposed and alpha-thrombin<br />
was injected into the MCA. The monkeys were subjected<br />
to somatosensory evoked potentials (SEPs)<br />
and MRI studies (T2, FLAIR, DWI, PWI and MRA)<br />
prior to, and following the acute (2 h) and chronic<br />
stages (24 h to 3 months) of stroke.<br />
imaging life<br />
Results: This feasibility study showed that, it is possible<br />
to induce ischemic lesions in the MCA territory<br />
of the monkey following the direct injection of<br />
thrombin into the lumen of the M1 segment of the<br />
MCA. This procedure leads to cortical or subcortical<br />
ischemic lesions and to a persistent impairment<br />
of somatosensory responses as evidenced by MRI<br />
and SEPs data, respectively.<br />
Conclusions: In situ induction of an endogenous fibrin<br />
clot together with the lack of mortality make<br />
this original model of stroke in large non-human<br />
primates, highly relevant to determine the effectiveness<br />
of drug administration including thrombolytic<br />
therapy and to validate new imaging procedures.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Automated radiosynthesis of [ 18 F]MPPF derivatives for imaging 5-HT 1A receptors<br />
Goblet D. (1) , Thonon D. (1) , Plenevaux A. (1) , Defraiteur C. (2) , Wouters L. (2) , Franci X. (2) , Luxen A. (1) .<br />
(1) University of Liege, Liege, Belgium<br />
Z2) GE Healthcare Diagnostic Imaging, Belgium<br />
david.goblet@ulg.ac.be<br />
Introduction: Dysfunction of the central serotoninergic<br />
system is implicated in numerous neurodegenerative<br />
disorders such as Alzheimer’s disease,<br />
dementia, depression, anxiety, schizophrenia, and<br />
Parkinson’s disease. 5-HT 1A receptors are involved<br />
in several physiological functions including sleep,<br />
mood, neurogenesis and learning [1]. Consequently,<br />
there have been huge efforts to find ligands for this<br />
receptor. [ 11 C]WAY-100635 is a high affinity radioligand<br />
used for quantifying 5-HT 1A receptors with<br />
positron emission tomography. An 18 F-labeled radioligand<br />
would be advantageous because of higher<br />
specific activity and physical/nuclear properties<br />
(t 1/2 = 109 min, 97% of positron decay and positron<br />
energy of 635 keV maximum). [ 18 F]MPPF, a selective<br />
5-HT 1A antagonist derived from WAY-100635,<br />
is currently one of the most successful PET ligands<br />
used for 5-HT 1A receptor imaging [2]. However the<br />
affinity is lower than WAY-100635 and the amount<br />
of [ 18 F]MPPF reaching the brain is relatively low,<br />
as MPPF is a substrate for P-glycoprotein [3].<br />
Methods: In order to improve the brain uptake of<br />
the radiotracer, a desmethylated analog has been<br />
developed in our lab and preliminary in vitro<br />
studies show positive results [4]. Nevertheless,<br />
the radiosynthesis takes place in two steps, as the<br />
removal of a protecting group is needed. A one<br />
step procedure with a MPPF derivative could be<br />
of very great interest. We have synthesized many<br />
MPPF derivatives in our lab (modification on the<br />
phenylpiperazine moiety) and developed an automated<br />
radiosynthesis procedure for the production<br />
of these radiotracers. [ 18 F]MPPF was chosen<br />
as the model compound. We used a GE Healthcare<br />
FASTlab TM module and made modifications to the<br />
[ 18 F]FDG synthesis sequence and cassette. [ 18 F]<br />
MPPF was synthesized by coupling of [ 18 F]FBA<br />
with the corresponding amine. After coupling, the<br />
crude solution was diluted with water and passed<br />
through a tC 18 cartridge for prepurification. After<br />
elution, the [ 18 F]MPPF was purified by semi-preparative<br />
HPLC.<br />
Results: Total synthesis time, including purification<br />
was approximately 100 min. [ 18 F]FBA and [ 18 F]MPPF<br />
were obtained at a corrected yield of 60% (n=20)<br />
and 45% (n=5) respectively. The radiochemical purity,<br />
checked by radio-TLC and UPLC, was >95%.<br />
Conclusions: We have developed an automated<br />
method for [ 18 F]MPPF (and derivatives) production<br />
using a commercial synthesizer (FASTlab TM<br />
from GE Healthcare) and a conventional HPLC<br />
system resulting in good yields and high (radio)<br />
chemical purity. By simply switching the vial containing<br />
the modified amine, an 18 F-labeled MPPF<br />
derivative could be obtained. Radiosynthesis is<br />
still under optimization and the radiotracers<br />
synthesized need to be tested as suitable 5-HT 1A<br />
radioligands.<br />
Acknowledgement: This work was supported by<br />
the Fondation Rahier of the University of Liege.<br />
This work was supported by a GE Healthcare Diagnostic<br />
Imaging grant.<br />
References:<br />
1. Filip M., Bader M. et Al, Pharmacol Rep. 2009 Sep-Oct;<br />
61(5):761-77<br />
2. Aznavour N, Zimmer L. Et Al, Neuropharmacology.<br />
2007 Mar; 52(3):695-707<br />
3. Laćan G., Plenevaux A. et Al, Eur J Nucl Med Mol<br />
Imaging. 2008 Dec;35(12):2256-66<br />
4. Defraiteur C., Plenevaux A. et Al., Br J Pharmacol. 2007<br />
Nov; 152(6):952-8<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-036<br />
poStEr<br />
NEUROIMAGING from BENCH to BEDSIDE
P-037<br />
150<br />
WarSaW, poland May 26 – 29, 2010<br />
The vitamine E analogue CR6 protects against the long-term microstructure damage induced<br />
by MCA occlusion: a longitudinal Diffusion Tensor Imaging study<br />
Justicia C. (1) , Soria G. (1) , Tudela R. (2) , Van Der Linden A. (3) , Messeguer A. (4) , Planas A. (5) .<br />
(1) Investigaciones Científicas (CSIC), Institut d‘Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain<br />
(2) CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Group of Biomedical Imaging of the University of Barcelona, Spain<br />
(3) University of Antwerp, Antwerp, Belgium<br />
(4) Institut de Química Avançada de Catalunya (IQAC), CSIC, ,Spain<br />
(5) Institut d‘Investigacions Biomèdiques de Barcelona (IIBB)-Consejo Superior de Investigaciones Científicas (CSIC), Institut d‘Investigacions Biomèdiques<br />
August Pi i Sunyer (IDIBAPS), Spain<br />
cjmfat@iibb.csic.es<br />
Introduction: Oxidative and nitrosative stress are<br />
targets for intervention after ischemia/reperfusion.<br />
CR-6 is a synthetic analogue of vitamin-E, with the<br />
additional capacity to scavenge nitrogen-reactive<br />
species. Recently it has been demonstrated that<br />
CR-6 exerts a protective action against cerebral ischemia/reperfusion<br />
injury. The aim of this study was<br />
to investigate whether CR-6 can protect the brain<br />
microstructure after brain ischemia as assessed by<br />
longitudinal Diffusion Tensor Imaging (DTI).<br />
Methods: Sprague–Dawley rats had the middle<br />
cerebral artery occluded for 90 mins to induce brain<br />
ischemia. CR-6 (100 mg/kg) or vehicle (oliva oil)<br />
was orally administered at 2 and 8 h after ischemia<br />
onset. Longitudinal MRI scans were performed under<br />
isofluorane anaesthesia in a BioSpec 70/30 horizontal<br />
animal scanner (Bruker BioSpin, Ettlingen,<br />
Germany), equipped with a 12 cm inner diameter<br />
actively shielded gradient system (400 mT/m). Receiver<br />
coil was a phased-array surface coil for rat<br />
brain. Animals were scanned before surgery and<br />
1, 3 and 5 weeks later. The lesion was monitored<br />
by T2 mapping of coronal slices acquired with<br />
a MSME sequence by applying 16 different echo<br />
times (TE), repetition time (TR) = 4764 ms, Field of<br />
view (FOV) = 40 x 40 x 21 mm3, matrix size = 256<br />
x 256 x 21 pixels, resulting in a spatial resolution of<br />
0.156 x 0.156 mm in 1.00 mm slice thickness. DTI<br />
images were acquired by using a EPI DTI sequence<br />
applying TR = 3800 ms, TE = 30.85 ms, 4 segments,<br />
b-value = 1000, 30 different diffusion directions, 5<br />
A0 images, slice thickness = 1 mm, number of slices<br />
= 14, FOV = 2.0 x 2.0 x 1.4 mm3, matrix size = 96<br />
x 96 x 14 pixels, resulting in a spatial resolution of<br />
0.21 × 0.21 mm in 1 mm slice thickness. T2 maps<br />
were analysed using ImageJ. DTI maps of the tensor<br />
diffusivities, fractional anisotropy (FA), apparent<br />
diffusion coefficient (ADC), axial diffusivity (λ =<br />
λ1) and radial diffusivity (λ = [λ2+ λ3/2]), were<br />
calculated using Paravision 5.0 software (Bruker<br />
Biospin, Etlingen, Germany) and custom programs<br />
written in Matlab (The MathWorks, Inc., Natick,<br />
MA, USA). ROIs were individually drawn for each<br />
imaging life<br />
subject and hemisphere, by an experienced neurobiologist<br />
blinded to the treatments, overlaying the<br />
MRI images with the digital Paxinos and Watson<br />
rat brain atlas.<br />
Results: DTI diffusion indices, particularly axial and<br />
radial diffusivities, demonstrated that microstructure<br />
was better preserved after brain ischemia in<br />
CR6-treated animals than in animals receiving the<br />
vehicle. The latter showed a significant increase of<br />
MD, axial and radial diffusivities in the ipsilateral<br />
anteroventral thalamus, caudate putamen, globus<br />
pallidus and internal capsula 3 and 5 weeks after<br />
ischemia versus pre-scan. However, CR6 treated<br />
animals did not show such increase of DTI indexes<br />
in any of the ROIs analysed revealing preserved microstructure<br />
of the brain tissue.<br />
Conclusions: This work demonstrates that transient<br />
cerebral ischemia induces long-term microstructure<br />
alterations of brain tissue that are detected by DTI<br />
magnetic resonance imaging technique, and that the<br />
vitamin-E analogue CR6 attenuates these alterations.<br />
Acknowledgement: S and RT are supported by CSIC<br />
(JaeDoc) and CIBER-BBN, respectively. We acknowledge<br />
the European Erasmus program supporting<br />
Sofie de Prins and Stephan Cools that helped in this<br />
study. Work supported by national grants (SAF2008-<br />
04515-C02-01, FIS PI081880), European Network<br />
of Excellence DiMI (LSHB-CT-2005-512146), and<br />
FP7/2007-2013 project (grant agreement n°201024).
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Design and synthesis of fluorescent probes for serotonin 5-HT1A receptors<br />
Leopoldo M. (1) , Lacivita E. (1) , Berardi F. (1) , Perrone R. (1) , Jafurulla M. (2) , Saxena R. (2) , Rangaraj N. (2) , Chattopadhyay A. (2) .<br />
(1) Università degli studi di Bari “A. Moro”, Bari, Italy<br />
(2) Council of Scientific and Industrial Research, Hyderabad, India<br />
leopoldo@farmchim.uniba.it<br />
Introduction: The serotonin1A<br />
receptor subtype (5-HT1A)<br />
OCH3 belongs to the large family of<br />
5-HT receptors that comprises<br />
at least 14 receptor subtypes.<br />
5-HT1A receptor is likely the<br />
most extensively studied serotonin<br />
receptor. The 5-HT1A<br />
receptor has been initially<br />
N<br />
N<br />
implicated in anxiety and de-<br />
O<br />
pression. Recent studies have<br />
O<br />
evidenced its implication in<br />
neuroprotection, cognitive<br />
N<br />
impairment, and pain [1].<br />
Many information are avail-<br />
1<br />
able about the molecular pharmacology of 5-HT1A<br />
receptor. However, the study of 5-HT1A pharmacology<br />
at the single cell and single molecule level<br />
by fluorescence-based techniques has not been possible<br />
due to the lack of an effective 5-HT1A fluorescent<br />
ligands. We here describe design, synthesis<br />
and preliminar pharmacological evaluation of two<br />
fluorescent probes for 5-HT1A receptor.<br />
Methods: The new fluorescent probes have been<br />
designed following a classic approach [2]: a pharmacophore<br />
moiety, selected from the literature, has<br />
been conjugated through a linker to a fluorescent<br />
dye. One red-emitting and one near infrared dye<br />
were selected because such excitation wavelengths<br />
cause reduced light scattering and do not cause cell<br />
damage. The synthesis and purification of the target<br />
compounds was accomplished by standard methods.<br />
The compounds 1 and 2 underwent binding assays to<br />
test their ability to displace [3H]-8-OH-DPAT from<br />
5-HT1A receptors overexpressed in HEK-298 cell<br />
membranes. The fluorescent ligand 1 was evaluated<br />
in visualization experiments of 5-HT1A receptor on<br />
CHO cells by confocal laser scanning microscopy.<br />
Results: Compounds were obtained in good yields<br />
and in good quantities to allow further biological<br />
studies. Both compounds 1 and 2 possessed good<br />
5-HT1A receptor affinities (Ki = 35 nM and 68.9<br />
O<br />
N +<br />
Br- O<br />
OCH 3<br />
N N +<br />
Cl- NaO 3S SO 3Na<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
N<br />
N<br />
nM, respectively). The target compounds displayed<br />
the same fluorescent properties as the corresponding<br />
fluorophores. In visualization experiments by confocal<br />
laser scanning microscopy compound 1 was able<br />
to label 5-HT1A receptors on CHO cells overexpressing<br />
the receptor. This interaction revealed to be specific<br />
since the compound was unable to bind wildtype<br />
CHO cells and also because 5-HT significantly<br />
displaced competitively 1 from the binding site.<br />
Conclusions: This study indicates that fluorescent<br />
probes for 5-HT1A receptor can be successfully<br />
designed on the basis of knowledge of structure-<br />
activity relationships of 5-HT1A receptor agents.<br />
The 5-HT1A fluorescent ligand that have been identified<br />
possess suitable characteristic for visualization<br />
of 5-HT1A receptors.<br />
References:<br />
1. Lacivita E et al; Curr Top Med Chem. 8:1024-1034<br />
(2008)<br />
2. Leopoldo M et al: Drug Disc Today 14:706-712 (2009)<br />
H<br />
N<br />
2<br />
S<br />
O<br />
P-038<br />
poStEr<br />
NEUROIMAGING from BENCH to BEDSIDE
152<br />
WarSaW, poland May 26 – 29, 2010<br />
P-039 Comparative evaluation of cerebral blood flow in a rat model of cerebral ischemia using 15 O-<br />
H 2 0 positron emission tomography and 99m Tc-HMPAO single-photon emission tomography<br />
Martin A. (1) , Boisgard R. (1) , Gervais P. (2) , Thézé B. (1) , Vuillemard C. (2) , Tavitian B. (1) .<br />
(1) CEA, DSV, I²BM, SHFJ, Laboratoire Imagerie Moléculaire Expérimentale; INSERM U803, Orsay, France<br />
(2) CEA, DSV, I²BM, SHFJ, France<br />
abraham.martin-munoz@cea.fr<br />
Introduction: Ischemic stroke occurs when cerebral<br />
blood flow is interrupted in a specific region of the<br />
brain. After ischemic stroke, cerebral parenchyma<br />
suffers perfusion changes over time which have been<br />
correlated with biological processes as compensatory<br />
growth of blood vessels to supply metabolic demand<br />
[1], underlying inflammation [2] and angiogenesis<br />
[3].Thereafter, a precise understanding of the cerebral<br />
blood flow evolution after ischemic stroke is essential<br />
for the comprehension of cerebral ischemia physiopathology.<br />
Here, a comparative imaging evaluation<br />
of cerebral blood flow using PET and SPECT during<br />
and after cerebral ischemia was performed in rats.<br />
Methods: [ 15 O] H20 and [ 99m Tc] HMPAO were used<br />
in a rat model of 2 hours transient middle cerebral<br />
artery occlusion (tMCAO) during occlusion, during<br />
early reperfusion and later on at 1, 2, 4 and 7 days.<br />
The tissue was analized ex vivo using histological<br />
(HE) and immunohistochemistry (CD31).<br />
Results: In vivo PET imaging showed a significant<br />
decrease of the ipsilateral or lesioned area versus<br />
contralateral ratios during the occlusion in<br />
relation to control, days 4 and 7 after reperfusion<br />
(P
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Comparison of dopamine transporter density in Parkinson’s disease patients with and<br />
without autonomic dysfunction using F-18 FP-CIT PET/CT<br />
Park E. , Park K.W. , Hwang Y.M. , Oh S.Y. , Choe J.G. .<br />
Korea University Anam Hospital, Korea University College of Medicine, Seoul<br />
angela_ekpark@yahoo.co.kr<br />
Introduction: Autonomic dysfunction is a common<br />
non-motor feature of Parkinson’s disease (PD)<br />
which can severely impair the life quality of PD patients.<br />
However, evaluation of striatal presynaptic<br />
dopaminergic function with SPECT or PET imaging<br />
using various radiotracers has been limited in<br />
the differential diagnosis of parkinsonism and in<br />
the severity assessment of Parkinson’s disease. We<br />
compared the dopamine transporter (DAT) density<br />
of PD patients with and without autonomic dysfunction<br />
using F-18 FP-CIT PET/CT, which has been<br />
approved recently by Korean FDA for clinical uses.<br />
Methods: Twenty clinically diagnosed PD patients<br />
(mean age 68.6±8.1 y, M:F=5:15) and 8 age-matched<br />
healthy normal controls (65.1±4.7 y, M:F=2:6) were<br />
studied with F-18-FP-CIT PET/CT. Among 20 PD<br />
patients, 10 had no significant autonomic dysfunction<br />
(PD-AD) while the other 10 had autonomic dysfunction<br />
(PD+AD). F-18-FP-CIT PET/CT images were<br />
obtained 120 minutes after injection of 185 MBq<br />
F-18-FP-CIT. Semi-quantitative analysis was performed<br />
using manual ROI method. A DAT parameter<br />
V3”, a measure directly related to the density of DAT,<br />
was calculated in striatal regions as (striatal ROI–<br />
cerebellar ROI mean radioactivity)/cerebellar ROI<br />
mean radioactivity on F-18-FP-CIT PET/CT images.<br />
Results: PD patients demonstrated significantly<br />
lower DAT V3” in the striatum (2.29±0.69), caudate<br />
nucleus (2.56±0.67), and putamen (1.99±0.77)<br />
than those of healthy normal controls (4.02±0.55,<br />
3.88±0.54 and 4.16±0.61, respectively) (p
154<br />
WarSaW, poland May 26 – 29, 2010<br />
P-041 Synthesis of tosylate and mesylate precursors for one-step radiosynthesis<br />
of [ 18 F]FECNT<br />
Pijarowska J. , Jaron A. , Mikolajczak R. .<br />
Insitute of Atomic Energy POLATOM, Otwock, Poland<br />
j.pijarowska@polatom.pl<br />
Introduction: Dopamine transporter (DAT) is critical<br />
to the regulation of dopamine neurotransmission and<br />
is decreased by Parkinson’s disease. Several tropane<br />
analogues of cocaine have been developed and used in<br />
PET studies to evaluate the physiology and pharmacology<br />
of the dopamine transporter (DAT). However,<br />
low selectivity and unfavourable kinetics of most of the<br />
compounds limit their use in quantitive PET studies.<br />
The fluorine-18 labelled ligand 2-beta-carbomethoxy-3-<br />
-beta-(4-chlorophenyl)-8-(2-fluoroethyl)-nortropane<br />
(FECNT) has promising properties and appears to be<br />
an excellent imaiging PET agent. The development of<br />
automated [18F]FECNT synthesis system is a crucial<br />
because high amounts of radioactivity and availability<br />
of radiotracer for multiple PET study is necessary. A<br />
semi-automated synthesis of [18F]FECNT based on<br />
the two-steps has been developed at 16% decay corrected<br />
yield [1]. We hypothesize that N-[18F]fluoroalkylnortropane<br />
analogs could be synthesized at hight<br />
yield by direct [18F]fluorination from appropriate precursors:<br />
N-tosylate and N-mesylate derivatives. This<br />
compounds and non-radioactive FECNT as a standard<br />
in order to characterize [ 18 F]FECNT on HPLC are<br />
synthesized in accordance with requirements for Investigational<br />
Medicinal Product (IMP).<br />
Methods: The synthetic approach which we adopted<br />
based upon the published procedures [2,3]<br />
with some modifications. The essential feature<br />
of this route was the reaction of Grignard reagent<br />
with the critical intermediate anhydroecognine<br />
methyl ester, which was obtained from<br />
cocaine hydrochloride by hydrolysis in HCl and<br />
esterification with methanol. 3-β-substituted tropane<br />
derivative obtained in Grignard reaction<br />
was subjected to demethylation, as described [4].<br />
Non-radioactive FECNT was prepared by direct<br />
N-(2- fluoroethyl) alkylation of analytically pure<br />
3-β-substituted nortropane precursor. The alkylating<br />
agent 2-fluoroethyl brosylate was prepared<br />
from 2-fluoroethanol and 4-bromobenzenesulfonoyl<br />
chloride. The crude product was purified<br />
by recrystallization. The tosylate (TsOECNT)<br />
and mesylate (MsOECNT) precursors were<br />
imaging life<br />
synthetised from 3-β-substituted nortropane precursor<br />
in two steps by N-hydroxyethylation with<br />
2-bromoethanol and subsequent tosylation of the<br />
obtained alcohol with appropriate anhydride. The<br />
crude products were purified by preparative HPLC.<br />
Results: In the present study we investigated and<br />
optimized synthetic route of non-radioactive<br />
FECNT, tosylate and mesylate analogs. Overall<br />
production yield were 74% for FECNT, 58%<br />
for TsOECNT and 81% for MsOECNT synthesis<br />
and a purity of this products were over<br />
99% measured by the analytical HPLC(UV, 220<br />
nm). The 1 H NMR and MS analysis confirmed<br />
a structure of this compounds.<br />
Conclusions: The synthesis method of tosylate<br />
and mesylate precursors were established and an<br />
automated radiosynthesis of [18F]FECNT will be<br />
evaluated. We expect that the new one–step method<br />
will provide a facile and reliable procedure<br />
for [18F]FECNT preparation in routine clinical<br />
applications.<br />
Acknowledgement: This work is supported by DiMI,<br />
LSHB-CT-2005-512146<br />
References:<br />
1. Voll R.J. et al. Appl. Rad. Isot. 2005 (63) 353<br />
2. Zirkle C. L et al. J. Org. Chem. 1962 (34) 1269<br />
3. Clarke R. L. et al. J. Med. Chem. 1973 (16) 1260<br />
4. Meegalla S. K. et al. J. Med. Chem. 1997 (40) 9
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Sex differences inDopamine D 2 Receptor Occupancy in the Amygdala using AMPT with PET<br />
and [ 18 F]fallypride<br />
Riccardi P. (1) , Park S. (2) , Carroll X. (1) , Anderson S. (3) , Benoit D. (2) , Li R. (2) , Bauernfeind A. (4) , Schmidt D. (2) .<br />
(1) Mercer University, Macon, United States<br />
(2) Vanderbilt university, United States<br />
(3) Georgia State University ,United States<br />
(4) George Washington university, United States<br />
riccardip@aol.com<br />
Introduction: Dopaminergic neurotransmission<br />
plays an important role in many psychiatric disorders<br />
which show sex differences in incidence, clinical<br />
course, and treatment outcomes. We examined<br />
whether PET studies using [ 18 F]fallypride performed<br />
prior to and following alphamethylparatyrosine<br />
(AMPT) administration could be used to estimate<br />
sex differences in baseline Dopamine D 2 receptors<br />
(DAD2r) occupancy.<br />
Methods: Four females and four males normal subjects<br />
were recruited with no history of psychiatric,<br />
neurological or medical illness. PET studies were<br />
performed using a GE Discovery LS PET scanner<br />
with 3-D emission acquisition and transmission<br />
attenuation correction. [ 18 F]fallypride PET scans<br />
(5.0 mCi, specific activity > 2,000 Ci/mmol) were<br />
performed prior to and following AMPT administration<br />
over 26 hours. Serial scans were obtained<br />
for 3.5 hours. Blood samples for HVA plasma levels<br />
were collected.<br />
Results: Analysis of variance of the ROI data with<br />
treatment status, region, sex and laterality as factors<br />
revealed significant effects of sex in the right<br />
(F = 9.403, P = 0.002) and left amygdala (F = 3.486,<br />
P = 0.05). No difference in b.p was found in the<br />
left amygdala at baseline, but significant differences<br />
were determined at baseline and post treatment in<br />
the right amygdala (p=0.005 and p=0.002) and post<br />
treatment in the left amygdala (p=0.019) with females<br />
demonstrating lower levels of D 2 /D 3 receptors<br />
compare to males. Effect of treatment was observed<br />
in females in the left amygdala with a percentage of<br />
change of 6.7%.<br />
Conclusions: The amygdala has been shown to be<br />
functionally asymmetrical in animals and humans,<br />
is involved in stress and emotion processing, and is<br />
importantly modulated by dopamine. We report here<br />
for the first time a sex differences in the occupancy<br />
of DA D 2 r by dopamine in vivo in the amygdala. Previous<br />
AMPT administration and [18F]fallypride PET<br />
studies to assess the baseline occupancy of DAD 2r by<br />
endogenous dopamine in-vivo reported no significant<br />
effects of treatment in the amygdala when males and<br />
females were grouped together. The results of this<br />
study underscore the importance of considering sex<br />
differences in the context of DAD 2r availability.<br />
Acknowledgement: Funding for this reaserch<br />
was provided by a NIH grant entltled “PET imaging<br />
of Extrastriatal Dopamine levels” NIMH 5RO1<br />
MH6898-03<br />
References:<br />
1. Verhoeff NP, Kapur S, Hussey D et al (2001). A simple<br />
method to measure baseline occupancy of neostriatal<br />
dopamine D2 receptors by dopamine in vivo in healthy<br />
subjects. Neuropsychopharmacology 25; 213-223<br />
2. Riccardi P., Baldwin R, Salomon R., et al. (2008).<br />
Estimation of baseline Dopamine D2 receptor<br />
occupancy in Striatum and extrastriatal regions in<br />
humans with Positron emission tomography with<br />
[18F]fallypride.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-042<br />
poStEr<br />
NEUROIMAGING from BENCH to BEDSIDE
156<br />
WarSaW, poland May 26 – 29, 2010<br />
P-043 Manual versus automatic delineation of VOIs for analysis of nuclear medicine images<br />
Svarer C. (1) , Hammers A. (2) , Heckemann R. A. (2) , Knudsen G.M. (1) .<br />
(1) Neurobiology Research Unit, Rigshospitalet,, Copenhagen, Denmark<br />
(2) The Neurodis Foundation, Lyon, France<br />
csvarer@nru.dk<br />
Introduction: Quantification and analysis of nuclear<br />
medicine images is performed by visual inspection in<br />
most cases. More objective and less observer-dependent<br />
analysis often requires automatic identification<br />
of volumes of interest (VOIs) in the images. In this<br />
study we investigated the levels of precision achievable<br />
with manual delineation on high resolution MR<br />
images and compared them to the precision of a fully<br />
automatic method.<br />
Methods: The method described in Svarer et al(1) has<br />
been refined to handle neighborhood voxels in labeled<br />
template volumes using a maximum-probability algorithm.<br />
We applied it to 19 MR data sets, each with 67<br />
manually delineated VOIs(2). To test the precision of<br />
the automatic algorithm, we performed a leave-oneout<br />
cross-validation-comparison: using each data set<br />
in turn as the target, we automatically generated two<br />
independent VOI sets by randomly bisecting the template<br />
pool, leading to two independent segmentations<br />
of each target by nine atlases each, and calculated the<br />
average VOI voxel overlap (intersection divided by<br />
average labeled volume). To test the reproducibility/<br />
precision of the manually delineated VOI sets, a third<br />
VOI set was generated for each target using the entire<br />
template pool but itself, and its overlap with the<br />
manual VOI set were calculated.<br />
Results: The voxel overlap for the two automatically<br />
generated VOI sets was 88.3±5.2%, whereas the voxel<br />
overlap between the automatically generated and the<br />
manually delineated VOI set was 76.3±9.8%.<br />
Conclusions: Of the 24% non-overlap between manual<br />
and automatic methods approx. 12 percentage points<br />
may be attributable to variation in the automatic method<br />
using different VOI template sets whereas precision<br />
in manual delineation of the VOIs may largely underlie<br />
the other half of the difference between manual and<br />
automatically generated VOI sets. This variation will<br />
be removed using an automatic approach based on<br />
multiple template sets.<br />
Acknowledgement: Supported by The Lundbeck Foundation,<br />
Rigshospitalet, and the Danish Medical Research<br />
Council. These studies were funded in part by<br />
the EC - FP6-project DiMI, LSHB-CT-2005-512146.<br />
imaging life<br />
References:<br />
1. Svarer C, Madsen K, Hasselbalch SG, Pinborg LH,<br />
Haugbøl S, Frøkjaer VG, Holm S, Paulson OB, and<br />
Knudsen GM (2005) MR-based automatic delineation<br />
of volumes of interest in human brain PET images<br />
using probability maps. Neuroimage 24: 969-979.<br />
2. Hammers A, Allom R, Koepp MJ, Free SL, Myers R,<br />
Lemieux L, Mitchell TN, Brooks DJ, and Duncan JS<br />
(2003) Three-dimensional maximum probability atlas<br />
of the human brain, with particular reference to the<br />
temporal lobe. Hum Brain Mapp 19: 224-247.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
PET Amyloid and Tau Ligand [18F]FDDNP uptake in early Alzheimer disease<br />
Tauber C. (1) , Beaufils E. (1) , Kepe V. (2) , Vercouillie J. (1) , Venel Y. (1) , Baulieu J.L. (1) , Barrio J. (2) , Hommet C. (1) , Camus V. (1) ,<br />
Guilloteau D. (1) .<br />
(1) UMRS INSERM U930 - CNRS ERL3106 - University of Tours, France<br />
(2) Dpt of Molecular and Medical Pharmacology, D. Geffen School of Medecine, UCLA, United States<br />
clovis.tauber@univ-tours.fr<br />
Introduction: The PET tracer [18F]FDDNP specifically<br />
binds amyloid-beta plaques and tau neurofibrillary<br />
tangles, which are typical in the development<br />
of the Alzheimer disease (AD). We evaluated<br />
the feasibility of a non-invasive quantification of<br />
[18F]FDDNP to detect these proteins and discriminate<br />
early AD patients from healthy controls (HC).<br />
This abstract presents the preliminary results on the<br />
currently included cohort of 4 AD and 2 controls.<br />
Methods: All the potential subjects underwent Neuropsychological<br />
Assessment (MMSE, Trail Making<br />
Test, Semantic Fluency Task, Free and Cued<br />
Recall Test, 80 item Boston Naming Test). Patients<br />
meeting research criteria for AD and cognitively<br />
normal controls underwent PET imaging with<br />
2-(1-{6-[(2-[F-18]fluoroethyl) (methyl)amino]-2naphthyl}ethylidene)malononitrile<br />
(FDDNP) and<br />
[18F]FDG. All subjects underwent MR 3D axial<br />
T1 weighted imaging. FDDNP distribution volume<br />
ratios (DVR) parametric images were generated using<br />
Logan graphical analysis with the cerebellum<br />
grey matter as a reference region. Regions of interest<br />
(ROIs) were defined in the Posterior Cingulate,<br />
Parietal, Frontal and Temporal regions. The DVR<br />
scores were measured as the mean DVR values of<br />
each of these regions. A global score was calculated<br />
as the mean DVR scores of all these regions.<br />
Results: All the AD patients had positive FDDNP<br />
scans by visual inspection, while all the HC had negative<br />
scans. Global values of the FDDNP-PET binding<br />
were significantly higher (p
158<br />
WarSaW, poland May 26 – 29, 2010<br />
P-045 Cryogenic brain injury as a model of brain trauma: Use of GFAP-luc mice to assess GFAP<br />
expression as an indication of neural injury<br />
Van Beek E., Blankevoort V., Snoeks T., Kaijzel E., Löwik C.W.G.M. .<br />
Leiden University Medical Center, The Netherlands<br />
e.r.van_beek@lumc.nl<br />
Introduction: Applying a cryogenic lesion of the<br />
cerebral cortex provides a simple and highly reproducible<br />
model of brain trauma without entering the<br />
intracranial cavity. In the present study we assessed<br />
and mapped the sequence of events that occur following<br />
induction of a cryogenic brain lesion using<br />
transgenic glial fibrillary acidic protein (GFAP)-luc<br />
reporter expressing mice. In these mice, the GFAP<br />
reporter is inducible following injury to the CNS<br />
and this model provides an easy model feasible for<br />
the study of transcriptional regulation of the GFAP<br />
gene and indications of possible neural injury.<br />
Methods: A brain lesion was induced by placing a<br />
liquid nitrogen cooled cone shaped copper device<br />
with a tip diameter of 1 mm for 1 min. onto the skinfree<br />
surface of the cranium of the cerebral cortex of<br />
a mouse. At different time points after lesion induction<br />
GFAP-luc activity was measured, mice were injected<br />
with Evans blue and brains were stained with<br />
2,3,5-Triphenyltetrazolium chloride (TTC).<br />
Results: 24h after induction of the cryogenic lesion, BLI<br />
measurement showed that, at the lesion site, GFAP-luc<br />
expression was increased 2-3 times over control level<br />
and gradually returned to basal after 72h. Evaluation<br />
imaging life<br />
Gfap-luc expression (Relative Light Units)<br />
Control GF AP–luc<br />
Control<br />
GFAP-luc expression expression<br />
24h<br />
24h after after freeze freeze injury injury<br />
6.0E+06<br />
5.0E+06<br />
4.0E+06<br />
3.0E+06<br />
2.0E+06<br />
1.0E+06<br />
0.0E+00<br />
of tissue viability using TTC staining showed that 24h<br />
after lesion, the primary lesioned cortex appeared as<br />
an unstained white area (dead tissue), whereas, the<br />
rest of the brain appeared red (living tissue). Moreover,<br />
at the lesion site, i.v. injected Evans blue leaked<br />
into the brain tissue, indicative for disruption of the<br />
blood brain barrier. This was also visualised in intact<br />
isolated brains by Fluorescence Imaging (FLI).<br />
Conclusions: Cryogenic lesion in the GFAP-luc mouse<br />
model showed a transient induction of GFAP expression,<br />
indicative for astrocyte activation in reaction<br />
Base 1 Base 2 24h 48h 72h<br />
to neural injury. Brain injury was confirmed by TTC<br />
staining and leakage of Evans blue over the blood<br />
brain barrier. GFAP-luc mice provide an easy and convenient<br />
model to study cryogenic brain trauma.<br />
Acknowledgement: This project was supported by<br />
EU-FP7 ENCITE (HEALTH-F5-2008-201842) and<br />
Volkswagen Stiftung.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Plaque burden in the APPPS1 mouse picked up with diffusion kurtosis magnetic resonance<br />
imaging<br />
Vanhoutte G. , Geys R. , Pereson S. , Veraart J. , Van Broeckhoven C. , Kumar-Singh S. , Sijbers J. , Van Der Linden A. .<br />
University of Antwerp, Belgium<br />
greetje.vanhoutte@ua.ac.be<br />
Introduction:Transgenic mouse models are essential<br />
in understanding the pathogenic role of the<br />
β-amyloidogenic pathway in Alzheimer(AD).In vivo<br />
detection of the amyloid deposits in the brain would<br />
be beneficial in terms of diagnosis and therapy follow-up.Therefore<br />
we investigated the sensitivity of<br />
a new method, diffusion kurtosis imaging (DKI), to<br />
detect amyloid burden, a correlate for brain damage<br />
in AD patients and transgenic APP (swe) -PS1 (L166p)<br />
mice. The use of this model was carefully chosen<br />
for its effective amyloidosis in the brain without the<br />
occurrence of neurodegeneration, tau-pathology or<br />
behavioural changes.All mice of 17months manifested<br />
amyloid burden in all brain regions(1).Since<br />
previous studies could show different ex vivo patterns<br />
for mean kurtosis in an APPPS1 mouse model,<br />
we hypothesize that the microstructural changes in<br />
the brain, due to extracellular amyloid deposits,can<br />
be measured in vivo by DKI(2). We investigated the<br />
neocortical and hippocampal regions linked to the<br />
cognitive impairment in AD. Further studies will be<br />
conducted to determine the longitudinal effects.<br />
Methods:Experiments were conducted on a 9,4T<br />
MR system(Bruker Biospec, Ettlingen Germany).<br />
DKI scans were performed on APP (swe) -PS1 (L166p)<br />
mice(n=5) and control WT mice(n=5). The mice<br />
were anaesthetized with isoflurane and monitored to<br />
maintain physiological parameters. The DKI protocol<br />
included 7 b 0 -images and 30 gradient directions<br />
with 7 b-values (400 to 2800s/mm²) acquired with<br />
multi-slice 2-shot SE-EPI(TR/TE=7500/24ms,δ=5ms,<br />
Δ=12ms,acquisition=96*64, FOV=19,2*12.8mm²,<br />
slice thickness=0,40mm, NEX=4). Realignment,<br />
was carried out by the vision lab (Univ. Of Antwerp)<br />
and diffusion kurtosis tensor and diffusion tensor<br />
derived parametric maps were computed (Matlab).<br />
These include mean kurtosis (MK), radial kurtosis<br />
(RK), axial kurtosis (AK), fractional kurtosis anisotropy<br />
(KA), fractional anisotropy (FA), mean diffusion<br />
(MD), axial and radial diffusion (AD, RD)<br />
maps. Regions of interest (cortex and hippocampus)<br />
were chosen based on the AD pathology and delineated<br />
on grey values of FA, MD and magnitude maps<br />
in AMIRA (Mercury Computer systems, San Diego,<br />
USA). Differences of diffusion parameters between<br />
WT and APPPS1 mice were computed by means of<br />
the Mann-Withney non-parametric statistical test in<br />
SPSS 16.0 (SPSS Inc. Chicago, USA).<br />
Results: This is the first in vivo study on AD mouse<br />
models using DKI.Already with a small set of<br />
number of animals, we could detect differences according<br />
to genotype. MK(p
160<br />
WarSaW, poland May 26 – 29, 2010<br />
P-047 In vivo Imaging of Rat Glioma using the TSPO-ligand [ 18 F]DPA-714<br />
Winkeler A. (1) , Boisgard R. (1) , Dubois A. (1) , Awde A. (1) , Zheng J. (1) , Ciobanu L. (2) , Siquier-Pernet K. (1) , Jego B. (1) , Dollé F. (1) ,<br />
Tavitian B. (1) .<br />
(1) CEA\DSV\I2BM\SHFJ, Orsay, France<br />
(2) roSpinCEA\DSV\I2BM\NeuroSpin,France<br />
alexandra.winkeler@cea.fr<br />
Introduction: In the last years there has been an<br />
enormous increase in the development of radioligands<br />
targeted against the translocator protein<br />
TSPO (18 kDa). TSPO expression is nearly absent<br />
in the intact CNS parenchyma but increases rapidly<br />
upon inflammation in activated microglia and<br />
serves as a biomarker for imaging cerebral inflammation<br />
(1). In addition, TSPO has also been reported<br />
to be over-expressed in a number of cancer cell<br />
lines (2, 3) and human tumours including glioma<br />
(4). Here, we investigated the use of the PET-radioligand<br />
[ 18 F]DPA-714 (5) as new marker to image<br />
glioma in vivo.<br />
Methods: 9L rat glioma cells have been stereotactically<br />
implanted in the striatum of Fisher, Wistar and<br />
Sprague Dawley rats. Dynamic [ 18 F]DPA-714 PET<br />
imaging was performed 11-14 days after implantation.<br />
The injected dosed was 1.24 + 0.30 mCi (mean<br />
+ std). T2w-MRI and/or [ 11 C]Methionine PET were<br />
acquired prior to the [ 18 F]DPA-714 PET imaging<br />
session in order to monitor tumor growth. The [ 18 F]<br />
DPA-714 PET images were then co-registered to<br />
the corresponding MRI. For quantitative analysis<br />
a volume-of-interest (VOI) analysis was performed<br />
on both the kinetic and summed image data sets. In<br />
addition, the expression of TSPO 9L rat glioma cells<br />
was investigated using Western Blot.<br />
Results: 9L glioma tumors grown in Fisher (n=5),<br />
Wistar (n=4) and Sprague Dawley (n=6) rats were imaged<br />
by [ 18 F]DPA-714 PET. Tumors grown in Fisher<br />
and Wistar rats were also monitored by MRI. All rats<br />
showed significant [ 18 F]DPA-714 PET accumulation<br />
at the site of tumor implantation compared to the<br />
contralateral site. Tthe %ID/cc in Fisher, Wistar and<br />
Sprague Dawley rats is listed in the following table:<br />
imaging life<br />
control (mean+std) tumor (mean+std)<br />
Fisher 0.15 + 0.02% 0.49 + 0.05%<br />
Wistar 0.13 + 0.06% 0.35 + 0.09%<br />
Sprague Dawley 0.11 + 0.05% 0.26 + 0.06%<br />
TSPO expression was confirmed by Western Blot in<br />
9L cells in vitro and by immunohistochemistry ex vivo.<br />
Conclusions: This study demonstrated the feasibility<br />
of using the TSPO-radioligand [ 18 F]DPA-714 to<br />
characterize 9L glioma in vivo in different rat models<br />
with PET imaging. [ 18 F]DPA-714 therefore has<br />
the potential to become a promising radiotracer to<br />
image human glioma.<br />
Acknowledgement: This work has been supported<br />
by the 6th FW EU grant EMIL (LSHC-CT-2004-<br />
503569) and DiMI (LSHB-CT-2005-512146).<br />
References:<br />
1. Winkeler A, Boisgard R, Martin A, & Tavitian B (2009) J<br />
Nucl Med 51, 1-4.<br />
2. Hardwick M, Fertikh D, Culty M, Li H, Vidic B, &<br />
Papadopoulos V (1999) Cancer Res 59, 831-842.<br />
3. Starosta-Rubinstein S, Ciliax BJ, Penney JB, McKeever<br />
P, & Young AB (1987) Proc Natl Acad Sci U S A 84, 891-<br />
895.<br />
4. Black KL, Ikezaki K, Santori E, Becker DP, & Vinters HV<br />
(1990) Cancer 65, 93-97.<br />
5. Damont A, Hinnen F, Kuhnast B, Schollhorn-<br />
Peyronneau MA, James M, Luus C, Tavitian B, Kassiou<br />
M, & Dolle F (2008) Journal of Labelled Compounds &<br />
Radiopharmaceuticals 51, 286-292.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
A novel 19F MRI-based migration assay: application to primary human dendritic cells<br />
Bonetto F. (1) , Srinivas M. (1) , Weigelin B. (1) , Cruz Ricondo L.J. (1) , Heerschap A. (2) , Figdor C. (1) , De Vries I.J. (1) .<br />
(1) Nijmegen Center for Molecular Life Science, Radboud University Nijmegen Medical Centre, The Netherlands<br />
(2) Radboud University Nijmegen Medical Centre, Nijmegen, , Netherlands<br />
bonetto.fernando@gmail.com<br />
Introduction: The decisive role of dendritic cells<br />
(DCs) in inducing immunity formed the rationale<br />
for DC immunotherapy: DCs loaded with tumor<br />
antigens are injected into cancer patients to stimulate<br />
T cells to eradicate tumors. However, success<br />
in clinical trials has been limited mainly due to<br />
an inefficient migration rate post-vaccination. As<br />
DC migration can be affected by several factors, a<br />
suitable in vitro assay is required to reproduce in<br />
vivo conditions. Here we present a novel 19 F MRIbased,<br />
quantitative assay to measure cell migration<br />
in varying chemokine environments in a 3D<br />
scaffold specially designed to mimic biological tissue.<br />
We obtained migration rates comparable with<br />
clinical results (using scintigraphy for quantification)<br />
[1] showing the potential application of this<br />
assay to simulate different in vivo migration conditions.<br />
Moreover, we observed that the percentage<br />
of migrating cells strongly depends on the initial<br />
cell density.<br />
Methods: Primary human DCs were cultured, as<br />
per standard protocols for DC vaccination trials<br />
[2]. For 19 F-labeling, a biocompatible polymer<br />
currently in clinical use, poly(D,L-lactide-co-glycolide)<br />
(PLGA) was used to entrap a perfluorcarbon<br />
tracer. After maturation, cells were harvested,<br />
and viability and maturation marker expression<br />
determined. The presence of label within the cells<br />
was checked by optical microscopy. For migration<br />
assays, a variable number of cells were embedded<br />
in a fixed volume of a scaffold matrix (cell layer)<br />
and a chemokine gradient was created above it. A<br />
chemokine-free gel set below the cell layer served<br />
as a control. The sample was placed vertically in<br />
the MRI scanner and only upward migration was<br />
considered to exclude the effects of gravity. Temperature<br />
was maintained at 37 o . All experiments<br />
were performed on a 7T horizontal bore MR system<br />
with a 1 H/ 19 F volume coil. 1 H 2D spin echo images<br />
and chemical shift spectroscopy (CSI) were used<br />
to track and quantify the migration of 1-15x10 6<br />
cells. Nine 19 F-CSI experiments (1.1 hours each)<br />
were sequentially performed in order to keep track<br />
of the migrating cells.<br />
Results: Cell migration was assessed by measuring<br />
cell movement relative to their initial position above<br />
and below the cell-gel layer. Minimal migration was<br />
observed in samples with 10-15×10 6 cells. However,<br />
with smaller cell numbers, 5×10 4 from 5×10 6 cells<br />
(1%) and 2.5×10 4 from 1×10 6 cells (2%) were found<br />
to migrate up. Migration was found to stop 10 hrs<br />
after the start of the experiment. No cell migration<br />
was found below the initial cell layer during the<br />
whole study for all cell layer numbers, indicating<br />
that the upward cell movement was truly caused by<br />
the chemokine gradient.<br />
Conclusions: In the present study we showed that<br />
19 F-CSI and 19 F-MRI can be used to track and quantify<br />
cell migration in 3D collagen scaffold assays.<br />
The number of cells in the initial cell layer was in the<br />
order of the typical cell bolus injection in patients<br />
[1] and the migration rates were measured to be in<br />
the order of 2%, similar to that obtained in clinical<br />
results. The study showed that the initial cell density<br />
plays a decisive role in DCs migration, which<br />
is important information to optimize cell migration<br />
in a clinical setting. Thus, this assay is suitably to<br />
simulate in vivo clinical conditions, giving the potential<br />
chance for detailed analysis of DC migration<br />
by MRI.<br />
Acknowledgement: This work was partially supported<br />
by NWO (VISTA grant) and ZONMW (911-06-<br />
021) for investments.<br />
References:<br />
1. P. Verdijk, T. W. Scheenen, et al.. Int J Cancer 120(5):<br />
978-84 (2007).<br />
2. I. J. de Vries, W. J. Lesterhuis et. al.. Nat. Biotechnol.<br />
23(11), 1407-1412 (2005).<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-048<br />
poStEr<br />
GENE and CELL based THERAPIES
P-049<br />
162<br />
WarSaW, poland May 26 – 29, 2010<br />
In vivo magnetic resonance imaging reveals altered migration of endogenous neural<br />
progenitor cells following cuprizone-induced central nervous system demyelination<br />
Guglielmetti C. , Praet J. , Vreys R. , Ponsaerts P. , Van Der Linden A. .<br />
University of Antwerp, Belgium<br />
carolineguglielmetti@hotmail.com<br />
Introduction: The Cuprizone mouse model represents<br />
a highly reproducible tool to study in vivo demyelination<br />
and remyelination processes. The time<br />
course of demyelination-remyelination during Cuprizone<br />
administration has been well characterized<br />
and it has been suggested histologically that endogenous<br />
subventricular zone neural stem/progenitors<br />
cells (NSPC) are recruited during the remyelination<br />
process [1] . We tested whether the recently validated<br />
in situ NSPC labelling technique with micron-sized<br />
iron oxide particles in combination with the transfection<br />
agent Poly-L-lysine [2] (MPIOs-PLL) is suitable<br />
to visualize NSPC migration towards demyelinated<br />
areas.<br />
Methods: 20 C57BL/6 mice (8 weeks old) were used.<br />
All mice were injected in the right lateral ventricle<br />
with 2 µl MPIOs-PLL (9.1 10 5 particles, 0.67 mg Fe/<br />
ml). 10 mice were fed a diet containing Cuprizone<br />
(0.2%) during a 4-week period post-injection (p.i).<br />
In vivo T 2 *-weighted 3D-MGE (78 µm isotropic resolution)<br />
was performed at 4 weeks (peak of inflammation),<br />
6 weeks (peak of proliferation of NSPC)<br />
and 12 weeks (complete remyelination) pi. All images<br />
were acquired on a 9.4T Bruker console. 5 animals<br />
of each group received an injection of 5-bromo-2’-deoxyuridine<br />
(BrdU; 50 mg/kg i.p.) twice a<br />
day over a period of 5 days before either the first or<br />
the second imaging time point.<br />
Results: MRI revealed hypointense voxels along the<br />
rostral migratory stream (RMS) and in the olfactory<br />
bulb (OB) for controls. In contrast, for the Cuprizone<br />
treated mice, hypointense areas towards the<br />
OB were detected only in 2 mice at week 4. From<br />
week 6 onward they were detected in both groups.<br />
Hypointense voxels are also found in the region of<br />
the external capsule (EC) at the ipsilateral side of<br />
injection from 4 weeks onward in the Cuprizone<br />
treated group. Each MR image is a compilation of<br />
5 consecutive MR slices. Histological analyses are<br />
being performed in order to confirm whether the<br />
hypointense voxels are MPIO particles in oligodendrocyte-differentiated<br />
NSPC.<br />
imaging life<br />
Conclusions: In situ labelling of endogenous NSPC<br />
by direct injection of MPIOs-PLL in the lateral ventricle<br />
revealed NSPC migration impairment towards<br />
the OB, as well as the presence of MPIOs in the EC<br />
in the Cuprizone mouse model. Histological analysis<br />
is ongoing in order to further characterise migrated<br />
MPIO-labelled cells.<br />
Acknowledgement: This work is supported by IWT<br />
(SBO/030238), EC-FP6-project DiMI (LSHB-CT-<br />
2005-512146) and IUAP-NIMI-P6/38<br />
References:<br />
1. Matsushima G K et al; Brain Pathology, 11: 107-116<br />
(2001)<br />
2. Vreys R et al; NeuroImage 49, 2094-2103 (2010)
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Evolution pathways of compartmentalization and distribution of labeling iron-oxide<br />
particles in tumor tissue<br />
Kotek G. , Van Tiel S. , Wielopolski P. , Krestin G. , Bernsen M. .<br />
Erasmus University Medical Center Department of Radiology, Rotterdam, Netherlands<br />
g.kotek@erasmus.nl<br />
Introduction: In our study we addressed the effects<br />
and the evolution of SPIO distribution on R2 and<br />
R2* values according to specific pathways, such as<br />
cell death, cell mixing and cell division. Also we<br />
investigated the effects of technical variations in<br />
labeling efficacy, cell density, imaging resolution<br />
and aggregation of labeling particles. We identify<br />
areas for improvement in cell labeling technique<br />
and imaging for quantitative cell tracking.<br />
Methods: Brown Norway 175 (BN175) sarcoma<br />
cells were labeled with iron-oxide (SPIO) particles.<br />
Various intravoxel SPIO distributions were<br />
prepared by methods mimicking biologically relevant<br />
processes (compartmentalization, mixing,<br />
division). R2* and R2 relaxometry was performed<br />
at high resolution at 3.0T, iron concentration<br />
was measured by optical emission spectrometry.<br />
Effects of spatial distribution and compartmentalization<br />
of SPIO on relaxivity (dR/dcFe) was<br />
analyzed.<br />
Results: We showed that relaxivity is sensitive to<br />
variations of cell labeling, cell density and imaging<br />
resolution. Our data suggest that intracellular<br />
variance of cell division rate potentially lead to<br />
breakdown of unique relaxation rate vs. iron concentration<br />
relationship. Our results indicate that<br />
cell death can be identified by parallel monitoring<br />
of R2 and R2* values, and we confirm that R2’ differentiates<br />
between intracellular and extra-cellular<br />
SPIO. We found a unique relaxation rate vs. iron<br />
concentration relationship in case of dominance<br />
of cell division. Our results suggest that tighter<br />
control on labeling variance put in place for stem<br />
cell labeling.<br />
Conclusions: We challenge labeled cell quantification<br />
by identifying sensitivity of the relaxivity<br />
to imperfections of labeling technique and imaging<br />
method; besides the numerous complications<br />
in quantification, with thorough consideration<br />
of limitations and monitoring of biologically relevant<br />
factors, quantification is feasible.<br />
In case of mixing labeled and non-labeled cells<br />
(likely process in stem cell tracking) a strong<br />
control on labeling efficiency is required, since<br />
R2*(cFe) and R2(cFe) curves are sensitive to initial<br />
intracellular iron content and cell density.<br />
References:<br />
1. Bowen CV, Zhang X, Saab G, et al.<br />
2. Application of the static dephasing regime theory to<br />
superparamagnetic iron-oxide loaded cells. Magn<br />
Reson Med 2002;48:52–61.<br />
3. Rad AM, Arbab AS, Iskander AS, et al. Quantification<br />
of superparamagnetic iron oxide (SPIO)-labeled cells<br />
using MRI. J Magn Reson Imaging 2007;26:366–74.<br />
4. Kuhlpeter R, Dahnke H, Matuszewski L, et al.R2 and R2*<br />
mapping for sensing cell-bound superparamagnetic<br />
nanoparticles: in vitro and murine in vivo testing.<br />
Radiology. 2007 Nov;245(2):449-57. Epub 2007 Sep 11.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-050<br />
poStEr<br />
GENE and CELL based THERAPIES
WarSaW, poland May 26 – 29, 2010<br />
P-051 Acupuncture Works on Endorphins via Activating Stretch-Activated Cation Channels<br />
164<br />
Liang J. (1) , Zhong P. (2) , Yang X. (3) , Li G. (3) , Yang E. (3) , Cheung P. (1) .<br />
(1) The University of Hong Kong, Hong Kong, Hong Kong<br />
(2) First Affiliated Hospital of Sun Yat-Sen University,<br />
(3) Hong Kong Applied Science and Technology Research Institute Company Limited, Hong Kong<br />
cmleung@eee.hku.hk<br />
Introduction: Acupuncture has been in use for three<br />
thousand years in China but was not practiced in the<br />
West until the last three decades. Among acupuncture<br />
therapies, the acupuncture-induced analgesic effect<br />
has been used widely to alleviate diverse pains, particularly<br />
chronic pain. To shed light on the 2500-yearold<br />
acupuncture analgesia, pain control by acupuncture<br />
through Ca2+-regulated release of opioid peptides<br />
is proposed.<br />
Methods: 4-week-old C57BL/6N mice were kept in<br />
a specially designed holder, with their hind legs and<br />
tails exposed during acupuncture. An acupuncture<br />
needle (Hwato) 0.4 mm in diameter, 50 mm in length<br />
was inserted into the right hind leg, between the<br />
tibia and fibula, approximately 5 mm lateral to the<br />
anterior tubercle of the tibia. The acupuncture needle<br />
was driven by a piezoelectric bending element at 1<br />
Hz. After receiving acupuncture treatment for 40<br />
minutes, animals were sacrificed. Blood samples were<br />
harvested from the left ventricle of the heart. Plasma<br />
was separated by centrifuging samples at 1000 × g<br />
for 15 minutes at 4 ˚C and diluted 1:10 in a sample diluent<br />
before assay. The levels of plasmaβ-endorphin<br />
were measured using a Mouse β-Endorphin ELISA kit<br />
from USCN Life Science. Method for in vivo monitoring<br />
of Ca2+ excitation in mouse skeletal muscle during<br />
acupuncture was described in [1].<br />
Results: Acupuncture was initiated by the stimulation<br />
of needle driver describe above in the hind-limb muscle<br />
of the mouse. Plasma β-endorphin was measured<br />
40 min after the acupuncture treatment by immunoassay.<br />
Elevation of β-endorphin levels is observed<br />
(Fig.1b) along with cytosolic Ca2+ activation in muscle<br />
fibers in vivo (Fig.1a) 40 min after the stimulation<br />
imaging life<br />
is applied. The acupuncture induced β-endorphin<br />
secretion is blocked by the intraperitoneal injection<br />
of Gd3+, thestretch-activated Ca2+ channels blocker.<br />
Conclusions: These findings suggest that acupuncture<br />
analgesia depends on the physiological afferent signal<br />
elicited in the mechanosensation pathway. The acupuncture<br />
needle manipulation induces a Ca2+-dependent<br />
secretion of β-endorphin via interactions with<br />
stretch-activated Ca2+ channels. The depolarizationevoked<br />
opioid peptide β-endorphin then penetrates<br />
the fenestrated capil ary vessels in the pituitary by diffusion,<br />
and so enters the general circulation. Our results<br />
are in agreement with the studies on endogenous<br />
neuropeptide release during electroacupuncture [2]<br />
and may lead to new directions for acupuncture analgesia<br />
research by unveiling its cellular signal transduction<br />
pathways.<br />
References:<br />
Fig1: Acupuncture stimulates<br />
ß -endorphin release via<br />
activating stretch-activated<br />
cation channels.<br />
1. Liang J.M., Li G., Yang E.S., Cheung P.Y.S. In Vivo Monitoring<br />
of Ca2+ Excitation in Mouse Skeletal Muscle during<br />
Acupuncture. WMIC 2009, p.527. [2] Han J.S. Acupuncture:<br />
neuropeptide release produced by electrical stimulation<br />
of different frequencies. Trends Neurosci. 26, 17-22 (2003).
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Labeling protocols for MRI and optical imaging of human muscle cells precursors<br />
Libani I.V. (1) , Lui R. (1) , Martelli C. (1) , Clerici M. (1) , Fiorini C. (2) , Lucignani G. (1) , Ottobrini L. (1) .<br />
(1) University of Milan, Rescaldina, Italy<br />
(2) Politecnico of Milan, Italy<br />
ilaria.libani@unimi.it<br />
Introduction: The interest about cell-mediated<br />
therapy finalized to tissues regeneration research<br />
is increased in the last few years. Although numerous<br />
protocols which include extraction of stem cells<br />
from healthy animals and implantation in diseased<br />
models were set up, important parameters such as<br />
the distribution and localization of the injected cells,<br />
cell survival, proliferation and differentiation cannot<br />
be evaluated in vivo. Here we refined and tested specific<br />
labelling protocols for in vivo visualization by<br />
MRI, SPECT and Optical Imaging of a human muscle<br />
cells precursor cell line as a proof of principle for<br />
the application of these procedure to stem cells in the<br />
evauation of muscle stem cell mediated treatments.<br />
Methods: Human Skeletal Muscle Cells (HSkMC)<br />
were labelled for 24 or 48h with different amounts<br />
of Endorem® (0-100–200 μg Fe/mL) in presence or<br />
not of Poly-L-Lysine (PLL), Protamine Sulfate (PrS),<br />
Polybrene (PB) or infected, with a lentiviral vector<br />
[1] carrying Luciferase gene under control of the<br />
muscle specific Myogenin promoter (pGZ.Myo.L<br />
vector). Labelled HSkMC were analized for viability,<br />
iron content (Perl’s Staining and spectrophotometer<br />
analysis [2]), morphology, differentiation capability<br />
or intrarterially (i.a.) injected into NUDE mice for<br />
in-vivo imaging by means of MRI, FLI or BLI. Initial<br />
cell distribution was also followed with scintigraphy<br />
after cell labelling with 111Indium-oxime (60<br />
μCi/106 cells) and gamma counting of explanted organ<br />
was performed to validate imaging data ex-vivo.<br />
Results: HSkMC incubated for 24 or 48h with 0-100-<br />
200 μg Fe/mL did not show significant differences,<br />
in terms of viability, between labelled/non-labelled<br />
cells in the presence or absence of PLL, PB or PrS<br />
(n=3) remaining higher than 84+8% after 24h and<br />
higher than 80,6+4,6% after 48h. The percentage of<br />
Iron+ cells increased in proportion to the iron content<br />
in the medium even if there are not significat<br />
differences between CTRL and PLL. In particular we<br />
obtained more than 90% Iron+ cells in the samples<br />
incubated with 200 μg Fe/mL for 24 or 48h. Intracellular<br />
iron content reached the higest levels in the<br />
samples loaded with 200ug/ml+PLL: 61,5+2,8 pg/<br />
cells after 24h and 114,9+9,6 pg/cells after 48h. For<br />
this reason 200 ug/mL endorem+PLL was deemed as<br />
the ideal condition for cell labeling for in vivo visualisation<br />
by MRI. Loaded HSkMC were injected i.a. into<br />
NUDE murine model of muscle inflammation. MRI<br />
permitted to follow over time HSkMC distribution<br />
into the injured muscle. SPECT and BLI of HSkMC<br />
not only confirmed celldistribution to muscle but also<br />
revealed an early localisation into the lung. HSkMC infected<br />
with pGZ.Myo.L, i.a. injected in the same mouse<br />
model, were detectable in muscle up to 5 weeks after<br />
injection. Interestingly, at this timepoint, the signal<br />
is still present only near the lesion area while disappeared<br />
in the rest of the body suggesting that this construct<br />
could be used to evaluate not only localisation<br />
but also the differentiation in vivo by means of BLI.<br />
Conclusions: We set up protocols to efficiently<br />
visualize human muscle cells precursors localization<br />
and differentiation by MRI, SPECT or in vivo<br />
optical imaging. These protocols will be useful to<br />
study the fate of cells once injected into recipient<br />
NUDE mice with different techniques and will<br />
make it possible to study their behaviour in vivo<br />
over time. Furthermore, it will be possible to use<br />
these instruments for the in vivo study of muscular<br />
stem cells in restoring skeletal muscles after<br />
damage.<br />
Acknowledgement: This work was supported by a<br />
Cariplo Foundation grant, the FP6 Hi-CAM project<br />
(LSHC-CT-2006-037737) and from the Doctorate<br />
School of Molecular Medicine, University of Milan.<br />
References:<br />
1. Naldini L. et al; Science 272(5259):263-7 (1996)<br />
2. Boutry N. et al; Contrast Media Mol Imaging 3(6):223-<br />
32 (2008)<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-052<br />
poStEr<br />
GENE and CELL based THERAPIES
WarSaW, poland May 26 – 29, 2010<br />
P-053 Studying molecular processes in-vivo: A framework for quantifying variability in molecular<br />
MRI<br />
166<br />
Plenge E. (1) , Kotek G. (1) , Guenoun J. (1) , Doeswijk G. (1) , Krestin G. (1) , Niessen W. (2) , Meijering E. (1) , Bernsen M. (1) .<br />
(1) Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands<br />
(2) Erasmus University Medical Center, Rotterdam and Faculty of Applied Sciences, Delft University of Technology, The Netherlands<br />
e.plenge@erasmusmc.nl<br />
Introduction: Quantitative characterization of cellular<br />
and molecular processes in-vivo is dependent<br />
on consistent image data. To justify conclusions regarding<br />
observed biological changes over time, the<br />
changes should exceed those attributed to imaging<br />
artifacts and inconsistencies. The aim of this work<br />
is to establish a framework for quantifying the variability<br />
inherent to molecular magnetic resonance<br />
imaging (mMRI) protocols.<br />
Methods: Our framework consists of variance maps,<br />
variance histograms, visualization and quantification<br />
of the precision of expert contouring. To demonstrate<br />
the efficacy of our framework we have compared the<br />
variability of two different acquisition protocols in<br />
the challenging environment of a rodent heart. SPIO<br />
labeled stem cells were injected into the myocardium<br />
of a rat and cardiac MRI performed. Without moving<br />
the anesthetized rat at any point, seven 3D nontriggered<br />
images and seven 2D cine sequences were<br />
acquired intermittently to capture inevitable changes<br />
due to e.g. breathing, coil-heating etc. in both datasets.<br />
The assumption was made that no biological changes<br />
occur within the acquisition time. After rigid registration<br />
of the images in each dataset, the per-voxel variance<br />
over each dataset was calculated. Variance maps<br />
were generated for visualization, variance distributions<br />
for quantification. Three experts manually segmented<br />
the cell cluster in each slice/frame of each 3D/cine sequence.<br />
The inter- and intra-observer variability was<br />
visualized and quantified by a similarity index (SI) [1].<br />
imaging life<br />
Results: The created framework allows objective<br />
quantification of the variability inherent to mMRI<br />
protocols. Fig. 1 and table 1 visualize and quantify<br />
the variance distribution of the datasets due to imaging<br />
inconsistencies, and the inter- and intra-observer<br />
variability of the expert segmentation. Through<br />
such a quantitative assessment a lower limit on the<br />
longitudinal changes in the biological process to be<br />
studied can be defined.<br />
Conclusions: We have proposed a framework for<br />
evaluating mMRI protocols in terms of variability.<br />
The proposed framework allows anyone to objectively<br />
assess how well-suited an mMRI protocol is<br />
for a longitudinal study of a given biological process.<br />
Acknowledgement: Supported by ENCITE, funded<br />
by the European Community under FP7.<br />
Inter-obs.<br />
variability, SI<br />
Intra-obs.<br />
variability, SI<br />
3D 2D cine<br />
0.70 0.79<br />
0.56 0.64<br />
Fig1: Top and bottom row shows visualizations related to the 3D<br />
and 2D cine datasets, respectively. Left: Slice/frame of each dataset.<br />
Middle: Histograms of per-voxel variance of each dataset. Right: Variability<br />
among three expert’s segmentations of cell cluster (colors represent<br />
the number of experts including the voxel in the cell cluster).<br />
References:<br />
1. Pohl KM et al; Med.Img.Analysis, 11:5:465-477 (2007)
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Clinically applicable cell tracking by MRI in cartilage repair using Superparamagnetic Iron<br />
Oxide (SPIO)<br />
Van Buul G. , Kotek G. , Wielopolski P. , Farrell E. , Uijtterdijk A. , Bos P. , Weinans H. , Verhaar J. , Krestin G. , Van Osch G. ,<br />
Bernsen M. .<br />
Erasmus MC, Rotterdam, The Netherlands<br />
g.vanbuul@erasmusmc.nl<br />
Introduction: Cell tracking is a useful tool for<br />
optimizing cell-based cartilage repair. Cell labeling<br />
using superparamagnetic iron oxides (SPIOs)<br />
enables non-invasive in vivo cell tracking by MRI,<br />
and has already been used experimentally in a<br />
clinical setting[1]. We investigated the clinical,<br />
intra-articular applicability of this cell tracking<br />
technique regarding safety, MRI traceability and<br />
label re-uptake.<br />
Methods: Part 1: Human bone marrow stromal<br />
cells (hBMSCs) were labeled with SPIO (ferumoxides-protamine<br />
sulphate complexes) in a range<br />
of 0 - 250 μg/ml. Cell viability was asses-sed and<br />
metabolic cell activity was quantified up to seven<br />
days. Part 2: SPIO-labeled hBMSCs (100,000 to<br />
5,000,000 cells) were injected ex vivo in pig knees,<br />
to mimic a clinically relevant sized model. Furthermore,<br />
SPIO-labeled cells (10,000 - 1,000,000<br />
per 75 μl) were seeded in cartilage defects in vitro.<br />
Scanning was performed on a clinical 3.0 T MRI<br />
scanner. Part 3: To show possible SPIO re-uptake<br />
by synovial cells, viable and dead GFP-SPIO double-labeled<br />
chondrocytes were seeded on human<br />
synovium explants for five days. Samples were<br />
analyzed using fluorescence- and light microscopy.<br />
Results: Part 1 Cell labeling<br />
and -behaviour:<br />
SPIO labeling resulted<br />
in labeling efficiencies<br />
of approximately 90%<br />
and did not negatively<br />
affect cell viability or<br />
cell proliferation for<br />
dosages up to 250 μg/ml.<br />
Part 3 SPIO re-uptake: GFP+-SPIO+ cells, indicating<br />
originally seeded cells, were seen in synovium<br />
samples containing living cells. GFP – -SPIO+ cells,<br />
indicating SPIO re-uptake by synovial cells, were<br />
found in samples containing dead cells.<br />
Conclusions: Although possible SPIO re-uptake<br />
by host cells might limit duration of accurate cell<br />
tracking, we showed promising results for the use<br />
of SPIO labeling for cell tracking in clinical cartilage<br />
repair procedures. This approach provides the<br />
extra advantage to simultaneously track cells and<br />
evaluate cartilage repair in one MRI session.<br />
Acknowledgement: This work is supp. by the Smart-<br />
Mix Prog. of the Neth. Min. of Econ. Aff. & the<br />
Neth. Min. of Educ., Cult. & Science; and the EC-<br />
FP7 project ENCITE (HEALTH-F5-2008-201842).<br />
Part 2 MRI traceability: Fig1: Intra-articular injected SPIO-labeled cells (1A) and cells seeded in circular cartilage defects in a volume of 75<br />
All SPIO-labeled cell dosages,<br />
both intra-articular<br />
µl (1B) were accurately visualized by MRI. The amount of intensity of signal voids was related to used cell number.<br />
injected or seeded in cartilage defects, were visualized<br />
by MRI (Fig. 1). The amount of signal voids<br />
was related to the used cell number. SPIO-labeled<br />
cells seeded in cartilage defects in vitro could be visualized<br />
and quantified using a T2* mapping MRI<br />
References:<br />
technique.<br />
1. Bulte JW; AJR Am J Roentgenol. 193(2):314-25 (2009)<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-054<br />
poStEr<br />
GENE and CELL based THERAPIES
168<br />
WarSaW, poland May 26 – 29, 2010<br />
P-055 Labeling of HUVEC with different iron oxide particles: An in vitro study about incorporation,<br />
distribution, retention and toxicity<br />
Van Tiel S. , Wielopolski P. , Houston G. , Krestin G. , Bernsen M. .<br />
ErasmusMC, Rotterdam, The Netherlands<br />
s.vantiel@erasmusmc.nl<br />
Introduction: For in vivo cell tracking it is essential<br />
that the cells have incorporated a label so that<br />
they can be distinguished from their surroundings<br />
in Magnetic Resonance Imaging (MRI)[1-3]. A vast<br />
amount of studies have been published dealing with<br />
labeling of various cell types with iron oxide nanoparticles.<br />
In these studies a large variety of labeling<br />
protocols have been described. While for every cell<br />
type tested efficient labeling and subsequent detection<br />
by MRI[4] has been reported, it is not clear<br />
how different labeling protocols may influence labeling<br />
efficiency. The purpose of this study was to<br />
systematically investigate the effect of variations in<br />
dose and duration of labeling on label incorporation,<br />
distribution, retention and toxicity using two commonly<br />
used types of iron oxide nanoparticles; the<br />
so-called SPIO and MPIO particles.<br />
Methods: Primary culture Human Umbilical Vein<br />
Endothelial Cells (HUVECs) were grown to 80-<br />
90% confluence and labeled with SPIO or MPIO<br />
at concentrations ranging from 0 - 100 µg Fe and<br />
incubation times of 4-48hrs. Cellular iron load was<br />
measured by Inductible Coupled Plasma- Optical<br />
Emission Spectrometry (ICP-OES). Cellular localization<br />
and retention over time of iron oxide complexes<br />
was assessed on cytospin slides. Cell functionality of<br />
labeled cells was tested by a tube forming assay. MRI<br />
traceability of labelled cells was tested using a 3D-<br />
SPGR sequence with TR/TE 41.1/10.5 ms, and a flip<br />
angle (α) of 50º with a resolution of 38 μm x 38 μm x<br />
100 μm and a FOV of 2 cm x 2 cm.<br />
Results: Under the conditions tested a maximal<br />
iron load of 18.2 pg per cell was obtained for SPIO.<br />
A much higher iron load of 661 pg per cell was<br />
achieved with MPIO. Inter and intra cellular distribution<br />
of label are both strongly dependent on<br />
the labeling protocol used. Labeling with high doses<br />
and short incubation times may result in large<br />
intra-cellular vesicles with multiple iron-oxide<br />
complexes. Labeling with low doses and long incubation<br />
times may result in small intra-cellular<br />
vesicles with just one iron-oxide complex. A better<br />
retention of label was observed after short incubation<br />
times and high labeling doses. For both MPIO<br />
imaging life<br />
and SPIO higher doses were tolerated at shorter incubation<br />
times. At equal incubation times, MPIO<br />
was better tolerated than SPIO. In FACS studies,<br />
clear changes in forward scatter and side scatter<br />
plots, corresponding to changes in cell size and cell<br />
granularity respectively were observed following<br />
labeling. Both effects were more pronounced after<br />
labeling with MPIO than with SPIO. At the highest<br />
doses of MPIO tested cell sizes increased 4-7<br />
times in cell volume compared to unlabeled control<br />
cells. The effects of SPIO and MPIO labeling<br />
on tube forming capacity of HUVECS was tested at<br />
all doses that did not significantly affect cell survival.<br />
For all these conditions tested HUVECs still<br />
displayed tube forming capacity. Sensitive imaging<br />
by MRI at the single cell level in vitro was possible<br />
for all conditions tested.<br />
Conclusions: HUVECs can be labeled efficiently with<br />
SPIO and MPIO, but dose and duration of exposure<br />
of cells to the particles strongly influence label incorporation,<br />
distribution, retention and toxicity.<br />
Acknowledgement: This research has been done in<br />
part through support from ENCITE - funded by the<br />
European Community under the 7th Framework<br />
program.<br />
References:<br />
1. Bulte JW. Methods Mol Med.124:419-439 (2006)<br />
2. Modo M et al. Mol Imaging. 4:143-164 (2005)<br />
3. Hoehn M et al. J Physiol. 584:25-30. (2007)<br />
4. van Buul GM et al. Contrast Media Mol Imaging. 4:230-<br />
236 (2009)
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Visualization of aberrant migration in the YAC 128 mouse model for Huntington’s disease by<br />
in situ labelling of neural progenitor cells with iron oxide particles<br />
Vreys R. (1) , Blockx I. (1) , Kandasamy M. (2) , Nguyen H.H.P. (3) , Verhoye M. (1) , Aigner L. (2) , Van Der Linden A. (1) .<br />
(1) University of Antwerp, Belgium<br />
(2) Paracelsus Medical University Salzburg, Austria<br />
(3) University of Tübingen, , Germany<br />
ruth.vreys@ua.ac.be<br />
Introduction: The outcome of a recent validation<br />
study of various in situ cell labelling strategies is<br />
that intraventricular injection of a small number of<br />
micron-sized iron oxide particles (MPIOs) in combination<br />
with the transfection agent Poly-L-lysine<br />
(PLL) is a successful method for the MRI visualization<br />
of endogenous neural progenitor cell (NPC)<br />
migration in the adult mouse brain [1] . As it was<br />
recently reported that NPC migration is impaired<br />
in a mouse model of Huntington’s disease (HD) [2] ,<br />
we tested if the in situ labelling technique using<br />
MPIOs-PLL is suitable to visualize aberrant NPC<br />
migration in YAC128 mice, a mouse model of HD.<br />
Methods: YAC128 transgenic mice (n=5; 66-69<br />
weeks old) maintained on a FVB/N background<br />
and age-matched non-transgenic littermates (n=5;<br />
wild-types) were used. Mice were injected intraventricular<br />
with 1.5 µl MPIOs-PLL (9.1 x 10 5 particles,<br />
0.67 mg Fe/ml). In vivo T 2 *-weighted 3D-GE<br />
(78 µm isotropic resolution; 9.4T) was performed<br />
at 1 week up to 13 weeks post injection. Ex vivo<br />
T 2 *-weighted 3D-GE (66 µm isotropic resolution;<br />
9.4T) was performed on perfused and fixed brains<br />
in their skulls. Four days before perfusion, mice<br />
received 5 times (every 3 h) an injection of 5-bromo-2’-deoxyuridine<br />
(BrdU; 50 mg/kg i.p). Immunohistochemistry<br />
was performed for BrdU on 25<br />
µm sagittal sections.<br />
Results: MRI revealed hypointense pixels along the<br />
rostral migratory stream (RMS) and in the olfactory<br />
bulb (OB) for all wild-types (WT). In contrast, for the<br />
YAC 128 mice (YAC HD), hypointense areas towards<br />
the OB were detected in only two mice. As neurogenesis<br />
is reduced upon ageing, the fraction of MPIOlabelled<br />
NPCs was very limited. The first column in<br />
the figure shows for both groups minimum intensity<br />
projection (mIP) compositions of ex vivo MR images<br />
comprising the RMS of five animals. The mIP of YAC<br />
HD shows less hypointense areas in the RMS and OB<br />
compared to the WT. Histological staining for BrdU<br />
shows that there are less BrdU + cells present in the<br />
RMS and OB of the YAC HD compared to the WT<br />
(figure, second and third column).<br />
Conclusions: In situ labelling of endogenous NPCs<br />
by intraventricular injection of MPIOs-PLL revealed<br />
aberrant NPC migration towards the OB in<br />
the YAC128 mouse model for HD.<br />
Acknowledgement: Supported in part by: IWT (Ph.D.<br />
grant; SBO/030238), EC-FP6-project DiMI (LSHB-<br />
CT-2005-512146) and IUAP-NIMI-P6/38<br />
References:<br />
1. Vreys R et al; NeuroImage 49, 2094-2103 (2010)<br />
2. Moraes L et al; Neuropathology 29, 140-147 (2009)<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-056<br />
poStEr<br />
GENE and CELL based THERAPIES
WarSaW, poland May 26 – 29, 2010<br />
P-057 Optimization of in vitro radiolabeling of mesenchymal stem cells with 18 Ffluorodeoxyglucose<br />
170<br />
Wolfs E. (1) , Bormans G. (2) , Van Santvoort A. (3) , Vermaelen P. (3) , Mortelmans L. (3) , Verfaillie C. (4) , Van Laere K. (3) , Deroose C. (3) .<br />
(1) K.U.Leuven, Leuven, Belgium<br />
(2) Laboratory for Radiopharmacy, K.U.Leuven, Belgium<br />
(3) Division of Nuclear Medicine, K.U.Leuven, Belgium<br />
(4) Stem Cell Institute, K.U.Leuven, Belgium<br />
Esther.Wolfs@med.kuleuven.be<br />
Introduction: Because of their great differentiation<br />
potential and immunomodulatory properties, mesenchymal<br />
stem cells (MSCs) are considered to be a<br />
potential source for tissue regeneration and immunomodulatory<br />
therapy [1-4]. For the optimization<br />
of this type of stem cell therapy, novel methods are<br />
required to follow the in vivo fate of stem cells after<br />
injection [5]. Stem cells can be labeled with radioisotopes<br />
in vitro, such as 18 F-fluorodeoxyglucose<br />
( 18 F-FDG), a positron emitting glucose-analogue<br />
which is taken up by cells in a similar manner as<br />
glucose. After phosphorylation, 18 F-FDG is trapped<br />
intracellularly, since it misses the 2’-hydroxyl group<br />
blocking further steps of the glycolysis pathway. The<br />
molecule stays in the cell until its decay [6]. The aim<br />
of this study is to optimize the radioactive labeling<br />
of MSCs in vitro with 18 F-FDG.<br />
Methods: Mouse MSCs were obtained from the<br />
Stem Cell Institute Leuven, and were seeded in 24<br />
well dishes for uptake experiments. 18 F-FDG (5µCi)<br />
was added to each well, in the presence of different<br />
insulin concentrations, and for uptake kinetics for<br />
up to 6 hours. In addition, 18 F-FDG washout after<br />
labeling was assessed. Additionally, 3 mice were<br />
injected with 500 000 18 F-FDG-labeled MSCs, and<br />
stem cell biodistribution was investigated with a<br />
µPET scanner 10 minutes after injection. Furthermore,<br />
a µCT image was acquired for coregistration<br />
with the µPET images.<br />
Results: 18 F-FDG uptake by MSCs was slightly higher<br />
with the addition of insulin (0,01 IU) but with only<br />
limited additional effect of higher concentrations.<br />
Furthermore, experiments also showed significantly<br />
higher 18 F-FDG uptake with longer incubation periods,<br />
slowly reaching a plateau after 6h of incubation.<br />
However, a significant tracer washout could be<br />
observed after 1 hour. In addition, in vivo µPET experiments<br />
with radiolabeled MSCs in mice showed<br />
almost exclusive pulmonary activity, confirming the<br />
intracellular location of the tracer.<br />
Conclusions: This study demonstrates that mouse<br />
MSCs can be successfully labeled with 18 F-FDG<br />
in vitro. Labeling efficiency increases even when<br />
very low insulin concentrations are added. Uptake<br />
imaging life<br />
kinetics assessment showed a significantly higher<br />
uptake with increasing incubation time for up to 6<br />
hours of incubation. Despite the tracer washout after<br />
one hour in vitro, in vivo µPET studies confirmed<br />
the intracellular location of the tracer through an<br />
almost exclusive pulmonary signal. Furthermore,<br />
in vitro labeling with the given dose (5µCi) permits<br />
solid imaging of stem cells injected in mice.<br />
References:<br />
1. Caplan A. Adult mesenchymal stem cells for tissue<br />
engineering versus regenerative medicine. J Cell<br />
Physiol 2007;213(2):341-7.<br />
2. Jackson L, Jones D, Scotting P, Scottile V. Adult<br />
mesenchymal stem cells: differentiation potential<br />
and therapeutic applications. J Postgrad Med<br />
2007;54(2):121-8.<br />
3. Caplan A. Why are MSCs therapeutic? New data: new<br />
insight. J Pathol 2009;217(2):318-24.<br />
4. Jiang Y, et al. Pluripotency of mesenchymal<br />
stem cells derived from adult marrow. Nature<br />
2002;418(6893):41-9.<br />
5. Lauwers E, et al. Non-invasive imaging of<br />
neuropathology in a rat model of a-synuclein<br />
overexpression. Neurobiol Aging 2007;28(2):248-57.<br />
6. Caracó C, et al. Cellular release of [18F]2-fluoro-<br />
2-deoxyglucose as a function of the Glucose-6phosphatase<br />
Enzyme system. J Biol Chem 2000; 275<br />
(24): 18489-2000
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Responsive MRI contrast agent for specific cell imaging of inhibitory, GABAergic neurons<br />
Aswendt M. (1) , Gianolio E. (2) , Kruttwig K. (1) , Brüggemann C. (1) , Aime S. (2) , Himmelreich U. (3) , Hoehn M. (1) .<br />
(1) Max Planck Institute for Neurological Research, Cologne, Germany<br />
(2) University of Turin, Italy<br />
(3) Katholieke Universiteit Leuven, Belgium<br />
Markus.Aswendt@nf.mpg.de<br />
Introduction: γ-Aminobutyric acid (GABA) is the<br />
major known inhibitory neurotransmitter. The ratelimiting<br />
step in the synthesis of GABA is the decarboxylation<br />
of glutamate by the enzyme glutamic acid<br />
decarboxylase (GAD), which exists in two isoforms:<br />
GAD65 and GAD67 [1].<br />
We exploited the feasibitity of cell specific contrast<br />
generation with the new smart contrast agent Gd-<br />
DOTAgad responsive to GAD activity. It consists of<br />
the chelate Gd-DOTA coupled to a long hydrocarbon<br />
backbone with glutamic acid residues. Upon cleavage<br />
of the glutamate moieties the hydration of the<br />
paramagnetic metal ion increases,<br />
leading to a higher relaxivity.<br />
Methods: Postnatal day 14,<br />
Wistar rat tissues were mechanically<br />
homogenized, and<br />
lysed with cell lysis reagent<br />
M-PER (Pierce, USA). After<br />
protein determination, same<br />
amounts were incubated at<br />
37°C for 24 hours with 1 mM<br />
Gd-DOTAgad together with<br />
the GAD activator pyridoxal-<br />
5’-phosphate. MR measurements<br />
were made at 4.7T (Bruker,<br />
Germany) using a custom<br />
made coil system. The MR phantoms consist of<br />
plastic tubes embedded in 1.5% agarose (Fluka,<br />
Switzerland). RAREVTR scans (TE=12.0ms,<br />
TR=30–250 ms, matrix=128x128; FOV=30.0 mm,<br />
resolution=0.234x0.234 mm; slice thickness=2.0<br />
mm). CGR8 murine embryonic stem cells were differentiated<br />
in a 3 step protocol using chemically<br />
defined media.<br />
Results: Tissue lysates of cerebellum, cortex and<br />
liver (as a negative control) were incubated with<br />
Gd-DOTAgad. Corresponding controls were Gd-<br />
DOTAgad in PBS and tissue lysates without contrast<br />
agent. T1 maps calculated from RAREVTR with an<br />
in-house software were used to evaluate the change<br />
in relaxation rate ΔR1 (Fig. 1A) identifying the highest<br />
changes with brain lysates. CGR8 cells were successfully<br />
differentiated in a 10 day-lasting protocol<br />
resulting in a high proportion of GAD65/67 positive<br />
cells, proven by immunocytochemistry (Fig. 1B).<br />
Conclusions: Gd-DOTAgad incubated with tissue<br />
lysates leads to enhanced ΔR1 rates in highly expressing<br />
GAD65/67 brain regions. A differentiation<br />
protocol to obtain GABAergic neurons from ES cells<br />
was successfully established. Efficient labelling with<br />
Gd-DOTAgad of murine ES and neuronal precursor<br />
cells is in progress for evaluation of differentiation<br />
induced contrast. With this approach it will be possible<br />
to label cells prior to transplantation and to<br />
follow their differentiation fate in vivo with MRI.<br />
Acknowledgement: This work was supported in part<br />
by grants from the European Union under FP6 program<br />
(StemStroke, LSHB-CT-2006-037526) (DiMI,<br />
LSHB-CT-2005-512146), and under FP7 program<br />
(ENCITE, HEALTH-F5-2008-201842).<br />
References:<br />
1. Erlander, M.G., et al., Two genes encode distinct<br />
glutamate decarboxylases. Neuron, 1991. 7(1): p. 91-100.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-058<br />
poStEr<br />
PROBE DESIGN
172<br />
WarSaW, poland May 26 – 29, 2010<br />
P-059 Novel ultrasound contrast agents for drug delivery<br />
Berti R.P. (1) , Freret L. (1) , Haiat G. (2) , Pisani E. (3) , Díaz-Lópeza R. (3) , Tsapis N. (3) , Pucci B. (4) , Fattal E. (4) , Taulier N. (1) , Urbach W. (1) .<br />
(1) Laboratoire d’Imagerie Paramétrique, PARIS, France<br />
(2) Laboratoire de Biomécanique et Biomatériaux Ostéo-Articulaires, France<br />
(3) Laboratoire de Pharmacie Galénique, France<br />
(4) Laboratoire de Chimie Bioorganique et des Systèmes Moléculaires Vectoriels, France<br />
romain.berti@upmc.fr<br />
Introduction: We are working on novel Ultrasound<br />
Contrast Agents (UCA) to improve the signal<br />
for echographic diagnosis and at the same time<br />
to extend their applications as possible drug carriers.<br />
Methods: We have investigated two types of agents:The<br />
first one is made of polymer PLGA (Poly Lactic Glycolic<br />
Acid) that encapsulates a liquid PFOB (PerFluoro-<br />
Octyl Bromide) core. The agent radius can be varied<br />
from 150 nm to 10 µm and it remains stable for weeks [1] .<br />
The second type is made of a telomer FTAC (fluorinated<br />
polymer) encapsulating a fluorinated liquid or gas core.<br />
It forms agent with a radius of about 100 nm and are<br />
stable over days. The size of both types of agent is weakly<br />
polydisperse. In addition, for a better understanding<br />
of the relationship between mechanical and ultrasound<br />
properties of the above contrast agents, we performed<br />
2D and 3D time domain simulations to compute the<br />
acoustic wave propagation in an our UCA solution.<br />
Results: We have measured in vitro the signal-to-noise<br />
ratio, backscattered signal, and destruction by ultrasound<br />
waves of the two nano-size ultrasound contrast<br />
agents, where the applied ultrasound signal has a frequency<br />
of either 5 or 50 MHz. In addition, the comparison<br />
between 2D numerical and experimental results<br />
shows a good agreement [3] , the 3D simulations are still<br />
under ways and should permit an improvement of our<br />
predictions. Our first tests performed in vivo showed<br />
that our agents induce a significant enhancement in the<br />
backscattered signal. For targeting purpose, the surface<br />
chemistry of the first UCA particles type was modified<br />
by incorporating phospholipids (fluorescent, pegylated,<br />
and biotinylated phospholipids) in the organic phase<br />
before emulsification [2] . Microscopy shows that phospholipids<br />
are present within the shell and that the core/<br />
shell structure is preserved. The functionalization did<br />
not modify the echographic signal arising from capsules.<br />
Conclusions: These results demonstrates that these<br />
nano and polymeric capsules are suitable ultrasound<br />
contrast agent and can be easily modified<br />
for targeted therapy or molecular imaging purpose.<br />
Acknowledgement: This work is supported by a<br />
grant from ANR (n° NT05-3-42548) and EC-<br />
FP6-project DiMI (LSHB-CT-2005-512146)<br />
imaging life<br />
References:<br />
1. Pisani et al. Adv. Funct. Mater. 18 (2008) 1-9<br />
2. Diaz-Lopez et al. Biomaterials 30 (2009) 1462-1472<br />
3. Haiat & Al, J. Acoust. Soc. Am. 127 1, (2010)
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Methods to study the interaction between aptamer probes and cell surface biomarkers<br />
Cibiel A. , Pestourie C. , Gombert K. , Janssens I. , Thézé B. , Tavitian B. , Ducongé F. .<br />
CEA,DSV,I²BM,SHFJ,INSERMU1023, Orsay, France<br />
agnes.cibiel@cea.fr<br />
Introduction: Aptamers are specific nucleic acidsbased<br />
ligands selected by an in vitro molecular evolution<br />
process (named SELEX). Recently, SELEX<br />
has been performed against living cells and allows<br />
for successful selection of aptamers against a specific<br />
transmembrane protein [1] or against cell surface<br />
biomarkers without prior knowledge of the target [2] .<br />
Here, we compared different techniques to study<br />
the interaction between aptamers and their target.<br />
Methods: For the binding experiments, 10 5 cells were<br />
first incubated with 5’- 32 P-labeled aptamers or control<br />
sequences for 15 minutes at 37°C and then washed.<br />
Bound sequences were recovered in 400µL of lysis<br />
buffer and the amount of radioactivity was counted.<br />
To optimise this protocol, we evaluated the number<br />
of washings and different combinations of unspecific<br />
competitors (tRNA, ssDNA and Polyinosine) at different<br />
concentrations. This allowed us to determine the<br />
protocol that yielded the highest signal/background<br />
ratio and to measure the affinity and the Cmax of different<br />
aptamers. In addition, an automation of the<br />
protocol has been performed. For microscopy analysis,<br />
aptamers were first labelled using Ulisys Alexa fluor<br />
546. Then, they were imaged using epifluorescence<br />
microscopy (Axio Observer Z1 Zeiss) at different time<br />
points during incubation (up to 40 minutes).<br />
Results:We observed that 5 washing cycles during the<br />
binding experiments were enough to decrease the<br />
background. In addition, we observed that the best<br />
combination of competitors seemed to be dependent<br />
on the cell type. In contrast, the optimal concentration<br />
of competitors was always around 100µg/ml. The use<br />
of higher concentrations did not have any effect suggesting<br />
that unspecific targets were saturated at this<br />
concentration. Finally, the use of competitor during<br />
pre-incubation and/or incubation of aptamers had the<br />
same impact on the signal/background ratio. Labelling<br />
aptamers with different amounts of Ulysis Alexa<br />
546 showed that when the ratio of Alexa/aptamer was<br />
increased, fluorescence intensity decreased, due to<br />
self-quenching phenomenon. This labelling method<br />
has been optimised to study the cellular localisation<br />
of aptamers by microscopy. In addition to providing<br />
information on the membrane or intracellular location<br />
of aptamers (after internalisation), microscopy<br />
allowed for evaluation of the kinetics of association<br />
between the aptamer and the target.<br />
Conclusions: The use of the above described two<br />
methods allowed us to obtain complementary results.<br />
Binding experiments led to the quantification<br />
of the kD or the number of targets on the cell surface<br />
whereas microscopy provided the localisation<br />
of the aptamer on the cell surface and its evolution<br />
over time. Aptamers selected against cell surface<br />
biomarkers could have many applications in the biomedical<br />
field (e.g. cell sorting, biomarker discovery,<br />
imaging, drugs design, etc.). Our methods can be<br />
used to rapidly assess their potential.<br />
Acknowledgements: This work was supported by<br />
grants from the European Molecular Imaging Laboratory<br />
(EMIL) network (EU contract LSH-2004-<br />
503569), the FMT-XCT program (EU contract<br />
201792) and l’Agence Nationale pour la Recherche<br />
(project ANR-Emergence ARTIC and ANR-TecSan<br />
DOT-IMAGER). AC was supported by a fellowship<br />
(Irtélis) from the CEA.<br />
References:<br />
1. Cerchia L et al. (2005) PLoS Biol 3(4)<br />
2. Pestourie C, Tavitian B, Duconge F (2005) Biochimie<br />
87(9-10): 921-930<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-060<br />
poStEr<br />
PROBE DESIGN
WarSaW, poland May 26 – 29, 2010<br />
P-061 MRI intelligent contrast agents as enzyme responsive nanosystems<br />
174<br />
Figueiredo S. (1) , Cittadino E. (1) , Terreno E. (1) , Moreira J.N. (2) , Geraldes C. F. (3) , Aime S. (1) .<br />
(1) Department of Chemistry IFM and Molecular Imaging Center, Torino, Italy<br />
(2) cLaboratory of Pharmaceutical Technology, Faculty of Pharmacy and Center for Neurosciences and Cell Biology, University of Coimbra, , Portugal<br />
(3) Department of Life Sciences, Faculty of Sciences and Technology, and Center for Neurosciences and Cell Biology, University of Coimbra, Portugal<br />
Saharic@gmail.com<br />
Introduction: When Magnetic Resonance is the imaging<br />
modality of choice it is necessary to design<br />
highly sensitive systems in order to overcome MRI<br />
relatively low sensitivity. We have envisaged an approach<br />
to enzyme-responsive agents based on the<br />
use of liposomes loaded in the aqueous cavity with a<br />
high number of paramagnetic complexes. Liposomes<br />
are self-assembled vesicles formed by saturated and<br />
unsaturated phospholipids commonly used in drug<br />
delivery. The overall relaxation enhancement of solvent<br />
water protons depends upon the permeability/<br />
disruption of the liposome membrane to water molecules.<br />
Our work has addressed the objective of i)<br />
modifying the permeability of liposome membrane<br />
thus pursuing an enhancement of the observed proton<br />
relaxation rate upon the enzymatic cleavage of<br />
peptides covalently bound to the phospholipid moieties<br />
or ii)promoting the disruption of low relaxivity<br />
aggregates formed by the binding capabilities of a<br />
macromolecular substrate that is selectively cleaved<br />
by the enzyme.<br />
Methods: Paramagnetic liposomes were prepared using<br />
the proper membrane by the thin film hydration<br />
method followed by extrusion. The lipidic film was<br />
hydrated with a 200mM solution of GdHPDO3A,<br />
followed by dialysis to remove non-entrapped material.<br />
The T1 measurements in vitro were carried<br />
out at 0.5T on a Stelar Spinmaster, whereas the in<br />
vivo measurements were acquired at 7T on a Bruker<br />
Avance 300 spectrometer. The temporal evolution of<br />
T1 contrast was determined in vivo after intratumor<br />
injection to mice bearing xenografted B16 melanoma.<br />
Results: i)The relaxometric properties of the liposomes<br />
loaded with the lipopeptide was tested in vitro<br />
measuring the r1 over time of three samples: a) the<br />
suspension of liposomes incorporating the lipopeptide<br />
in the presence (I) and absence (II) of MMP1<br />
and b) liposomes incorporating the stearic acid in<br />
the presence of MMP1. The results reported indicated<br />
that sample I showed a slight increase in the relaxivity<br />
likely due to partial instability of the liposome.<br />
In the presence of MMP, a more pronounced enhancement<br />
was observed. Importantly, the liposomal<br />
sample in which the incorporated lipopeptide was<br />
replaced by stearic acid did not show any significant<br />
imaging life<br />
enhancement, confirming that the enhancement observed<br />
for sample a-I) is related to the MMP1 activity.<br />
This different behaviour can be well appreciated<br />
by looking at the different contrast exhibited in the<br />
corresponding T1weighted MR image. In vivo kinetic<br />
experiment following the intratumor injection of<br />
the lipopeptide-based paramagnetic liposome indicated<br />
a rapid washout of the imaging probe, consistent<br />
with a relevant release of the Gd(III) complex in<br />
the extracellular fluid, where MMPs accumulates. ii)<br />
The interaction of anionic liposomes and protamine<br />
yields supramolecular adduct with low relaxivity. The<br />
action of trypsin causes the digestion of protamine<br />
and the consequent de-assembly of the adduct. The<br />
process is accompanied by an overall relaxation enhancement<br />
as consequence of the recovering of the<br />
original permeability of the liposome membrane to<br />
water molecules. An illustrative example of the utilization<br />
of this responsive probe consists in the entrapment<br />
of the supramolecular assembly in alginate<br />
vesicles. The detected change in r1 due to trypsin is<br />
correlated to the one in the absence of alginate. Thus,<br />
an in vivo exploitation relies on the entrapment of<br />
micron-sized particles into an alginate matrix that<br />
has often been considered as a bio-compatible device<br />
in cell-based therapies.<br />
Conclusions: We have now envisaged a molecular<br />
probe that work as an enzymatic substrate in a particular<br />
microenvironment, hence enhancing the MRI signal<br />
as a function of enzymatic activity. As further goal,<br />
an anti-tumoral drug will be co-encapsulated with the<br />
MRI probe, allowing supervise the tumoral therapy.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Standardization of molecular PBCA-microbubbles for routine use<br />
Fokong S. , Liu Z. , Gätjens J. , Kiessling F. .<br />
Helmholtz Institute, Aachen, Germany<br />
sfokong@ukaachen.de<br />
Introduction: To develop standardized highly monodisperse<br />
targeted polybutylcyanoacrylate (PBCA)microbubbles<br />
for contrast enhanced molecular<br />
ultrasound imaging.<br />
Methods: PBCA-microbubbles were produced by<br />
mechanical agitation and size isolated by centrifugation.<br />
Physical parameters of the size optimized<br />
microbubbles and regular (Sonovist) microbubbles<br />
were compared. Targeting of the microbubbles for<br />
molecular imaging was achieved by covalently binding<br />
streptavidin molecules onto the shell of surface<br />
activated PBCA-microbubbles and the subsequent<br />
attachment of biotinylated markers. The amount of<br />
targeting ligands on the surface of the microbubbles<br />
was quantified using a fluorescence activated cell<br />
sorter (FACS). The suitability of these microbubbles<br />
for destructive imaging methods like power Doppler<br />
ultrasound, used for the evaluation of the degree of<br />
angiogenesis and the effect of antiangiogenic therapy,<br />
was investigated in gelatin phantoms.<br />
Results: Following a new protocol for the synthesis<br />
of PBCA microbubbles, highly monodisperse populations<br />
could be isolated. Curves obtained from<br />
particle sizer measurements showed size isolated<br />
microbubbles which are normally distributed with<br />
a narrower standard deviation (> 97% ± 1.0-3.0 µm)<br />
in comparison to regular Sonovist microbubbles<br />
(> 97% ± 0.2–10 µm). The high monodispersity was<br />
also confirmed by SEM (scanning electron microscopy)<br />
pictures. The population distribution remained<br />
constant even with prolonged storage in solution<br />
(over 4 months), indicating high stability. Comparison<br />
of the resonance frequencies and the persistence<br />
in an ultrasound field showed a significantly lower<br />
resonance frequency and a lower persistence in the<br />
ultrasound field for the monodispersed microbubbles<br />
compared to the polydispersed microbubbles.<br />
The high monodispersity was maintained even with<br />
covalent coupling of streptavidin molecules onto the<br />
shell of the microbubbles. A quantification of the<br />
number of streptavidin molecules on the surface by<br />
the use of a FACS gave approximately 2 x 10 4 streptavidin<br />
molecules per microbubble. This number can<br />
be tuned according to the degree of surface activation<br />
of the microbubbles. Destructive imaging using<br />
SPAQ (Sensitive Particle Acoustic Quantification)<br />
[1] was also possible with these monodispersed microbubbles<br />
showing a highly reproducible destruction<br />
with high mechanical index ultrasound waves.<br />
Conclusions: Size optimized non modified PBCAmicrobubbles<br />
are more suitable for use as ultrasound<br />
contrast agents in comparison to regular Sonovist<br />
microbubbles. The simplified synthetic protocol allows<br />
for a speed up in the synthesis and purification<br />
process (6 days vs. 3 h). The low resonance frequency<br />
and persistence lead to more efficient detection using<br />
power Doppler techniques. Also, given the relative<br />
high number of targeting ligands which can be<br />
easily attached to their surface, and the possibility to<br />
efficiently quantify their amounts in a region of interest,<br />
they are very suitable for molecular imaging of<br />
intravascular targets. In summary, the tuned properties<br />
of the microbubbles presented in this study, will<br />
make them very interesting as building blocks for<br />
tailoring of specific contrast agents for ultrasound.<br />
Acknowledgement: This work is supported by the<br />
German Federal Ministry of Education and Research<br />
(BMBF-0315017).<br />
References:<br />
1. M. Reinhardt, P. Hauff, A. Briel, V. Uhlendorf, M. Schirner,<br />
Sensitive particle acoustic quantification (SPAQ),<br />
Investigative Radiology 40 (2005) 2-7.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-062<br />
poStEr<br />
PROBE DESIGN
WarSaW, poland May 26 – 29, 2010<br />
P-063 Novel Gd(III)-based probes for MR molecular imaging of matrix metalloproteinases<br />
176<br />
Gringeri C. (1) , Catanzaro V. (2) , Menchise V. (3) , Digilio G. (1) , Aime S. (2) .<br />
(1) Department of Environmental and Life Sciences, University of Eastern Piedmont “A. Avogadro”, Alessandria, Italy<br />
(2) Department of Chemisty IFM & Center for Molecular Imaging, University of Turin, Italy<br />
(3) Institute for Biostructures and Bioimages (CNR) c/o Molecular Biotechnology Center (University of Turin), Italy<br />
cgringeri@gmail.com<br />
Introduction: The assessment of the activity of a<br />
selected panel of MMPs in a given tissue or anatomical<br />
district is very important for the typization<br />
and staging of cancer and autoimmune diseases,<br />
and for the evaluation of the efficacy of therapies.<br />
[1] “Molecular Imaging” is a relatively new and rapidly<br />
growing branch of diagnostic imaging devoted<br />
to visualize tissue specific patho-physiological processes<br />
on the basis of their cellular/biochemical molecular<br />
signatures. MRI is one of the most clinically<br />
relevant imaging techniques, because of its great<br />
spatial resolution (
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Functionalization of nanoparticles for molecular imaging; a covalent approach<br />
Herranz F. (1) , Salinas B. (1) , Rosell Y. (1) , Desco M. (2) , Ruiz-Cabello J. (1) .<br />
(1) Universidad Complutense de Madrid- CIBERES, Madrid, Spain<br />
(2) Hospital Gregorio Marañón, Spain<br />
fherranz@pdi.ucm.es<br />
Introduction: The key point in the development<br />
of new nanoparticles (NPs) for imaging is the<br />
surface functionalization. By the attachment of<br />
new molecules one should, ideally, provide stability<br />
in physiological conditions, with a narrow<br />
size distribution and a functional group for the<br />
binding of biomolecules. These changes on the<br />
NPs surface can be made by weak non-specific<br />
interactions or by strong specific covalent bonds.<br />
Methods: Iron oxide nanoparticles were synthesized<br />
by the decomposition of organic precursors redendering<br />
hydrophobic Fe 3 O 4 NPs. These nanoparticles<br />
have oleic acid as surfactant, providing excellent size<br />
distribution, crystallinity and stability. To transfer<br />
the NPs to water the chemical structure of the oleic<br />
acid was modified by chemical methods, obtaining<br />
water stable NPs ready for further modification.<br />
Results: Fe 3 O 4 NPs were synthesized (7 ± 1 nm) by<br />
the decomposition of organic precursors. The surfactant<br />
of the NPs (oleic acid) was oxidized by means<br />
of potassium permanganate in a two phase system.<br />
This way we obtained water stable, carboxylic acid<br />
functionalized NPs, that were fully characterized<br />
(47 ± 4 nm, Zeta potential -46 mV, r 1 =4 s -1 mM -1<br />
and r 2 = 115 s -1 mM -1 , FTIR and 1 H-NMR). 1 These<br />
NPs are stable in buffer conditions and are being<br />
used for in vivo MRI. Besides, we took advantage of<br />
the carboxylic acid on the surface to covalently funcionalize<br />
the NPs with different molecules and dyes,<br />
like glucose, EDANS, 2 and streptavidin-alexa647.<br />
Conclusions: Here we report a new approach for the<br />
covalent functionalization of superparamagnetic<br />
nanoparticles. We demonstrate the usefulness of<br />
the method with several examples of covalent functionalization<br />
with different molecules and in vivo<br />
MRI use.<br />
Acknowledgement: This work was supported in part<br />
by MAT2008-01489 and SAF2008-0512-C02-01.<br />
References:<br />
1. Herranz, F.; Morales, M. P.; Roca, A. G.; Desco, M.; Ruiz-<br />
Cabello, J., Chemistry A European Journal 2008, 14,<br />
(30), 9126-30.<br />
2. Herranz, F.; Morales, M. P.; Roca, A. G.; Vilar, R.; Ruiz-<br />
Cabello, J., Contrast Media Mol. Imaging 2008, 3, (6),<br />
215-22.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-064<br />
poStEr<br />
PROBE DESIGN
178<br />
WarSaW, poland May 26 – 29, 2010<br />
P-065 Comparison of different chelating systems for the synthesis of Ga-68 labelled peptides for<br />
molecular imaging using RGD-peptides as model compound<br />
Knetsch P. (1) , Petrik M. (1) , Rangger C. (1) , Griessinger C. (2) , Fani M. (3) , Wester H.J. (4) , Pichler B. (2) , Pietzsch H.J. (5) ,<br />
Decristoforo C. (1) , Haubner R. (1) .<br />
(1) Medical University Innsbruck, Innsbruck, Austria<br />
(2) University of Tuebingen, Germany<br />
(3) University of Freiburg, Germany<br />
(4) Technische Universitaet Muenchen, Germany<br />
(5) Research Center Dresden-Rossendorf, Germany<br />
peter.knetsch@i-med.ac.at<br />
Introduction: Due to its increasing availability<br />
Ga-68 attracts increasing interest in molecular imaging<br />
with PET. Moreover, due to the straightforward<br />
labelling protocols especially for labelling of<br />
peptides this is an interesting alternative to F-18<br />
labelling strategies. Here the imaging properties<br />
of c(RGDfK) conjugated to different chelating systems<br />
are compared.<br />
Methods: Peptides were synthesised using standard<br />
SPPS protocols. After cyclisation in solution<br />
and selective deprotection of the amino function<br />
of the lysine the chelating moieties were conjugated<br />
via in situ activation. The chelating systems<br />
include 1,4,7,10-tetraazacyclododecane-1,4,7,10acetic<br />
acid (DOTA), a 1,4,7–triaaza-10-oxocyclododecane-1,4,7-acetic<br />
acid derivative (B505),<br />
1,4,7-triaazacyclononane-4,7-acetic acid-1-2-glutaric<br />
acid (NODAGA), and a tris(2-mercaptoethyl)<br />
amine derivative (NS3). Labelling was carried out<br />
using the fractionated elution method in sodium<br />
acetate or phosphate buffer, respectively. In vitro<br />
evaluation included determination of the partition<br />
coefficient, protein binding properties, metabolic<br />
stability, binding affinity, and cell uptake characteristics.<br />
In vivo evaluation was carried out using nude<br />
mice bearing alpha(v)beta3-positive and alpha(v)<br />
beta3–negative tumours. For all tracer biodistribution<br />
data were collected. For the most promising<br />
also small animal PET imaging was carried out.<br />
Results: All peptides could be labelled with Ga-68<br />
in good radiochemical yields. Labelling of NOD-<br />
AGA-RGD could be achieved even at room temperature.<br />
Whereas labelling of NS3-RGD has to be<br />
followed by Seppak separation to obtain the product<br />
in high radiochemical purity. The compounds<br />
showed comparable partition coefficients, binding<br />
affinity for the alpha(v)beta3 integrin as well as receptor<br />
specific uptake. However, great differences<br />
were found in the protein binding properties. Out<br />
of the four peptides tested only NODAGA-RGD<br />
showed low protein binding. This is also reflected<br />
in the biodistribution data. Lowest activity concentration<br />
in blood and best tumour/background ratios<br />
imaging life<br />
were found for NODAGA-RGD. Subsequent small<br />
animal imaging showed best imaging properties<br />
for NODAGA-RGD, which seems to be comparable<br />
with F-18-Galacto-RGD.<br />
Conclusions: In this series NODAGA-RGD revealed<br />
most promising properties for molecular<br />
imaging applications. Easy radiolabelling at room<br />
temperature, low amount of protein bound activity<br />
and the resulting lower activity concentration<br />
found in blood compared to the other compounds<br />
makes it to an interesting alternative to F-18-Galacto-RGD<br />
for imaging alpha(v)beta3 expression.<br />
However, the general advantage of NOTA derivatives<br />
for imaging purposes have to be confirmed by<br />
additional studies using other peptide structures.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
GdDOTA-PIB: a potential MRI marker for Alzheimer’s disease<br />
Martins A. (1) , Morfin J.F. (1) , Hamplova A. (1) , Kubicek V. (1) , Suzenet F. (2) , Salerno M. (3) , Lazar A. (4) , Duyckaerts C. (4) ,<br />
Geraldes C. (5) , Toth E. (1) .<br />
(1) Centre de Biophysique Moléculaire,CNRS, Orléans, France<br />
(2) Université d’Orléans, France<br />
(3) Université Paris 13, France<br />
(4) Hôpital de la Pitié-Salpêtrière, France<br />
(5) University of Coimbra, Portugal<br />
andre.martins@cnrs-orleans.fr<br />
Introduction: Alzheimer’s disease (AD) is the most<br />
frequent form of intellectual deterioration in elderly<br />
individuals, characterized by the brain deposition of<br />
amyloid plaques and neurofibrillary tangles. Early detection<br />
of the β-amyloid (Aβ) deposits in vivo is very<br />
difficult. Recently 11 C-radiolabeled small-molecules<br />
have been developed, capable of entering the brain<br />
and specifically targeting amyloid plaques for imaging<br />
with PET, such as several Thioflavin T derivatives<br />
[1-2]. In particular, the uncharged analogue 6-OH-<br />
BTA-1 (Pittsburgh compound B - PIB) is highly efficient<br />
both in crossing the BBB and in selective binding<br />
to AD amyloid aggregates. A major limitation of PET<br />
is the requirement for the markers to be labelled with<br />
short-lived isotopes. The use of Aβ marker linked to<br />
a MRI CA would constitute an attractive noninvasive<br />
in vivo imaging approach. Recently, Poduslo used CA<br />
aided MRI to image AD plaques with Gd(III)DTPA<br />
conjugated to a putrescine-modified human Aβ peptide<br />
able to cross the BBB and selectively target individual<br />
amyloid plaques in the brain of Alzheimer’s<br />
disease transgenic mice. Nevertheless, due to its large<br />
size, several days (weeks) of incubation with the CA<br />
are necessary to obtain the labeling of amyloid plaques<br />
in transgenic mouse brain in vivo. In an attempt to label<br />
Aβ plaques using small metal complexes for the<br />
diagnostics of Alzheimer disease, we synthesized a<br />
PIB-derivative of DOTA.<br />
Methods: DOTA-PIB was synthesized using a new,<br />
versatile strategy. The Gd 3+ complex has been characterized<br />
by relaxometric methods. The compound<br />
forms micelles in aqueous solution; the critical micellar<br />
concentration has been measured. Experiments<br />
on human brain slices have been carried out to assess<br />
binding of the compound to the β-amyloid deposits.<br />
HOOC<br />
N<br />
N<br />
O<br />
N<br />
H<br />
N N<br />
HOOC COOH<br />
DOTA-PIB<br />
S<br />
N<br />
O<br />
Results: The 1 H NMRD profiles evidence aggregation<br />
of the GdDOTA-PIB complex in aqueous solution,<br />
with a cmc of ~1.5 mM. The preliminary experiments<br />
on human brain slices show good binding affinity of<br />
the LnDOTA-PIB compound towards the amyloid<br />
plaques.<br />
Conclusions: We synthesized and investigated a<br />
novel Gd 3+ complex with good binding properties to<br />
β-amyloid deposits.<br />
Acknowledgement: We thank the support from the<br />
F.C.T. Portugal (project SFRH / BD / 46370 / 2008 and<br />
COST D38.<br />
References:<br />
1. Mathis CA, Bacskai BJ, Kajdasz ST, McLellan ME, Frosch<br />
MP, Hyman BT, Holt DP, Wang Y, Huang GF, Debnath ML,<br />
Klunk WE. (2002) Bioorg Med Chem Lett.12(3):295-8.<br />
2. Nesterov EE, Skoch J, Hyman BT, Klunk WE, Bacskai<br />
BJ, Swager TM. (2005) Angew Chem Int Ed Engl.<br />
26(34):5452-6.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-066<br />
poStEr<br />
PROBE DESIGN
WarSaW, poland May 26 – 29, 2010<br />
P-067 A comparative study of the self-elimination of para-aminobenzyl alcohol and hemithioaminalbased<br />
linkers. Application to the design of Caspase-3 sensitive pro-fluorescent probes<br />
180<br />
Meyer Y. (1) , Richard J. A. (1) , Delest B. (2) , Noack P. (2) , Renard P. Y. (1) , Romieu A. (1) .<br />
(1) University of Rouen, Mont Saint Aignan, France<br />
(2) Quidd: smart molecular imaging, Mont Saint Aignan, France<br />
yvesmeyer@estvideo.fr<br />
Introduction: This study focuses on the disassembly-behavior<br />
of self-immolative pro-fluorescent<br />
linkers under physiological conditions occurring<br />
via an enzyme-initiated domino reaction. The targeted<br />
linkers are based on para-aminobenzylalcohol<br />
(PABA) or hemithioaminal derivatives of para-carboxybenzaldehyde<br />
or glyoxilic acid. We found that a<br />
fine tuning of the kinetic properties can be obtained<br />
through the modulation of the linker structure, giving<br />
either a fast signal response or customizable<br />
systems suitable for the design of protease-sensitive<br />
fluorogenic probes or prodrug systems.<br />
Methods: Five model compounds bearing specific<br />
self-immolative linkers were synthesised and all<br />
integrate both: (1) a phenylacetamide moiety to be<br />
cleaved by Penicillin G Acylase (PGA) functionning<br />
as the triggering agent, and (2) a masked umbelliferone<br />
(i.e., 7-hydroxycoumarin) unit to be released as<br />
the final product and to elicit turn-on fluorescence.<br />
All these fluorogenic probes were incubated at the<br />
same concentration (3 µM) at 37°C with PGA (0.12<br />
U) in phosphate buffered saline (PBS, pH 7.5) and<br />
the corresponding fluorescence time-courses were<br />
recorded at λ = 460 nm.<br />
Results: Comparison of the resulting fluorescence<br />
recovery curves clearly indicates that the decomposition<br />
of PABA-based self-immolative linkers was<br />
faster than with the hemithioaminal counterparts.<br />
No nonspecific cleavage of these pro-fluorescent<br />
probes was detected in control reactions when incubated<br />
only in PBS. These results demonstrate that<br />
the use of PABA or hemithioaminal based linkers<br />
affords enzyme-reactive pro-fluorophores with<br />
high chemical stability. Despite the slower release<br />
of umbelliferone from the hemithioaminal probe<br />
derived from glyoxylic acid, this linker presents a<br />
peptide-like structure able to be readily and widely<br />
functionalised.<br />
Conclusions: PABA derivatives will be used for getting<br />
fast-response probes whereas the hemithioaminal<br />
spacers will be preferred for the construction of<br />
finely tunable (bio)functionalised probes. A first<br />
generation of Caspase-3 (apoptosis process) sensitive<br />
pro-fluorescent probes using PABA linkers has<br />
imaging life<br />
been obtained (AcDEVD-PABA-Umbelliferone) and<br />
in vitro fluorescence assay was performed with the<br />
corresponding recombinant human protease: 10fold<br />
increase of the enzyme velocity was obtained as<br />
compared to the commercially available profluorophore<br />
AcDEVD-AMC.<br />
Acknowledgement: This work is supported by CNRS,<br />
Quidd: Smart Molecular Imaging and La Région<br />
Haute-Normandie.<br />
References:<br />
1. R. Erez and D. Shabat, Org. & Biomol. Chem., 2008, 15,<br />
2669-2672. H. Y. Lee, X. Jiang and D. Lee, Org. Lett.,<br />
2009, 11, 2065-2068.<br />
2. C. Fossey, A.-H. Vu, A. Vidu, I. Zarafu, D. Laduree, S.<br />
Schmidt, G. Laumond and A.-M. Aubertin, J. Enzyme<br />
Inhib. Med. Chem., 2007, 22, 591. C. Fossey, N.-T. Huynh,<br />
A.-H. Vu, A. Vidu, I. Zarafu, D. Laduree, S. Schmidt, G.<br />
Laumond and A.-M. Aubertin, J. Enzyme Inhib. Med.<br />
Chem., 2007, 22, 608.<br />
3. Y. Meyer, J. A. Richard, M. Massonneau, P. Y. Renard and<br />
A. Romieu, Org. Lett., 2008, 10, 1517-1520.<br />
4. Y. Meyer, J. A. Richard, B. Delest, P. Noack, P. Y. Renard<br />
and A. Romieu, Org. & Biomol. Chem., 2010, In Press<br />
DOI: 10.1039/b926316k.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Olefin Metathesis for the functionalization of superparamagnetic nanoparticles<br />
Salinas B. (1) , Ruiz-Cabello J. (1) , Desco M. (2) , Herranz F. (1) .<br />
(1) Universidad Complutense Madrid- CIBERES, Madrid, Spain<br />
(2) Hospital Gregorio Marañón, Spain<br />
besalina@pdi.ucm.es<br />
Introduction: One of the most important points in<br />
the synthesis of new nanoparticles (NPs) for molecular<br />
imaging is the functionalization of the surface<br />
with new molecules. There is a necessity for new approaches,<br />
allowing more versatile synthesis and the<br />
introduction of biomolecules for specific interactions.<br />
This modification of the surface should be done covalently<br />
in mild conditions. Olefin metathesis offers<br />
many of those features thanks to the new family of<br />
catalysts, especially Hoveyda-Grubbs 2 nd generation. 1<br />
Methods: Iron oxide nanoparticles were synthesized<br />
by the decomposition of organic precursors redendering<br />
hydrophobic Fe 3 O 4 NPs, with oleic acid as<br />
surfactant. We carried out the olefin metathesis between<br />
the double bond in oleic acid structure and<br />
methyl acrylate. After the hydrolysis of the ester,<br />
water stable dispersion of superparamagnetic nanoparticles<br />
were obtained.<br />
Results: Fe 3 O 4 NPs were synthesized (10 ± 2 nm) by<br />
the decomposition of organic precursors. 2 The NPs<br />
were reacted in dry conditions with methyl acrylate<br />
in the presence of catalytic amounts (4%mol) of<br />
Hoveyda-Grubbs 2 nd generation catalyst. After hydrolysis<br />
of the ester water stable NPs, with narrow<br />
size distribution (30 ± 5 nm) and a Zeta potential<br />
corresponding to the introduced carboxylic acid<br />
(-46 mV) were obtained. The presence of the new<br />
diacid on the surface was confirmed by 1 H-NMR<br />
and FTIR.<br />
Conclusions: Here we report, for the first time,<br />
the use of olefin metathesis for the synthesis of<br />
water stable Fe 3 O 4 NPs with excellent yield and<br />
selectivity. This synthesis opens up the possibility<br />
for the attachment of new molecules in one step<br />
from the hydrophobic nanoparticles in a mild<br />
and selective way.<br />
Acknowledgement: This work was supported in part<br />
by MAT2008-01489 and SAF2008-0512-C02-01.<br />
References:<br />
1. Rybak, A.; Meier, M. A. Green Chem. 2008, 1099-1104.<br />
2. Herranz, F.; Morales, M. P.; Roca, A. G.; Desco, M.; Ruiz-<br />
Cabello, J., Chemistry A European Journal 2008, 14,<br />
(30), 9126-30.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-068<br />
poStEr<br />
PROBE DESIGN
182<br />
WarSaW, poland May 26 – 29, 2010<br />
P-069 Pyridine-based lanthanide complexes : towards bimodal agents operating as near infrared<br />
luminescent and MRI reporters<br />
Toth E. (1) , Bonnet C. (1) , Villette S. (1) , Suzenet F. (2) , Buron F. (2) , Shade C. (3) , Petoud S. (1) .<br />
(1) Centre de Biophysique Moléculaire, CNRS, Orleans, France<br />
(2) Université d’Orléans, France<br />
(3) University of Pittsburgh, USA<br />
eva.jakabtoth@cnrs-orleans.fr<br />
Introduction: Among the state of the art bioimaging<br />
modalities, some are characterized by high<br />
resolution but low sensitivity (magnetic resonance<br />
imaging, MRI) and others by high sensitivity but<br />
low macroscopic resolution (optical imaging). Luminescent/MRI<br />
bimodal imaging offers the advantage<br />
of combining the high resolution of MRI<br />
with the high sensitivity of luminescence and the<br />
development of contrast agents active for both<br />
techniques is of prime importance. Lanthanides<br />
offer unique opportunity to develop such bimodal<br />
contrast agents given their magnetic and optical<br />
properties. Nevertheless, it was long thought that<br />
the conditions required for both applications were<br />
non-compatible. Here, we report on a versatile pyridine-based<br />
scaffold for Ln 3+ complexation where<br />
MRI and near infrared (NIR) luminescence requirements<br />
are both satisfied using the same ligand.<br />
Methods: The synthesis of the ligands and the complexes<br />
will be briefly described. Potentiometric<br />
titrations have been performed to assess to thermodynamic<br />
stability of the complexes, together<br />
with kinetic measurements to quantify their inertness.<br />
To characterize the MRI properties, the exchange<br />
rate of the water molecules directly bound<br />
the Gd 3+ was determined by measuring 17 O longitudinal<br />
relaxation times. Finally the NIR spectra<br />
of the corresponding Nd 3+ and Yb 3+ were recorded,<br />
as well as the lifetimes of the excited states and the<br />
quantum yield of the complexes to quantify their<br />
luminescent properties.<br />
Results: The bishydrated complexes are found to be<br />
thermodynamically stable and the ligands show a significant<br />
selectivity for Ln 3+ over endogenous cations<br />
such as Zn 2+ , Ca 2+ and Cu 2+ . The kinetic inertness is<br />
also remarkable for such bishydrated complexes. The<br />
chelates do not form ternary complexes with endogenous<br />
donors which does not limit relaxivity in biological<br />
media. All the complexes give rise to NIR emission<br />
and the quantum yields are remarkable. 1 They are in<br />
the same range as those of non-hydrated complexes optimized<br />
for fully protecting the NIR emitting Ln 3+ for<br />
aqueous applications. The modification of the pyridine<br />
into quinoline was successful in shifting the excitation<br />
wavelength of the system towards higher values.<br />
imaging life<br />
Conclusions: The pyridine synthon is a prime candidate<br />
for the development of bimodal NIR/MRI imaging<br />
probes, as the bishydrated Ln 3+ complexes are thermodynamically<br />
and kinetically stable and display a high<br />
NIR quantum yield. The successful modification of the<br />
pyridine into a quinoline did not modify the thermodynamic<br />
properties of the complexes, but it resulted<br />
in a shift of the excitation energy towards lower values<br />
preventing damages to biological samples and allowing<br />
deeper tissue penetration of the excitation photons. The<br />
pyridine platform offers also easy routes for coupling<br />
the probes to biological vectors and optimizing the<br />
MRI properties.<br />
Acknowledgement: This work was financially supported<br />
by the Institut National du Cancer, La Ligue contre<br />
le Cancer, France, and was carried out in the frame of<br />
the COST action D38.<br />
References:<br />
1. L. Pellegatti, J. Zhang, B. Drahos, S. Villette, F. Suzenet,<br />
G. Guillaumet, S. Petoud, E. Toth, Chem. Commun.,<br />
2008, 6591-6593.<br />
2. S. Comby, D. Imbert, C. Vandevyver, J.-C. G. Bünzli,<br />
Chem. Eur. J., 2007, 13, 936.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Delivery of multiple F-18 tracers from a single automated platform (FASTlab TM synthesizer)<br />
Bhalla R. .<br />
GE Healthcare, Amersham, United Kingdom<br />
rajiv.bhalla@ge.com<br />
Introduction: The majority of F-18 radiotracers<br />
prepared in the clinic are synthesized on be-spoke<br />
automated rigs, which require modifications (and<br />
time) in order to switch to the production of different<br />
tracers. The increasing demand to facilitate<br />
the production of multiple F-18 tracers from a single<br />
clinical site (and preferably from a single Hot Cell)<br />
has necessitated the need to develop an easy to use<br />
automated platform which can readily accommodate<br />
the production of multiple F-18 tracers.<br />
O<br />
18<br />
TsO n F<br />
18<br />
F<br />
O<br />
R<br />
Fig1: Example of radiochemistry on FASTlabTM<br />
18<br />
R n F<br />
Methods: The FASTlab TM is an automated PET radiochemistry<br />
synthesis platform incorporating a<br />
disposable cassette. The disposable cassette contains<br />
a reaction vessel, pre-filled reagent vials and SPE<br />
cartridge(s). The FASTlab TM performs transfers (of<br />
F-18, reagents, solvents etc) in and out of the reaction<br />
vessel using a combinations of syringe drivers, pressure<br />
and vacuum – this combination of processes provides<br />
a high degree of control, allowing manipulations to be<br />
carried out with a high degree of precision and accuracy.<br />
The F-18 labelling is preformed in the reaction vessel<br />
and subsequent purification is performed either on the<br />
cassette using SPE cartridges or externally via a HPLC.<br />
Results: Figure 1 presents a snapshot of some the<br />
chemistry which has been successfully transitioned<br />
onto the FASTlab TM , demonstrating that this platform<br />
is capable of accommodating a diverse range<br />
of chemistry. Examples of F-18 tracers transferred<br />
to the FASTlab TM and currently in use in the clinic<br />
will be presented.<br />
N<br />
R<br />
18<br />
E n F<br />
R<br />
18<br />
F<br />
18<br />
F<br />
Synthon chemistry<br />
Fluoroalkylkation<br />
Direct labelling<br />
S N 2<br />
Direct labelling<br />
S N Ar<br />
Synthon chemistry<br />
Oxime synthesis<br />
Conclusions: FASTlab TM is an automated synthesizer<br />
which is capable of producing GMP quality F-18<br />
tracers. We have demonstrated the versatility of<br />
FASTlab TM by transitioning a wide variety of chemistry<br />
onto the platform to produce a large number of<br />
F-18 tracers, many of which are now being assessed<br />
in the clinic. We are now focussing on expanding<br />
the range of chemistry and the number of tracers<br />
available on FASTlab TM (both GE Healthcare proprietary<br />
and non proprietary).<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-070<br />
poStEr<br />
TECHNOLOGY
184<br />
WarSaW, poland May 26 – 29, 2010<br />
P-071 Monte-carlo modelling of a silicon detector insert combined with a PET scanner<br />
Brzezinski K. , Oliver J.F. , Llosá G. , Solevi P. , Linhart V. , Cabello J. , Lacasta C. , Rafecas M. .<br />
Instituto de Física corpuscular, CSIC/Universidad de Valencia, Spain<br />
brzezinski@ific.uv.es<br />
Introduction: Recent works have explored the capabilities<br />
of insert devices to improve the performance<br />
of clinical [1,2] as well as small animal [3,4] PET scanners.<br />
The development of a high resolution probe to<br />
be mounted inside a conventional PET scanner to<br />
increase its spatial resolution and sensitivity is one of<br />
the goals of the EU project MADEIRA. This paper describes<br />
the modelling of the MADEIRA set-up using<br />
Monte-Carlo (MC) techniques. These techniques are<br />
vital for optimizing the configuration of the proposed<br />
system by maximizing efficiency and spatial resolution.<br />
Furthermore, simulations allow characterization<br />
of the system and are useful for modelling its physical<br />
response, which can be included in image reconstruction.<br />
In the probe-and-ring system, a pair of annihilation<br />
photons has several ways of being detected. This<br />
work focuses on the classification and quantification<br />
of the basic detection modes.<br />
Methods: A preliminary study was conducted to validate<br />
the physics models of GEANT4 for the purpose of<br />
modelling the silicon (Si) detector probe. One layer of<br />
a Si detector was irradiated by a Ba-133 source and energy<br />
spectra measured. The full probe-and-ring system<br />
was modelled using the MC toolkit GATE (based on<br />
GEANT4). The model includes a probe consisting of<br />
ten layers of 26x40 pixel Si detectors, with 1x1x1 mm 3<br />
pixels, in coincidence with an existing partial-ring PET<br />
scanner with two opposing groups of 12 block detectors.<br />
The scanner diameter is 1 m and each partial ring<br />
spans 67.5 o out of 180 o so that it must be rotated to three<br />
different positions to cover the full FOV. Each detector<br />
block consists of an array of 32 BGO crystals of 6x2x30<br />
mm 3 . Initial simulations were run with points sources<br />
of 0.1 and 1.5 mCi in the centre of the FOV and the<br />
probe at a 50 mm. A temporal resolution of 5 ns was<br />
applied. The coincidences were classified as ring-ring<br />
and ring-probe; for each type, the contribution of accidental<br />
coincidences (randoms) was estimated.<br />
Results: The spectra measured with the Si detector<br />
were successfully reproduced by the GEANT4 code.<br />
For the full probe-and-ring system, coincidences<br />
where constructed using a 10 ns time window. The<br />
simulations permitted to quantify the kinds of coincidences<br />
as well as to evaluate the sensitivity and random<br />
fractions for each type (see table I).<br />
imaging life<br />
random fraction (%)<br />
Sensitivity (%)<br />
ring-ring ring-probe<br />
0.1 mCi 0.013 1.3<br />
1.5 mCi 0.2 15.5<br />
0.1 mCi 9.7 0.42<br />
1.5 mCi 9.0 0.39<br />
Table1: Random Fractions and Sensitivities<br />
Simulations are now being carried out with more<br />
complex activity distributions. An iterative reconstruction<br />
algorithm, based on ML-EM, developed<br />
for previous two-dimensional simulations of the<br />
MADEIRA system is now being modified to reconstruct<br />
the new three-dimensional data.<br />
Conclusions: The goal of a high resolution Si detector<br />
probe in coincidence with a conventional PET<br />
scanner is improving its spatial resolution and sensitivity.<br />
MC simulations of the proposed system<br />
have been performed and basic processes quantified.<br />
Other types of events such as those with various<br />
detections in the probe are now being studied and<br />
could potentially be exploited to increase the system<br />
sensitivity. The GATE toolkit will be shown to be<br />
useful in simulating such a non conventional scanner<br />
geometry. The coincidence data is now being applied<br />
to reconstruction.<br />
Acknowledgement: Supported by TEC2007-61047<br />
References:<br />
1. Janecek M et al; IEEE Trans Nucl Sci. 53 No.3: 1143-1149<br />
(2006)<br />
2. Zhou J et al; Phys Med Biol. 54:5193-5208 (2008)<br />
3. Wu H et al; J Nucl Med. 49:1668-1676 (2008)<br />
4. Park SJ et al; Phys Med Biol. 52 4653-4677 (2007)
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Autofluorescence corrected multispectral red-shifted fluorescent protein tomography<br />
Deliolanis N. (1) , Wurdinger T. (2) , Tannous B. (2) , Ntziachristos V. (1) .<br />
(1) Helmholtz Zentrum Muenchen, Neuherberg, Germany<br />
(2) Massachusetts General Hospital, United States<br />
ndeliolanis@yahoo.com<br />
Introduction: The development of fluorescent proteins<br />
(FPs) that operate in the far-red and nearinfrared<br />
part of the spectrum, enable the macroscopic<br />
visualization of FP activity deep in tissues.<br />
We demonstrate herein a multispectral fluorescence<br />
tomography method that allowed the visualization<br />
of labeled glioma tumors in animal brains operating<br />
with two-orders of magnitude better sensitivity<br />
compared to imaging GFP. We discuss how the<br />
detection sensitivity can be improved by at least an<br />
order of magnitude using further shifted FP’s and<br />
the potential of the method for accelerating discovery<br />
associated with functional genomics, stem cell<br />
research and systems biology.<br />
Methods: The method makes use of a novel spectral<br />
inversion scheme that integrates three-dimensional<br />
image reconstruction and auto-fluorescence<br />
correction that works seamlessly in the steep absorption<br />
transition from visible to near-infrared.<br />
The method is based on non-contact full angular<br />
projection Fluorescence Molecular Tomography.<br />
Results: We have successfully imaged mCherry labeled<br />
glioma tumors located deep in tissue in animal<br />
brains. The results show almost perfect anatomical<br />
localization of the tumors that is verified<br />
by MRI and histology.<br />
Conclusions: The approach offers therefore the ability<br />
for tomographically visualizing the emerging<br />
new class of red-shifted fluorescent proteins though<br />
entire animals. We discuss how the detection sensitivity<br />
can be improved by at least an order of magnitude<br />
using further shifted FP’s and the potential<br />
of the method for accelerating discovery associated<br />
with functional genomics, stem cell research and<br />
systems biology.<br />
Acknowledgement: This research is supported by a<br />
Marie Curie Intra-European Fellowship within the<br />
7th European Community Framework Programme.<br />
References:<br />
1. Shaner, N. C. et al. “Improved monomeric red, orange<br />
and yellow fluorescent proteins derived from<br />
Discosoma sp red fluorescent protein”. Nat. Biotechnol.<br />
22, 1567-1572, 2004.<br />
2. N. Deliolanis et al. “Free-space fluorescence molecular<br />
tomography utilizing 360° geometry projections”, Opt.<br />
Lett. 32 382-384 (2007)<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-072<br />
poStEr<br />
TECHNOLOGY
P-073<br />
186<br />
WarSaW, poland May 26 – 29, 2010<br />
Acquiring the sample surface from co-registered FMT/MR measurements of a murine tumor<br />
model<br />
Dikaiou K. (1) , Stuker F. (1) , Vats D. (1) , Ratering D. (1) , Keist R. (1) , Klohs J. (1) , Ripoll J. (2) , Rudin M. (1) .<br />
(1) Institute for Biomedical Engineering, Zurich, Switzerland<br />
(2) Institute of Electronic Structure and Laser, Heraclion, Greece<br />
dikaiou@biomed.ee.ethz.ch<br />
Introduction: The combination of MRI and FMT<br />
is promising in preclinical imaging, combining the<br />
high spatial resolution and soft tissue contrast of<br />
MRI for deriving structural and physiological information<br />
with high sensitivity of fluorescence imaging<br />
for studying molecular targets/interactions. Moreover,<br />
MR information can be used as a prior in the<br />
FMT reconstruction. The necessary steps to this end<br />
are the co-registration of the two datasets, the acquisition<br />
and use of the sample surface for reconstructing<br />
fluorescence images, and the characterization of<br />
different tissue types within the sample. The first two<br />
steps are presented here for an in vivo measurement.<br />
Methods: We measured nude mice bearing<br />
subcutaneous tumors on the thigh flank. 106<br />
colon cancer-derived C51 cells had been injected<br />
9 days prior to measurement. The protease-activatable<br />
probe ProSense 680 (VisEn<br />
Medical, Bedford, USA) was administered<br />
via the tail vein in two doses of 13nmol each,<br />
48h and 24h prior to measurement.<br />
We used a custom-made FMT/MR compatible<br />
animal support equipped with an<br />
MR transceiver surface coil. Each animal<br />
was fixed under anesthesia on the stage and<br />
measured on FMT. The optical signal from a<br />
1.5x1.2cm2 ROI around the tumor was collected<br />
upon excitation with a 671nm cw laser<br />
at 680nm and 720 nm. Thereafter, the stage<br />
was inserted into a Biospec 94/30 MR scanner<br />
(Bruker BioSpin MR, Ettlingen, Germany) operating<br />
at 9.4 T. 14 transversal slices with a FOV of 3.8x1.5cm2<br />
and 1.0mm thickness covering the tumor were acquired<br />
with a FLASH sequence (TE/TR = 5/250ms)<br />
for high sample/background contrast. The elapsed<br />
time between FMT/MR measurements was 30min.<br />
The MR data was automatically segmented according<br />
to [1]. Iso-surfaces were determined in<br />
order to compute the top surface height map,<br />
which was interpolated to match the optical image<br />
pixel dimensions. As both the height map and<br />
the optical white light image are oriented along<br />
yz on the coordinate system, they were used for<br />
co-registration. Reference points on the tumor<br />
imaging life<br />
outline were interactively selected to compute<br />
an affine transformation between the two images.<br />
The co-registered surface was subsequently used<br />
in FMT reconstruction.<br />
Results: The co-registered FMT/MR dataset for one<br />
mouse is shown, zoomed on the ROI for clarity. The<br />
reconstructed fluorescence is plotted on the whitelight<br />
image. The top surface is shown in green.<br />
Conclusions: A framework for co-registering FMT/<br />
MR data and recording the sample surface was presented.<br />
It constitutes an essential step towards full<br />
FMT/MR data integration and future use of MR a<br />
priori information in the FMT reconstruction.<br />
Acknowledgement: This work was supported financially<br />
by the EU FP7 FMT/XCT project.<br />
References:<br />
1. N.Otsu, A Threshold Selection Method from Gray-Level<br />
Histograms, Automatica, 1975
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
fDOT/ PET/CT imaging of biological processes in tumors<br />
Garofalakis A. , Dubois A. , Kuhnast B. , Dupont D. , Jassens I. , Mackiewicz N. , Dollé F. , Tavitian B. , Ducongé F. .<br />
CEA, Institut d’Imagerie BioMédicale, Service Hospitalier Frédéric Joliot, Laboratoire d’Imagerie Moléculaire Expérimentale, Orsay, France, Metropolitan<br />
anikitos.garofalakis@cea.fr<br />
Introduction: Small animal Fluorescence Diffuse<br />
Optical Tomography (fDOT) is a relatively new<br />
technology that can provide quantitative imaging<br />
of molecular processes. It allows using smart activatable<br />
probes which can measure biological processes<br />
that are inaccessible using nuclear probes. For<br />
instance, fluorescent sensors have been designed<br />
to monitor specific proteolytic activities using<br />
quenched NIRF probes that become fluorescent<br />
when they are cleaved by a protease of interest. In<br />
this work, we performed experiments aiming in integrating<br />
fDOT imaging of fluorescent probes with<br />
PET-FDG and a X-ray micro-CT imaging.<br />
Methods: For performing combined fDOT/PET/CT<br />
measurements we have developed a simple approach<br />
that incorporates a multimodal mouse supporting<br />
system that can fit in all three modalities. We performed<br />
multimodal imaging of two processes in a<br />
tumour using the fluorine-18- FluoroDeoxyGlycose<br />
([ 18 F]-FDG) and a fluorescent activatable probe. For<br />
optical monitoring we used probes for monitoring<br />
cathepsin activity and the localization of integrin<br />
alpha-v-beta-3 in tumor models by using different<br />
commercially available probes (Prosense680, Integrisense680,<br />
Visen Medical, USA and AngioStamp,<br />
Fluoptics, France). We used as models nude mice<br />
bearing a subcutaneous xenograft of two different<br />
cell lines, the MDA-MB-231 and the NIH-MEN2A.<br />
For the multimodal measurements we followed a<br />
protocol that allows for the optimal correlation of<br />
the fDOT and the PET data. Each mouse has been<br />
firstly measured by PET and was sequentially placed<br />
on the fDOT system for optical imaging. Once the<br />
mouse was placed in the PET, an intravenous injection<br />
of FDG with an activity of 200 μCi was performed<br />
and the dynamic PET scan was initiated.<br />
Optical measurements were performed 24h after<br />
the probe injection.<br />
Results: We reconstructed the 3D cathepsin activity<br />
and the localization of Integrin with respect to the<br />
tumor volume as given by PET. In the all xenograft<br />
models, we observed that the glucose consumption<br />
and the fluorescent probes were just partially<br />
co-localized in the tumour. Indeed, the [ 18 F]-FDG<br />
labelled all the tumour xenograft whereas the<br />
fluorescence signal was predominantly located at<br />
the base and only partially overlapped with the tumor<br />
volume as imaged by μPET.<br />
Conclusions: In this study we explored the potential<br />
of integrating information collected by nuclear and<br />
optical imaging taking advantage of the unique possibilities<br />
that each modality can provide. We found<br />
that the activatable probes used are concentrated<br />
underneath the tumor predominantly connected to<br />
the stroma while the highest glucose consumption<br />
appears to be uniformly distributed in the tumour<br />
tissue. Cathepsin activity is regulated by complex<br />
interactions between extracellular matrix components<br />
and cells populating the tumor like stromal<br />
cells and therefore it is expected to be reconstructed<br />
underneath the FDG signal. We proved that cancer<br />
imaging can benefit from the development of<br />
dual PET/Optical methods can act synergistically<br />
and that can provide complementary information<br />
enhancing thus the information collected from a<br />
single subject.<br />
Acknowledgement: This work was supported by<br />
grants from the European Molecular Imaging Laboratory<br />
(EMIL) network (EU contract LSH-2004-<br />
503569 and the european program FMT-XCT “Hybrid<br />
Fluorescence Molecular Tomography (FMT)<br />
– X-ray Computed Tomography (XCT) method and<br />
system” contract No 201792.<br />
References:<br />
1. Ntziachristos, V., Ripoll, J., Wang, L.V. & Weissleder, R.<br />
Looking and listening to light: the evolution of wholebody<br />
photonic imaging. Nat. Biotechnol 23, 313-320 (2005).<br />
2. Weissleder, R., Tung, C.H., Mahmood, U. & Bogdanov, A.<br />
In vivo imaging of tumors with protease-activated nearinfrared<br />
fluorescent probes. Nat. Biotechnol 17, 375-378<br />
(1999).<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-074<br />
poStEr<br />
TECHNOLOGY
P-075<br />
188<br />
WarSaW, poland May 26 – 29, 2010<br />
Deep tissue molecular imaging with fluorescent biomarkers using multispectral optoacoustic<br />
tomography. A simulation study<br />
Glatz J. , Deliolanis N. , Schulz R. , Razansky D. , Ntziachristos V. .<br />
Helmholtz Zentrum Muenchen, Neuherberg, Germany<br />
ndeliolanis@yahoo.com<br />
Introduction: Fluorescent protein<br />
markers have established themselves<br />
as a valuable tool in biomedical<br />
research. Their applicability in<br />
multispectral optoacoustic tomography<br />
(MSOT) has recently been<br />
demonstrated with fluorochromes<br />
and fluorescent proteins [1,2].<br />
Methods: A simulation study was<br />
conducted for the proteins GFP, mRaspberry, IFP<br />
and AF750. Theoretical calculations, based on light<br />
and sound propagation models suggests that IFP and<br />
AF750 yield an acoustic signal that is acoustic signal<br />
that is three orders of magnitude higher than that of<br />
GFP. Two protein inclusions of a concentration of<br />
1 μM were simulated in a cervical mouse structure<br />
and reconstructed by the backprojection algorithm.<br />
Results: It was shown that the protein concentration<br />
can be unmixed using only three multispectral<br />
measurements. Using blind source separation<br />
techniques this could even be achieved without<br />
prior spectral information. The unmixed components<br />
of the different proteins are shown in Figure<br />
1. The distinctively weaker signal strength from<br />
GFP and mRaspberry is a consequence of the<br />
strong tissue absorption in their spectral region.<br />
In order to obtain a stronger signal from the center<br />
the reconstructions were normalized for the light<br />
fluence inside the sample. From the simulation study<br />
the optimal measurement wavelengths could be determined<br />
for each protein. Their usage, as well as the<br />
blind source separation, was verified in a practical<br />
experiment using a tissue mimicking phantom with<br />
fluorochrome inclusions.<br />
Conclusions: The new red-shifted proteins can boost<br />
the acoustic signal intensity by over three order of<br />
magnitude. Protein concentrations can be unmixed<br />
in deep tissue and correcting for the light attenuation<br />
is an important step towards quantitative unmixing.<br />
Acknowledgements: This research is supported by a<br />
Marie Curie Intra-European Fellowship within the<br />
7th European Community Framework Programme.<br />
imaging life<br />
Fig. 1: Unmixing of tissue and protein distribution for simulated data<br />
References:<br />
1. D. Razansky et al. Multispectral photoacoustic imaging<br />
of fluorochromes in small animals Opt. Letters, 32,<br />
2891-2893, 2007<br />
2. D. Razansky et al. Multispectral opto-acoustic<br />
tomography of deep-seated fluorescent proteins in<br />
vivo Nat. Photonics, 3, 412-417, 2009
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Microfluidic [ 11 C]-carbonylation reactions for the rapid synthesis of radiolabelled compounds<br />
for PET<br />
Miller P. (1) , Audrain H. (2) , Bender D. (2) , Demello A. (1) , Gee A. (3) , Long N. (1) , Vilar R. (1) .<br />
(1) Imperial College London, London, United Kingdom<br />
(2) Arhus University Hospital PET Centre, Denmark<br />
(3) GSK, United Kingdom<br />
philip.miller@imperial.ac.uk<br />
Introduction: The synthesis of 11C compounds for<br />
PET requires fast and specialised chemical techniques<br />
owing to the short half-life of the 11C radioisotope<br />
(t1/2 = 20.4 min) and sub-micromolar reaction scales.<br />
[1] Microfluidic reactors are emerging as a valuable<br />
technology for the rapid and small scale synthesis of<br />
short-lived radiopharmaceuticals for PET imaging.<br />
[2] The palladium mediated 11C-carbonylation reaction<br />
is a highly versatile route for the preparation<br />
of a wide range of 11C-carbonyl compounds[3],<br />
however, the low molecular concentrations of<br />
11CO coupled with its poor solubility in organic<br />
solvents make this a particularly challenging<br />
transformation. Here we report the application of<br />
a microfluidic reactor for improving the synthesis<br />
of 11C labelled amide and ester molecules via the<br />
palladium mediated 11C-carbonylation reaction.<br />
Methods: The microfluidic reactor (figure 1) was<br />
fabricated from glass using chemical wet etching<br />
techniques and contains two inlets, one outlet and a<br />
5 metre long reaction channel. A simple mixing tee<br />
motif is used bring the gas and liquid reagents into<br />
contact with each other. The palladium mediated<br />
11C-carbonylation reaction of a range of aryl halides<br />
was investigated (scheme 1). In a typical 11CO<br />
labelling experiment the coupling reagents (aryl halide,<br />
palladium catalyst and amine) were premixed<br />
and loaded into a 50 uL loop on an injector port.<br />
11CO, produced via the high temperature reduction<br />
of 11CO2 over Mo, was preconcentrated and trapped<br />
onto molecular sieves. The coupling reagents were<br />
injected into the microfluidic device while at the<br />
same time 11CO was released from the molecular<br />
sieves and passed into the device for reaction.<br />
Results: The total reaction and processing times for<br />
a typical reaction, including trapping and release of<br />
X<br />
+<br />
H 2 N<br />
R<br />
X = I or Br;<br />
R = CN, CF3 or OCH3 Scheme 1<br />
11 CO, Pd catalyst<br />
microfluidic chip<br />
R<br />
O<br />
* N<br />
H<br />
11CO, was 15 min from end of bombardment. A series<br />
of amide and ester molecules were labelled with<br />
11C using our microfluidic reaction system (scheme<br />
1). Radiochemical yields (RCY) of labelled products<br />
were found to be dependent on the type of aryl halide<br />
and nucleophile used for the reaction. Generally,<br />
iodoaryl substrates with activating groups (CF3<br />
or CN) gave consistently higher RCYs (>80%) and<br />
radiochemical purities (>95%) than aryl halide substrates<br />
with deactivating groups (OCH3).<br />
Conclusions: A glass fabricated microfluidic device<br />
has been used to effectively perform high speed 11CO<br />
radiolabelling reactions. The larger surface area-tovolume<br />
ratio within the microfluidic reactor improves<br />
the gas liquid contact area and is thought to enhance<br />
the problematic CO insertion step of this reaction.<br />
Acknowledgement: PWM is grateful to the EPSRC for the<br />
award of a Life Sciences Interface fellowship (EP/E039278/1).<br />
References:<br />
Figure 1<br />
1. P. W. Miller et al., Angew. Chem. Int. Ed., 2008, 47,<br />
8998.<br />
2. P. W. Miller, J. Chem. Technol. Biotechnol. 2009, 84, 309.<br />
3. B. Langstrom et al., J. Labelled Compd. Radiopharm.,<br />
2007, 50, 794.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-076<br />
poStEr<br />
TECHNOLOGY
WarSaW, poland May 26 – 29, 2010<br />
P-077 Boosting image quality in low-dose RC-gated 5D cone-beam micro-CT<br />
190<br />
Sawall S. (1) , Bergner F. (1) , Lapp R. (2) , Mronz M. (2) , Karolczak M. (1) , Kachelrieß M. (1) .<br />
(1) Institute of Medical Physics (IMP), Erlangen, Germany<br />
(2) CT Imaging GmbH, Erlangen, Germany<br />
stefan.sawall@imp.uni-erlangen.de<br />
Introduction: Micro-CT imaging of the animal<br />
heart typically requires respiratory and cardiac<br />
(RC) gating. This can either be done prospectively<br />
or retrospectively. For functional imaging, and<br />
for multi-modality imaging, it is often desired to<br />
obtain the full 5D information (volumetric + respiratory<br />
+ cardiac) and retrospective gating is<br />
the method of choice. The amount of information<br />
available to reconstruct one volume for a given respiratory<br />
and cardiac phase is significantly lower<br />
than the total amount of information acquired.<br />
For example the reconstruction of a volume from a<br />
10% wide respiratory and a 20% wide cardiac window<br />
uses only 2% of the data acquired. Achieving<br />
a similar image quality as a non-gated scan would<br />
typically require to increase the dose by a factor of<br />
up to 50. Our aim is to provide similarly high image<br />
quality at low dose levels (100 to 500 mGy).<br />
Methods: We implemented a two-step iterative image<br />
reconstruction algorithm based on the McKinnon-Bates<br />
approach. The first step, aiming at R<br />
gating only, uses a prior image consisting of the<br />
reconstruction of all data. The RC gating step uses<br />
the image of the first step as a prior. An edge-preserving<br />
anisotropic diffusion filter is applied to the<br />
volume data after each iteration to perform spatial<br />
and temporal resolution-preserving noise reduction<br />
in up to five dimensions. We demonstrate our<br />
new reconstruction approach using mouse data<br />
scanned with a dedicated in-vivo micro-CT scanner<br />
(TomoScope Synergy, CT Imaging GmbH, Erlangen,<br />
Germany). We derived an intrinsic gating<br />
signal (kymogram) from the rawdata to synchronize<br />
our reconstruction. The scan itself consisted<br />
of ten rotations with 7200 projections in total.<br />
imaging life<br />
The scan time was five minutes, the tube voltage 65<br />
kV. The gating window widths were set to 10% in the<br />
respiratory and to 20% in the cardiac cycle.<br />
Results: Although the mouse data available to us<br />
shows only an untypically low enhancement of about<br />
110 HU (blood vs. myocardium) our approach yields<br />
an image noise of as low as 35 HU while preserving the<br />
spatial resolution of about 100 µm. We also performed<br />
a standard RC-gated reconstruction. Its high noise<br />
levels of about 170 HU are prohibitive and significant<br />
artifacts are observed due to sparse view sampling.<br />
The dose of our protocol is about 500 mGy. Reconstructions<br />
using less than the available 10 rotations<br />
show that one can achieve good image quality in<br />
RC-gated micro-CT with about 100 mGy, provided<br />
that the contrast agent delivers sufficient contrast.<br />
Conclusions: Using advanced image reconstruction<br />
techniques enables us to perform high fidelity<br />
low-dose double-gated imaging of free breathing<br />
small animals.<br />
Acknowledgement: This work was supported by<br />
the Deutsche Forschungsgemeinschaft (DFG) under<br />
grant FOR 661.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Methodological approach using microscopy for quantitative evaluation of neo-angiogenesis<br />
and tumour progression in pre-clinical cancer models<br />
Thézé B. , Beynel A. , Chapotot L. , Boisgard R. , Tavitian B. .<br />
CEA /Inserm 1023, Orsay, France<br />
benoit.theze@cea.fr<br />
Introduction: In vivo molecular imaging methods can<br />
localize sites of angiogenesis and obtain functional<br />
data, whereas microscopic methods provide their<br />
highest resolution on preserved tissue specimens. To<br />
bridge the gap between molecular imaging methods<br />
and microscopy, we developed a method to evaluate<br />
neo-angiogenesis and tumour volume on formalinfixed<br />
tissues samples.<br />
Methods: In order to visualize the mammary tumour<br />
vessels density in the MMTV-PyMT transgenic model<br />
of mammary carcinoma, mice were injected i.v.<br />
with Horse Radish Peroxidase (HRP)– tomato lectin<br />
(at 6.66 g/kg), which binds surface glycoproteins of<br />
red blood cells and endothelial cells inside the vascular<br />
lumen. Tumours were immediately sampled, fixed<br />
in formalin and frozen. For this pilot study, four tumours<br />
from each of two mice were sectioned every<br />
300 µm . For every section, HRP-lectin was revealed<br />
with 3,3´-diaminodbenzidine (DAB) and the tissues<br />
were counterstained with haematoxylin. Panoramic<br />
views of each tissue section were acquired in brightfield<br />
with a motorized AxioObserver Z1 Zeiss microscope.<br />
Tissue staining and image acquisition parameters<br />
were standardized for quality control. Using<br />
imageJ image analysis software, a macro was developed:<br />
(i) to separate blue and brown colours from the<br />
RGB original image using the colour deconvolution<br />
plugin in batches of images, and (ii) to evaluate the<br />
area occupied by the tumour in the whole sample. A<br />
treatment pipeline was designed with the Cellprofiler<br />
software for threshold and segmentation of vessels<br />
(brown) versus tumour masses (blue). Object-based<br />
filtering was applied to vessels according to their size<br />
and to their localization inside or outside of the tumour<br />
masses in order to separate neo-vessels from<br />
pre-existing vessels and areas of necrosis.<br />
Results: Using this approach, we were able to measure<br />
areas occupied by vessels and tumours and, (i)<br />
to obtain an estimate of neo-angiogenesis defined as<br />
the ratio between tumour blood vessels’ volume and<br />
tumour volume (1.27% ± 0.61%), (ii) to determinate<br />
the real volume of tumour in the sample (75%<br />
± 7%), which also contain muscular, adipose and<br />
conjunctive tissue, (iii) to obtain the ratio between<br />
total blood volume and total sample volume (5.99%<br />
± 0.42%), and (iiii) to discriminate between small<br />
(55% ± 9.6%), medium (32% ± 2.8%), and large<br />
(12.9% ± 7.8%) blood vessels.<br />
Conclusions: The data from this feasibility study<br />
provides morphological information about the vascular<br />
network in the PyMT model. Further validation<br />
steps should now allow correlating the results<br />
with functional information obtained by PET imaging,<br />
and provide a method for the evaluation of antiangiogenic<br />
drugs in animal tumour models.<br />
Fig1 from left to right: original image, blue and brown colour deconvolved images and final segmented image<br />
Acknowledgement: This work was supported by the<br />
6th FW EU grants EMIL (LSHC-CT-2004-503569)<br />
and DiMI (LSHB-CT-2005-512146)<br />
References:<br />
1. Rasband, W.S., ImageJ, U. S. National Institutes of<br />
Health, 1997-2009<br />
2. Jones TR et al. (2008) CellProfiler Analyst: data<br />
exploration and analysis software for complex imagebased<br />
screens. BMC Bioinformatics<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-078<br />
poStEr<br />
TECHNOLOGY
192<br />
WarSaW, poland May 26 – 29, 2010<br />
P-079 Changes of heart stroke volume index established by 99m Tc MIBI GSPECT scintigraphy after<br />
radioiodine treatment of patients with subclinical hyperthyroidism<br />
Kaminski G. , Podgajny Z. , Szalus N. , Bilski M. , Dziuk M. .<br />
Military Institute of Health Services, Warsaw, Poland<br />
gkam@wim.mil.pl<br />
Introduction: Stroke volume index (SVI) is an indicator<br />
of heart load. Increased heart load is one of<br />
causes of cardiac death. Subclinical hyperthyroidism<br />
(SH yper ) increases mortality mostly due to cardiovascular<br />
events. SH yper affects about 1% of population including<br />
patients with cardiovascular diseases. The<br />
aim of the investigation was to estimate an influence<br />
of cure with radioiodine of SH yper on heart stroke volume<br />
index (SVI) measured by heart scintigraphy -<br />
99m Tc MIBI GSPECT.<br />
Methods: 44 patients (37 women, 7 men) aged<br />
45.9±11, with 12.8±9.8 month history of only autonomous<br />
SH yper (TSH=0.16±0.1 IU/l), were examined<br />
with 99m Tc MIBI GSPECT twice: before<br />
and 5.7±4.2 months after TSH normalization<br />
(TSH=1.32±0.1 IU/l) after radioiodine treatment<br />
(at dose 12.1±5.7 mCi) . The radioiodine ( 131 I)<br />
and 99m Tc MIBI were carried by POLATOM/Poland.<br />
The average time between examinations was<br />
12.5 ± 6 months. The Local Ethical Committee approval<br />
for this investigation has been obtained.<br />
Results: The cure of SH yper caused decrease of SVI<br />
from 26.36 to 24.21 ml/m 2 (p=0.042)<br />
Conclusions: Cure of autonomous subclinical hyperthyroidism<br />
with radioiodine decreases heart<br />
load. This finding indicates to treat subclinical hyperthyroidism,<br />
especially in patients with cardiovascular<br />
diseases.<br />
imaging life<br />
[ml/m 2 ]<br />
27<br />
26<br />
26<br />
25<br />
25<br />
24<br />
24<br />
23<br />
26,36<br />
przed po<br />
24,21<br />
Fig.1. Mean values of SVI before (left) and after (right) radioiodine<br />
treatment p = 0,042)<br />
References:<br />
1. Parle J.V., Maissoneuve P., Sheppard M.C., Boyle P.,<br />
Franklyn J.A.: Prediction of all- cause and cardiovascular<br />
mortality in elderly people from one low serum<br />
thyrotropin result: a 10 -year cohort study.<br />
2. Lancet, 2001, 358: 861 - 865.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
PET/CT investigations with 68Ga-DOATATE in neuroendocrine tumors - first clinical<br />
experience<br />
Kunikowska J. (1) , Krolicki L. (2) , Pawlak D. (3) , Kobylecka M. (2) .<br />
(1) Medical University of Warsaw, Poland<br />
(2) Medical University of Warsaw, Poland<br />
(3) IEA POLATOM, Świerk, Poland<br />
jolanta.kunikowska@wum.edu.pl<br />
Introduction: Neuroendocrine tumors (NETs) have<br />
distinct biological and clinical characteristics, in<br />
particular a high density of somatostatin receptors<br />
at the cell membrane. It is this property that allows<br />
the use of radiolabeled somatostatin analogs for imaging<br />
of these tumors. Novel techniques PET/CT<br />
with 68Ga-DOTATATE open new possibilities in the<br />
diagnosis of patients with NET. Sensitivity of that<br />
techniques is depending on SSTR expression, but average<br />
range is 60-94%.<br />
The aim of this study was to evaluate the diagnostic<br />
usefulness of a new somatostatin analog, 68Ga-<br />
DOTATATE, for PET/CT in patients with diagnosis<br />
of neuroendocrine tumors.<br />
Methods: 55 patients with NET were examined (24<br />
men, 31 women; age range, 18-86 y; mean age +/- SD,<br />
51.4 +/- 12.5 y). For analysis, patients were divided into<br />
3 groups: detection of unknown primary tumor (n =<br />
13 patients), follow-up after surgery (n = 23 patients),<br />
staging of disease (n= 19). PET imaging was performed<br />
on PET/CT scanner Biograph 64, 60 minutes<br />
post injection of 120-185 MBq 68Ga-DOTATATE.<br />
Results: In the group patients with unknown primary<br />
tumors, 68Ga-DOTATATE revealed 9 primary<br />
foci. 7 were not visible in CT (4 in intestinum, 3 in<br />
pancreas) and 2 foci observed in CT and PET/CT<br />
- small nodule in lung. In 4 cases primary tumors<br />
were not found.<br />
In the cases of patients after surgery, examination<br />
shown new foci in 5 patients (liver-3, lymph nodes<br />
in abdominal cavity-2, peritoneum-1, pancreas-1).<br />
In the group of staging of disease in 12/19 cases<br />
PET and CT shown the same foci. In 7/19 (37 %)<br />
patients in 68Ga-DOTATATE examination was revealed<br />
new lesions (intestinum-1, liver-3, bone-1,<br />
pancreas-4, lymph nodes in abdominal cavity-2)<br />
Conclusion: Results of our study shown that 68Ga-<br />
DOTATATE PET/CT is very useful non-invasive<br />
techniques in diagnosis of patients with NET.<br />
68Ga-DOTATATE PET/CT examination should<br />
be performed for staging and restaging of disease<br />
and it gives more clinically useful information<br />
than CT.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-080<br />
poStEr<br />
ENDOCRINE DISEASES
194<br />
WarSaW, poland May 26 – 29, 2010<br />
P-081 Influence of number of subsets and iterations of Ordered Subsets Expectation Maximization<br />
(OSEM 3D Flash) reconstruction on quantitative assessment of small and medium detected<br />
lesions in SPECT study with used in 99m Tc[EDDA/HYNIC]Octreotate for patients with GEP-NET<br />
Lenda-Tracz W. .<br />
Nuclear Medicin Unit, Krakow, Poland<br />
wtracz@su.krakow.pl<br />
Introduction: The algorithm OSEM 3D Flash generally<br />
is the most appropriate available method of<br />
reconstruction. The choice of appropriate sets of<br />
OSEM 3D Flash reconstruction is crucial in interpretation<br />
of scintigraphy images. The number<br />
of subsets and iterations significantly influences<br />
the lesion to noise ratio. Therefore the aim of the<br />
study was to find the optimum number of subsets<br />
and iterations which present the most effective<br />
lesion to noise ratio in quantitative assessment<br />
of small and medium lesions detected with<br />
the use of 99m Tc[EDDA/HYNIC]Octreotate.<br />
Methods: The results of 20 patients with confirmed<br />
neuroendocrine tumors (GEP-NET) were<br />
analyzed. SPECT studies, acquisition 3-4 h after<br />
injection of 740 MBq 99m Tc[EDDA/HYNIC]<br />
Octreotate, were performed. The E.CAM 180<br />
(Siemens), double-head gamma-camera, was<br />
equipped with parallel, low-energy, high-resolution<br />
collimators. Data were acquired with 180<br />
rotation with 128 non-circular projections (30s<br />
per view) using a 128x128 matrix with 1.23 zoom.<br />
OSEM 3D Flash reconstruction (subsets number<br />
8, 16, 32 for 2-30 iterations) was performed.<br />
Results: Lesion to noise ratio in voxels was analyzed<br />
for different setting combinations (n,m)<br />
of number of subsets (n) and iterations (m) of<br />
OSEM 3D Flash reconstruction. An increasing<br />
number of subsets and iterations influences the<br />
increasing values of lesion to noise ratio. No difference<br />
for settings (16,m) and (32,m) was observed<br />
for quantitative assessment of small and<br />
medium lesions detected. Differences between lesion<br />
to noise ratio were observed in a group with<br />
8 subsets (8,m). However, the quality of images is<br />
variable for all setting combinations (n,m).<br />
Conclusions: The high number of subsets improves<br />
the image quality and the images are<br />
smoother. The increasing number of iterations<br />
on the one hand gives a little better contrast but<br />
on the other hand the shape of the lesions and organs<br />
is sharper. In spite of the fact that the image<br />
quality is changed with the increasing number of<br />
subsets and iterations, for quantitative assessment<br />
imaging life<br />
only (8,m) setting is changed significantly. Therefore,<br />
for quantitative assessment the best choice<br />
is setting with 8 subsets and 2-30 iterations but at<br />
least 6 and no more than 22 iterations with step<br />
equal at least 4 iterations. The appropriate number<br />
of iterations depends on the image quality<br />
assessment.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
The precise localization of metastatic lesion with used SPECT/CT with CoDe system after<br />
131I – MIBG therapy in patients with disseminated pheochromocytoma<br />
Szalus N. (1) , Podgajny Z. (2) , Kaminski G. (3) , Mazurek A. (1) , Giżewska A. (1) , Dziuk E. (1) .<br />
(1) Department of Nuclear Medicine,Military Institute of Medicine, Warsaw, Poland<br />
(2) Department of Endocrinology and Radioisotope Therapy2 - Military Institute of Medicine, Warsaw, Poland<br />
(3) Department of Endocrinology and Radioisotope Therapy - Military Institute of Medicine, Warsaw, Poland<br />
nszalus@wp.pl<br />
Introduction: Pheochromocytoma is a rare tumor<br />
that originates from chromaffin cells such as the adrenal<br />
medulla and sympathetic ganglia. Malignant<br />
pheochromocytoma is uncommon, and metastases<br />
typically affect the bones, liver, lungs, and lymph<br />
nodes. Meta-iodo-benzyl guanidine (MIBG) is a<br />
norepinephrine analog, and 131I- and 123I-MIBG<br />
have been widely used for the diagnosis of pheochromocytoma.<br />
This technique has high specificity and<br />
detectability not only for primary tumors but also<br />
metastatic lesions when compared with morphologic<br />
imaging such as computed tomography (CT) and<br />
magnetic resonance imaging (MRI). Co-registered<br />
data have been shown to be useful in the evaluation<br />
of patients with cancer at diagnosis and staging, in<br />
monitoring the response to treatment, and during<br />
follow up, for early detection of recurrence. Gamma<br />
camera with CoDe system is a new modality to the<br />
PET/CT and SPECT/CT imaging to the precise localization<br />
metastatic lesions.<br />
Aim of study: The aim of this study is to investigate<br />
the precise localization 131-MIBG with used SPECT/<br />
CT CoDe system for metastatic diseases in patients<br />
with malignant pheochromocytoma.<br />
Material and methods: Two patients with disseminated<br />
pheochromocytoma (the first patient with metastases<br />
to the liver, bones and lung; the second with<br />
metastases to the bone) were referred for study. Routine<br />
whole body scan with I-131 was performed with<br />
a dual head gamma camera (Infinia Hawkeye General<br />
Electric Milwaukee with CoDe system, USA) using<br />
a large field of view with high energy collimator<br />
a 20 % energy window centered at 364 keV and, 1024<br />
x 512 matrix. The data acquisition was performed 72<br />
hours after 131-MIBG therapy. Whole body anterior<br />
and posterior views were obtained. SPECT images of<br />
thorax and abdomen were obtained with 45 sec/frame,<br />
60 projections, 20 % window centered at 364 keV,<br />
matrix size of 128 x 128 and zoom factor of 1.0. This<br />
was followed by CT acquisition using single slice (1<br />
cm thickness). Using volumetrix software in Xeleris,<br />
fused images in coronal, sagittal and transaxial views<br />
were then obtained. Whole body planar images were<br />
first interpreted alone. Then, they were reassessed<br />
with the addition of SPECT/CT coregistered images.<br />
Results: 1. In these patients SPECT/CT revealed<br />
30 % more pathological lesions than planar studies<br />
alone. 2. SPECT/CT provided precise anatomical<br />
localization not clearly evident in planar images<br />
alone. 3. It also enabled exclusion of disease in sites<br />
of physiologic tracer deposition found suspicious in<br />
planar studies alone<br />
Conclusion: SPECT/CT allows more precise localization<br />
and interpretation of 131I-MIBG whole<br />
body scan thereby improving its diagnostic accuracy.<br />
It also has impact on correct restaging after therapy<br />
with 131I-MIBG preparation.<br />
References:<br />
1. Bas Havekes at al. Clinical Endocrinology (2010) 72,<br />
137–145<br />
2. Akie Takano at al. Ann Nucl Med (2008) 22:395–401<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-082<br />
poStEr<br />
ENDOCRINE DISEASES
196<br />
WarSaW, poland May 26 – 29, 2010<br />
P-083 Multimodal in vivo imaging of pancreatic beta-cells via antibody mediated targeting of<br />
beta-cell tumors<br />
Vats D. (1) , Dikaiou K. (1) , Stuker F. (1) , Honer M. (2) , Wang H. (3) , Schibli R. (2) , Rudin M. (1) .<br />
(1) Institute for Biomedical Engineering, ETH Zurich, Zurich, Switzerland<br />
(2) Institute of Pharmaceutical Sciences, ETH Zurich, Switzerland<br />
(3) F.Hoffman La-Roche, Basel, Switzerland<br />
vats@biomed.ee.ethz.ch<br />
Introduction: Pancreatic beta-cells regulate glucose<br />
metabolism by producing and secreting insulin in<br />
sufficient amounts. Progressive loss of beta-cell mass<br />
and function surmounts to acute diabetes. Diagnosis<br />
of diabetes and the evaluation of potential therapeutics<br />
suffer from lack of established methods for in<br />
vivo imaging of beta-cells. This study demonstrated<br />
the in vivo targeting of a novel antibody to a beta-cell<br />
surface protein in beta-cell tumor models. The pilot<br />
study evaluated the binding capacity of 89 Zr-lableled<br />
and alexa680 labeled monoclonal antibody against<br />
hTMEM27, a human beta-cell surface glycoprotein<br />
(1), for targeted imaging of beta-cell tumors in nude<br />
mice using positron emission tomography (PET) and<br />
fluorescence imaging.<br />
Methods: Insulinoma cell-line (beta-cells), Ins1E,<br />
was taken as the parental cell-line for generating<br />
stable cell lines (2) over-expressing hTMEM27 (Ins-<br />
TM) while blank Ins1E cells (Ins-only) were taken<br />
as controls. Ins-TM and Ins-only cells were used to<br />
generate subcutaneous tumors in nude mice. 1.5MBq<br />
of 89 Zr-anti-hTMEM27 monoclonal antibody ( 89 Zr-<br />
in vivo fluorescence imaging<br />
Ins-TM Ins-only Ins-TM-HA<br />
ROI ROI ROI<br />
alexa680-anti-hTMEM-mAb alexa680-anti-HA-mAb<br />
TM-mAb) and 2mg/kg alexa680-anti-hTMEM27<br />
monoclonal antibody (alexa680-TM-mAb) and<br />
alexa680-anti-HA control monoclonal antibody (alexa680-HA-mAb)<br />
were injected i.v. in tumor bearing<br />
nude mice. The animals were in vivo imaged three<br />
days after antibody administration: PET for 89 Z-TMmAb<br />
and fluorescence imaging (both near infrared<br />
fluorescence reflectance imaging and near infrared<br />
fluorescence molecular tomography (NIR-FMT)) for<br />
alexa680-TM-mAb and alexa680-HA-mAb. The antibody<br />
retention was quantified using gamma counting<br />
of excised tumors for the 89 Zr labeled antibody and<br />
the fluorescence intensity was derived from region<br />
of interest (ROI) quantification for reflectance mode<br />
and NIR-FMT data (using MATLAB tools). The<br />
data was compared between the hTMEM27 over expressing<br />
insulinomas (Ins-TM), control insulinomas<br />
imaging life<br />
(Ins-only) and control antibody in hTMEM27 over<br />
expressing tumors (TM-HA), for antibody specificity<br />
over a period of 6 days. Individual tumors from<br />
optical study were further subjected to histological<br />
analysis for accurate localization of the dye distribution<br />
within tumor tissue.<br />
Results: We found 6-7 times higher retention of the<br />
antibody in TMEM27 over expressing beta-cells,<br />
when compared to control beta-cells or with control<br />
antibody by both 89 Zr-PET and NIR-imaging (Figure<br />
1). The fluorescence microscopy results confirmed<br />
antibody retention to TMEM27 in target insulinomas<br />
(Ins-hTMEM-tumors).<br />
Conclusions: The pilot study could demonstrate<br />
the dual modal imaging of beta-cell mass, in a betacell<br />
tumor model, and identified a novel antibody<br />
for image-guided targeting of a beta-cell surface<br />
glycoprotein.<br />
Acknowledgement: This work is funded by<br />
F.Hoffmann La-Roche Ltd.<br />
Figure 1.<br />
Av. Fl. intensitiy<br />
References:<br />
1.40E+05<br />
1.20E+05<br />
1.00E+05<br />
8.00E+04<br />
6.00E+04<br />
4.00E+04<br />
2.00E+04<br />
0.00E+00<br />
Fluorescence quantification<br />
pre 24h 3d 6d<br />
Time after injection<br />
Ins-only<br />
Ins-TM<br />
Ins-TM-HA<br />
1. Akpinar P et al.; Cell Metab. 2(6):385-97 (2005)<br />
2. Wang H and Iyenedjian P B.; PNAS. 94: 4372-4377<br />
(1997)
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
6-[ 18 F]Fluoro-PBR28, a novel TSPO 18 kDa radioligand for imaging neuroinflammation with<br />
PET<br />
Boisgard R. (1) , Damont A. (1) , Blossier A. (1) , Jego B. (1) , Siquier K. (1) , Kassiou M. (2) , Dolle F. (1) , Tavitian B. (1) .<br />
(1) CEA, Orsay, France<br />
(2) Sydney University, Australia<br />
raphael.boisgard@cea.fr<br />
Introduction: The peripheral benzodiazepine receptor<br />
(PBR or TSPO 18 kDa) is expressed by microglial<br />
cells in many neuropathologies involving<br />
neuroinflammation. [ 11 C]PK11195 is today the<br />
most widely used radioligand for the in vivo imaging<br />
of PBR using PET, and this in spite of its low<br />
brain uptake and its high level of non-specific binding.<br />
Numerous PK11195 challengers are currently<br />
under investigation [1,2], and of particular interest<br />
are the N-benzyl-N-(2-phenoxyaryl)-acetamides, a<br />
series which includes [ 11 C]PBR28 [3]. A fluorinecontaining<br />
analogue, namely 6-fluoro-PBR28 (N-(2methoxybenzyl)-N-(6-fluoro-4-phenoxypyridinyl-<br />
3-yl)acetamide), has been labeled with the longer<br />
half-life positron-emitter fluorine-18 and pharmacologically<br />
evaluated in a rat model of neuroinflammation<br />
(unilaterally, AMPA-induced, striatum-lesioned<br />
rats) with PET.<br />
A<br />
18 F<br />
N<br />
N<br />
O<br />
O<br />
O<br />
B<br />
Fig1: Structure of 6-[18F]fluoro-PBR28 (A) and microPET images (B) obtained in AMPA lesioned rat (60 min p.i.)<br />
Methods: 6-Fluoro-PBR28, as well as the corresponding<br />
precursors for labeling, were synthesized<br />
from 4-chloro-3-nitropyridine. 6-Fluoro-PBR28 was<br />
labeled with fluorine-18 by nucleophilic heteroaromatic<br />
substitution using K[ 18 F]F-Kryptofix ® 222,<br />
purified by HPLC (Waters Symmetry ® C-18) and<br />
formulated for i.v. injection. The AMPA rat model<br />
was used to study in vitro and in vivo specific and<br />
non-specific binding using autoradiography and<br />
µPET imaging on a Concorde Focus P220 PET<br />
camera, including displacement with PK11195<br />
and non-labeled 6-fluoro-PBR28 (1 mg/kg).<br />
Results: Starting from a 37 GBq cyclotron-produced<br />
[ 18 F]fluoride batch, 3.3-3.7 GBq of 6-[ 18 F]<br />
fluoro-PBR28, > 99% radiochemically pure and<br />
ready-to-inject, were obtained within 90 minutes<br />
(Figure 1A). In PET experiments, 6-[ 18 F]fluoro-<br />
PBR28 showed a higher contrast between the lesioned<br />
area and the corresponding area in the intact<br />
contralateral hemisphere (ratio ipsi/contra at<br />
60 min post-injection: 6-[ 18 F]fluoro-PBR28 : 2.2)<br />
(Figure 1B). Furthermore, 6-[ 18 F]fluoro-PBR28<br />
was displaced by PK11195 or 6-fluoro-PBR28. Finally,<br />
modelisation of the PET data using the “simplified-reference-tissue-model”<br />
showed increased<br />
binding potential (BP) in comparison to the BP<br />
of [ 11 C]PK11195 measured in the same model<br />
(2.0±0.6 versus 1.1±0.2). Immunohistochemical<br />
analyses correlate with PET-imaging and showed<br />
strong activation of microglia in and around the<br />
lesion.<br />
Conclusions: Dynamic µPET studies in rats demonstrate<br />
the potential of 6-[ 18 F]fluoro-PBR28 to<br />
image neuroinflammation.<br />
Acknowledgements: Supported in part by the EC -<br />
FP6-project DiMI (LSHB-CT-2005-512146) and<br />
EMIL (LSH-2004-503569).<br />
References:<br />
1. Chauveau F et al; Eur J Nucl Med Mol Imag 35: 2304-<br />
2319 (2008)<br />
2. Dollé F et al; Curr Med Chem 16: 2899-2923 (2009)<br />
3. Briard E et al. J Med Chem 51: 17-30 (2008)<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-084<br />
poStEr<br />
INFECTION and INFLAMMATION
WarSaW, poland May 26 – 29, 2010<br />
P-085 Neuroinflammation is increased in the brain of ageing corpulent (JCR:LA-cp) rats: a positron<br />
emission tomography study<br />
198<br />
Boutin H. (1) , Drake C. (1) , Denes A. (1) , Mccoll B. (1) , Prenant C. (1) , Brown G. (1) , Kassiou M. (2) , Herholz K. (2) , Rothwell N. (2) .<br />
(1) University of Manchester, United Kingdom<br />
(2) University of Sydney, Australia<br />
herve.boutin@manchester.ac.uk<br />
Introduction: Despite intense research and development<br />
of several animal models, drugs efficient in<br />
preclinical model of cerebral ischaemia so far have<br />
failed when reaching clinical trial [1] . One striking<br />
feature of the animal models is the lack of co-morbidities<br />
and risk factors when compared to clinical<br />
set-up, in which patients have atherosclerosis, high<br />
blood pressure, chronic and/or acute inflammation<br />
due to chronic inflammatory diseases and infections.<br />
Inflammation and neuroinflammation in particular<br />
are known aggravating factors of stroke outcome [2] .<br />
Here we investigate the impact of known risk factors<br />
of stroke such as obesity and atherosclerosis in<br />
JCR:LA-cp (corpulent) rats on neuroinflammation as<br />
measured by TSPO expression in activated microglia.<br />
Methods: Neuroinflammation was assessed with<br />
[ 18 F]DPA-714 by PET in Lean (control: Cp/?)) and<br />
JCR:LA-cp (corpulent: Cp/Cp) rats PET imaging. 2<br />
groups of rats were scanned at 9 months or 12 and<br />
15 months of age (n=4 per group). PET images were<br />
co-registered with a MRI template [3] for analysis<br />
and automatic segmentation performed for userindependent<br />
ROI determination [4,5] . Euthanasia was<br />
performed at 9 months and 15 months of age 3 to 7<br />
days after PET imaging to assess various neuroinflammation<br />
biomarkers (GFAP, IBA1, VCAM) by<br />
immunohistochemistry (IHC).<br />
Results: Our results show an increase (+38%) in<br />
neuroinflammation in the brain of corpulent rats<br />
when compared to control. In older rats (12 and<br />
15 months old), neuroinflammation was even further<br />
increased but in both lean and corpulent rats.<br />
imaging life<br />
Neuroinflammation, as quantified by PET, was<br />
mainly localised in peri-ventricular and thalamic<br />
areas of the brains. IHC for microglial activation<br />
confirmed the PET data in 15 months old animals<br />
(Figure below).<br />
Conclusions: Our data show here the importance<br />
of including risk and co-morbidity factors in preclinical<br />
models of stroke as they have a significant<br />
impact on neuroinflammation. This study shows<br />
the crucial role of molecular imaging with the<br />
high translational value of PET imaging to investigate<br />
such paradigms. A more detailed study of<br />
the localisation of neuroinflammation as localised<br />
by PET and IHC is now ongoing. Further investigation<br />
either in animals<br />
with spontaneous<br />
stroke or with induced<br />
cerebral ischaemia will<br />
be required to compare<br />
the impact of co-morbidity<br />
and risk factors<br />
in this animal model.<br />
Acknowledgement: Prof. N. Rothwell and Dr H. Boutin<br />
are funded by MRC. This study was carried out<br />
within the EC-FP6 project DiMI (LSHB-CT-2005-<br />
512146) framework.<br />
References:<br />
1. Dirnagl U. (2006) J Cereb Blood Flow Metab. 26:1465-<br />
1478;<br />
2. McColl B.W. et al. (2009) Neuroscience. 158:1049-<br />
1061;<br />
3. Schwarz A.J. et al. (2006) Neuroimage. 32:538-550;<br />
4. Maroy R. et al. (2008) IEEE Trans.Med.Imaging. 27:342-<br />
354;<br />
5. Maroy R. et al. (2010) J Nucl Med (submitted).
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Detection of inflammatory diseases by NIRF imaging with specific probes targeting<br />
leukotriene receptor CysLT 1 R<br />
Busch C. (1) , Passon M. (1) , Lehmann F. (2) , Socher I. (1) , Kaiser W.A. (1) , Hilger I. (1) .<br />
(1) University Hospital Jena, IDIR, Jena, Germany<br />
(2) DYOMICS GmbH, Jena, Germany<br />
Corinna.Busch@med.uni-jena.de<br />
Introduction: Leukotriene synthesis occurs early<br />
in inflammatory processes and plays a major role<br />
for the recruitment of leukocytes to the inflamed<br />
region (1). A key representative of these eicosanoids,<br />
leukotriene D4 (LTD4), shows high affinity<br />
to G-protein coupled cysteinyl leukotriene<br />
receptor 1 (CysLT 1 R). Detection of CysLT 1 R by<br />
molecular imaging (2) with near-infrared (NIR)<br />
fluorophores could be a suitable diagnostic tool<br />
for early identification of inflammatory processes.<br />
Aim of this study was the design and characterization<br />
of NIRF-based contrast agents specifically<br />
targeting CysLT 1 R in order to develop future diagnostic<br />
tools for inflammatory diseases, particularly<br />
in early stages.<br />
Methods: Polyclonal rabbit CysLT 1 R antibody<br />
(CysLT 1 R*DY-734) or polyclonal rabbit-IgG<br />
(IgG*DY-734) as well as the corresponding Fab<br />
fragments (Fab-CysLT 1 R*DY-734, Fab-IgG*DY-<br />
734) were bound to activated NHS ester of NIRfluorophore<br />
DY-734 (Dyomics, Jena, Germany).<br />
Probes were characterized by determining dye/protein<br />
ratios. After verification of CysLT 1 R expression<br />
(PCR, flow cytometry) in HL-60 cells, binding<br />
of the synthesized probes in vitro was assessed by<br />
flow cytometry. In vivo, an ear edema was induced<br />
in mice (3), and NIR fluorescence was measured<br />
with whole body imaging system Maestro2.2 after<br />
i.v.-probe administration. Ex vivo biodistribution<br />
studies were performed.<br />
Results: Flow cytometry proved binding of CysLT 1 R*DY-<br />
734 and IgG*DY-734 to CysLT 1 R-expressing HL-60. In<br />
vivo, all probes revealed stronger binding to the edematous<br />
than to the corresponding healthy region. 6<br />
h post injection, specific CysLT 1 R*DY-734 and Fab-<br />
CysLT 1 R*DY-734 demonstrated 1.9 and 1.2 fold higher<br />
binding than IgG*DY-734 and Fab-IgG*DY-734,<br />
respectively. Investigation of isolated organs revealed<br />
that full length IgG´s are eliminated via liver, while<br />
Fab fragments additionally accumulated in kidney.<br />
Conclusions: A novel NIRF-based probe specifically targeting<br />
Leukotriene D 4 receptor CysLT 1 R allows detection<br />
of inflammatory processes in ear edema-induced<br />
mice in early stages.<br />
Acknowledgement: The present investigations were<br />
supported by the “Deutsche Forschungsgemeinschaft”<br />
within the DFG program Hi 689/6-1.<br />
References:<br />
1. Hui Y, Funk C. Cysteinyl leukotriene receptors. Biochem.<br />
Pharmacol. 2002;64:1549-57.<br />
2. Weissleder R, Mahmood U. Molecular Imaging.<br />
Radiology 2001;219:316-33.<br />
3. Kurnatowska I, Pawlikowski M. Anti-inflammatory<br />
effects of somatostatin analogs on zymosaninduced<br />
earlobe inflammation in mice:<br />
comparison with dexamethasone and ketoprofen.<br />
Neuroimmunomodulation 2001;9:119-24.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-086<br />
poStEr<br />
INFECTION and INFLAMMATION
200<br />
WarSaW, poland May 26 – 29, 2010<br />
P-087 PET imaging of Hypoxia by 18 F-Fluoromisonidazole ([ 18 F]FMISO) to detect early stages of<br />
experimental arthritis<br />
Fuchs K. (1) , Grießinger C. (1) , Fischer K. (1) , Mannheim J. (1) , Wiehr S. (1) , Judenhofer M. (1) , Reischl G. (2) , Röcken M. (3) ,<br />
Pichler B. (1) , Kneilling M. (3) .<br />
(1) Laboratory for Preclinical Imaging and Imaging Technology of the Werner Siemens-Foundation, Department of Radiology, Eberhard- Karls University,<br />
Tübingen, Germany<br />
(2) Radiopharmacy, Department of Radiology, Eberhard- Karls University, Tübingen, Germany<br />
(3) Department of Dermatology, Eberhard- Karls University, Tuebingen, Germany University Hospital Tübingen - Department of Radiology, Tübingen, Germany<br />
Kerstin.Fuchs@med.uni-tuebingen.de<br />
Introduction: Early detection of autoimmune diseases<br />
such as rheumatoid arthritis is essential for<br />
early interventional anti-inflammatory treatment<br />
to prevent cartilage- and bone deterioration. Hypoxia<br />
can induce angiogenesis via stabilization of<br />
the transcription factor hypoxia inducible factor<br />
(HIF)-1α/2α in resident and infiltrating cells by induction<br />
of pro-angiogenic mediators. Also, hypoxia<br />
is hypothesized to be one of the early indicators of<br />
inflammation. The aim of our study was to examine<br />
initial phases of hypoxia-induced angiogenesis and<br />
inflammation in rheumatoid arthritis, by in vivo<br />
small animal PET, even before clinical symptoms<br />
or histological joint inflammation are detectable.<br />
Therefore, we used the hypoxia tracer 18 F-Fluoromisonidazole<br />
([ 18 F]FMISO), which selectively accumulates<br />
in hypoxic tissue, and [ 18 F]Fluordesoxyglucose<br />
([ 18 F]FDG).<br />
Methods: We induced arthritis in BALB/c mice via<br />
intraperitoneal injection of serum containing autoantibodies<br />
against glucose-6 phosphate-isomerase<br />
(GPI). Mice underwent [ 18 F]FMISO-, or [ 18 F]FDG<br />
- PET investigations, 6 - 52 hours after induction<br />
of GPI-arthritis. Additionally, we performed H&Estaining,<br />
Western Blot (HIF-1α/2α) and real-time<br />
PCR analysis of gene expression patterns (bFGF,<br />
VEGF, IL-1β, TNF, IL-6, and COX-2) in joint tissue<br />
6 and 12 hours after initiation of arthritis.<br />
Results: Starting 6 hours after induction of GPI-arthritis<br />
we detected an enhanced [ 18 F]FMISO uptake<br />
in arthritic joints compared to healthy joints. Differences<br />
in [ 18 F]FMISO uptake between arthritic<br />
and healthy joints reached a level of significance 13<br />
hours after induction of GPI-arthritis. In contrast<br />
to [ 18 F]FMISO, no increase in [ 18 F]FDG-uptake was<br />
detectable at these early time points (6-13 hours).<br />
Comparable to the in vivo [ 18 F]FDG-PET data, no<br />
histological visible signs of arthritis were examined<br />
in H&E-stained slices of arthritic joint tissue. In line<br />
with the in vivo [ 18 F]FMISO-PET-data, RT-PCR analysis<br />
performed 6 hours after GPI-serum injection<br />
showed a 7.5-fold enhanced expression of HIF-2α<br />
mRNA. Interestingly, mRNA-levels of pro-angiogenic<br />
imaging life<br />
and pro-inflammatory mediators such as bFGF and<br />
VEGF, TNF, IL-6, and COX-2 were not elevated 6h<br />
after induction of GPI-arthritis. Starting 54h after<br />
induction of GPI-arthritis we detected significant<br />
differences in [ 18 F]FDG uptake in arthritic ankles,<br />
and a 6.5-1550 fold enhanced expression NF- k B induced<br />
genes such as COX-2, IL-6, IL-1β and, TNF.<br />
Conclusions: Non invasive in vivo examination of<br />
hypoxia-induced angiogenesis using [ 18 F]FMISO<br />
is a powerful tool to detect initial phases of angiogenesis<br />
in autoimmune diseases such as rheumatoid<br />
arthritis even before joint inflammation becomes<br />
detectable by other methods.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Intracellular [ 64 Cu]PTSM and extracellular [ 64 Cu]DOTA-antibody labelling of ovalbuminspecific<br />
Th1 cells for in vivo PET investigations of Th1 cell trafficking in OVA-specific lung<br />
inflammation<br />
Griessinger C.M. (1) , Wiehr S. (1) , Bukala D. (1) , Kesenheimer C. (1) , Röcken M. (1) , Ehrlichmann W. (3) , Reischl G. (3) , Pichler B. (1) ,<br />
Kneilling M. (2) .<br />
(1) Laboratory for Preclinical Imaging and Imaging Technology of the Werner Siemens-Foundation, Department for Radiology, Eberhard Karls University of<br />
Tübingen, Germany<br />
(2) Department for Dermatology, Eberhard Karls University of Tübingen, Germany<br />
(3) Radiopharmacy, Eberhard Karls University of Tübingen, Germany<br />
Christoph.Griessinger@med.uni-tuebingen.de<br />
Introduction: T helper cells play an important role<br />
in the development of autoimmune diseases. For detailed<br />
in vivo analysis of the migration properties of<br />
Th1 cells, high sensitive imaging modalities, such<br />
as small animal PET are powerful tools. So far basic<br />
migration properties like kinetics, homing, and<br />
sites of T cell proliferation in animal models for autoimmune<br />
diseases are still poorly understood. The<br />
aim of our study was to establish new T cell labelling<br />
strategies to gain new insights in Th1 cell trafficking<br />
in vivo using small animal PET. In our studies Th1<br />
cells were in vitro labelled intracellularly with the<br />
lipophilic tracer [ 64 Cu]PTSM or extracellularly with<br />
[ 64 Cu]DOTA-linked antibodies prior to injection<br />
into diseased mice and tracking by small animal PET.<br />
Methods: To investigate whether intracellular [ 64 Cu]<br />
PTSM labelling or extracellular [ 64 Cu]DOTA-antibody<br />
labelling impair ovalbumin (OVA)-specific<br />
Th1 cells, we analysed cell viability and functionality.<br />
OVA-T cell receptor (TCR) transgenic CD4+ T<br />
cells were isolated from spleen and lymph nodes of<br />
DO.11.10 mice and cultured together with irradiated<br />
antigen presenting cells (APC), Oligo 1668 peptide,<br />
anti-IL-4, and IL-2 for 12-14 days. 10 6 OVA-Th1 cells<br />
were labelled with 0.7 MBq [ 64 Cu]PTSM for 3 hours<br />
or with 0.7 MBq radiolabelled OVA-TCR-specific<br />
antibody (KJ1-26), which was linked to [ 64 Cu] via<br />
the chelator DOTA, for 0.5 hours. Th1 cell viability<br />
was assessed by trypan blue staining after incubation<br />
with increasing amounts of activity. Specific<br />
Th1 cell functioning was analyzed through interferon-gamma<br />
(ELISA) levels in supernatants of specific<br />
activated OVA-Th1 cells (T cells + irradiated APC +<br />
OVA peptide). In vivo T cell migration was investigated<br />
in an animal model for OVA-induced lung<br />
inflammation. Mice were sensitized with OVA (i.p.)<br />
and challenged intranasally twice after four weeks<br />
to induce OVA-specific lung inflammation. A total<br />
of 10 7 [ 64 Cu]PTSM or [ 64 Cu]DOTA-KJ1-26 antibody<br />
labelled OVA-Th1 cells were injected i.p. into diseased<br />
and healthy mice. Static PET-scans in combination<br />
with CT, biodistribution, and autoradiography<br />
were performed 24 and 48 hours after OVA-Th1<br />
cell transfer.<br />
Results: In vitro investigations revealed an activity<br />
dependent impairment of OVA-Th1 viability and<br />
functionality after [ 64 Cu]PTSM or [ 64 Cu]DOTA-<br />
KJ1-26 antibody labelling. After a time period of 24<br />
hours post labelling, the cell viability sunk to 80%<br />
and functionally was decreased by 20% compared<br />
to unlabelled control cells. Analyzing OVA-specific<br />
Th1 cell migration in the mouse model for lung inflammation,<br />
we detected an accumulation of [ 64 Cu]<br />
PTSM labelled OVA-Th1 cells in lung tissue and the<br />
thymus already 24h after the final challenge. Detection<br />
of [ 64 Cu]DOTA-KJ1-26 antibody labelled OVA-<br />
Th1 cells was even possible for up to 48 hours. In<br />
vivo PET data were further confirmed by ex vivo<br />
biodistribution and autoradiography. Compared to<br />
[ 64 Cu]PTSM labelled OVA-Th1 cells we gained a<br />
more defined distribution of extracellularly [ 64 Cu]<br />
DOTA-KJ1-26 labelled cells in the peritoneum (the<br />
site of injection), draining lymphatic tissue and the<br />
sites of OVA-specific lung inflammation. Furthermore<br />
we detected a significant accumulation of<br />
OVA-Th1 cells in the omentum majus.<br />
Conclusions: Both [ 64 Cu]-based labelling methods<br />
cause an impairment of Th1 cells viability and functionality.<br />
However, both labelling strategies are applicable<br />
for in vivo PET-imaging, revealing a detection<br />
limit of 500 OVA-Th1 cells in draining lymph<br />
nodes and sites of OVA-specific lung inflammation<br />
over a time period of 48 hours.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-088<br />
poStEr<br />
INFECTION and INFLAMMATION
202<br />
WarSaW, poland May 26 – 29, 2010<br />
P-089 [ 18 F]DPA-714, [ 18 F]PBR111 and [ 18 F]FEDAA1106: Radiosyntheses on a TRACERLAb FX-FN<br />
synthesizer<br />
Kuhnast B. , Damont A. , Demphel S. , Le Helleix S. , Boisgard R. , Tavitian B. , Dollé F. .<br />
CEA, Orsay, France<br />
bertrand.kuhnast@cea.fr<br />
Introduction: Neuroinflammation is involved in<br />
acute and chronic neurological disorders through<br />
the activation of microglial cells or the recruitment<br />
of peripheral macrophages. Both microglia and<br />
macrophage activation results in the notable overexpression<br />
on the outer mitochondrial membranes<br />
of the so-called translocator protein (TSPO 18 kDa),<br />
supporting today extensive efforts in the design of<br />
radioligands for the in vivo imaging of this pharmacological<br />
target by Positron Emission Tomography<br />
[1]. Of particular interest are DPA-714 [2], PBR111<br />
[3] and FEDAA1106 [4], three ligands belonging to<br />
different chemical classes (the pyrazolo[1,5-a]pyrimidineacetamides,<br />
the imidazo[1,2-a]pyridineacetamides<br />
and the N-benzyl-N-(2-phenoxyaryl)acetamides,<br />
respectively) but all designed for a<br />
labelling with the positron-emitter fluorine-18 via a<br />
tosyoxy-for-fluorine nucleophilic aliphatic substitution.<br />
Production of [ 18 F]DPA-714, [ 18 F]PBR111 and<br />
[ 18 F]FEDAA1106 on the advanced, commercially<br />
available, automated module TRACERLab TM FX-FN<br />
synthesizer is presented.<br />
Methods: The automated process implemented on<br />
the TRACERLab TM FX-FN synthesizer involves: (A)<br />
the preparation of the K[ 18 F]F-Kryptofix ® 222 complex<br />
in two heating steps, first at 60°C for 7 min<br />
under a stream of N 2 and then at 120°C under reduced<br />
pressure for 5 min, followed by (B) reaction<br />
of K[ 18 F]F-Kryptofix ® 222 with the appropriate tosylprecursors<br />
(4 to 5 mg) at 165°C for 5 min in DMSO<br />
(0.7 mL), then (C) SepPak ® Plus Alumina N cartridge<br />
pre-purification after dilution of the reaction mixture<br />
with HPLC solvent (4 mL) and finally (D) semipreparative<br />
HPLC purification. HPLC purifications<br />
were performed on a X-Terra® column for [ 18 F]DPA-<br />
714 (Solvent : NH 4 OAc 0.1M pH 10 / MeCN : 60/40<br />
(v/v), Flow rate : 5 mL/min, Rt = 11-12 min), on a<br />
Symmetry ® C-18 column for [ 18 F]PBR111 (Solvent :<br />
H 2 O / MeCN / PicB7 : 60/40/2 (v/v/v), Flow rate : 5<br />
mL/min, Rt = 14-15 min) and on a Symmetry ® C-18<br />
column for [ 18 F]FEDAA1106 (Solvent : H 2 O / MeCN<br />
/ TFA : 60/40/0.1 (v/v/v), Flow rate : 5 mL/min, Rt =<br />
21-22 min). The HPLC-collected fraction containing<br />
pure [ 18 F]DPA-714, [ 18 F]PBR111 or [ 18 F]FEDAA1106<br />
imaging life<br />
were automatically formulated using a SepPak ® Plus<br />
C-18 cartridge ((i) HPLC-collected fraction dilution<br />
and loading on the cartridge, (ii) cartridge washing<br />
with 10 mL of water, (iii) cartridge elution with 2 mL<br />
of EtOH, and (iv) final dilution with 8 mL of saline).<br />
The process was programmed on the TRACERLab TM<br />
FX-FN synthesizer in one single “method” divided<br />
in three “time-lists”.<br />
Results: Starting from a 37.0 GBq cyclotron-produced<br />
[ 18 F]fluoride batch, 6.7 to 8.5 GBq (18-23%<br />
non decay corrected yields) of [ 18 F]DPA-714 or [ 18 F]<br />
PBR111 or [ 18 F]FEDAA1106, > 99% radiochemically<br />
pure and ready-to-inject, were obtained within 50-<br />
60 min. The overall decay corrected radiochemical<br />
yield reached up to 30%. Specific radioactivities<br />
ranged from 74 to 222 GBq/µmol (2-6 Ci/µmol).<br />
Conclusions: Radiosynthesis of [ 18 F]DPA-714, [ 18 F]<br />
PBR111 and [ 18 F]FEDAA1106 has been successfully<br />
implemented on a TRACERLab TM FX-FN<br />
synthesizer.<br />
Acknowledgements: Supported in part by the EC -<br />
FP6-project DiMI (LSHB-CT-2005-512146) and<br />
EMIL (LSH-2004-503569).<br />
References:<br />
1. Dollé F et al; Curr Med Chem 16: 2899-2923 (2009)<br />
2. Damont A et al; J label Compds Radiopharm 51: 286-<br />
292 (2008)<br />
3. Dollé F et al; J label Compds Radiopharm 51: 435-439<br />
(2008)<br />
4. Zhang MR et al; J Med Chem 49: 2735-2742 (2006)
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
In vivo near-infrared fluorescence imaging of lung matrix metalloproteinases in an acute<br />
cigarette smoke-induced airway inflammation model in different mice strains<br />
Perez-Rial S., Del Puerto-Nevado L., Giron-Martinez A., Gonzalez-Mangado N., Peces-Barba G. .<br />
Instituto de Investigacion Sanitaria-Fundacion Jimenez Diaz-CIBERES, Madrid, Spain<br />
sperezr@fjd.es<br />
Introduction: Recent studies have suggested that<br />
pulmonary macrophage-derived metalloproteases<br />
(MMPs) are the critical mediators of cigarette smoke<br />
exposure (CSE)-induced emphysema, but it has never<br />
been seen via imaging techniques [1] . The purpose<br />
of this study was to visualize and quantify acute pulmonary<br />
inflammation by real-time near-infrared<br />
fluorescence (NIRF)-mediated molecular imaging<br />
[2] in the lung tissue evaluating MMPs activity in response<br />
to CSE in mice strains with different susceptibility<br />
to develop smoking-induced emphysema.<br />
Methods: To accomplish this task, susceptible<br />
(C57BL/6j) and resistant (129S2/SvHsd) mice [3]<br />
were exposed to acute CSE using a whole-body exposition.<br />
24h after CSE MMPs activity was assessed<br />
via optical imaging system by a MMPs-sensitive activatable<br />
fluorescence probe in order to characterize<br />
the distinctive profile of CSE-induced acute inflammation.<br />
Furthermore MMPs protein levels in the<br />
lung tissue were analyzed by Western blot analysis.<br />
Results: In vivo semiquan- in vivo lung imaging<br />
titative optical imaging<br />
analysis of MMPs activity<br />
in the lung revealed<br />
increased acute-CSE-associated<br />
MMPs activity in<br />
C57BL/6j but not in 129S2/<br />
SvHsd. Only in susceptible<br />
mice most important<br />
MMPs protein levels were<br />
significantly increased in the lung tissue of smokers<br />
compared with the non-smokers group.<br />
Conclusions: Optical imaging via NIRF offers a simple,<br />
effective, and rapid technique for noninvasive<br />
monitoring and semiquantitative analysis of lung<br />
inflammation and MMPs expression. We are able to<br />
distinguish between susceptible and resistant mice<br />
strains in terms of the profile of MMPs activity in<br />
the early stages of pulmonary disease. The results of<br />
our study suggest that mechanisms underlying different<br />
susceptibilities to CSE can be detected at the<br />
beginning of the disorder. They produce different<br />
response to acute tobacco smoke.<br />
Acknowledgement: This work is supported in part by the<br />
Spanish “Ministerio de Ciencia e Innovación” (SAF2008-<br />
05412-C02- 02) and CIBERES (CB06/06/0009).<br />
References:<br />
1. Churg A et al; Am J Respir Crit Care Med. 167(8):1083-9<br />
(2003)<br />
2. Haller J et al; J Appl Physiol. 104(3):795-802 (2008)<br />
3. Morris A et al; J Pharmacol Exp Ther. 327(3):851-62<br />
(2008)<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-090<br />
poStEr<br />
INFECTION and INFLAMMATION
204<br />
WarSaW, poland May 26 – 29, 2010<br />
P-091 Development and pre-clinical evaluation of a novel class of 18 F labelled PET ligands for<br />
evaluation of PBR/TSPO in the brain<br />
Trigg W. , Ahmad R. , Arstad E. , Avory M. , Hirani E. , Jones P. , Khan I. , Luthra S. , Morisson-Iveson V. , O’shea D. ,<br />
Passmore J. .<br />
GE Healthcare, Amersham, United Kingdom<br />
william.trigg@ge.com<br />
Introduction: The peripheral benzodiazepine receptor<br />
(PBR; otherwise known as TSPO (18kDa)) is a<br />
well-established target for imaging activated microglial<br />
cells and macrophages in inflammatory diseases<br />
such as MS, Alzheimer’s disease and a wide range<br />
of both peripheral and brain diseases 1 . Starting from<br />
a core tetracyclic indole pharmacophore 2 , which displayed<br />
high affinity for the PBR, we have designed<br />
a series of molecules to assess the SAR around the<br />
pharmacophore and to determine the best site to introduce<br />
the radiolabel.<br />
Methods: Compounds have been assessed for PBR<br />
affinity in a radioligand binding assay and in a range<br />
Compound (Ki)<br />
[ 11C]PK11195 (1.24nM)<br />
[ 18F]AH114011 (0.37nM)<br />
[ 18F]AH114629 (0.40nM)<br />
imaging life<br />
Initial brain<br />
uptake (%ID/g)<br />
OB @ 2 min<br />
(%ID/g)<br />
* Whole brain value not calculated<br />
** [3H]PK11195 used for autoradiography studies<br />
OB @ 30<br />
min<br />
(%ID/g)<br />
2:30 Striatum<br />
ratio<br />
OB : Striatum<br />
ratio<br />
(30 min)<br />
Metabolism<br />
Profile - % Parent<br />
in brain at 60<br />
min p.i.<br />
FNA Model lesion<br />
: non lesion ratio<br />
(in vitro)<br />
0.28-0.48* 0.42 0.21 3.20 2.10 100 2.8**<br />
0.32 0.39 0.31 1.73 2.07 96.0 2.3<br />
0.42 0.51 0.28 4.75 3.50 97.6 NT<br />
of in vitro ADME assays. Following on from the in<br />
vitro assessments, promising compounds were radiolabelled<br />
and assessed in vivo for biodistribution<br />
and metabolism profiles. The compounds with the<br />
most appropriate profiles were assessed using autoradiography<br />
in the Facial Nerve Axotomy (FNA)<br />
model described by Banati et al. 3<br />
The corresponding data for the archetypal PBR ligand<br />
PK11195 was generated for comparison.<br />
Results: The olfactory bulb (OB) has high expression<br />
of PBR and is used to measure specific uptake,<br />
with the striatum used as a low expression area for<br />
comparative purposes. Key data obtained are summarised<br />
in the table below.<br />
Conclusions: Preclinical evaluation of the 18F labelled<br />
tetracyclic indole class of ligands for PBR<br />
shows that this class of molecules represents a<br />
promising class of PET ligands that should be further<br />
evaluated.<br />
References:<br />
1. Cagnin et al., Neurotherapeutics, Vol. 4, No. 3, 443-452<br />
(2007)<br />
2. Okubo et al., Bioorg Med. Chem. 12(2):423-438 (2004)<br />
3. Banati et al., J. Neurocytol. 26:77-82. (1997)
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Local administration of adeno-associated virus into the mammary gland ductules<br />
Hamm J. (1) , Cojoca R. (1) , Iezzi M. (2) , Mautino A. (1) , Turco E. (1) , Silengo L. (1) , Musiani P. (2) , Forni G. (1) .<br />
(1) University of Turin, Italy<br />
(2) University of Chieti Pescara, Italy<br />
jorg_hamm@yahoo.com<br />
Introduction: Adeno-associated virus (AAV) is a<br />
single-stranded DNA parvovirus with charateristics<br />
that render it attractive for gene therapy applications<br />
(1). More than 14 AAV serotypes have<br />
been characterized which differ in efficiency of<br />
infection and tissue tropisms. Cell entry seems to<br />
occur by AAV receptor mediated endocytosis, the<br />
receptors recognised by the capsid proteins vary in<br />
different serotypes and might be an determinant<br />
for tissue tropism. The DNA remains mainly extrachromosomal,<br />
does not replicate, and is unable to<br />
produce infectious particles, features desirable for<br />
gene therapy vectors. In the majority of the applications<br />
AAV2 vector is used for gene transfer experiments,<br />
but other serotypes have been explored<br />
recently because they can offer superior transduction<br />
efficiencies or different cell tropisms. Furthermore,<br />
neutralising antibodies against AAV2<br />
are frequently found in human sera and can compromise<br />
efficiency of gene transfer. AAV9 has been<br />
reported to allow a robust expression in heart and<br />
muscle, but other expression sites have also been<br />
indicated.<br />
Methods: AAV9 vectors expressing luciferase as a reporter<br />
gene driven by the cytomegalo virus promoter<br />
(AAV9-CMV-luc) or by the murine EF1alpha promoter<br />
(AAV9-EF1a-luc) were administered locally into<br />
the mammary gland network by intraductal injection<br />
(2) into BALB/c female mice. Expression profile and<br />
body distribution were determined by in vivo and<br />
ex vivo optical imaging, and by histological analysis.<br />
Results: AAV9-CMV-luc migrates from the injected<br />
gland to ipsilateral glands, but not to contralateral<br />
glands. Luciferase expression is observed predominantly<br />
in muscle cells and is stable for months. The<br />
observed expression of luciferase in the ipsilateral<br />
lymph nodes indicate that the virus might use the<br />
lymphatic system to reach all of the five ipsilateral<br />
mammary glands.<br />
Conclusions: AAV9 vectors appear to be well suited<br />
for targeted, long-lasting gene expression in muscle<br />
tissue. Mammary epithelia cells are apparently not<br />
infected efficiently, not even after site specific injection<br />
into the duct of mammary glands.<br />
References:<br />
1. Büning et al.; J Gene Med 2008; 10: 717–733.<br />
2. Murata et al.; Cancer Res. 2006 Jan 15;66(2):638-45.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-092<br />
poStEr<br />
TARGETED THERAPY
206<br />
WarSaW, poland May 26 – 29, 2010<br />
P-093 Copper-64- and Gallium-68- NODAGA-conjugated bombesin antagonists as new PET tracers<br />
Mansi R. , Dumont R. , Jamous M. , Tamma M. , Nicolas G. , Fani M. , Cescato R. , Reubi J.C. , Weber W. , Maecke H. .<br />
Nuclear Medicine, Freiburg, Germany<br />
rosalba.mansi@uniklinik-freiburg.de<br />
Introduction: The gastrin-releasing peptide or<br />
bombesin receptor (GRPr) is frequently overexpressed<br />
in several human cancers including prostate,<br />
breast, small cell lung and pancreatic cancer<br />
[1,2]. Specific radiolabeled ligand for this receptor<br />
offer new opportunities for the diagnosis and<br />
treatment of these diseases. Many bombesin antagonists<br />
have shown high affinity for the GRPr<br />
[3]. In this study, we evaluated the potential of a<br />
statine-based bombesin antagonist, conjugated to<br />
NODAGA through a polyethyleneglycol spacer, to<br />
specifically target GRPr expressing cancer cells.<br />
We determine the effect of two different radioisotopes<br />
Ga-68 and Cu-64 on the tumor targeting efficacy<br />
and in vivo pharmacokinetics. Moreover we<br />
evaluated the PET imaging properties of the two<br />
radiotracers.<br />
Methods: The peptide assembling and NODAGAconjugation<br />
were accomplished on solid phase. The<br />
conjugate MJ5 was radiolabeled with Ga-68 and<br />
Cu-64 and the radioconjugates were evaluated in<br />
vitro and in vivo in tumor-bearing nude mice, using<br />
the GRP-receptor positive prostate carcinoma<br />
cell line PC-3. To study the bombesin antagonistic<br />
properties of MJ5 cells were treated either with 10<br />
nmol/L bombesin, or with 1 µmol/L MJ5 or, with<br />
10 nmol/L bombesin in the presence of a 100-fold<br />
excess MJ5 for 30 min at 37°C. GRPr internalization<br />
was studied by immunofluorescence.<br />
Results: The immunofluorescence assays confirmed<br />
the strong antagonist properties of the conjugates: MJ5<br />
failed to induce significant internalisation of GRPr and<br />
when given at a concentration of 1 µmol/L together with<br />
10 nmol/L bombesin, MJ5 was able to antagonize bombesin-induced<br />
receptor internalisation. Biodistribution<br />
studies revealed high and specific uptake of both conjugates<br />
in PC-3 tumors and in GRPr positive tissues such<br />
as pancreas and intestine. The Ga-68-MJ5 biodistribution<br />
data showed a good tumor uptake at 1h (4.54±0.52%<br />
I.A./g) and good tumor to kidney and tumor to blood<br />
ratios (4.1 and 10.9 respectively). These promising data<br />
prompted us to investigate the biodistribution of MJ5<br />
with a longer lived radionuclide. The tumor uptake of<br />
the Cu-64-MJ5 was 3.7 times higher than the Ga-68labeled<br />
analog at 1h (16.80±3.22% I.A./g) and remained<br />
imaging life<br />
high at 4h (13.97±3.68% I.A./g). At 4 h higher tumor to<br />
kidney (8.6), tumor to blood (36.2) and tumor to pancreas<br />
(18.2) ratios were achieved than for Ga-68-MJ5 at<br />
1 h. The PET/CT images demonstrated exellent visualization<br />
of the PC3 tumors by Ga-68- and Cu-64 MJ5.<br />
Conclusions: The labeling with the two radionuclides<br />
distinctly influences the pharmakokinetics of the radiopeptides<br />
in particular in regard to the uptake in<br />
the tumor and receptor positive organs. The high<br />
tumor uptake and the good tumor to background<br />
ratio of the Cu-64 labeled analog at 4h warrant clinical<br />
testing of this probe for PET imaging in humans.<br />
Acknowledgement: We acknowledge COSTD38 and<br />
the Swiss National Science Foundation for the financial<br />
support.<br />
References:<br />
1. R.Markwalder, J.C. Reubi, Cancer Res., 155 (1999) 1152.<br />
2. J.C. Reubi, M. Korner, et al., Eur.J.Nucl.Med.Mol.Imaging,<br />
31 (2004) 803<br />
3. R.T. Jensen, D.H. Coy, Trends Pharmacol. Sci., 12 (1991) 13
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
A novel indocyanine green nanoparticle probe for non invasive fluorescence imaging in vivo<br />
Mérian J. (1) , Navarro F. (1) , Josserand V. (2) , Texier I. (1) .<br />
(1) CEA LETI MINATEC, Grenoble, France<br />
(2) CRI INSERM U823, France<br />
juliette.merian@cea.fr<br />
Introduction: Fluorescence imaging, a non invasive,<br />
non ionizing and sensitive technology, is opening a<br />
new era in medical application such as image-guided<br />
surgery. Indocyanine Green (ICG), the only Near InfraRed<br />
optical contrast agent approved by the FDA<br />
[1], is encapsulated in lipidic nanoparticles (LNP).<br />
Using LNP as nanocargo presents advantages such as<br />
improvement of the dye chemical stability, biocompatibility<br />
and passive targeting, as well as suitable<br />
properties for fluorescence detection of tumors [2].<br />
Methods: LNP are composed of a lipid core, stabilized<br />
by phospholipids and pegylated surfactants and are<br />
dispersed in aqueous buffer. ICG (Infracyanine) is<br />
incorporated into the lipid mixture as a concentrated<br />
solution in ethanol. Solvent is evaporated and this<br />
oily phase is mixed with aqueous phase before sonication<br />
is performed at 40°C for a whole 5min period<br />
(VCX750 Ultrasonic processor). Particle size, size<br />
distribution, and surface charges are evaluated by<br />
dynamic light scattering (DLS). Optical properties<br />
Nano ICG<br />
Free ICG<br />
characterizations are performed using visible absorbance<br />
and fluorescence spectrometries. MTT assay<br />
is performed using 3T3 fibroblasts to assess LNP cytotoxic<br />
index. The in vivo distribution of ICG-loaded<br />
LNP is investigated in Nude mice bearing xenografted<br />
sub-cutaneous TS/Apc tumors using a NIR<br />
whole animal imaging device (Fluobeam 800), and<br />
compared to that of free ICG in aqueous solution.<br />
Results: ICG loading does not modify the size (30nm<br />
diameter, one population) and the polydispersity index<br />
(from 0.11 to 0.13) of the LNP, but decreases<br />
the zeta potential, which becomes more negative<br />
(-5.8±2.5mV for nude LNP, versus -18.2±2.1mV for<br />
ICG loaded LNP). The dye encapsulation within<br />
LNP induces a 16nm red-shift of its absorption and<br />
emission (maximum at 820nm); as well as an improvement<br />
of its fluorescence quantum yield and a<br />
longer lifetime in comparison to free dye in water.<br />
LNP carrier is well tolerated in vitro (IC50~1 mg/mL<br />
of lipids). Furthermore, ICG loaded LNP injection<br />
in Nude mice implanted with subcutaneous Ts/Aps<br />
tumors, shows a better fluorescence signal in tumor<br />
site in comparison of free ICG at the same dose.<br />
Conclusions: LNP vectorization provides ICG a<br />
modification of its pharmacokinetics in addition<br />
to an improvement of its optical properties. These<br />
characteristics are suitable for long term and sensitive<br />
in vivo imaging required for efficient tumor<br />
detection. ICG loaded LNP, thanks to their low size,<br />
takes advantages of the Enhanced Permeability and<br />
Retention (EPR) effect and are passively accumulated<br />
with time into the tumor.<br />
Acknowledgement: J.Mérian1, F. Navarro 1 , V. Josserand 2 ,<br />
I. Texier 1 : 1CEA LETI Minatec, 2 CRI-INSERM U823<br />
References:<br />
1. Frangioni, J.V. In vivo near infrared fluorescence<br />
imaging. Curr. Opinion Chem. Biol. 7, 2003:626-634<br />
2. Texier, I. Goutayer, M. and al Journal of Biomedical<br />
Optics, 14(5), 2009: 054005<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-094<br />
poStEr<br />
TARGETED THERAPY
WarSaW, poland May 26 – 29, 2010<br />
P-095 Evaluation and optimization of the concept of an antibody directed enzyme-prodrug therapy<br />
using noninvasive imaging technologies<br />
208<br />
Napp J. (1) , Dullin C. (2) , Krewer B. (3) , Von Hof J.M. (3) , Schmuck K. (3) , Mathejczyk J. (4) , Hartung F. (4) , Stühmer W. (4) , Tietze L. F. (3) ,<br />
Alves F. (4) , Pardo L. A. (4) .<br />
(1) MI for exp Medicine, Göttingen, Germany<br />
(2) University Medicine Göttingen, Germany<br />
(3) University Göttingen, Germany<br />
(4) MPI for exp Medicine, Göttingen, Germany<br />
jnowako1@gwdg.de<br />
Introduction: Relatively low selectivity to tumor versus<br />
normal cells challenges virtually all cancer chemotherapies.<br />
Site-specific activation of prodrugs in<br />
tumors is one strategy to achieve high efficacy and<br />
specificity of treatment, decreasing toxicity in normal<br />
tissues. Here, we present the design and validation<br />
of an Antibody Directed Enzyme-Prodrug Therapy<br />
(ADEPT) in which an antibody against Eag1 is used<br />
to carry the drug-activating enzyme, ß-galactosiase<br />
(ß-gal) to the tumor tissue. Eag1 (ether-à-go-go1)<br />
voltage-gated potassium channel has been chosen as<br />
a tumor-specific target since this plasma-membrane<br />
protein is easily accessible to extracellular interventions<br />
and Eag1 is aberrantly expressed (>75%) in tumors<br />
from diverse origin but basically not detected<br />
in healthy tissue outside the central nervous system.<br />
Methods: Two monoclonal anti-Eag1 antibodies,<br />
mAb62 and mAb56, a humanized 56 antibody, as<br />
well as a single chain fragment of the mAb62, scFv62,<br />
were tested for their feasibility to deliver the drugactivating<br />
enzyme ß-gal to the tumor. Near infrared<br />
fluorescence (NIRF) imaging was used to study<br />
the biodistribution and binding characteristics of<br />
the anti-Eag1 antibodies in vivo in a subcutaneous<br />
Eag1-expressing MDA-MB-435S tumor model in<br />
nude mice. Fluorescence intensity, lifetime and location<br />
of Cy5.5 labeled antibodies in vivo was measured<br />
with the time-domain NIRF imager, Optix<br />
MX2 (ART, Advanced Research Technologies; Canada),<br />
at certain time points. Fluorescence lifetime<br />
(the average time during the molecule stays in its excited<br />
state) was used to discriminate between nonspecific<br />
and probe-derived signals. Distribution of<br />
the fluorescent probe in tumor sections ex vivo was<br />
further investigated by the Odyssey infrared imaging<br />
system (LI-COR Biosciences, Germany) as well<br />
as by NIRF microscopy (Axiovert 200M, Carl Zeiss,<br />
Germany). For the tumor-specific activation of the<br />
prodrug, the mAb62 was conjugated to ß-gal, resulting<br />
in 62-gal. The ß-gal activity of the 62-gal conjugate<br />
and its ability to bind to the Eag1 epitope were<br />
tested in vitro on Eag1-expressing MDA-MB-435S<br />
cells and control AsPC-1 cells using a colorimetric<br />
CPRG (chlorophenolred-ß-D-galactopyranoside)<br />
imaging life<br />
assay. The ß-gal activity in mice was analyzed by<br />
NIRF imaging using the fluorescent activatable probe,<br />
DDAOG (9H-(1,3-dichloro-9,9-dimethylacridin-2-one-<br />
7-yl) β-d-galactopyranoside) by NIRF imaging.<br />
Results: All tested antibodies targeting Eag1 bound<br />
specifically to MDA-MB-435S tumors with maximal<br />
intensity peaks at 24-48 h after application; fluorescence<br />
was still detectable for at least 1 week in vivo.<br />
We confirmed specific binding of the antibodies to<br />
the tumors by ex vivo NIRF imaging of tumors isolated<br />
from mice injected with fluorescently labeled<br />
antibodies 24 h prior to section, as well as by NIRF<br />
microscopy of tumor slices. Moreover, we show that<br />
monoclonal antibodies against Eag1, but not the<br />
scFv62 fragment, resulted in strong fluorescence<br />
signals in the area over liver, detectable for at least 4<br />
days in vivo. Similar fluorescence signals over liver<br />
were also observed in tumor-bearing mice injected<br />
with Cy5.5-labeled control IgGĸ2B, confirming that<br />
the liver signals did not result from Eag1-mediated<br />
binding of those antibodies to cells within liver.<br />
Furthermore, we show that the 62-gal conjugate<br />
specifically binds in vitro to Eag1-expressing MDA-<br />
MB-435S, but not to control Eag1-non expressing<br />
AsPC-1 cells and that 62-gal possess high ß-gal activity,<br />
when bound to MDA-MB-435S cells. Moreover,<br />
24 h after application of the 62-gal to the tumor<br />
bearing mice we detected ß-gal activity in vivo over<br />
the tumor area.<br />
Conclusions: Here, we successfully applied NIRF<br />
imaging to evaluate anti-Eag1 antibodies as tools for<br />
a novel concept of targeted cancer therapy. Since in<br />
vivo 62-gal 1) specifically binds to Eag1-expressing<br />
tumors and 2) shows measurable ß-gal activity at the<br />
tumor site, this conjugate can further be applied in<br />
the ADEPT for specific activation of cytotoxic prodrugs<br />
at the tumor site.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
A novel [ 18 F] PET imaging agent for the epidermal growth factor receptor<br />
Pisaneschi F. (1) , Shamsaei E. (1) , Nguyen Q.D. (1) , Glaser M. (2) , Robins E. (2) , Kaliszczak M. (1) , Smith G. (1) , Spivey A.C. (1) ,<br />
Aboagye E.O. (1) .<br />
(1) Imperial College London, London, United Kingdom<br />
(2) Medical Diagnostic Discovery (part of GE Healthcare), United Kingdom<br />
f.pisaneschi@imperial.ac.uk<br />
Introduction: The Epidermal Growth Factor Receptor<br />
(EGFR/c-ErbB1/HER1) is overexpressed in<br />
many cancers including breast, ovarian, endometrial<br />
and non-small cell lung cancer. 1, 2 An EGFR specific<br />
imaging agent could facilitate clinical evaluation of<br />
primary tumours and/or metastases.<br />
Methods: We designed and synthesized a small array<br />
of fluorine containing compounds based on<br />
a 3-cyanoquinoline core. 3 The compounds were<br />
screened in vitro for their affinity in cell-free EGFR<br />
autophosphorylation assay and for their activity in<br />
the inhibition of the EGFR tyrosine kinase in EGFR<br />
overexpressing A431 cell lines.<br />
Results: A lead compound, incorporating 2’-fluoroethyl-1,2,3-triazole<br />
was selected for evaluation as a<br />
radioligand based on its high affinity for EGFR kinase<br />
(IC 50 = 1.81 ± 0.18 nM), good cellular potency<br />
(IC 50 = 21.97 ± 9.06 nM), low lipophilicity and good<br />
metabolic stability. ‘Click’ labelling 4 afforded [ 18 F]-<br />
2’-fluoroethyl-1,2,3-triazole derivative in 7% end<br />
of synthesis (EOS) yield from aqueous fluoride in a<br />
total synthesis time of 3 h and >99% radiochemical<br />
purity. The compound showed good stability in vivo<br />
and a 4-fold higher uptake in A431 tumour xenografts<br />
relative to muscle. Furthermore, the radiotracer<br />
could be visualized in A431 tumour bearing mice<br />
by small animal PET imaging (NUV 60 = 0.13±0.02).<br />
Conclusions: The novel [ 18 F]-imaging agent constitutes<br />
a promising radiotracer for further evaluation<br />
for imaging of EGFR status.<br />
Acknowledgement: This work was funded by Cancer<br />
Research UK programme grant C2536/A7602 and<br />
UK Medical Research Council core funding grant<br />
U.1200.02.005.00001.01.<br />
References:<br />
Bazley, L. A.; Gullick, W. J. Endoncr. Relat. Cancer 2005, 12,<br />
S17.<br />
Marmor, M. D.; Skaria, K. B.; Yarden, Y. Int. J. Radiat. Oncol.<br />
Biol. Phys. 2004, 58, 903.<br />
Wissner, A.; Overbeek, E.; Reich, M. F.; Floyd, M. B.; Johnson,<br />
B. D.; Mamuya, N.; Rosfjord, E. C.; Discafani, C.; Davis, R.;<br />
Shi, X.; Rabindran, S. K.; Gruber, B. C.; Ye, F.; Hallett, W. A.;<br />
Nilakantan, R.; Shen, R.; Wang, Y.-F.; Greenberger, L. M.; Tsou,<br />
H.-R. J. Med. Chem. 2003, 46, 49.<br />
Glaser, M.; Årstad, E. Bioconjugate Chem. 2007, 18, 989.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-096<br />
poStEr<br />
TARGETED THERAPY
210<br />
WarSaW, poland May 26 – 29, 2010<br />
P-097 Structural methods in subcellular image analysis<br />
Dietlmeier J. , Whelan P.F. .<br />
Centre for Image Processing and Analysis, Dublin, Ireland<br />
julia.dietlmeier@ieee.org<br />
Introduction: From a computer vision perspective<br />
subcellular imaging is an extremely complex and dynamic<br />
environment as can be inferred from Fig.1(a).<br />
Mitochondria form an important category of membrane<br />
enclosed, on average 200nm large organelles<br />
which reside inside every living cell. Mitochondrial<br />
morphology is crucial to the understanding of<br />
apoptosis mechanisms and the subsequent development<br />
of therapies targeting age- and cancer-related<br />
diseases[1],[2]. There is a high demand in automated<br />
segmentation which can provide an objective quantitative<br />
information in a reasonable time frame[2].<br />
However, the state-of-the-art is dominated by manual<br />
tools. Early attempts to automate the segmentation<br />
are based on the machine-learning framework[3].<br />
Methods: Instead of pursuing the machine-learning<br />
pathway we approach the segmentation and localization<br />
problem from the structural point of view which<br />
also has an appealing theoretical aspect. Here, we<br />
apply the well developed and widely acknowledged<br />
framework of Mathematical Morphology. Our multistage<br />
segmentation targets (i) specific challenges<br />
of image acquisition such as low contrast, non-uniform<br />
illumination and speckle noise; (ii) structural<br />
challenges such as cluttered scene, clustered and deformed<br />
mitochondria and deformed cristae.<br />
Results: We outline our preliminary results by examining<br />
Fig.1. The first and the key step is localization<br />
which is based on the analysis of mitochondrial<br />
morphology. After extracting localiza tion markers<br />
we apply a seeded region grow algorithm which fills<br />
the inner-membrane space of each organelle, as can<br />
be seen in Fig.1(e). Gap-free control boundary is<br />
currently achieved by using morphological thickening<br />
and thinning operators on the binary image. In<br />
order to separate clustered mitochon-dria we apply a<br />
seeded watershed algorithm. The results of extracted<br />
sha-pes are provided in Fig.1(f)-(g). We verify that<br />
our segmentation works well on small-scale images<br />
containing a small number of mitochondria as can<br />
be seen in Fig.1(f)-(l). The other technique to obtain<br />
mitochondrial contour is recon-struction-by-dilation.<br />
Here, we correlate the localization markers with<br />
extracted contours in order to yield correct result.<br />
imaging life<br />
Fig.1 (a) TEM image of STS-treated DU-145 prostate cell. (b). Example<br />
of two clustered mitochondria. (c)-(l) Selected segmentation results.<br />
Conclusions: The major challenge is firstly to extract<br />
the mitochondrial shape within reasonable<br />
accuracy. Secondly, we attempt to expand our detection<br />
approach to a larger scale problem such as<br />
the whole cell image. We plan to validate this on a<br />
larger representative mitochondria image database<br />
and in doing so compare our approach to existing<br />
machine-learning algorithms.<br />
Acknowledgement: This research was supported by<br />
NBIP Ireland funded under the Higher Education<br />
Authority PRTLI Cycle 4, co-funded by the Irish<br />
Government and the European Union - Investing in<br />
your future. Special thanks to Royal College of Surgeons<br />
in Ireland (RCSI) for sample preparation and<br />
acquisition of TEM images. We would like to thank<br />
American Society for Cell Biology (ASCB) and Nature<br />
Publishing Group3 for the permission to use<br />
selected micrographs.<br />
References:<br />
1. Perkins GA et al; Methods in Enzymology. 456:29–52<br />
(2009)<br />
2. Sun MG et al; Nature Cell Biology. 9:1057–1065 (2007)<br />
3. Narasimha R et al; Pattern Recognition. 42:1067–1079<br />
(2009)
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
In vivo-post mortem multimodal image registration in a rat glioma model<br />
Dubois A. , Boisgard R. , Jego B. , Lebenberg J. , Hérard A. S. , Dollé F. , Lebon V. , Delzescaux T. , Tavitian B. .<br />
CEA-I2BM, Orsay, France<br />
albertine.dubois@cea.fr<br />
Introduction: Histological staining techniques can<br />
identify the regulation of specific biomarkers in<br />
small animal models of glioma and provide indicators<br />
of cellular dysfunction. The correlation of in<br />
vivo imaging signal changes and molecular indicators<br />
of tissue damage in histological brain sections<br />
represents an important means of understanding the<br />
cellular mechanisms responsible for these changes<br />
under pathological conditions. This requires an accurate<br />
image registration that can compensate the<br />
distortions that occur in the brain during the extraction,<br />
fixation, and staining process. Here, we present<br />
the preliminary results obtained by applying an<br />
overall registration strategy for the fusion of in vivo<br />
PET and MRI data with post mortem brain images in<br />
a rat 9L-glioma model.<br />
Methods: Experiments were conducted on male<br />
Wistar rats. Twelve days after intrastriatal injection<br />
of 9L rat glioma cells, we acquired T2-weighted MRI<br />
and 60 min dynamic PET using [18F]DPA-714 [1]<br />
for in vivo evaluation of peripheral benzodiazepine<br />
receptor (PBR) expression. Following in vivo imaging,<br />
animals were euthanized. The entire brains were<br />
cut into 20 µm-thick coronal sections and processed<br />
for H&E staining and PBR immunohistochemistry.<br />
A blockface photograph was also recorded prior to<br />
each section. The overall co-registration strategy relied<br />
on using the blockface photographs as an intermediate<br />
reference, onto which the in vivo MRI and<br />
PET images and the digitized histo- and immunohistochemical<br />
brain sections were registered separately<br />
and superimposed so as to obtain in vivo-post<br />
mortem registration [2;3].<br />
Results: By way of feasibility study, the co-registration<br />
strategy was only performed on one rat’s right<br />
hemisphere. As illustrated in Figure 1, after each registration<br />
task, both the external contours, the outer<br />
edges of the cortex and inner structures such as the<br />
corpus callosum, the hippocampus, the striatum and<br />
even the tumor were correctly superimposed whatever<br />
the modality.<br />
Conclusions: We obtained promising registration<br />
results of T2-weighted MRI and [18F]DPA-714 PET<br />
with post mortem brain volumes. Once results from<br />
additional animals had been provided, our approach<br />
could be used to evaluate, quantify and compare<br />
tumor volume, pharmacokinetic and physiological<br />
parameters (e.g. ligand differential uptake areas<br />
Fig1: Fusion of (A) PET (rainbow)<br />
and MRI (black and<br />
white), (B) Blockface (black<br />
and white) and H&E (pink)<br />
volumes, (C) MRI (black<br />
and white) and blockface<br />
volume (rainbow), (D) MRI<br />
(black and white) and H&E<br />
volume (pink) and (E) PET<br />
(rainbow) and H&E volume<br />
(black and white)<br />
within the tumor) measured from in vivo MRI and<br />
PET data with those derived from corresponding<br />
post mortem histo- and immunohistochemistry.<br />
References:<br />
1. Damont A et al; J label Compds Radiopharm. 51 (7):<br />
286-292 (2008)<br />
2. Dauguet J et al; J Neurosci Methods. 164 (1): 191–204<br />
(2007)<br />
3. Lebenberg J et al; Neuroimage. In press (2010)<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-098<br />
poStEr<br />
MI DATA ANALYSIS METHODS
212<br />
WarSaW, poland May 26 – 29, 2010<br />
P-099 Feasibility and success of Independent Component Analysis of resting state fmri data from<br />
the rat<br />
Jonckers E. , Van Auderkerke J. , Van Der Linden A. , Verhoye M. .<br />
Bio-Imaging Lab, Sint Lenaarts, Belgium<br />
elisabeth.jonckers@ua.ac.be<br />
Introduction: Resting state fMRI is used with growing<br />
interest with the purpose to spot age1 or pathology2<br />
induced abnormalities in functional connectivity<br />
(FC) in the human brain. Only recently resting state<br />
FC measurements were acquired in rats3, opening the<br />
potential of assessing FC in the rat brain in several<br />
imaging life<br />
Fig 1: 3 Components resulting from ICA of rat resting state data. Colors representing z-values, higher z-values<br />
meaning a higher convergence between time course of the voxel and mean time course for the component.<br />
neuropathologies (e.g. schizophrenia). The human<br />
resting state networks are identified using a seed-based<br />
approach or independent component analysis (ICA)4.<br />
Since ICA analysis of resting state fMRI of rodents is<br />
up to now not published, we performed a pilot study,<br />
implementing the technique in rodents and testing<br />
the reproducibility of the ICA outcome.<br />
Methods: A group of 5 male rats was imaged 4 times.<br />
On 2 time points with one week in between 2 consecutive<br />
resting state data were acquired using single<br />
shot gradient echo EPI. Rats were anesthetized with<br />
Medetomidine. Imaging was done on a 9.4T scanner<br />
using TR 2s and TE 16ms. 12 slices of 1 mm were<br />
acquired with a FOV of (3x3) cm and matrix size of<br />
128x128. ICA was implemented on the dataset using<br />
GIFT (Group ICA of fMRI toolbox), working in matlab2008.<br />
The number of components for the ICA of<br />
the individual subjects or group (5 rats x 4 repetitions)<br />
was set at 15.<br />
Results: The outcome of our ICA analysis, clearly<br />
revealed different brain regions within 10 of the 15<br />
components. Figure 1 demonstrates 3 components of<br />
clearly functional different cortical regions.<br />
Each ICA component was evaluated over the different<br />
time points. Mean components (for the 5 animals)<br />
were very reproducible both for measurements on the<br />
same day as measurements with one week in between.<br />
Also single subject components were similar over time.<br />
Although the differences are bigger between measurements<br />
with one week in between, indicating that there<br />
could be an influence of scanner variability and physiological<br />
state of the animal.<br />
Conclusions: This study implementing ICA on rat<br />
resting state data proves the usability of the technique<br />
for studying FC in the rat brain in a reproducible<br />
way. This paves the way to use this tool for assessing<br />
FC changes under different circumstances<br />
such as both physiological changes and pathologies.<br />
Implementing the technique in animal models<br />
can help to unravel the underlying processes.<br />
References:<br />
1. Damoiseaux JS et al (2008) Cereb Cortex. 18(8), 1856-<br />
1864.<br />
2. Greicius MD et al (2004) Proc Natl Acad Sci U S A. 101(13),<br />
4637-4642.<br />
3. Pawela CP et al (2008) Magn Reson Med. 59(5), 1021-1029.<br />
4. Beckmann CF et al (2005) Philos Trans R Soc Lond B<br />
Biol Sci. 360(1457), 1001-1013.
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
A fast and robust acquisition scheme for CEST experiments<br />
Longo D. , Cittadino E. , Terreno E. , Aime S. .<br />
University of Torino, Italy<br />
dario.longo@unito.it<br />
Introduction: Chemical Exchange Saturation Transfer<br />
(CEST) agents are a new class of MRI contrast<br />
agent based on the selective irradiation of a mobile<br />
proton pool in slow/intermediate exchange with<br />
water [1] . Long irradiation pulses at the resonant frequency<br />
(∆ω) are needed to obtain a complete saturation<br />
of the CEST pool and a correct saturation transfer<br />
(ST%) quantification requires the acquisition<br />
of many images at different frequency offsets (Zspectrum),<br />
thus making a CEST experiment a timeconsuming<br />
procedure depending on the number of<br />
sampled frequency offsets [2] . A trade-off between<br />
the number of frequency offsets and the accuracy of<br />
ST% determination has to be found in order to distinguish<br />
the characteristic ST% time course for individual<br />
voxels. The development of fast and robust<br />
methods are therefore mandatory to correctly detect<br />
CEST molecules in Molecular Imaging applications.<br />
In this work a computational procedure has been<br />
developed to evaluate the accuracy of ST% quantification<br />
as a function of the number of frequency offsets<br />
centered around the resonant frequency of the<br />
mobile proton pool with different levels of noise and<br />
of B 0 inhomogeneities. We also proposed a different<br />
acquisition procedure, by acquiring first a complete<br />
Z-spectrum followed by the sampling of a limited<br />
number of frequency offsets and then replacing<br />
these points in the first Z-spectrum, thus improving<br />
the temporal resolution of CEST contrast quantification,<br />
without sacrifying the ST% accuracy.<br />
Methods: Z-spectra were simulated by using a twopool<br />
model solving the Bloch equation (T 1A = 2 s,<br />
T 2A = 0.1 s, T 1B = 1 s, T 2B = 0.015 s, ∆ω = 4.2 ppm, k ex<br />
= 160 s -1 , 30 mM diacest agent, saturation pulse 3<br />
μT for 5 s). Gaussian noise was added both in the<br />
signal intensities and in the frequency axis and zero<br />
shifts were introduced in the range 0.1-1 ppm. Zspectra<br />
were interpolated by smoothing spline (with<br />
zero shift correction) by different number of points<br />
around the resonant frequency (with step of 0.1 ppm)<br />
both at positive (∆ω) and negative offsets (-∆ω): i) 7<br />
points, ii) 5 points, iii) 3 points, iv) 3 points with 0.2<br />
ppm step, v) 1-(∆ω/-∆ω) (ON/OFF scheme) with<br />
and vi) without zero-shift correction, compared to<br />
a full Z-spectrum in the range ±10 ppm with steps<br />
of 0.1 ppm. In in vivo CEST images were acquired<br />
on a 7 Tesla Bruker spectrometer with a complete<br />
Z-spectrum (single-shot RARE spin-echo, TR 6 s,<br />
centric encoding, MTX 64, saturation pulse: 3 μT<br />
for 5 s) followed, upon injection of a CEST agent by<br />
the dynamic acquisition of only 3 points around the<br />
resonant frequency (∆ω = 4.2 ppm) for 30 min (50<br />
scans, temporal resolution: 36 s).<br />
Results: The ON/OFF scheme with and without zero-shift<br />
correction showed the highest mean ST errors,<br />
up to 2 % and 5%, respectively and with high<br />
standard deviation values. The method iv) with 3<br />
points spaced of 0.2 ppm, in comparison with the<br />
more accurate but also time consuming i) and ii)<br />
methods, displayed mean ST errors lower than 1%,<br />
but with a drastic reduction in acquisition time. In<br />
in vivo the continous acquisition of only 3 frequency<br />
offsets around the resonant frequency and the correction<br />
for zero shifts by using the pre-contrast Zspectrum<br />
allowed to evaluate the ST% time course<br />
with a temporal resolution of few seconds and to<br />
discriminate between enhancing and not-enhancing<br />
pixels in kidneys.<br />
Conclusions: The acquisition of 3 points spaced of 0.2<br />
ppm around the resonant frequency of the mobile proton<br />
pool resulted to be sufficient enough to provide a robust<br />
and accurate ST% quantification, with a fast temporal<br />
resolution by using a modified Z-spectrum acquisition.<br />
Acknowledgement: Economic support from regional<br />
government ( NanoIGT project - CIPE 2007) and<br />
EC-FP7 project ( ENCITE: FP7-HEALTH-2007A).<br />
References:<br />
1. Ward KM, et al.; J Magn Reson. 2000; 143: 79<br />
2. Liu G, et al.; Magn Reson Med. 2009; 61: 399<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-100<br />
poStEr<br />
MI DATA ANALYSIS METHODS
214<br />
WarSaW, poland May 26 – 29, 2010<br />
P-101 Binding potential estimation in 11C-PE2I PET brain striatal images: impact of partial volume<br />
correction under segmentation errors<br />
Maroy R. , Dusch E. , Comtat C. , Leroy C. , Trebossen R. .<br />
CEA, Orsay, France, Metropolitan<br />
renaud.maroy@cea.fr<br />
Introduction: Numerous methods have been proposed<br />
for the correction of the Partial Volume Effect<br />
(PVE) that hampers striatal PET studies. While<br />
their quantification accuracy is known for most,<br />
their ability to recover correct pharmacokinetic parameters<br />
in case of segmentation errors is less clear.<br />
The work proposes to compare the binding potential<br />
estimations using 4 distinct Time Activity Curve<br />
(TAC) estimation methods.<br />
Methods: A phantom based on the Zubal phantom<br />
of a 11C-PE-2I PET exam with kinetics generated<br />
using the simplified tissue model of Lammertsmaa 1<br />
(R1=1.28, k2=.09, BP=17) was analytically simulated<br />
on a ECAT HRRT (Siemens, 2.4mm intrinsic<br />
resolution). PET images were reconstructed with<br />
1.2�1.2�1.2mm 3 voxels and 20 frames using both<br />
RM-OP-OSEM 2 , which compensate for PVE, and<br />
OP-OSEM.<br />
Twenty realizations of caudate segmentations containing<br />
errors ranging between 40% volume underestimation<br />
(-40%) and 40% volume overestimation<br />
imaging life<br />
(40%) were defined 3 . Four TAC estimation methods<br />
were compared for the caudate: the mean TAC measurement<br />
in the standard OP-OSEM image (ME) and<br />
in the RM-OP-OSEM image (MRO), the Geometric<br />
Transfer Matrix method (GTM) and an improved<br />
GTM 3 method using voxel selection (GTM20). The<br />
R1, k2 and binding potential (BP) estimated with<br />
the estimated TACs using 1 were compared based<br />
on the Apparent Recovery Coefficient (ARC).<br />
Results: Unlike k2 and R1,<br />
the BP is globally underestimated<br />
by the methods.<br />
The lowest performances<br />
are obtained without correction,<br />
using ME. The<br />
best ARC for the TACs (Fig<br />
1.A) and R1 (Fig 1.C) are<br />
achieved using MRO, but<br />
the use of MRO leads to<br />
suboptimal BP (Fig 1.D),<br />
which is the model parameter<br />
of major interest. The<br />
best ARC for BP and k2<br />
(Fig 1.B) are achieved using<br />
GTM20, which provides<br />
better TACs than GTM,<br />
leading also to better ARC<br />
than GTM.<br />
Conclusions: Our improved GTM method with voxel<br />
selection achieves the TAC estimation in terms of<br />
binding potential and k2 recovery.<br />
References:<br />
1. A A Lammertsma et al. Neuroimage, 1996<br />
2. F C Sureau et al. JNM, 2008<br />
3. R Maroy et al. SNM, 2009
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Automated quantification scheme based on an adapted probabilistic atlas based<br />
segmentation of the brain basal nuclei using hierarchical structure-wise registration<br />
Maroy R. (1) , Leroy C. (1) , Douaud G. (2) , Trebossen R. (1) .<br />
(1) CEA, Orsay, France, Metropolitan<br />
(2) Radcliffe Hospital, Oxford, United Kingdom<br />
renaud.maroy@cea.fr<br />
Introduction: The work<br />
proposes: 1) a new basal<br />
ganglia segmentation<br />
method based on probabilistic<br />
atlas construction<br />
and compared to<br />
manual segmentation,<br />
2) a validation method<br />
for segmentation of structures<br />
using a co-acquired<br />
PET image.<br />
Methods: T1 MRI (T1) and<br />
18F-PEII PET images were<br />
acquired in 12 healthy<br />
adults and co-registered.<br />
The PET images, acquired<br />
on the HRRT PET system,<br />
were reconstructed with<br />
both the AWOSEM (NoPSF) and the 3D-OP-<br />
OSEM PSF (PSF) methods. The basal nuclei were<br />
segmented manually in a knowledge base (KB) of<br />
24 T1 and in the 12 acquired subjects T1 (IS). A<br />
probabilistic atlas adapted to IS was constructed<br />
using a structure-wise hierarchical registration of<br />
each KB image on IS. Segmentation was obtained<br />
simply through atlas probability maximization.<br />
A GTM correction was applied on the NoPSF<br />
using as spatial domain 1) the manually drawn<br />
structures or 2) the automatically drawn structures,<br />
with A) ROI defined as in [Frouin, 2002]<br />
or B) with adequate selection of 20% (GTM20)<br />
of the corresponding spatial domain voxels.<br />
The estimated values were compared for 1)+A)<br />
and 2)+B) to the mean TAC in PSF, considered<br />
as the reference, inside manually drawn<br />
eroded regions using the estimation error (E).<br />
Results: GTM20 performed significantly better<br />
than GTM for both the manual and automated<br />
delineation. Besides, the gain using together the<br />
automated segmentation and GTM20 (E1)+A)/<br />
E2)+B)) was 6.1 for the caudate, 3.6 for the globus<br />
pallidus, 4.6 for the putamen and 1.4 for the<br />
thalamus for an increased reproducibility.<br />
Conclusions: We have proposed a quantification<br />
scheme using an adapted probabilistic atlas based<br />
segmentation of the basal nuclei and a partial volume<br />
correction method that enhances both the<br />
precision and the reproducibility of the PVE corrected<br />
measures.<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-102<br />
poStEr<br />
MI DATA ANALYSIS METHODS
216<br />
WarSaW, poland May 26 – 29, 2010<br />
P-103 VHISTdiff - comparing workflow histories (VHIST/VINCI)<br />
Vollmar S. , Hüsgen A. , Sué M. , Nock J. , Krais R. .<br />
Max Planck Institut for Neurological Research, Köln, Germany<br />
vollmar@nf.mpg.de<br />
Introduction: VHIST [1] has been developed to<br />
document workflows in multi-modality imaging<br />
(however, it is not at all limited to this field). The<br />
VHIST file format is PDF compatible and it can be<br />
displayed with any PDF viewer (“human readable”).<br />
However, VHIST files also contain structured information<br />
on each workflow step (embedded XML)<br />
suitable for automated processing. In one current<br />
project, we are integrating VHIST into VINCI [2],<br />
our package for visualization and analysis of tomographical<br />
data. This enables us to natively create<br />
VHIST files which can store meta data of original<br />
file formats, filter operations, “image arithmetics”<br />
and registration parameters.<br />
Methods: An interesting application of VHIST files<br />
is the comparison of workflow histories belonging<br />
to similar but subtly different image data, e.g. image<br />
data of one subject which has been aquired by<br />
the same scanner but which has been processed in a<br />
different way (type and order of filter steps; thresholding;<br />
application of masks; different types of normalization,<br />
different reconstruction parameters;<br />
different approaches when converting raw data). For<br />
this kind of comparison we are currently developing<br />
a new tool, VHISTdiff, which allows to automatically<br />
find corresponding workflow steps and report<br />
the differences.<br />
The figure depicts a graphical representation of the<br />
“macroscopic” differences between two VHIST files<br />
(A.vhist, B.vhist) as they were found by the VHISTdiff<br />
algorithm: each tree represents the workflow<br />
history of one image. Dotted lines denote corresponding<br />
workflow steps, white text marks workflow<br />
steps that do not have a pendant. VHIST files<br />
can contain other VHIST files: in this example, the<br />
registration step of the A-tree contains file C.vhist,<br />
and likewise D.vhist is contained in the other registration<br />
step. The report of differences between<br />
corresponding workflow steps (e.g. different filter<br />
parameters) are not part of this particular graphical<br />
representation which has been rendered fully automatically<br />
using Graphviz [3].<br />
VHISTdiff ’s algorithm uses some ideas of the traditional<br />
UNIX diff command for comparison of text<br />
imaging life<br />
files. However, the concept has been generalized to<br />
tree structures: VHISTdiff uses Dijkstra’s algorithm<br />
[4] to optimize a cost function which favours association<br />
strings of similar workflow steps.<br />
Outlook: First results of this new tool look promising.<br />
We will investigate strategies to define cost<br />
functions that try to be useful for a wide range of<br />
real-world use cases.<br />
References:<br />
1. VHIST, http://www.nf.mpg.de/vhist<br />
2. VINCI, http://www.nf.mpg.de/vinci<br />
3. The Graphviz software package, http://www.graphviz.org<br />
4. Dijkstra, E. W. (1959). “A note on two problems in<br />
connexion with graphs”. Numerische Mathematik 1:<br />
269–271
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Fast matrix-free method for fluorescence imaging<br />
Zacharopoulos A. (1) , Garofalakis A. (2) , Ripoll J. (1) , Arridge S. (3) .<br />
(1) FORTH IESL , Heraklion, Greece<br />
(2) CEA, I2BM , France<br />
(3) UCL CS, United Kingdom<br />
azacharo@iesl.forth.gr<br />
Introduction: In non-contact Fluorescence Molecular<br />
Tomography, the large number of measurements<br />
poses a challenge since the reconstruction methods<br />
used rely on the inversion of a derivative operator<br />
and the explicit formulation and storage of this operator<br />
in a matrix is generally<br />
not feasible. We test a matrixfree<br />
method that addresses the<br />
problems of large data sets and<br />
reduces the computational cost<br />
and memory requirements<br />
for the reconstructions. More<br />
specifically we challenged<br />
the Matrix-Free method with<br />
in-vivo measurements from<br />
mice where fluorescence tubes<br />
of different but controlled<br />
concentrations are inserted,<br />
to assess the quantification<br />
performance of the method.<br />
Methods: Our approach initially presented in [1], is<br />
based on a formulation of the diffusion approximation<br />
for the fluorescence case and the TOAST Image<br />
Reconstruction in Optical Tomography FEM<br />
package, [2] and uses a matrix free formulation.<br />
The explicit calculation and storage of the Jacobian<br />
is avoided by replacing it by a vector times matrix<br />
operator and a vector times adjoint matrix operator.<br />
Since we wanted to assess the quantification properties<br />
of the matrix-free method we aquired in-vivo<br />
measurements using a balb/c mouse where capillary<br />
of Alexa Fluor 647 of controlled concentrations<br />
a)60.5uM, b)22uM, c)8.5uM, d)2.2uM and e)0.9 uM.<br />
was inserted hypodermically in the ventral side. For<br />
the reconstructions, a slab-like geometry of dimensions<br />
41mm x 41mm x 12mm was used with 5733<br />
nodes and 4800 voxel-elements. For the optical<br />
parameters we assumed μa =0.06 mm-1 and μs =1.<br />
mm-1 for the 615nm excitation and μa =0.05 mm-1<br />
and μs =1.5 mm-1 for the 700nm emission wavelengths.<br />
We set 1458 detectors positions by sampling<br />
the images, which for the 36 sources created<br />
two vectors of 48285 measurements each.<br />
Results: The results for the five different experiments<br />
are presented as iso-surfaces in 3D in the<br />
figure where the white light image of the mouse<br />
is rendered in the background as a reference. The<br />
average time for the reconstruction was 50sec, in a<br />
Pentium 2Ghz machine with 2GB of memory.<br />
Conclusions: Using the Matrix-free method we<br />
managed to reconstruct for the positions of the<br />
fluorescent tubes and a relative quantification accuracy<br />
and sensitivity. More specifically the algorithm<br />
demonstrated an almost linear response between<br />
the controlled concentrations and the reconstructed<br />
ones.<br />
Acknowledgement: This work was funded by the<br />
EC Seventh Framework Grant, FMT-XCT, grant<br />
201792.<br />
References:<br />
1. Zacharopoulos A, et al (2009) Opt. Express , 17, 3042-<br />
-3051.<br />
2. Arridge R S (1999) Inverse Problems, 15, 41--93 .<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-104<br />
poStEr<br />
MI DATA ANALYSIS METHODS
P-105<br />
218<br />
WarSaW, poland May 26 – 29, 2010<br />
TOPIC: Cancer Biology<br />
PET and MRI studies applied on characterization of Fisher/F98 rat glioma model<br />
Valtorta S. (1) , Ronchetti F. (2) , Lo Dico A. (3) , Politi L.S. (4) , Masiello V. (5) , Matarrese M. (5) , Zara G. (6) , Zenga F. (7) , Scotti G. (4) ,<br />
Mauro A. (2) , Moresco R.M. (5) .<br />
(1) Università degli Studi di Milano; IBFM-CNR, Segrate, Italy<br />
(2) Istituto Auxologico Italiano, Italy<br />
(3) San Raffaele Scientific Institute; IBFM-CNR; L.A.T.O., Italy;<br />
(4) San Raffaele Scientific Institute, Italy;<br />
(5) San Raffaele Scientific Institute; IBFM-CNR; Università degli Studi di Milano-Bicocca, Italy;<br />
(6) Università di Torino, Italy;<br />
(7) Università di Brescia, Italy<br />
silvia.valtorta@unimi.it<br />
Introduction: Preclinical brain tumor models<br />
have provided a wealth of information on the<br />
biology, imaging and experimental therapeutics<br />
of brain tumors [1],[2] . The aim of our study is<br />
characterized Fisher/F98 rat glioma model using<br />
Positron Emission Tomography (PET) and<br />
Magnetic Resonance (MR) analysis to set up an<br />
experimental model useful to study the efficacy<br />
of new colloidal vectors for chemotherapy.<br />
Methods: Syngenic rat brain-glioma models<br />
(Fisher/F98) was obtained by stereotactic (x=2;<br />
y=5; z=3) implantation of different cell concentrations<br />
(10 2 , 10 3 , 10 4 and 10 5 ). To monitor tumor<br />
growth progression, rats underwent once a week<br />
Gadolinium enhanced T1-MRI studies followed<br />
by [ 18 F]FDG PET studies, starting from 7 days<br />
after surgery. A group of animals performed also<br />
[ 18 F]FAZA PET studies to evaluate regional tissue<br />
hypoxia. To improve quantification, PET and<br />
MRI images were fused using PMOD 2.7 software.<br />
Max radiotracers uptake was calculated for tumor,<br />
frontal cortex, cerebellum and background using<br />
region of interest (ROI) analysis. Radioactivity<br />
concentration values expressed in MBq/g were<br />
then transformed into percentage of injected dose<br />
per gram of tissue (%ID/g). Moreover, histological<br />
analysis of proliferation, apoptosis, differentiation,<br />
neoangiogenesis and hypoxia markers were<br />
performed.<br />
Results: Mean survival time of rats injected with<br />
10 4 and 10 5 cells was nine days. One week after<br />
surgery, MRI revealed a rapid growth that reached<br />
0.11 cm 3 mean tumour volume. Animals injected<br />
with 10 3 and 10 2 cells showed a mean survival time<br />
of 18 and 24 days respectively. In rats injected with<br />
10 3 cells, tumor was revealed 14 days after surgery<br />
at MRI and [ 18 F]FDG PET and successively tumors<br />
rapidly increased. Disease course in 10 2 cells<br />
injected rats was slower. Tumors were characterized<br />
by high [ 18 F]FDG uptake and hypoxic subareas<br />
which only partially overlapped. Hypoxic<br />
imaging life<br />
areas were mainly localized in correspondence<br />
to Gd-enhanced regions whereas hyper glucose<br />
metabolic areas were localized in the outer part<br />
of the tumors. At histological analysis tumoral<br />
masses showed an infiltrative pattern of growth<br />
and moderate neoangiogenesis. Tumors obtained<br />
at animals death showed diffused necrotic areas.<br />
HIF1 was clearly expressed by glial and neuronal<br />
cells in oedematous and hypoxic areas.<br />
Conclusions: Our study indicates that Fisher/<br />
F98 rat glioma model reproduce s the characteristic<br />
of aggressiveness of human glioblastoma.<br />
Tumor was characterized by high glucose<br />
metabolism and by hypoxic sub-areas. The concentration<br />
of 10 2 cells permits to better monitor<br />
disease onset and progression and to plan<br />
experiments to test new anti-neoplastic therapies<br />
efficacy.<br />
Acknowledgement: This work was supported in part<br />
by grants from: Regional AIRC 2008 n°6278 and<br />
FIRB-CNR n°RBIP06M8ZA.<br />
References:<br />
1. Spaeth N et al; Eur J Nucl Med Mol Imaging. 33:673-<br />
682 (2006)<br />
2. Brioschi AM et al; J Nanoneurosci. 1:65-74 (2009)
TOPIC: Cancer Biology<br />
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Non-invasive “E2F sensing” system for monitoring DNA damage alteration induced by BCNU<br />
Monfared P. (1) , Rudan D. (1) , Viel T. (1) , Waerzeggers Y. (1) ,Hadamitzky M. (1) , Schneider G. (1) , Rapic S. (1) ,Neumaier B. (1) , Backes H. (1) ,<br />
Winkeler A. (1) , Jacobs A.H.. (1,2).<br />
(1) Max Planck Institute for Neurological Research, Cologne,<br />
(2) European Institute for Molecular Imaging (EIMI), University of Muenster, Germany<br />
Parisa.Monfared@nf.mpg.de<br />
Introduction: Imaging transcriptional regulation of<br />
endogenous genes in living animals using noninvasive<br />
imaging techniques provide a clear perception<br />
of normal and cancer-related biological processes.<br />
Radiolabeled reporter probes and PET imaging can<br />
be translated into human studies in the near future.<br />
In our preliminary study, the endogenous expression<br />
of E2F, a gene that affects several important<br />
biological processes, has been imaged in vivo with<br />
bioluminescence imaging. A retroviral vector, Cis-<br />
E2F/LUC-IRES-TKEGFP, was generated by placing<br />
the reporter genes under control of an artificial<br />
cis-acting E2F-specific enhancer element. Following<br />
retroviral transduction of tumor cells in established<br />
xenografts, DNA damage induced alteration<br />
of E2F transcriptional activity, which correlated<br />
with the expression of E2F-dependent downstream<br />
genes as assessed by biolumencsnce imaging.<br />
Aim: To verify whether the cis-reporter system<br />
(Cis-E2F/LUC-IRES-TKEGFP) is sufficiently sensitive<br />
to image endogenous transcriptional gene<br />
regulation by [ 18 F] FHBG PET imaging.<br />
Methods: U87dEGFR-E2F-LITG cells were injected<br />
subcutaneously in nude mice and the<br />
development of the tumours was followed by<br />
Multimodal imaging. Two weeks after implantation,<br />
bioluminescence imaging, FLT and<br />
FHBG were performed before and 24h after<br />
treatment with low and high doses of BCNU.<br />
Results: Here, we validate the utility of [ 18 F]FLT-<br />
PET to image proliferation rate of the tumor in response<br />
to DNA damage and compare with [ 18 F]<br />
FHBG uptake which is associated with E2F transcriptional<br />
activity. In keeping with in vitro findings,<br />
after 24 h post-treatment, low dose of BCNU<br />
induced an increase in [ 18 F]FHBG uptake as compared<br />
to non-treated mice. However, with high<br />
dose of BCNU [ 18 F]FHBG uptake decreased in E2F<br />
xenografts. [ 18 F]FLT accumulation in E2F xenografts<br />
decreased with low and high doses of BCNU<br />
at 24 and 48 hours. Quantitative changes in tumor<br />
[ 18 F]FLT uptake were associated with decreased<br />
tumor proliferation and tumor [ 18 F]FHBG uptake<br />
correlated with transcriptional gene regulation of<br />
E2F in response to DNA damage<br />
Conclusions: We show the utility of [ 18 F]FHBG-<br />
PET to image DNA damage induced by BCNU and<br />
shown the tumor-specific activity of E2F. We propose<br />
that these types of reporter systems, will allow<br />
a detailed insight into the kinetics of cell cycle<br />
control and for the development of new cell cycle<br />
targeted molecular therapies.<br />
Acknowledgement: This work is supported in part<br />
by the EC-FP6 European DiMI, (LSHC-CT-2004-<br />
503569) LSHB-CT-2005-512146 and Clinigene<br />
(LSHB-CT-06-018933).<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
P-106<br />
poStEr<br />
LATE BREAKING
P-107<br />
220<br />
WarSaW, poland May 26 – 29, 2010<br />
TOPIC: Neuroimaging<br />
Multi-tracer PET imaging of a mouse model of Alzheimer´s disease to assess microglial<br />
activation related to ageing and anti-inflammatory treatment<br />
Rapic S. (1) , Backes H. (1) , Viel T. (1) , Hadamitzky M. (1) , Monfared P. (1) , Rudan D. (1) , Vollmar S. (1) , Neumaier B. (1) , Hoehn M. (1) , Van der<br />
Linden A. (2) , Heneka M.T. (3) , Jacobs A.H. (1,4)<br />
(1) Max Plank Institute for Neurological Research, Cologne, Germany<br />
(2) Bio-Imaging Lab, University of Antwerp, Belgium<br />
(3) Department of Neurology, University of Bonn, Germany<br />
(4) European Institute for Molecular Imaging (EIMI)<br />
Sara.Rapic@nf.mpg.de<br />
Introduction: Alzheimer´s disease (AD), the leading<br />
cause of dementia in elderly people, is characterized<br />
by the deposition amyloid-β plaques in the<br />
brain surrounded by activated microglia. Activated<br />
microglia play an important role in amyloid clearance<br />
but also secrete pro-inflammatory molecules<br />
that lead to chronic neuroinflammation, and toxins<br />
that trigger cell death cascades in neurons, both<br />
eventually resulting in neurodegeneration. The<br />
nuclear peroxisome proliferator-activated receptor<br />
gamma (PPAR-γ) plays an important role in inflammatory<br />
processes. Agonists that bind and activate<br />
PPAR-γ, suppress inflammation by inhibiting the<br />
expression of pro-inflammatory molecules at transcriptional<br />
level. Determination of the contribution<br />
of neuroinflammation to the progression of AD can<br />
provide new insights in the development of therapy.<br />
Aim: To assess with in vivo positron emission tomography<br />
(PET) whether microglial activation is correlated<br />
with age in APP/PS1 transgenic mice and wildtype<br />
mice and if anti-inflammatory treatment with a<br />
PPAR-γ agonist can reduce neuroinflammation.<br />
Methods: Multi-tracer micro-PET imaging was performed<br />
in 13 months old APP Swe /PS1 dE9 transgenic<br />
mice (n = 5) and C57BL/6J wild type mice (n = 7).<br />
Dynamic imaging was performed after intravenous<br />
injection of [ 11 C]PK11195, a radioligand for the<br />
translocator protein-18 kDa which is upregulated in<br />
activated microglia and [ 18 F]FDG for the quantification<br />
of cerebral glucose metabolic rate. [ 18 F]Fluoride<br />
bone imaging was performed after every scan for coregistration<br />
purposes. The animals were imaged at<br />
baseline and treated for 4 weeks with a PPAR-γ agonist.<br />
Right after treatment and 4 weeks off treatment,<br />
all animals were investigated again using the same<br />
imaging protocol to assess the effect of the therapy.<br />
Results: Preliminary results show that uptake of<br />
[ 11 C]PK11195 is upregulated in transgenic mice<br />
compared to wild-type mice in the cortex (SUV<br />
of 75.15 and 57.20 respectively), thalamus (SUV<br />
of 78.90 and 63.63 respectively) and cerebellum<br />
(SUV of 82.12 and 65.47 respectively). Uptake of<br />
imaging life<br />
[ 18 F]FDG in transgenic mice is elevated as well,<br />
compared to wild-type mice, in the cortex (SUV<br />
of 162.10 and 106.78 respectively), thalamus (SUV<br />
of 172.07 and 115.33 respectively) and cerebellum<br />
(SUV of 166.50 and 114.46 respectively). Data were<br />
corrected for the total injected dose (ID). First image<br />
processing of the data obtained after treatment<br />
shows decreased brain retention of both tracers in<br />
transgenic mice.<br />
Conclusions: The higher uptake of [ 11 C]PK11195 in<br />
the brain of transgenic mice compared to wild-type<br />
mice indicates the presence of activated microglia,<br />
suggesting neuroinflammation of the Alzheimer<br />
brain. Reduction of [ 11 C]PK11195 brain retention<br />
after treatment with the PPAR-γ agonist reflects its<br />
anti-inflammatory effect.<br />
With the help of animal models for Alzheimer’s disease<br />
and in vivo molecular imaging, longitudinal detection of<br />
microglial cells is made possible and may be of vital importance<br />
in defining their role in the progression of the<br />
disease and in the development of therapeutic strategies.<br />
Acknowledgement: This work is supported in part by<br />
EC-FP6-project and DiMI LSHB-CT-2005-512146.
��������� ����� ������������� �������� ���������� ���� �����<br />
������������������������������������������������������<br />
������������������������������������������������������������<br />
�������� ���� ���������� ��������� ������������� �����<br />
���������������<br />
�<br />
• ������������������������������������������������������������<br />
��������������������������<br />
• ����������������������������������������������������������<br />
����������������������������������<br />
• ��������������������������������������������������<br />
• ������� ����� ��������� ����� ���� ������� �������� �����<br />
����������������������<br />
• ������������������������������������������������������<br />
• ���� ����������� ��������� �������� ����������� ��� ���������<br />
������������������������<br />
�<br />
��������������<br />
���������������������������������������������������������������������<br />
����������������������������������������������������������������������������������<br />
���������������������������������������<br />
�������������������������������������������������������������������������������<br />
���<br />
����<br />
����
index
INDEX
ANIMASCOPE<br />
High TECHNOLOGY for High TRANSPARENCY<br />
• High Technology for High Transparency<br />
o Non invasive imaging technologies<br />
o Small animals Preclinical imaging<br />
o Multimodality imaging services (Ultrason, MRI, Optical, PET, SPECT, CT Scan)<br />
• Reduce, Refine, Replace<br />
o Quantitative, Precise, Predictive<br />
o Reduces experimental Artifacts<br />
o Longitudinal Studies - Reduce Animal Usage (minus 70-80%)<br />
o Reduction and Refinement of animal works are Cost and Time-effective on R&D<br />
• Bridge the gap between preclinical and clinical research<br />
o Drug Delivery and Liberation (drug to target)<br />
o Efficacy, Safety, Pathology (desiderable and undesirable effects)<br />
o Ligand-Target interaction (receptors, enzymes, transporters) including Dose<br />
Occupancy relationships<br />
o Dynamic Biodistribution and Kinetics<br />
• One stop shop for :<br />
o biology,<br />
o cardiovascular,<br />
o cell therapy, gene therapy, immunization,<br />
o musculoskeletal,<br />
o neurology, nephrology,<br />
o oncology,<br />
o reproduction, development,<br />
o nutrition (nutraceuticals, dietary supplements and<br />
functional food).<br />
Contact : Daniel CHRISTIAEN<br />
ZI EUREKALP 38660 St Vincent de Mercuze (F)<br />
d.christiaen@animascope.eu<br />
Tel +33 (0)476 97 94 87<br />
www.animascope.eu<br />
Give to your study a new look
Index<br />
A<br />
Abasolo I. 126<br />
Abiraj K. 77<br />
Aboagye E.O. 209<br />
Adamczak J. 64<br />
Aelvoet S. A. 63<br />
Agarwal A. 41<br />
Agin V. 148<br />
Ahmad R. 204<br />
Aigner L. 62, 81, 169<br />
Aime S. 49, 79, 114,<br />
171,174, 176, 213<br />
Allard S. 90<br />
Alves F. 128, 208<br />
Anderson S. 155<br />
Arena F. 49<br />
Arridge S. 217<br />
Arstad E. 204<br />
Ashitate Y. 55<br />
Aswendt M. 171<br />
Audrain H. 189<br />
Autio A. 54, 130<br />
Avory M. 204<br />
Awde A. 160<br />
B<br />
Baatenburg De Jong R.J.<br />
119<br />
Backes H. 134, 219, 220<br />
Baekelandt V. 63, 85<br />
Barnard P. 77<br />
Barré L. 78<br />
Barré W. 35<br />
Barrio J. 157<br />
Bauernfeind A. 155<br />
Baulieu J. L. 157<br />
Bauwens M. 116<br />
Beaufils E. 157<br />
Bednar B. 89<br />
Behe M. 117<br />
Béhé M. 52<br />
Bellard E. 127<br />
Bender D. 189<br />
Benoit D. 155<br />
Benyó Z. 37<br />
Berardi F. 151<br />
Bergner F. 190<br />
Bergström J. P. 78<br />
Bernhardt P. 52<br />
Bernsen M. 118, 163,<br />
166,167, 168<br />
Berthezene Y. 65<br />
Berti R.P. 172<br />
Beynel A. 191<br />
Bhalla R. 183<br />
Bijster-Marchand M. 118<br />
Bilski M. 192<br />
Biserni A. 90, 91<br />
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Blanc A. 53<br />
Blankevoort V. 158<br />
Blockx I. 169<br />
Blossier A. 197<br />
Boehm-Sturm P. 64<br />
Bogaert-Buchmann A. 147<br />
Bogner W. 115<br />
Bohmer M. 103<br />
Boisgard R. 152, 160,<br />
191,197, 202, 211<br />
Bonetto F. 161<br />
Bonnet C. 182<br />
Bonzom S. 43<br />
Borelli M. 84<br />
Bormans G. 85, 170<br />
Boschi F. 42<br />
Bos P. 167<br />
Botnar R. 97<br />
Botta M. 48<br />
Boussel L. 68<br />
Boutin H. 198<br />
Brepoels L. 30<br />
Brown G. 198<br />
Brüggemann C. 171<br />
Brzezinski K. 184<br />
Bukala D. 201<br />
Burdinski D. 44<br />
Buron F. 182<br />
Busch C. 199<br />
Bzyl J. 72, 122<br />
C<br />
Cabello J. 184<br />
Calandrino R. 42<br />
Calderan L. 42<br />
Calotti F. 120<br />
Camus V. 157<br />
Cannet E. 68<br />
Carelli S. 56<br />
Carlsen H. 100<br />
Carpenter A. 36<br />
Carroll X. 155<br />
Casteels C. 33<br />
Catanzaro V. 79, 176<br />
Caveliers V. 29, 136<br />
Cemazar M. 127<br />
Cescato R. 206<br />
Céspedes M. V. 126<br />
Chapotot L. 191<br />
Chattopadhyay A. 151<br />
Chauveau F. 65<br />
Chazalviel L. 148<br />
Cheung P. 164<br />
Choe J. G. 153<br />
Choi H. S. 55<br />
Cho T. H. 65<br />
Christofori G. 52<br />
Ciana P. 90, 91<br />
Cibiel A. 173<br />
Ciobanu L. 160<br />
Cittadino E. 79, 114,<br />
174,213<br />
Clark C. 36<br />
Clerici M. 84, 165<br />
Clerici M. S. 56<br />
Cojoca R. 205<br />
Coleman P. 89<br />
Coll J. L. 139<br />
Comtat C. 214<br />
Contag C.H. 21<br />
Cordula D. 140<br />
Cottet M. 135<br />
Couillaud F. 83<br />
Crosby 61<br />
Cruz Ricondo L. J. 161<br />
Cuhlmann S. 100<br />
Curtis A. 41<br />
Custers E. 73<br />
D<br />
D´Alessandria C. 87<br />
D’Ambrosio D. 42<br />
Damont A. 197, 202<br />
Dastrù W. 114<br />
Debeissat C. 83<br />
Debyser Z. 63, 85<br />
Deckers N. 116<br />
Decristoforo C. 178<br />
Defraiteur C. 149<br />
De Geeter F. 101<br />
Degrassi A. 84<br />
Degroot T. 30<br />
De Jong M. 104, 107, 118<br />
Delest B. 180<br />
Deliolanis N. 185, 188<br />
Delli Castelli D. 114<br />
Delpassand E. S. 105<br />
Del Puerto-Nevado L. 203<br />
Del Vecchio S. 143<br />
Delzescaux T. 211<br />
Demello A. 189<br />
Demmer O. 87<br />
Demphel S. 202<br />
Denes A. 198<br />
De Poel M. 118<br />
De Rooij K. 142<br />
Deroose C. 85, 170<br />
De Saint-Hubert M. 30,116<br />
Desco M. 177, 181<br />
De Smet M. 103<br />
De Spirito M. 121<br />
De Swart J. 118<br />
De Vocht N. 57<br />
Devoogdt N. 29, 136<br />
Devos E. 30, 116<br />
Devos H. 101<br />
De Vries A. 73<br />
De Vries I. J. 161<br />
D’huyvetter M. 136<br />
Díaz-Lópeza R. 172<br />
Diependaele A. S. 148<br />
Dietlmeier J. 210<br />
Digilio G. 79, 176<br />
Dijkgraaf I. 87<br />
Dikaiou K. 186, 196<br />
Dilworth J. 77<br />
Doeswijk G. 166<br />
Dollé F. 160, 187, 197<br />
202,211<br />
Douaud G. 215<br />
Douek P. 68<br />
Drake C. 198<br />
Dresch C. 82<br />
Dubois A. 160, 187, 211<br />
Ducongé F. 173, 187<br />
Dullin C. 128, 208<br />
Dumont R. 117, 206<br />
Duong L. T. 89<br />
Dupont D. 147, 187<br />
Durroux T. 135<br />
Dusch E. 214<br />
Duyckaerts C. 179<br />
Dziuk E. 195<br />
Dziuk M. 192<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
E<br />
Ehrlichmann W. 201<br />
Ell P. J. 52<br />
Emond P. 78<br />
Emonds K. 137<br />
Etard O. 148<br />
Euskirchen P. 123<br />
Evans P. 100<br />
Evens N. 85<br />
F<br />
Fani M. 77, 117, 178, 206<br />
Farde L. 75<br />
Farrell E. 167<br />
Farr T. D. 64<br />
Fattal E. 172<br />
Fedeli F. 79<br />
Fekete K. 37<br />
Fekete M. 48<br />
Fenzi A. 42<br />
Fernández Y. 126<br />
Figdor C. 161<br />
Figueiredo S. 174<br />
Finnema S. 75<br />
Fiorini C. 84, 165<br />
Fischer K. 200<br />
Flamen P. 138<br />
Fokong S. 122, 175<br />
Forni G. 205<br />
IndEx
226<br />
WarSaW, poland May 26 – 29, 2010<br />
Fortin P. Y. 83<br />
Franci X. 149<br />
Frangioni J. 55<br />
Freret L. 172<br />
Fuchs K. 200<br />
G<br />
Gadella T.W.J. 60, 61<br />
Gaetjens J. 122<br />
Garcia C. 138<br />
Garcia E. 53<br />
Garnuszek P. 70<br />
Garofalakis A. 187, 217<br />
Gätjens J. 175<br />
Gauberti M. 66, 145, 148<br />
Gee A. 189<br />
Genevois C. 83<br />
Geraldes C. 179<br />
Geraldes C.F. 174<br />
Gerhard A. 32<br />
Gervais P. 152<br />
Geys R. 159<br />
Ghanem G. 138<br />
Gianolio E. 49, 79, 171<br />
Gillet B. 147<br />
Giron-Martinez A. 203<br />
Giżewska A. 195<br />
Glaser M. 209<br />
Glatz J. 188<br />
Gleason A. 89<br />
Glowa B. 70, 146<br />
Glowalla A. 144<br />
Goblet D. 129, 149<br />
Goedhart J. 61<br />
Goethals L. 101<br />
Golzio M. 127<br />
Gombert K. 173<br />
Gonzalez-Mangado N. 203<br />
Gorio A. 56<br />
Gourand F. 78<br />
Grabner G. 115<br />
Gremse F. 72<br />
Griessinger C. 178<br />
Grießinger C. 200<br />
Griessinger C.M. 201<br />
Gringeri C. 176<br />
Groetzinger C. 140<br />
Grote M. 131<br />
Grouls C. 122<br />
Gruber S. 115<br />
Gruell H. 44, 47, 73, 103<br />
Gruetter R. 46<br />
Gsell W. 100<br />
Guedin P. 148<br />
Guenoun J. 166<br />
Guglielmetti C. 162<br />
Guilloteau D. 76, 78, 157<br />
Gulyas B. 78<br />
imaging life<br />
H<br />
Haberkorn U. 102<br />
Hadamitzky M. 123, 134,<br />
219, 220<br />
Haeck J. 118<br />
Haiat G. 172<br />
Halldin C. 75, 78<br />
Hammers A. 156<br />
Hamm J. 205<br />
Hamplova A. 179<br />
Harlaar N. J. 99<br />
Hartung F. 208<br />
Haskard D. 100<br />
Hasselbalch S. G. 35<br />
Haubner R. 117, 178<br />
Heckemann R. A. 156<br />
Heerschap 31<br />
Heerschap A. 161<br />
Heijman E. 103<br />
Helbich T. 115<br />
Heneka M.T. 220<br />
Hennink W. 132<br />
Herance J. R. 126<br />
Hérard A. S. 211<br />
Herholz K. 198<br />
Hernandez L. 43<br />
Hernot S. 136<br />
Herranz F. 177, 181<br />
Herzog E. 99<br />
Higuchi T. 97<br />
Hijnen N. 103<br />
Hilger I. 199<br />
Hillebrands J. L. 99<br />
Himmelreich U. 171<br />
Hink M.A. 61<br />
Hirani E. 204<br />
Hoeben R. 120<br />
Hoehn M. 64, 171, 220<br />
Hogset A. 49<br />
Hommet C. 157<br />
Honer M. 196<br />
Horváth I. 37<br />
Houston G. 168<br />
Hubalewska-Dydejczyk A.<br />
70, 146<br />
Hüsgen A. 216<br />
Huskens J. 44<br />
Hutteman M. 55, 142<br />
Hwang Y. M. 153<br />
I<br />
Ibrahimi A. 30, 63, 85<br />
Iezzi M. 205<br />
Iommelli F. 143<br />
J<br />
Jacobs A.H. 123, 134,<br />
219, 220<br />
Jafurulla M. 151<br />
Jalkanen S. 54<br />
Jamous M. 206<br />
Janssens I. 173<br />
Jaron A. 154<br />
Jassens I. 187<br />
Jego B. 160, 197, 211<br />
Jikeli J. 64<br />
Jiskoot W. 132<br />
Jonckers E. 212<br />
Jones H. 100<br />
Jones P. 204<br />
Joshi A. 36<br />
Josserand V. 139, 207<br />
Jucker M. 34<br />
Judenhofer M. 200<br />
Justicia C. 150<br />
K<br />
Kachelrieß M. 190<br />
Kaijzel E. 106, 119, 120,<br />
124, 125, 132,<br />
142, 158<br />
Kaiser W. A. 199<br />
Kaisin G. 129<br />
Kaliszczak M. 209<br />
Kallur T. 64<br />
Kaminski G. 192, 195<br />
Kandasamy M. 169<br />
Karczmarczyk U. 70, 146<br />
Karhi T. 130<br />
Karolczak M. 190<br />
Kassiou M. 197, 198<br />
Kaufholz P. 131<br />
Keereweer S. 106, 119,125<br />
Keil B. 52<br />
Keist R. 53, 186<br />
Kepe V. 157<br />
Keramidas M. 139<br />
Kerrebijn J. 119<br />
Kesenheimer C. 201<br />
Kessler H. 87, 128<br />
Keupp J. 103<br />
Khan I. 204<br />
Kiessling F. 72, 122, 175<br />
Klaubert D. 90<br />
Klohs J. 186<br />
Kneilling M. 200, 201<br />
Knetsch P. 178<br />
Knödgen E. 123<br />
Knudsen G. M. 35, 156<br />
Knuuti J. 71<br />
Kobylecka M. 193<br />
Komm B. 91<br />
Kossodo S. 89<br />
Kotek G. 163, 166, 167<br />
Krais R. 216<br />
Krams R. 100<br />
Krautkramer M. 36<br />
Krenning E.P. 107<br />
Krestin G. 163, 166, 167,<br />
168<br />
Krewer B. 208<br />
Krolicki L. 193<br />
Krucker T. 41<br />
Kruttwig K. 171<br />
Krzanowski M. 70, 146<br />
Kubicek V. 179<br />
Kuhnast B. 187, 202<br />
Kumar-Singh S. 159<br />
Kunikowska J. 193<br />
Kuppen P. 55, 142<br />
Kuśnierz-Cabala B. 146<br />
Kyrgyzov I. 43<br />
L<br />
Labate V. 121<br />
Lacasta C. 184<br />
Lacivita E. 151<br />
Laget M. 135<br />
Lahoutte T. 29, 101, 136<br />
Laine J. 71<br />
Laitinen I. 71<br />
Lamberton F. 148<br />
Langereis S. 44, 103<br />
Lapp R. 190<br />
Lazar A. 179<br />
Lebenberg J. 211<br />
Lebon V. 211<br />
Lederle W. 72, 122<br />
Le Helleix S. 202<br />
Lehel S. 35<br />
Lehmann F. 199<br />
Lehmann S. 53<br />
Lemaire C. 129<br />
Le Masne Q. 43<br />
Lenda-Tracz W. 194<br />
Leopoldo M. 151<br />
Lepetit-Coiffé M. 83, 88<br />
Leppänen P. 71<br />
Leroy C. 214, 215<br />
Lettieri A. 143<br />
Levrey O. 43<br />
Liang J. 164<br />
Libani I. V. 56<br />
Libani I.V. 165<br />
Li G. 164<br />
Linhart V. 184<br />
Lin S. A. 89<br />
Li R. 155<br />
Liu Z. 175<br />
Llosá G. 184<br />
Lo Dico A. 218<br />
Long N. 189<br />
Longo D. 213<br />
López M. 126
López M.E. 126<br />
Löwik C.W.G.M. 55, 106,<br />
119, 120, 124, 125,<br />
132, 142, 158<br />
Lub J. 73<br />
Lucignani G. 56, 84, 165<br />
Lui R. 56, 165<br />
Luoto P. 130<br />
Luthra S. 204<br />
Luxen A. 129, 149<br />
M<br />
Mackeyev Y. 133<br />
Mackiewicz N. 187<br />
Macrez R. 145<br />
Madaschi L. 56<br />
Madsen K. 35<br />
Maecke H. 52, 77, 117, 206<br />
Maggi A. 90, 91<br />
Maier F. C. 34<br />
Maina T. 107<br />
Mainini F. 114<br />
Maitrejean S. 43<br />
Mali A. 130<br />
Mangues R. 126<br />
Mannheim J. 34, 200<br />
Mansfield J. 41<br />
Mansi R. 52, 206<br />
Marengo M. 42<br />
Marfia G. 56<br />
Markelc B. 127<br />
Marner L 35<br />
Maroy R. 214, 215<br />
Marra F. 56<br />
Marsouvanidis I.P. 107<br />
Martelli C. 84, 165<br />
Martin A. 152<br />
Martinelli J. 48<br />
Martins A. 179<br />
Masiello V. 218<br />
Massberg S. 26<br />
Matarrese M. 218<br />
Máthé D. 37<br />
Mathejczyk J. 208<br />
Mathejczyk J.E. 128<br />
Mathis G. 135<br />
Maubert E. 145<br />
Maulucci G. 121<br />
Maurin M. 70<br />
Mauro A. 218<br />
Mautino A. 205<br />
Mazurek A. 195<br />
Mccoll B. 198<br />
Meijering E. 166<br />
Mele M. 121<br />
Menchise V. 79, 176<br />
Mercier F. 129<br />
Mérian J. 207<br />
<strong>5th</strong> <strong>EuropEan</strong> <strong>MolEcular</strong> <strong>IMagIng</strong> <strong>MEEtIng</strong> – EMIM2010<br />
Merli D. 56<br />
Messeguer A. 150<br />
Meyer A. 131<br />
Meyer Y. 180<br />
Mezzanotte L. 120<br />
Michelini E. 120<br />
Mieog J. 142<br />
Mieog S. 55<br />
Mikołajczak R. 70, 146<br />
Miller P. 74, 189<br />
Miranda S. 126<br />
Mol I. 106, 119, 124, 125<br />
Monfared P. 123, 134, 219,<br />
220<br />
Montagne A. 66, 145<br />
Moonen C. 83, 88<br />
Moreira J.N. 174<br />
Moresco R. M. 218<br />
Morfin J.F. 179<br />
Morisson-Iveson V. 204<br />
Mortelmans L. 30, 116,<br />
137, 170<br />
Moser E. 115<br />
Mottaghy F. 30, 116, 137<br />
Mronz M. 190<br />
Musiani P. 205<br />
Muylle K. 138<br />
N<br />
Napolitano R. 79<br />
Napp J. 128, 208<br />
Narula J. 95<br />
Nataf S. 65<br />
Navarro F. 207<br />
Nekolla S. 97<br />
Neumaier B. 134, 219, 220<br />
Nguyen H. H. P. 169<br />
Nguyen Q. D. 209<br />
Nicolaij K. 47<br />
Nicolas G. 206<br />
Nicolay K. 73<br />
Niessen W. 166<br />
Nighoghossian N. 65<br />
Noack P. 180<br />
Nock B.A. 107<br />
Nock J. 216<br />
Ntziachristos V. 99, 185,<br />
188<br />
Nuyts J. 137<br />
O<br />
Odenthal J. 34<br />
Odoardi F. 51<br />
Oh S. Y. 153<br />
Oikonen V. 130<br />
Oliver J. F. 184<br />
Opalinska M. 70, 146<br />
Orset C. 66, 145, 148<br />
O’shea D. 204<br />
Ottobrini L. 56, 84, 165<br />
P<br />
Pach D. 146<br />
Palmowski M. 122<br />
Panieri E. 121<br />
Pani G. 121<br />
Pardo L. A. 208<br />
Paris J. 129<br />
Park E. 153<br />
Park K. W. 153<br />
Park S. 155<br />
Passmore J. 204<br />
Passon M. 199<br />
Pauli J. 128<br />
Pawlak D. 193<br />
Peces-Barba G. 203<br />
Peleman C. 29<br />
Pereson S. 159<br />
Perez-Rial S. 203<br />
Perkuhn M. 72<br />
Perrone R. 151<br />
Pesenti E. 84<br />
Pestourie C. 173<br />
Peterson J. 89<br />
Petoud S. 45, 182<br />
Petrik M. 178<br />
Pichler B. 34, 178, 200, 201<br />
Pickarski M. 89<br />
Pietzsch H.J. 178<br />
Pijarowska J. 154<br />
Pikkemaat J. 44<br />
Pinker K. 115<br />
Pirozzi G. 143<br />
Pisaneschi F. 209<br />
Pisani E. 172<br />
Planas A. 150<br />
Plenevaux A. 149<br />
Plenge E. 166<br />
Pluchino S. 80<br />
Podgajny Z. 192, 195<br />
Politi L. S. 218<br />
Ponsaerts P. 162<br />
Pontecorvo M. 36<br />
Praet J. 162<br />
Prenant C. 198<br />
Pucci B. 172<br />
Q<br />
Que I. 106, 120, 124, 132<br />
Quesson B. 83<br />
R<br />
Rafecas M. 184<br />
Rainone V. 84<br />
Rajopadhye M. 89<br />
Rakowski T. 70<br />
Rando G. 91<br />
Rangaraj N. 151<br />
Rangger C. 178<br />
Raphael B. 43<br />
Rapic S. 134, 219, 220<br />
Ratering D. 186<br />
Raynaud J.S. 145<br />
Razansky D. 99, 188<br />
Reder S. 97<br />
Reischl G. 34, 200, 201<br />
Renard P.Y. 180<br />
Resch-Genger U. 128<br />
Reubi J. C. 52, 77<br />
Reubi J.C. 206<br />
Reumers V. 63<br />
Reutelingsperger C. 116<br />
Rexin A. 140<br />
Riccardi P. 155<br />
Richard J.A. 180<br />
Righini C. 139<br />
Riou A. 65<br />
Ripoll J. 186, 217<br />
Rix A. 72, 122<br />
Robillard M. 47<br />
Robins E. 209<br />
Röcken M. 200, 201<br />
Roda A. 120<br />
Roivainen A. 54, 71, 130<br />
Rojas S. 126<br />
Romanowicz G. 36<br />
Romieu A. 180<br />
Ronchetti F. 218<br />
Rosell Y. 177<br />
Rossin R. 103<br />
Rothwell N. 198<br />
Rubio M. 145<br />
Rudan D. 123, 134, 219,<br />
220<br />
Rudin M. 39, 53, 186<br />
Ruiz-Cabello J. 177, 181<br />
Russo M. 84<br />
Rutten E. 138<br />
<strong>EuropEan</strong> SocIEty for <strong>MolEcular</strong> <strong>IMagIng</strong> – <strong>ESMI</strong><br />
S<br />
Saanijoki T. 54, 130<br />
Saha K. 36<br />
Salerno M. 179<br />
Salinas B. 177, 181<br />
Salvatore M. 143<br />
Sanches P. 103<br />
Saraste A. 97<br />
Sawall S. 190<br />
Saxena R. 151<br />
Sbarbati A. 42<br />
Schäfers M. 98<br />
Schellenberger E. 69<br />
Schibli R. 77<br />
Schibli R. 53, 196<br />
IndEx
228<br />
WarSaW, poland May 26 – 29, 2010<br />
Schmid A. 34<br />
Schmidt D. 155<br />
Schmuck K. 208<br />
Schneider G. 134, 219<br />
Schober A. 72<br />
Schulze A. 131<br />
Schulz P. 140<br />
Schulz R. 72, 188<br />
Schwaiger M. 97<br />
Schwartz Jr S. 126<br />
Scotti G. 218<br />
Sebrie C. 147<br />
Sée V. 24, 25<br />
Sersa G. 127<br />
Shade C. 182<br />
Shamsaei E. 209<br />
Sherif H. 97<br />
Sigovan M. 68<br />
Sihver W. 131<br />
Sijbers J. 159<br />
Silengo L. 205<br />
Silvola J. 71<br />
Sims-Mourtada J. 105, 133<br />
Sipilä H. 54, 71<br />
Siquier K. 197<br />
Siquier-Pernet K. 160<br />
Skovronsky D. 36<br />
Slütter B. 132<br />
Smith G. 209<br />
Snoeks T. 106, 119, 124,<br />
125, 158<br />
Socher I. 199<br />
Soema P. 132<br />
Solevi P. 184<br />
Soria G. 150<br />
Sowa-Staszczak A. 70, 141,<br />
146<br />
Spadaro M. 114<br />
Spinelli A. E. 42<br />
Spivey A. C. 209<br />
Srinivas M. 161<br />
Stadelbauer A. 115<br />
Stein J. 38<br />
Stiller D. 34<br />
Stompor T. 70, 146<br />
Strijkers G. 96<br />
Stühmer W. 208<br />
Stuker F. 186, 196<br />
Suárez L. 126<br />
Sué M. 216<br />
Suilamo S. 130<br />
Sułowicz W. 146<br />
Sur C. 89<br />
Suzenet F. 179, 182<br />
Svarer C. 156<br />
Swinnen J. 137<br />
Szalus N. 192, 195<br />
Szigeti K. 37<br />
imaging life<br />
T<br />
Takano A. 78<br />
Tamma M. 206<br />
Tamma M. L. 77<br />
Tannous B. 185<br />
Tapfer A. 97<br />
Taruttis A. 99<br />
Tatsi A. 107<br />
Tauber C. 157<br />
Taulier N. 172<br />
Tavitian B. 152, 160, 173,<br />
187, 191, 197,<br />
202, 211<br />
Tchouate Gainkam O 136<br />
Tei L. 48<br />
Teissie J. 127<br />
Teräs M. 130<br />
Terreno E. 114, 174, 213<br />
Texido G. 84<br />
Texier I. 207<br />
Thézé B. 152, 173, 191<br />
Thonon D. 129, 149<br />
Tiemann K. 103<br />
Tietze L. F. 128, 208<br />
Toelen J. 63, 85<br />
Torres E. 114<br />
Toth E. 179, 182<br />
Tousseyn T. 30<br />
Trabattoni D. 84<br />
Trattnig S. 115<br />
Trebossen R. 214, 215<br />
Trigg W. 204<br />
Trinquet E. 135<br />
Tsapis N. 172<br />
Tudela R. 150<br />
Turco E. 205<br />
Tworowska I. 105, 133<br />
U<br />
Uijtterdijk A. 167<br />
Urbach W. 172<br />
V<br />
Vahrmeijer A. 55, 142<br />
Vainio J. 130<br />
Vainio P. 130<br />
Valtorta S. 218<br />
Van Auderkerke J. 212<br />
Van Beek E. 158<br />
Van Beers B.E. 28<br />
Van Broeckhoven C. 159<br />
Van Buul G. 167<br />
Van Dam G. M. 99<br />
Van Den Haute C. 63<br />
Vandeputte C. 85<br />
Van Der Heiden K. 100<br />
Van Der Linden A. 57,<br />
138, 150, 159, 162,<br />
169,212, 220<br />
Van Der Vorst J. 55, 142<br />
Van De Velde C. 55, 142<br />
Vandormael S. 138<br />
Van Driel P. 106, 119, 125<br />
Van Duijnhoven S. 47<br />
Vaneycken I. 29, 136<br />
Vanhoutte G. 159<br />
Vanhove C. 101<br />
Van Laere K. 33, 85, 170<br />
Van Osch G. 167<br />
Van Santvoort A. 170<br />
Van Tiel S. 163, 168<br />
Van Weerden W. 137<br />
Van Weeren L. 61<br />
Varrone A. 75<br />
Vats D. 186, 196<br />
Venel Y. 157<br />
Veraart J. 159<br />
Verbruggen A. 30, 85, 116<br />
Vercouillie J. 157<br />
Verfaillie C. 170<br />
Verhaar J. 167<br />
Verhoye M. 169, 212<br />
Vermaelen P. 170<br />
Verwijnen S. 118<br />
Viel T. 123, 134, 219, 220<br />
Vilar R. 189<br />
Villette S. 182<br />
Vivien D. 66, 145, 148<br />
Vollmar S. 216, 220<br />
Von Hof J. M. 208<br />
Vreys R. 162, 169<br />
Vuillemard C. 152<br />
W<br />
Waerzeggers Y. 219<br />
Wang H. 196<br />
Watson J. 90<br />
Weber C. 72<br />
Weber W. 27, 117, 206<br />
Wehrl H. F. 34<br />
Weidl E. 97<br />
Weigelin B. 161<br />
Weinans H. 167<br />
Wester H.J. 87, 97, 178<br />
Whelan P.F. 210<br />
Wiart M. 65<br />
Wicki A. 52<br />
Wiedenmann B. 140<br />
Wiehr S. 34, 200, 201<br />
Wielopolski P. 163, 167, 168<br />
Wilczynski G. 67<br />
Wild D. 52<br />
Wilson L. J. 133<br />
Winkeler A. 160, 219<br />
Woff E. 138<br />
Wolfs E. 170<br />
Wouters L. 149<br />
Wurdinger T. 185<br />
X<br />
Xavier C. 29, 136<br />
Xie B. 106, 119, 125<br />
Y<br />
Yang E. 164<br />
Yang X. 164<br />
Yared W. 89<br />
Ylä-Herttuala S. 71<br />
Young A. 148<br />
Yudina A. 88<br />
Z<br />
Zacharopoulos A. 217<br />
Zannetti A. 143<br />
Zara G. 218<br />
Zeebregts C. J. 99<br />
Zenga F. 218<br />
Zheng J. 160<br />
Zhong P. 164<br />
Ziegler S. 40<br />
Zwier J. 135
230<br />
WarSaW, poland May 26 – 29, 2010<br />
<strong>ESMI</strong>/DiMI management office<br />
c/o MPI for neurological research<br />
Gleueler Str. 50<br />
50931 Köln<br />
T ++49 2 21 4 78 8 72 44<br />
++49 2 21 4 78 8 79 60<br />
E office@e-smi.eu<br />
Layout: Doris Kracht<br />
Binding and Printing: Hundt Druck GmbH<br />
imaging life